{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Copyright Namu Park, 2020, Yonsei Digital Analytics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import re\n",
    "import operator\n",
    "import fasttext\n",
    "import glob"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from tqdm import tqdm_notebook"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "file_path = glob.glob('34 paper final/*.txt')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "total_raw = []\n",
    "for x in file_path:\n",
    "    with open(x, 'r', encoding='iso-8859-1') as f:\n",
    "        a = f.read()\n",
    "    total_raw.append(a)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(total_raw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'A data-driven drug repositioning framework discovered a\\n\\npotential therapeutic agent targeting COVID-19\\n\\nYiyue Ge1,2,\\n\\n, Tingzhong Tian1,2,\\n\\n, Suling Huang3,\\n\\n, Fangping Wan1,\\n\\n, Jingxin Li2,\\n\\n,\\n\\nShuya Li1\\n\\n, Hui Yang11\\n\\n, Lixiang Hong1\\n\\n, Nian Wu1\\n\\n, Enming Yuan1\\n\\n, Lili Cheng4\\n\\n, Yipin\\n\\nLei11\\n\\n, Hantao Shu1\\n\\n, Xiaolong Feng6,7\\n\\n, Ziyuan Jiang5\\n\\n, Ying Chi2\\n\\n, Xiling Guo2\\n\\n, Lunbiao\\n\\nCui2\\n\\n, Liang Xiao10\\n\\n, Zeng Li10\\n\\n, Chunhao Yang3\\n\\n, Zehong Miao3\\n\\n, Haidong Tang4\\n\\n, Ligong\\n\\nChen4\\n\\n, Hainian Zeng11\\n\\n, Dan Zhao1,*\\n\\n, Fengcai Zhu2,8,*\\n\\n, Xiaokun Shen10,*\\n\\n, Jianyang\\n\\nZeng1,9,*\\n\\n1\\n\\nInstitute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, 100084, China.\\n\\n2\\n\\nNHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Diseases\\n\\nControl and Prevention, Nanjing, Jiangsu Province, 210009, China.\\n\\n3\\n\\nShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.\\n\\n4\\n\\nSchool of Pharmaceutical Sciences, Beijing Advanced Innovation Center for Structural Biology,\\n\\nTsinghua University, Beijing, 100084, China.\\n\\n5\\n\\nDepartment of Automation, Tsinghua University, Beijing, 100084, China.\\n\\n6\\n\\nSchool of Electronic Information and Communications, Huazhong University of Science and\\n\\nTechnology, Wuhan, Hubei Province, 430074, China.\\n\\n7\\n\\nInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and\\n\\nTechnology, Wuhan, Hubei Province, 430030, China.\\n\\n8\\n\\nCenter for Global Health, Nanjing Medical University, Nanjing, Jiangsu Province, 210009, China.\\n\\n9\\n\\nMOE Key Laboratory of Bioinformatics, Tsinghua University, Beijing, 100084, China.\\n\\n10\\n\\nConvalife (Shanghai) Co., Ltd., Shanghai, 201203, China.\\n\\n11\\n\\nSilexon AI Technology Co., Ltd., Nanjing, Jiangsu Province, 210033, China.\\n\\n\\n\\nThese authors contributed equally to this work.\\n\\n*\\n\\nCorresponding authors.\\n\\nAbstract\\n\\nThe global spread of SARS-CoV-2 requires an urgent need to find effective therapeu-\\n\\ntics for the treatment of COVID-19. We developed a data-driven drug repositioning\\n\\nframework, which applies both machine learning and statistical analysis approaches\\n\\nto systematically integrate and mine large-scale knowledge graph, literature and tran-\\n\\nscriptome data to discover the potential drug candidates against SARS-CoV-2. The\\n\\nretrospective study using the past SARS-CoV and MERS-CoV data demonstrated that\\n\\nour machine learning based method can successfully predict effective drug candidates\\n\\nEmail addresses: zhaodan2018@tsinghua.edu.cn (Dan Zhao), jszfc@vip.sina.com (Fengcai\\n\\nZhu), steve.shen@convalife.com (Xiaokun Shen), zengjy321@tsinghua.edu.cn (Jianyang Zeng)\\n\\nMarch 11, 2020\\n\\n(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.\\n\\nagainst a specific coronavirus. Our in silico screening followed by wet-lab validation\\n\\nindicated that a poly-ADP-ribose polymerase 1 (PARP1) inhibitor, CVL218, currently\\n\\nin Phase I clinical trial, may be repurposed to treat COVID-19. Our in vitro assays\\n\\nrevealed that CVL218 can exhibit effective inhibitory activity against SARS-CoV-2\\n\\nreplication without obvious cytopathic effect. In addition, we showed that CVL218\\n\\nis able to suppress the CpG-induced IL-6 production in peripheral blood mononuclear\\n\\ncells, suggesting that it may also have anti-inflammatory effect that is highly relevant to\\n\\nthe prevention immunopathology induced by SARS-CoV-2 infection. Further pharma-\\n\\ncokinetic and toxicokinetic evaluation in rats and monkeys showed a high concentration\\n\\nof CVL218 in lung and observed no apparent signs of toxicity, indicating the appealing\\n\\npotential of this drug for the treatment of the pneumonia caused by SARS-CoV-2 infec-\\n\\ntion. Moreover, molecular docking simulation suggested that CVL218 may bind to the\\n\\nN-terminal domain of nucleocapsid (N) protein of SARS-CoV-2, providing a possible\\n\\nmodel to explain its antiviral action. We also proposed several possible mechanisms to\\n\\nexplain the antiviral activities of PARP1 inhibitors against SARS-CoV-2, based on the\\n\\ndata present in this study and previous evidences reported in the literature. In sum-\\n\\nmary, the PARP1 inhibitor CVL218 discovered by our data-driven drug repositioning\\n\\nframework can serve as a potential therapeutic agent for the treatment of COVID-19.\\n\\n1. Introduction\\n\\nThe outbreak of the pneumonia named COVID-19 caused by the novel coronavirus\\n\\nSARS-CoV-2 (2019-nCoV) has infected over 110,000 people worldwide by 8th March,\\n\\n2020. Apart from China, other countries or regions including South Korea, Iran, and\\n\\nEurope have reported a rapid increase in the number of COVID-19 cases, implying that\\n\\nthis novel coronavirus has posed a global health threat. Under the current circumstance\\n\\nof the absence of the specific vaccines and medicines against SARS-CoV-2, it is urgent\\n\\nto discover effective therapies especially drugs to treat the resulting COVID-19 disease\\n\\nand prevent the virus from further spreading. Considering that the development of a\\n\\nnew drug generally takes years, probably the best therapeutic shortcut is to apply the\\n\\ndrug repositioning strategy (i.e., finding the new uses of old drugs) [1, 2, 3] to identify\\n\\nthe potential antiviral effects against SARS-CoV-2 of existing drugs that have been\\n\\napproved for clinical use or to enter clinical trials. Those existing drugs with potent\\n\\nantiviral efficacy can be directly applied to treat COVID-19 in a short time, as their\\n\\nsafety has been verified in principle in clinical trials.\\n\\nIn this study, we applied a data-driven framework that combines both machine\\n\\nlearning and statistical analysis methods to systematically integrate large-scale avail-\\n\\nable coronavirus-related data and identify the drug candidates against SARS-CoV-2\\n\\nfrom a set of over 6000 drug candidates (mainly including approved, investigational\\n\\nand experimental drugs). Our in silico screening process followed by experimental val-\\n\\nidation revealed that a poly-ADP-ribose polymerase 1 (PARP1) inhibitor, CVL218,\\n\\ncurrently in Phase I clinical trial, may serve as a potential drug candidate to treat\\n\\nCOVID-19. Our in vitro assays demonstrated that CVL218 can exhibit effective in-\\n\\nhibitory activity against SARS-CoV-2 replication in a dose-dependent manner and with\\n\\nno obvious cytopathic effect. In addition, we found that in human peripheral blood\\n\\nmononuclear cells (PBMCs), CVL218 is able to suppress the CpG-induced production\\n\\nof IL-6, which has been reported previously to be of high relevance to the viral patho-\\n\\ngenesis of COVID-19, especially for those intensive care unit (ICU) patients infected by\\n\\nSARS-CoV-2. Further in vivo pharmacokinetic and toxicokinetic studies in rats and\\n\\nmonkeys showed that CVL218 was highly distributed in the lung tissue and no apparent\\n\\nsign of toxicity was observed, which makes it an appealing potential drug candidate for\\n\\nthe treatment of the novel pneumonia caused by SARS-CoV-2 infection. Moreover, our\\n\\nmolecular docking study suggested that CVL218 may bind to the N-terminal domain\\n\\nof nucleocapsid (N) protein of SARS-CoV-2, providing a possible mode of its antiviral\\n\\naction against SARS-CoV-2. Based on the data present in this study and previous\\n\\nknown evidences reported in the literature, we also discussed several putative mech-\\n\\nanisms of the anti-SARS-CoV-2 effects for CVL218 or other PARP1 inhibitors to be\\n\\ninvolved in the treatment of COVID-19. Overall, our results indicated that the PARP1\\n\\ninhibitor CVL218 identified by our drug repositioning pipeline may serve as an effective\\n\\ntherapeutic agent against COVID-19.\\n\\n2. Results\\n\\n2.1. Overview of our drug repositioning framework\\n\\nThe overview of our data-driven drug repositioning framework is shown in Fig-\\n\\nure 1A. We first constructed a virus related knowledge graph consisting of drug-target\\n\\ninteractions, protein-protein interactions and similarity networks from publically avail-\\n\\nable databases (Methods). Three different types of nodes (i.e., drugs, human targets\\n\\nand virus targets) within the knowledge graph were connected through edges describ-\\n\\ning their interactions, associations or similarities to establish bridges of information\\n\\naggregation and knowledge mining. We then applied a network-based knowledge min-\\n\\ning algorithm to predict an initial list of drug candidates that can be potentially used\\n\\nto treat SARS-CoV-2 infection (Figure 1B and Methods). Next, we further narrowed\\n\\ndown the list of drug candidates with the previously reported evidences of antiviral\\n\\nactivities based on the text mining results from the large-scale literature texts, which\\n\\nwere derived through a deep learning based relation extraction method named BERE [4]\\n\\n(Figure 1C and Methods), followed by a minimum of manual checking. After that, we\\n\\nused the connectivity map analysis approach [5] with the gene expression profiles of\\n\\nten SARS-CoV-infected patients [6] to further refine the list of drug candidates against\\n\\nSARS-CoV-2 (Figure 1D, Table 1, Table S1 and Methods). The above screening pro-\\n\\ncess revealed that a poly-ADP-ribose polymerase 1 (PARP1) inhibitor PJ-34 could\\n\\npotentially have the antiviral activities against SARS-CoV-2.\\n\\n2.2. Validation of our network-based knowledge mining results\\n\\nTo demonstrate that our computational pipeline for drug repositioning can yield\\n\\nreasonably accurate prediction results, we also validated our network-based knowledge\\n\\nmining algorithm (Figure 1B) using the retrospective data of the two coronaviruses\\n\\nthat are closely related to SARS-CoV-2 and had been relatively well studied in the\\n\\nliterature, i.e., SARS-CoV and MERS-CoV. With the aid of our developed text mining\\n\\ntool BERE, we found that many of the drugs that had been reported previously in the\\n\\nliterature to have antiviral activities against the corresponding coronavirus, were also\\n\\namong the top list of our predicted results (Table 2). For example, chloroquine, an\\n\\nFDA-approved drug for treating malaria [7], which was previously reported to exhibit\\n\\nmicromolar anti-SARS-CoV activity in vitro [8], was also repurposed for targeting the\\n\\nsame virus by our prediction framework. Gemcitabine, which was originally approved\\n\\nfor treating certain types of cancers [9], was also predicted for targeting SARS-CoV\\n\\nwith validation by previous in vitro studies [10]. Cyclosporine, a calcineurin inhibitor\\n\\napproved as an immunomodulatory drug [11], was observed to block the replication of\\n\\nSARS-CoV [12], and also successfully predicted by our approach. Among the predicted\\n\\ntop list for MERS-CoV, miltefosine, which was approved for treating leishmaniasis [13],\\n\\nwas previously identified to have anti-MERS-CoV activity [14]. Chlorpromazine and\\n\\nimatinib, which were used for treating schizophrenia [15] and leukemia [16], respectively,\\n\\nwere also selected by our computational pipeline as anti-MERS-CoV drugs and can be\\n\\nvalidated by previous in vitro experiments [10]. Thus, the above retrospective study\\n\\nillustrated that our computational framework is able to predict effective drug candidates\\n\\nagainst a specific coronavirus.\\n\\n2.3. CVL218 exhibits in vitro inhibitory activity against SARS-CoV-2 replication\\n\\nAs PJ-34 is still currently in the pre-clinical trial stage (DrugBank ID: DB08348, [17]),\\n\\nwe selected two PARP1 inhibitors, including olaparib and mefuparib hydrochloride\\n\\n(CVL218) (Figure S1), that are currently FDA-approved and at Phase I clinical trial,\\n\\nrespectively, for our initial study. We first conducted a pilot experimental test in vitro\\n\\n(Methods) on the anti-SARS-CoV-2 activities of olaparib, CVL218 and several other re-\\n\\nlated drugs (Figure 2A). We found that both PARP1 inhibitors olaparib and CVL218\\n\\nexhibited inhibitory effects against SARS-CoV-2 replication. Nevertheless, CVL218\\n\\nshowed a much higher inhibition rate than olaparib. More specifically, olaparib inhib-\\n\\nited SARS-CoV-2 replication by 15.48% at a concentration of 3.2 µM, while CVL218\\n\\nreached 35.16% reduction at a concentration of 3 µM.\\n\\nNotably, the antiviral efficacy of CVL218 even surpassed arbidol, which is one\\n\\nof the standard treatments for COVID-19 in the Diagnosis and Treatment Proto-\\n\\ncol for Novel Coronavirus Pneumonia (Trial Version 6) promulgated by the Chinese\\n\\n351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf). In particular, ar-\\n\\nbidol inhibited SARS-CoV-2 replication by 21.73% at 3 µM, much lower than that of\\n\\nCVL218 at the same concentration (Figure 2A). In contrast, oseltamivir, zanamivir\\n\\n(drugs used for preventing influenza virus infection) and baricitinib (JAK1/2 inhibitor,\\n\\nwhich was recommended in [18] to treat COVID-19) showed no inhibitory activities\\n\\nagainst SARS-CoV-2 at the concentration of 3 µM or 3.2 µM.\\n\\nBased on the above pilot experimental results, we then chose CVL218 for subsequent\\n\\nexperimental studies. Our further in vitro assays (Methods) showed that CVL218 exhib-\\n\\nited effective inhibitory activity against SARS-CoV-2 replication in a dose-dependent\\n\\nmanner, with an EC50 of 5.12 µM (Figure 2B). We also assessed the cytotoxicity of\\n\\nCVL218 by the CCK8 assay (Methods), and found that CVL218 had a CC50 of 91.05\\n\\nµM in Vero E6 cells. In addition, immunofluorescence microscopy (Methods) revealed\\n\\nthat, at 14 h post SARS-CoV-2 infection, virus nucleoprotein (NP) expression in the\\n\\nCVL218-treated cells demonstrated a dose-response relationship with the treated drug\\n\\nconcentrations, and was significantly lower upon CVL218 treatment compared with\\n\\nthat in the DSMO treated cells (Figure 2C). No obvious cytopathic effect was observed\\n\\nin the infected cells treated with CVL218 at 25 µM.\\n\\nTo systematically assess the inhibitory activities of CVL218 against SARS-CoV-\\n\\n2, we also performed a time-of-addition assay (Methods) to determine at which stage\\n\\nCVL218 inhibits viral infection. Remdesivir, which has entered the clinical trials for\\n\\nthe treatment of COVID-19 (https://clinicaltrials.gov/ct2/show/NCT0425765\\n\\n6), was also tested in this assay for comparison. In particular, as compared to the\\n\\nDMSO control group, both CVL218 and remdesivir showed potent antiviral activities\\n\\nduring the full-time procedure of the SARS-CoV-2 infection in Vero E6 cells (Fig-\\n\\nure 2D). The results of the time-of-addition assay indicated that CVL218 can partially\\n\\nwork against the viral entry and significantly inhibit the replication of virus post-entry,\\n\\nwhile the remdesivir can only function at the post-entry stage (Figure 2D, 2E). All\\n\\ntogether, the results of these in vitro assays indicated that CVL218 can be further\\n\\nevaluated as a potential therapeutic agent for treating COVID-19.\\n\\n2.4. CVL218 inhibits IL-6 production in PBMCs induced by CpG-ODN 1826\\n\\nRecently it has become evident that interleukin-6 (IL-6) is one of the most impor-\\n\\ntant cytokines during viral infection [19], and emerging clinical studies in humans and\\n\\nanimals have linked the excessive synthesis of IL-6 with the persistence of many viruses,\\n\\nsuch as human immunodeficiency virus (HIV) [20], foot and mouth disease virus [21]\\n\\nand vesicular stomatitis virus (VSV) [22]. In addition, an in vivo study in the Friend\\n\\nretrovirus (FV) mouse model showed that IL-6 blockage can reduce viral loads and en-\\n\\nhance virus-specific CD8+ T-cell immunity [23]. These findings supported a hypothesis\\n\\nthat rapid production of IL-6 might be a possible mechanism leading to the deleteri-\\n\\nous clinical manifestations in viral pathogenesis [24]. Recently published researches on\\n\\nthe clinical characteristics of severe patients with SARS-CoV-2 infection showed that\\n\\nIL-6 was significantly elevated especially in those ICU patients, which caused excessive\\n\\nactivated immune response [25, 26, 27, 28, 29]. The pathological role of IL-6 in SARS-\\n\\nCoV-2 infection indicated that IL-6 blockade may provide a feasible therapy for the\\n\\ntreatment of COVID-19.\\n\\nTo test whether CVL218 is able to regulate the IL-6 production in vitro, we stim-\\n\\nulated the IL-6 production of the peripheral blood mononuclear cells (PMBCs) by\\n\\nCpG-ODN 1826, which is an effective stimulator of cytokines and chemokines. Incuba-\\n\\ntion of PBMCs with 1 µM CpG-ODN 1826 for 6 h (Methods) induced IL-6 production\\n\\nby 40%, when compared to untreated cells (Figure 3). In the presence of CVL218,\\n\\nthe stimulatory effect of CpG-ODN 1826 was counteracted. Further study showed that\\n\\nCVL218 inhibited the CpG-induced IL-6 upregulation in a time- and dose-dependent\\n\\nmanner (Figure 3). More specifically, exposure with CVL218 at concentrations 1 µM\\n\\nand 3 µM for 12 h attenuated the CpG-induced IL-6 production by 50% and 72.65%,\\n\\nrespectively. These results provided an in vitro evidence to support CVL218 as a poten-\\n\\ntial therapeutic agent for treating pro-inflammatory response caused by SARS-CoV-2\\n\\ninfection.\\n\\n2.5. CVL218 possesses good pharmacokinetic and toxicokinetic characteristics in ani-\\n\\nmals\\n\\n2.5.1. CVL218 has the highest tissue distribution in lung of rats\\n\\nWe further performed in vivo pharmacokinetic and toxicokinetic evaluation of CVL218\\n\\nin animals (Methods). We first examined the concentrations of CVL218 over different\\n\\ntissues in rats at different time points post oral administration at different doses (Fig-\\n\\nure S2 and Table S2), which was also previously reported in [30]. Among seven tissues\\n\\n(i.e., lung, spleen, liver, kidney, stomach, heart and brain), we observed that lung\\n\\nhad the highest CVL218 concentration, which was 188-fold higher compared to that of\\n\\nplasma (Table 3). The observation that lung had the highest concentration of CVL218\\n\\nwas in line with the fact that the SARS-CoV-2 virus has the most pathological impact\\n\\nin lung with high viral loads, which suggested that CVL218 has the potential to be used\\n\\nfor the indications of the lung lesions caused by SARS-CoV-2 infection, if its antiviral\\n\\nprofile can be established in animal models and clinical trials.\\n\\nFurthermore, we compared the pharmacokinetic data between CVL218 and arbidol,\\n\\na broad-spectrum antiviral drug commercialized in China since 2016, had been recom-\\n\\nmended to treat the SARS-CoV-2-infected patients by the Chinese government. We\\n\\nfound that the pharmacokinetic parameters of CVL218 and arbidol were comparable,\\n\\nwith similar plasma concentrations and drug exposures (Table S3). Arbidol was mostly\\n\\ndistributed in stomach and plasma post administration in rats. In contrast, higher\\n\\ndistributions of CVL218 in tissues especially in lung rather than plasma compared to\\n\\nthose of arbidol indicated a superior pharmacokinetic profile of CVL218, which may\\n\\nrender it as a better potential antiviral treatment of SARS-CoV-2 infection in lung.\\n\\n2.5.2. The toxicity study demonstrated a safety profile of CVL218 in rats\\n\\nIn rats after being orally administrated 20/60/160 mg/kg of CVL218 for 28 consec-\\n\\nutive days and followed by 28 more days without drug administration (Methods), we\\n\\nobserved no significant difference in body weight of rats among different dosage and the\\n\\ncontrol groups (Figure 4A).\\n\\nWe next conducted a toxicokinetic analysis of CVL218 in rats (Methods). In par-\\n\\nticular, rats were given CVL218 20/60/160 mg/kg by oral gavage once a day for con-\\n\\nsecutive 28 days, followed by 28 days without CVL218 administration, to investigate\\n\\nthe reversibility of the toxic effects of the compound and examine whether there is\\n\\nany potential delayed-onset toxicity of this drug in rats. The results showed that, the\\n\\nmaximum tolerable dose (MTD) and the no-observed adverse effect level (NOAEL)\\n\\nwere 160 mg/kg and 20 mg/kg, respectively. The exposure of female rats to CVL218\\n\\n(AUC0-24) was 7605 h·ng/mL in day 1 and 6657 h·ng/mL in day 28, while that of male\\n\\nrats (AUC0-24) was 9102 h·ng/mL in day 1 and 10253 h·ng/mL in day 28 (Table S4).\\n\\nBased on the toxicokinetic results from the repeated dose studies, all rats survived after\\n\\na 28-day treatment period and showed no apparent signs of toxicity.\\n\\n2.5.3. CVL218 exhibits a favorable safety profile in monkeys\\n\\nMonkeys were administered CVL218 (5, 20 or 80 mg/kg) by nasogastric feeding\\n\\ntubes with a consecutive daily dosing schedule for 28 days, followed by a 28-day recovery\\n\\nperiod (Methods). Only a slight decrease of body weight was observed in the high-\\n\\ndose (80 mg/kg) group, and all changes were reversed after a 28-day recovery period\\n\\n(Figure 4B), demonstrating a favorable safety profile for CVL218 in monkeys. Further\\n\\nexamination of the toxicokinetic data of CVL218 in monkeys showed that the increase\\n\\nof the exposure of CVL218 (AUC0-24) was approximately dose proportional, and after\\n\\nconsecutive 28 days of drug administration, the accumulation was not apparent. The\\n\\nexposure of female monkeys to CVL218 (AUC0-24) was 19466 h·ng/ml in day 1 and\\n\\n18774 h·ng/ml in day 28 (Table S5), while that of male monkeys (AUC0-24) was 16924\\n\\nh·ng/ml in day 1 and 22912 h·ng/ml in day 28. The maximum tolerable dose (MTD)\\n\\nof CVL218 in monkeys was 80 mg/kg, and the dose of 5 mg/kg was considered as the\\n\\nno-observed adverse effect level (NOAEL).\\n\\nOverall, the above in vivo data showed that CVL218 possesses good pharmacokinetic\\n\\nand toxicokinetic characteristics in rats and monkeys, and its high-level distribution in\\n\\nthe therapeutically targeted tissue (i.e., lung) may greatly favor the treatment of SARS-\\n\\nCoV-2 infection.\\n\\n2.6. Molecular docking suggests the interactions between PARP1 inhibitors and the N-\\n\\nterminal domain of coronavirus nucleocapsid protein\\n\\nAs the previous studies have reported that the PARP1 inhibitor PJ-34 can target\\n\\nthe N-terminal domain (NTD) of the coronavirus nucleocapsid (N) protein to reduce its\\n\\nRNA binding and thus impede viral replication [31, 32, 33], we speculated that olaparib\\n\\nand CVL218 may also interact with the N protein of SARS-CoV-2 to perform the similar\\n\\nantiviral function. To test this hypothesis, we conducted molecular docking to study\\n\\nthe potential interactions between these two drugs and the N-NTD of SARS-CoV-2\\n\\n(Methods).\\n\\nThe overall structure of HCoV-OC43 (another coronavirus phylogenetically closely\\n\\nrelated to SARS-CoV-2) and SARS-CoV-2 share similar compositions of secondary\\n\\nstructure elements, including five conserved  strands and flexible loops (Figure 5A).\\n\\nIn addition, their sequences covering the corresponding binding pocket regions are well\\n\\nconserved (Figure 5C). Thus, their structures may provide common molecular features\\n\\nin terms of interactions with small molecules at this binding pocket. Therefore, we\\n\\nalso used the experimentally solved structure of HCoV-OC43-N-NTD complexed with\\n\\nPJ-34 as a reference to analyze our docking results.\\n\\nOur docking results (more details can also be found in Supplementary Materials)\\n\\nshowed that both CVL218 and olaparib can bind to the N-NTD of SARS-CoV-2 around\\n\\nthe same binding pocket as in the experimentally solved complex structure between PJ-\\n\\n34 and the corresponding protein of HCoV-OC43, though with different binding poses\\n\\n(Figure 5B). Examination of docked structures indicated that CVL218 exhibits stronger\\n\\nbinding ability than olaparib in terms of the hydrogen bond formation. Meanwhile, the\\n\\nkey residues (i.e., S51, Y109 and Y111) participating in the binding with the drugs on\\n\\nSARS-CoV-2-N-NTD are also highly conserved among other viruses including SARS-\\n\\nCoV, HCoV-OC43, mouse hepatitis virus (MHV) and infectious bronchitis virus (IBV)\\n\\n(Figure 5C), suggesting that the N-NTDs of different viruses most likely display similar\\n\\nbinding behaviors for PJ-34, CVL218 or other PARP1 inhibitors. Overall, our docking\\n\\nresults indicated that CVL218 should be more effective in binding toward the nucleo-\\n\\ncapsid protein of SARS-CoV-2 compared to olaparib, thus better beneficial to intervene\\n\\nthe nucleocapsid-dependent assembly of viral genome and thus inhibit viral replication.\\n\\n3. Discussion\\n\\nIn this study we reported a top down data integration approach by combining both\\n\\nmachine learning and statistical analysis techniques, followed by web-lab experimental\\n\\nvalidation, to identify potential drug candidates for treating SARS-CoV-2 infection. We\\n\\nshowed that the PARP1 inhibitor CVL218 discovered by our in silico drug repurposing\\n\\nframework may have the therapeutic potential for the treatment of COVID-19. Al-\\n\\nthough we mainly conducted in vitro assays to experimentally validate the anti-SARS-\\n\\nCoV-2 effects of olaparib and CVL218 due to limited time, it is natural to speculate\\n\\nthat other PARP1 inhibitors may also have antiviral activities against SARS-CoV-2\\n\\ninfection, based on our computational prediction and experimental validation results.\\n\\nBased on the data present in this study and the previously known evidences re-\\n\\nported in the literature, we propose several potential mechanisms to help understand\\n\\nthe involvement of PARP1 inhibitors in the treatment of COVID-19 (Figure 6). First,\\n\\nduring the life cycle of the coronavirus, PARP1 inhibitors may inhibit the viral growth\\n\\nthrough suppressing viral replication and impeding the binding of the nucleocapsid\\n\\nprotein to viral RNAs [31, 34, 35, 36], which can also be supported by our molecular\\n\\ndocking results (see Section 2.6). Second, PARP1 inhibitors have been previously re-\\n\\nported to play a critical role in regulating inflammatory response by modulating the\\n\\nexpression of pro-inflammatory factors such as NF-B, AP-1, IL-6 and downstream\\n\\ncytokines and chemokines [37, 38, 39, 40]. Also, it has been shown that the overacti-\\n\\nvation of PARP1 promotes energy (NAD+\\n\\n/ATP) consumption and drives cell death,\\n\\nexacerbating the inflammation response [37, 38, 39, 41]. PARP1 inhibitors thus may\\n\\nrepress the NF-B-mediated pro-inflammatory signals, and reduce energy failure and\\n\\nsubsequent cell death induced by necrosis, thus providing a clinical potential for attenu-\\n\\nating the cytokine storm and inflammatory response caused by SARS-CoV-2 infection.\\n\\nThird, ADP-ribosylation is a conserved post-translational modification on the nucle-\\n\\nocapsid proteins across different coronavirus lineages, implying that it may have an\\n\\nimportant regulatory role for the structure packing of viral genome. Several previous\\n\\nstudies have demonstrated that PARP1 is critical for viral replication [35, 42, 43]. For\\n\\nexample, PARP1 has been reported to interact with hemagglutinin (HA) of influenza A\\n\\nvirus (IAV) and promote its replication by triggering the degradation of host type I IFN\\n\\n12\\n\\nreceptor [44]. In addition, the ADP-ribosylation of adenoviral core proteins displays an\\n\\nantiviral defense mechanism [34]. Therefore, intervening the ADP-ribosylation medi-\\n\\nated interplay between PARP1 and viral proteins may be another important pathway\\n\\nfor PARP1 inhibitors to prevent SARS-CoV-2 infection. Of course, to throughly un-\\n\\nderstand the anti-SARS-CoV-2 roles of PARP1 inhibitors, more experimental studies\\n\\nand direct (clinical) evidences will be needed in the future.\\n\\nConsidering the pro-inflammatory role of PARP1, the therapeutic effects of PARP1\\n\\ninhibitors in inflammatory-mediated diseases have been extensively studied over past\\n\\ntwo decades [45, 46]. PJ-34, the early generation PARP1 inhibitor, has been suggested\\n\\nin previous studies to have neuroprotective effects in stroke model and protect mice\\n\\nfrom necroptosis-associated liver injuries by repressing the IL-33 expression [47, 48].\\n\\nIn addition, the FDA-approved PARP1 inhibitor, olaparib, has been reported to pro-\\n\\ntect against the LPS (Lipopolysaccharide)-induced acute lung and kidney injuries in\\n\\na NF-B-dependent manner in mice [49]. Numerous pre-clinical studies demonstrated\\n\\nthat PARP1 inhibitors play an essential role in a range of inflammatory injuries and\\n\\nrelated diseases, especially the lung inflammatory disorders including ARDS (Acute\\n\\nRespiratory Distress Syndrome), COPD (Chronic Obstructive Pulmonary Disease) and\\n\\nasthma [40, 46, 50, 51]. All these studies suggest that PARP1 inhibitors are of high\\n\\nrelevance to the treatment of the novel pneumonia caused by SARS-CoV-2 infection,\\n\\npossibly via their roles in modulating inflammatory response.\\n\\nNotably, current pathological studies have shown that the severe patients infected by\\n\\nSARS-CoV-2 generally have higher plasma levels of IL-2, IL-6, IL-10, TNF, IFN- [25,\\n\\n27, 28, 29], implying a high risk of the inflammatory-associated cytokine storm after vi-\\n\\nral infection. In addition, reduction and functional exhaustion of T cells have also been\\n\\nobserved in COVID-19 patients [27]. Therefore, blocking the overactive inflammatory\\n\\nresponse may be an effective strategy for the treatment of COVID-19, particularly for\\n\\nthose ICU patients infected by SARS-CoV-2. Recently, tocilizumab, a monoclonal anti-\\n\\n13\\n\\nbody drug targeting IL-6, has been recommended for the treatment of COVID-19 in the\\n\\nDiagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)\\n\\n2003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8c\\n\\ne964.pdf), which also highlights the vital role of anti-inflammatory response in current\\n\\ntherapeutics against SARS-CoV-2. Our in vitro study has showed that CVL218 can\\n\\neffectively inhibit the IL-6 production induced by CpG in PBMCs (Figure 3). This\\n\\nfinding indicates that CVL218 may also possess the IL-6 specific anti-inflammatory\\n\\neffect that is applicable to those severe patients infected by SARS-CoV-2.\\n\\nPARP1 inhibitors are originally used for targeting homologous recombination repair\\n\\ndefects in cancers, and mainly categorized as oncology drugs. Thus, it would generally\\n\\nneed more safety data to justify any repurposing of PARP1 inhibitors for non-oncology\\n\\nindications. Fortunately, there are numerous existing pre-clinical and clinical studies\\n\\non repurposing PARP1 inhibitors into non-oncological diseases, including the aforemen-\\n\\ntioned acute diseases (e.g., acute respiratory distress syndrome (ARDS), stroke) [52]\\n\\nand chronic diseases (e.g., rheumatoid arthritis and vascular diseases) [52, 53]. All these\\n\\nevidences indicate the possibility of repurposing PARP1 inhibitors as a safe therapeu-\\n\\ntic agent to treat the current acute lung disease caused by SARS-CoV-2 infection. In\\n\\naddition, our pharmacokinetic and toxicokinetic data in rats and monkeys shown in\\n\\nour study indicate that CVL218 may have a relatively acceptable safety profile to be\\n\\nrepositioned for the antiviral purpose. Moreover, CVL218 has been approved to enter\\n\\nPhase I clinical trial in 2017 by National Medical Products Administration (NMPA)\\n\\nin China for cancer treatment. The preliminary data from the Phase I clinical trial\\n\\nhave shown that CVL218 is well tolerated in ascending dose studies at doses as high as\\n\\n1000 mg QD and 500 mg BID, and no Grade II and above adverse events have been\\n\\nobserved, which indicates that CVL218 is also quite safe and well tolerated in human.\\n\\nOur pharmacokinetic examination in rats has shown that CVL218 has the highest\\n\\n14\\n\\nlevel distribution in the lung tissue, 188-fold higher concentration compared to that\\n\\nin plasma. Such a tissue specific enrichment in lung may bring an extra advantage\\n\\nfor CVL218 to be used for the anti-SARS-CoV-2 purpose, as lung is the therapeuti-\\n\\ncally targeted tissue for COVID-19. Moreover, high level distribution in lung may also\\n\\nsuggest that only low dosage is needed in order to ensure the therapeutic efficacy of\\n\\nCVL218 against SARS-CoV-2, which may further reduce the risk of adverse events.\\n\\nThus, CVL218 may have great potential to be repurposed as an effective therapeutic\\n\\nagent to combat SARS-CoV-2 and prevent future epidemic outbreak.\\n\\n15\\n\\n4. Methods\\n\\n4.1. Construction of the virus-related knowledge graph\\n\\nThe virus-related knowledge graph was constructed for predicting the coronavirus\\n\\nrelated drugs. In total seven networks were considered in the constructed knowl-\\n\\nedge graph (Figure 1B), including a human target-drug interaction network, a virus\\n\\ntarget-drug interaction network, a human protein-protein interaction network, a virus\\n\\nprotein-human protein interaction network, a drug molecular similarity network, a\\n\\nhuman protein sequence similarity network, and a virus protein sequence similarity\\n\\nnetwork. The human target-drug interaction network was derived from DrugBank\\n\\n(version 5.1.0) [17]. The virus target-drug interaction network was constructed from\\n\\nthe integrated data from DrugBank (version 5.1.0) [17], ChEMBL (release 26) [54],\\n\\nTTD (last update 11 Nov, 2019) [55], IUPHAR BPS (release 13, Nov, 2019) [56],\\n\\nBindindDB [57] and GHDDI (https://ghddi-ailab.github.io/Targeting2019-nCo\\n\\nV/CoV_Experiment_Data/), with a cut-off threshold of IC50/EC50/Ki/Kd <10 µM. The\\n\\nhuman protein-protein interaction network and the virus protein-human protein in-\\n\\nteraction network were constructed from the integrated data from BioGRID (release\\n\\n3.5.181) [58], HuRI [59], Instruct [60], MINT (2012 update) [61], PINA (V2.0) [62],\\n\\nSignaLink (V2.0) [63] and innatedb [64]. The drug molecular similarity network was\\n\\nobtained by calculating the Tanimoto similarities from Morgan fingerprints with a ra-\\n\\ndius of 2 computed using the rdkit tool [65]. The protein sequence similarity networks\\n\\nof both human and virus were obtained by calculating the Smith-Waterman similari-\\n\\nties of the amino acid sequences derived from UniProt [66] using a sequence alignment\\n\\nsoftware provided in [67]. Noted that we collected additional protein sequences of\\n\\nSARS-CoV-2 from UniProt [66] and added them into the corresponding networks for\\n\\nthe final prediction. Those drugs without drug-target interactions or outside the Drug-\\n\\nBank database were removed from the corresponding networks. We then constructed\\n\\nthe virus-related knowledge graph by merging together all the nodes and edges of the\\n\\n16\\n\\nabove seven networks (Figure 1B). The constructed knowledge graph G = (V, E) is an\\n\\nundirected graph, in which each node v  V in the node set V belongs to one of the\\n\\nnode types (including drugs, human proteins, and virus proteins), and each edge e  E\\n\\nin the edge set E  V × V × R belongs to one of the relation types from the relation\\n\\ntype set R (including two drug-target interactions, two protein-protein interactions and\\n\\nthree similarities).\\n\\n4.2. The network-based knowledge mining algorithm\\n\\nThe initial list of drug candidates targeting SARS-CoV-2 was first screened using a\\n\\nnetwork-based knowledge mining algorithm modified from our previous work [68, 69].\\n\\nThe goal was to capture the hidden virus-related feature information and accurately\\n\\npredict the potential drug candidates from the constructed knowledge graph, which was\\n\\nrealized through learning a network topology-preserving embedding for each node.\\n\\nMore specifically, our model used a graph convolution algorithm [70] to gather and\\n\\nupdate feature information for each node in the constructed heterogeneous knowledge\\n\\ngraph network from neighborhoods so that the network topology information can be\\n\\nfully exploited. Suppose that we perform T iterations of graph convolution. At iteration\\n\\n1  t  T, the message mt\\n\\nv passed to node v can be expressed as:\\n\\nmt\\n\\nv =\\n\\nrR uNr(v),\\n\\ne=(u,v,r)E\\n\\nAu,v,rReLU(W t\\n\\nr ht-1\\n\\nu + bt\\n\\nr), (1)\\n\\nwhere av,u,r stands for the weight for edge e = (u, v, r), Au,v,r = av,u,r\\n\\nu av,u,r\\n\\n, W t\\n\\nr  Rd×d\\n\\nand bt\\n\\nr  Rd\\n\\nstand for the learnable parameters, ReLU(x) = max(0, x), and Nr(v) =\\n\\n{u, u  V, u = v, (u, v, r)  E} denotes the set of adjacent nodes connected to v  V\\n\\nthrough edges of type r  R.\\n\\nThen the feature ht\\n\\nv of node v is updated by\\n\\nht\\n\\nReLU(W t\\n\\nconcat(ht-1\\n\\nv , mt\\n\\nv) + ht-1\\n\\nv + bt\\n\\n)\\n\\n||ReLU(W tconcat(ht-1\\n\\nv + bt)||2\\n\\n, (2)\\n\\n17\\n\\nwhere W t\\n\\n Rd×d\\n\\n Rd\\n\\nstand for the learnable parameters, and concat(·, ·)\\n\\nstands for the concatenation operation.\\n\\nFinally, the confidence score su,v of the relation r between node u and node v is\\n\\nderived from the learned node embeddings and the corresponding projection matrices,\\n\\nthat is,\\n\\nsu,v = ht\\n\\nu · Gr · Hr · ht\\n\\nv, (3)\\n\\nwhere Gr, Hr  Rd×k\\n\\nstand for the edge-type specific projection matrices.\\n\\nWe minimized the Bayesian personalized ranking (BPR) loss [71] for drug-target\\n\\ninteraction reconstruction, by regarding those edges not in the edge set E as missing\\n\\nvalues rather than negative samples, that is,\\n\\nrR u,v,w,xV,\\n\\n(u,v,r)E,\\n\\n(w,x,r)/E\\n\\n- log (su,v - sw,x) , (4)\\n\\nwhere, su,v and sw,x stand for the confidence scores of the relation r between u and v\\n\\nand between w and x, respectively, and (·) stands for the sigmoid activation function.\\n\\nIntuitively, in the above loss function, the confidence scores of the node pairs (u, v) in\\n\\nthe edge set (i.e., (u, v, r)  E) were encouraged to be higher than those of unseen pairs\\n\\n(w, x) (i.e., (w, x, r) / E).\\n\\nWe predicted the confidence scores under the relation of virus target-drug interac-\\n\\ntions for each virus target-drug pair using Equation (3). Then the confidence scores\\n\\nwere averaged across all the proteins of a certain virus (e.g., SARS-CoV, MERS-CoV\\n\\nor SARS-CoV-2), and the corresponding p-values were obtained by z-test. For each\\n\\nvirus, we selected those predictions with a p-value < 0.05 as drug candidates.\\n\\n4.3. Automated relation extraction from large-scale literature texts\\n\\nWe used a deep learning based relation extraction method named BERE [4] to\\n\\nextract the coronavirus related drugs from large-scale literature texts. More specifically,\\n\\n18\\n\\nthe sentences mentioning the two entities of interest, i.e., name (or alias) of a coronavirus\\n\\nor coronavirus target, or name (or alias) of a drug, were first collected using a dictionary-\\n\\nbased name entity recognition method (string matching). For each pair of entities\\n\\n(e1, e2), there are usually more than one sentence describing the underlying relations.\\n\\nTherefore, we used a bag of sentences Se1,e2 , denoting the set of all the sentences\\n\\nmentioning both e1 and e2, to predict the relation between these two entities.\\n\\nWe first encoded each sentence s  Se1,e2 in a semantic and syntactic manner using\\n\\na hybrid deep neural network (h : s  Rd\\n\\n), including a self-attention module [72], a bi-\\n\\ndirectional gated recurrent unit (GRU) module [73] and a Gumbel tree-GRU module [4,\\n\\n74]. Each sentence representation h(s) was then scored by a sentence-level attention\\n\\nmodule to indicate its contribution to the relation prediction, that is,\\n\\n(s) =\\n\\nexp (Ws · h(s))\\n\\ns Se1,e2\\n\\nexp (Ws · h(s ))\\n\\n, (5)\\n\\nwhere (s)  R stands for the weight score, and Ws  Rd×1\\n\\nstands for the learnable\\n\\nweight parameters. Finally, the relation was predicted by a binary classifier, based on\\n\\nthe weighted sum of sentence representations, that is,\\n\\nre1,e2 = classifier\\n\\nsSe1,e2\\n\\n(s) · h(s) , (6)\\n\\nwhere re1,e2 stands for the probability of the relation of interest between entities e1 and\\n\\ne2 mentioned by the bag of sentences Se1,e2 .\\n\\nThe training corpus we used was curated automatically from nearly 20 million\\n\\nIn detail, the names (or aliases) of drugs or targets in sentences were first annotated\\n\\nby a dictionary-based named entity recognition method (string matching), in which\\n\\nthe name dictionary was derived from DrugBank (version 5.1.0) [17], with ambiguous\\n\\nnames (e.g., common words) removed. Next, the label for each bag of sentences co-\\n\\n19\\n\\nmentioning a drug-target pair of interest was annotated automatically by the known\\n\\ndrug-target interactions in DrugBank. The unlabeled corpus that we used in this work\\n\\nfor text-mining the coronavirus related drugs was obtained from approximately 2.2 mil-\\n\\nlion PMC full-text articles, with entities of interest annotated using the aforementioned\\n\\nnamed entity recognition approach. A coronavirus related drug was extracted as a hit\\n\\ncandidate if the model found a bag of sentences describing a relation between this drug\\n\\nand a target in the coronavirus of interest.\\n\\n4.4. Connectivity map analysis\\n\\nWe used the transcriptome analysis approach to further filter the potential drug\\n\\ncandidates for treating the COVID-19 patients infected by SARS-CoV-2. Due to the\\n\\nlack of gene expression data from the SARS-CoV-2 infected patients, we used those from\\n\\nthe SARS-CoV infected patients to screen the potential therapeutic drug candidates\\n\\nagainst COVID-19. Such a strategy is reasonable as SARS-CoV and SARS-CoV-2\\n\\nare two closely related and highly similar coronavirus. First, the genome of SARS-\\n\\nCoV-2 is phylogenetically close to that of SARS-CoV, with about 79% of sequence\\n\\nidentity [76], and the M (membrane), N (nucleocapsid) and E (envelope) proteins of\\n\\nthese two coronaviruses have over 90% sequence similarities [77]. In addition, the\\n\\npathogenic mechanisms of SARS-CoV-2 and SARS-CoV were highly similar [78].\\n\\nIn particularly, we collected the gene expression profiles of the peripheral blood\\n\\nmononuclear cells (PBMCs) from ten SARS-CoV infected patients (GEO:GSE1739) [6].\\n\\nThe raw gene expression values were first converted into logarithm scale, and then the\\n\\ndifferential expression values (z-scores) were computed by comparing to those of healthy\\n\\npersons using the same protocol as described in [5], that is,\\n\\nZinfected =\\n\\nXinfected - median(Xhealthy)\\n\\nC · MAD(Xhealthy)\\n\\n, (7)\\n\\nMAD(Xhealthy) =median(|Xhealthy - median(Xhealthy)|), (8)\\n\\n20\\n\\nwhere Zinfected stands for the z-scores of the SARS-CoV infected patients, Xinfected\\n\\nand Xhealthy stand for the gene expression values in logarithm scale of the infected\\n\\nand healthy persons, respectively, median(·) stands for the median operation, MAD(·)\\n\\nstands for the median absolute deviation operation, and C = 1.4826 is a constant for\\n\\nnormalization. The p-values for all the genes with measured expression values during\\n\\nthe analysis were also computed based on the z-scores. The up- and down-regulated\\n\\ngenes were then identified using a cut-off threshold of p-value < 10-10\\n\\n. We used the\\n\\nconnectivity map (CMap) [5], which contains the cellular gene expression profiles under\\n\\nthe perturbation of 2428 well annotated reference compounds, to measure the associa-\\n\\ntions of gene expression patterns between SARS-CoV infected patients and the reference\\n\\ncompound-perturbed cells. The connectivity map scores were computed based on the\\n\\nup- and down-regulated gene sets of SARS-CoV infected patients using the web tool\\n\\n(https://clue.io/query). Under the hypothesis that the gene expression pattern\\n\\nresulting from the perturbation by a therapeutic compound should be negatively corre-\\n\\nlated with that resulting from the coronavirus infection, we selected those compounds\\n\\nthat have significant negative connectivity map scores, that is, the list of drug can-\\n\\ndidates predicted to treat the coronavirus infected patients was obtained by selecting\\n\\nthe compounds with the connectivity map scores < -90, which was suggested by the\\n\\noriginal paper [5].\\n\\n4.5. Cells and virus\\n\\nThe African green monkey kidney Vero E6 cell line was purchased from the Cell\\n\\nResources Center of Shanghai Institute of Life Science, Chinese Academy of Sciences\\n\\n(Shanghai, China) and cultured in DMEM medium (Gibco Invitrogen, no. 12430-054)\\n\\ncontaining 10% fetal bovine serum (FBS; Gibco Invitrogen) at 37 \\n\\nC with 5% CO2 at-\\n\\nmosphere. BetaCoV/JS03/human/2020 (EPI ISL 411953), a SARS-CoV-2 virus strain,\\n\\nwas isolated from nasopharyngeal swab of a 40-year old female confirmed as COVID-19\\n\\ncase by reverse transcriptase polymerase chain reaction (RT-PCR) in December 2019.\\n\\n21\\n\\nThe virus was propagated in Vero E6 cells, and the viral titer was determined by the\\n\\n50% tissue culture infective dose (TCID50) based on microscopic observation of cyto-\\n\\npathic effects. All the in vitro SARS-CoV-2 infection experiments were performed in a\\n\\nbiosafety level-3 (BLS-3) laboratory in Jiangsu Provincial Center for Diseases Control\\n\\nand Prevention, Jiangsu, China.\\n\\n4.6. Antiviral drugs\\n\\nPotential antiviral drugs, including zanamivir, oseltamivir, remdesivir, baricitinib,\\n\\nolaparib and arbidol, were all provided by MCE (Medchem Express, China). The\\n\\nPARP1 inhibitor mefuparib hydrochloride (CVL218) with a purity of more than 99.0%\\n\\nwas provided by Convalife, Shanghai, China.\\n\\n4.7. Cytotoxicity test and virus infection assay\\n\\nThe cytotoxicity of the tested drugs on Vero E6 cells was determined by the CCK8\\n\\nassays (Beyotime, China). At 48 h post addition of the tested drugs, 20 µL CCK8\\n\\nwas added to each well and incubated at 37 \\n\\nC for 1 h. Then optical density was\\n\\nmeasured at 450 nm. The 50% cytotoxic concentration (CC50) values were calculated\\n\\nusing GraphPad Prism (GraphPad Software, USA). Vero E6 cells were seeded into\\n\\n96-well plates with a density of 5 × 104\\n\\ncells/well for incubation in DMEM medium\\n\\nsupplemented with 10% FBS for 16 h in an incubator with 5% CO2 at 37 \\n\\nC, for cells\\n\\nto reach 80% confluent. Then, cell culture medium of each well was removed, and PBS\\n\\nwas used to wash the cells once, before evaluating the antiviral efficacy of the drugs.\\n\\nFour duplicated wells were made for each dose of drugs, and the cells were pre-treated\\n\\nwith different doses of antiviral drugs diluted by the cell maintenance solution (50 µL\\n\\nper well) for 1 h. For the virus control and cell control wells, cell medium containing\\n\\nDMSO or only medium of 50 µL per well was added. Next, pre-treated or untreated\\n\\ncells in each well were infected with the virus with multiplicity of infection (MOI) of\\n\\n0.05 for 2 h. After that, the virus-drug mixture was removed and cells were further\\n\\n22\\n\\ncultured with fresh drug-containing medium at 37 \\n\\nC with 5% CO2 atmosphere for 48\\n\\nh. Then culture supernatant per well was harvested and inactivated at 56 \\n\\nC for 30\\n\\nmin to further extract and quantify viral RNA.\\n\\n4.8. Viral RNA extraction and quantitative real-time PCR (qRT-PCR)\\n\\nViral RNA was extracted from culture supernatant using the HP RNA Isolation\\n\\nKit (Roche) according to the manufacturer\\'s instructions. RNA was eluted in 30 µL\\n\\nRNase-free water. Reverse transcription was performed with a SARS-CoV-2 nucleic\\n\\nacid detection kit (BioGerm, China) according to the manufacturer\\'s instructions. The\\n\\nPCR reaction system was configured as follows: 6 µL of qRT-PCR reaction solution, 2\\n\\nµL of qRT-PCR enzyme mixture, 2 µL of primer probe and 2.5 µL of template, and the\\n\\nreaction was performed as follows: 50 \\n\\nC for 10 min, 95 \\n\\nC for 5 min, followed by 40\\n\\ncycles of 95 \\n\\nC for 10 s, 55 \\n\\nC for 40 s. The values of 2-CT\\n\\nwere calculated according\\n\\nto the CT value measured from the PCR instrument, to represent the relative virus\\n\\ncopies of the drug group to the control group. The virus replication inhibition rate (%)\\n\\nwas calculated as (1-2-CT\\n\\n)×100%. The dose-response curves were plotted according\\n\\nto viral RNA copies and the drug concentrations using GraphPad Prism (GraphPad\\n\\nSoftware, USA).\\n\\n4.9. Time-of-addition assay\\n\\nTo facilitate the observation of the antiviral effects of drugs against SARS-CoV-2\\n\\nat different timing, relative high doses of the tested drugs (CVL218 at 20 µM and\\n\\nremdesivir at 10µM) were used for the time-of-addition assay. Vero E6 cells with a\\n\\ndensity of 5 × 104\\n\\ncells per well were treated with the tested drugs, or DMSO as\\n\\ncontrols at different stages of virus infection. The cells were infected with virus at an\\n\\nMOI of 0.05. The \"Full-time\" treatment was to evaluate the maximum antiviral effects,\\n\\nwith the tested drugs in the cell culture medium during the whole experiment process,\\n\\nwhich was consistent with the descriptions in the virus infection assay. For the \"Entry\"\\n\\n23\\n\\ntreatment, the tested drug was added to the cells for 1 h before virus infection, and\\n\\nthen cells were maintained in the drug-virus mixture for 2 h during the virus infection\\n\\nprocess. After that, the culture medium containing both virus and the tested drug\\n\\nwas replaced with fresh culture medium till the end of the experiment. For the \"Post-\\n\\nentry\" experiment, virus was first added to the cells to allow infection for 2 h before the\\n\\nvirus-containing supernatant was replaced with drug-containing medium until the end\\n\\nof the experiment. At 14 h post infection, the viral inhibition in the cell supernatants\\n\\nof the tested drug was quantified by qRT-PCR, and calculated using the DMSO group\\n\\nas reference.\\n\\n4.10. Indirect immunofluorescence assay\\n\\nVero E6 cells were treated with CVL218 at 5 µM, 15 µM and 25 µM, respectively,\\n\\nfollowing the same procedure of \"full-time\" treatment. Infected cells were fixed with\\n\\n80% acetone in PBS and permeabilized with 0.5% Triton X-100, and then blocked with\\n\\n5% BSA in PBS buffer containing 0.05% Tween 20 at room temperature for 30 min.\\n\\nThe cells were further incubated with a rabbit polyclonal antibody against a SARS-CoV\\n\\nnucleocapsid protein (Cambridgebio, USA) as primary antibody at a dilution of 1:200\\n\\nfor 2 h, followed by incubation with the secondary Alexa 488-labeled goat anti-rabbit\\n\\nantibody (Beyotime, China) at a dilution of 1:500. Nuclei were stained with DAPI\\n\\n(Beyotime, China). Immunofluorescence was observed using fluorescence microscopy.\\n\\n4.11. Western blot assay\\n\\nNP expression in infected cells was analyzed by Western blot. Protein samples were\\n\\nbranes (Millipore, USA), before being blocked with 6% Rapid Block Buff II (Sangon\\n\\nBiotech, China) at room temperature for 10 min. The blot was probed with the anti-\\n\\nbody against the viral nucleocapsid protein (Cambridgebio, USA) and the horseradish\\n\\nperoxidase-conjugated Goat Anti-Rabbit IgG (Abcam, USA) as the primary and the\\n\\n24\\n\\nsecondary antibodies, respectively. Protein bands were detected by chemiluminescence\\n\\nusing an ECL kit (Sangon Biotech, China).\\n\\n4.12. CpG-PDN1826 induced IL-6 production in PBMCs\\n\\nPeripheral blood mononuclear cells (Yicon, China) were cultured at 37 \\n\\nC at con-\\n\\ncentration 5% CO2 atmospheric on a 96-well plate in RPMI1640 cell growth medium\\n\\n(Corning, Cat.10-040-CVR). For stimulation, PBMC cells were incubated with 1 µM\\n\\nCpG-ODN1826 (InvivoGen, Cat. tlrl-1826). To test whether CVL218 can inhibit IL-\\n\\n6 production, 1 µM and 3 µM concentrations of CVL218 were added to cell culture\\n\\nmedium for 6 and 12 h, respectively. The concentration of IL-6 was determined by\\n\\nELISA using a commercial kit (Dakewe Biotech, Cat. 1110602).\\n\\n4.13. Pharmacokinetics and toxicity study\\n\\nSprague-Dawley rats were purchased from Shanghai Laboratory Animal Center,\\n\\nChina. The animals were grouped and housed in wire cages with no more than six\\n\\nper cage, under good laboratory conditions (temperature 25 ± 2\\n\\nC; relative humidity\\n\\n50 ± 20%) and with dark and light cycle (12 h/12 h). Only healthy animals were\\n\\nused for experimental purpose. The pharmacokinetics and biodistribution study in\\n\\nSprague-Dawley rats was approved by Center for Drug Safety Evaluation and Research,\\n\\nShanghai Institute of Materia Medica, Chinese Academy of Sciences. A total of 144\\n\\nSprague-Dawley rats with each sex were used for toxicity study. Animals were ran-\\n\\ndomly separated into four groups (18/sex/group). CVL218 was administered at doses\\n\\nof 20, 40, 60 and 160 mg/kg. For all the groups, 20 rats (10/sex/group) were randomly\\n\\nselected and euthanized at day 28, and their sections of various tissues and organs were\\n\\nobtained and frozen. Ten (5/sex/group) animals were euthanized after a 28-day drug\\n\\nfree period, and their sections of tissues and organs were obtained and frozen. Six\\n\\n(3/sex/group) were euthanized after the blood-samples were obtained. For pharma-\\n\\ncokinetic and toxicity evaluation, clinical symptoms, mortality and the animals\\' body\\n\\n25\\n\\nweight were examined. Serum (0.5 mL) was collected to analyze toxicokinetics at dif-\\n\\nferent time points post drug administration. The plasma concentration-time data were\\n\\nanalyzed using a non-compartmental method (Phoenix, version 1.3, USA) to derive the\\n\\npharmacokinetic parameters.\\n\\n4.14. Biodistribution study\\n\\nThirty Sprague-Dawley rats were randomly divided into three time point groups\\n\\n(3/sex/group). At 3, 6 and 8h after CVL218 administration, animals were sacrificed,\\n\\nand the brain, heart, lung, liver, spleen, stomach and kidney tissues were collected.\\n\\nTissue samples were washed in ice-cold saline, blotted with paper towel to remove\\n\\nexcess fluid, and weighed. Tissue samples were fluid, weighted and stored at -20 ± 2\\n\\nC until the determination of drug concentration by LC-MS-MS.\\n\\n4.15. Toxicity study in cynomolgus monkeys\\n\\nHealthy male and female cynomolgus monkeys aged 3\\xad4 years were purchased from\\n\\nGuangdong Landau Biotechnology, China. The animals were maintained in accordance\\n\\nwith the Guide for the Care and Use of Laboratory Animals.\\n\\nCynomolgus monkey (5/sex/group) were selected using a computerized random-\\n\\nization procedure, and administered CVL218 by nasogastric feeding at dose levels of\\n\\n0 (control), 5, 20, 80 mg/kg. Individual dose volumes were adjusted weekly based on\\n\\nbody weight of monkeys. The monkeys were observed twice daily for viability/mortality\\n\\nand for any change in behavior, reaction to treatment or ill-health. Electrocardiograms,\\n\\nintraocular pressure, rectal temperature and body weight were recorded. For all the\\n\\ngroups, 2/3 of the animals were randomly selected and euthanized at day 28. The re-\\n\\nmaining animals were euthanized after a 28-day drug free period. Blood samples were\\n\\ntaken before and at 0.5, 1, 2, 4, 8 and 24 h post-dose on days 1 and 28 of the treat-\\n\\nment period. Pharmacokinetic evaluation was performed using a non-compartmental\\n\\nmethod (Phoenix, version 1.3, USA) and pharmacokinetic parameters were calculated\\n\\n26\\n\\nfor individual monkeys.\\n\\n4.16. Statistical analysis\\n\\nAll data represent the means ± standard deviations (SDs) of n values, where n cor-\\n\\nresponds to the number of data points used. The figures were prepared using GraphPad\\n\\nPrism (GraphPad Software, USA). The statistical significance was calculated by SPSS\\n\\n(ver.12), and two values were considered significantly different if the p-value is < 0.05.\\n\\n4.17. Molecular docking\\n\\nThe docking program AutoDock4.2 [79] was used to model the molecular interactions\\n\\nbetween PARP1 inhibitors CVL218 and olaparib to the N-terminal domain of the N\\n\\nprotein of SARS-CoV-2 (SARS-CoV-2-N-NTD). The structure of SARS-CoV-2-N-NTD\\n\\nused for molecular docking was built from homology modeling [80]. The AutoGrid\\n\\nprogram was used to generate a grid map with 60×60×60 points spaced equally at\\n\\n0.375 °A for evaluating the binding energies between the protein and the ligands.\\n\\n27\\n\\nAcknowledgement\\n\\nThis work was supported in part by the National Natural Science Foundation of\\n\\nChina (61872216, 81630103, 31900862), Jiangsu Provincial Emergency Project on Pre-\\n\\nvention and Control of COVID-19 Epidemic (BE2020601), the Nation Science and Tech-\\n\\nnology Major Projects for Major New Drugs Innovation and Development (2018ZX09711003-\\n\\n004-0022019ZX09301010), Pudong New Area Science and Technology Development\\n\\nFoundation (PKX2019-S08), and the Turing AI Institute of Nanjing, and the Zhong-\\n\\nguancun Haihua Institute for Frontier Information Technology. The authors thank Dr.\\n\\nFeixiong Cheng for email communications on the connectivity map analysis.\\n\\n28\\n\\n29\\n\\nfor discovering the potential drugs to treat the COVID-19 disease. (A). The overview\\n\\nof our drug screening pipeline. The initial drug set for screening contains 6255 drug\\n\\ncandidates, mainly including 1786 approved drugs, 1125 investigational drugs and 3290\\n\\nexperimental drugs. The number of drug candidates after each filtering step is also\\n\\nshown. (B). The network-based knowledge mining module. Seven individual networks\\n\\ncontaining three types of nodes (i.e., drugs, human targets and virus targets) and the\\n\\ncorresponding edges describing their interactions, associations or similarities are first\\n\\nconstructed based on the known chemical structures, protein sequences and relations\\n\\nderived from publically available databases. Then a deep learning based method, which\\n\\nlearns and updates the feature representation of each node through information aggre-\\n\\ngation, is used to predict the potential drug candidates against a specific coronavirus.\\n\\n(C). The automated relation extraction module. The structure of each sentence from\\n\\nthe literature texts is first learned from the encoded word features using the Gumbel\\n\\ntree gated recurrent unit technique [4, 74]. Then the learned sequence structures as\\n\\nwell as the corresponding encoded word features are fed into a relation classifier to au-\\n\\ntomatically extract the relations between two entities from large-scale documents in the\\n\\nliterature. (D). The connectivity map (CMap) analysis module. The transcriptome pro-\\n\\nfiles of the Peripheral Blood Mononuclear Cell (PBMC) samples from the SARS-CoV\\n\\ninfected patients and healthy persons are compared to derive the query gene expression\\n\\nsignatures, which are then correlated to the drug-perturbed cellular expression profiles\\n\\nin the connectivity map [5] to filter out the anti-SARS-CoV drug candidates.\\n\\n30\\n\\n31\\n\\n(A). The in vitro inhibition rates of multiple tested drugs on SARS-CoV-2 replication\\n\\nat individual concentrations. (B). The concentration-dependent inhibition curve of\\n\\nCVL218 against SARS-CoV-2 replication and its cytotoxicity results. (C). Visualization\\n\\nof virus nucleoprotein (NP) expression of the infected cells upon treatment of CVL218\\n\\nat 14 h post the SARS-CoV-2 infection using fluorescence microscopy. (D). Time-of-\\n\\naddition results on the inhibition of CVL218 and remdesivir against SARS-CoV-2 in\\n\\nvitro. The viral inhibitory activities of CVL218 and remdesivir were measured at \"full-\\n\\ntime\", \"entry\", and \"post-entry\" stages, respectively. (E). Virus NP expression in the\\n\\ninfected cells upon the treatment of CVL218 and remdesivir was analyzed by Western\\n\\nblot.\\n\\n32\\n\\nFigure 3: CVL218 attenuates the CpG-induced IL-6 production in a time- and dose-\\n\\ndependent manner.\\n\\n33\\n\\nFigure 4: Effects of CVL218 on body weight in rats (A) and monkeys (B). Rats and\\n\\nmonkeys were orally administered 20/60/160 mg/kg and 5/20/80 mg/kg of CVL218,\\n\\nrespectively, for 28 consecutive days and then followed by 28 more days without drug\\n\\nadministration.\\n\\n34\\n\\n35\\n\\ncleocapsid protein (N-NTD) of SARS-CoV-2 complexed with PARP1 inhibitors. (A).\\n\\nOverall complex structures of HCoV-OC43-N-NTD (i.e., the N-NTD of HCoV-OC43)\\n\\nbound to PJ-34 (PDB ID: 4kxj), and SARS-CoV-2-N-NTD (i.e., the N-NTD of SARS-\\n\\nCoV-2) bound to CVL218 and olaparib (both modeled by AutoDock4.2) in ribbon\\n\\nview. The structure of SARS-CoV-2-N-NTD that we used for docking simulation was\\n\\nderived from homology modeling [80], with residues ranging from 47 to 177 (GenBank:\\n\\nQHD43423). (B). Detailed molecular interactions between the coronavirus N-NTDs\\n\\nand PARP1 inhibitors. Left panel: The experimentally solved complex structure of\\n\\nHCoV-OC43-N-NTD (cyan ribbon) bound to PJ-34 (yellow sticks). Middle panel: The\\n\\nmodeled complex structure of SARS-CoV-2-N-NTD (purple ribbon) bound to CVL218\\n\\n(yellow sticks). Right panel: The modeled complex structure of SARS-CoV-2-N-NTD\\n\\n(purple ribbon) bound to olaparib (yellow sticks). The key residues interacting with\\n\\nthe inhibitors are shown as green sticks. The hydrogen bonds are denoted as pink\\n\\ndashes. (C). Multiple sequence alignment (performed using MUSCLE [81]) of the N-\\n\\nNTDs among SARS-CoV-2, SARS-CoV, HCoV-OC43, mouse hepatitis virus (MHV)\\n\\nand infectious bronchitis virus (IBV). The virus names are listed on the left with avail-\\n\\nable PDB codes shown in the parentheses. The sequence of SARS-CoV-2-N-NTD was\\n\\nobtained from GenBank (QHD43423). Secondary structure elements of HCoV-OC43-N\\n\\nare depicted above the sequence alignment. Asterisks indicate the key residues inter-\\n\\nacting with the inhibitors. The residues conserved among all five viruses are shaded\\n\\nin red, the residues with the percentage of conservation larger than 50% are shaded in\\n\\ngreen, and the similar residues are shaded in yellow.\\n\\n36\\n\\n37\\n\\nthe COVID-19 disease, derived based on the data present in this study and the known\\n\\nantiviral activities of PARP1 inhibitors previously reported in the literature. (A).\\n\\nSchematic diagram showing the possible antiviral mechanisms of PARP1 inhibitors in\\n\\nthe life cycle of coronavirus in human cells. PARP1 inhibitors have been previously re-\\n\\nported in the literature to suppress viral replication and imped the binding of nucleocap-\\n\\nsid protein to viral RNAs, thus preventing the virus infection [31, 34, 35, 36]. (B). Po-\\n\\ntential protective effects of PARP1 inhibitors in the treatment of COVID-19. The anti-\\n\\ninflammation effects of PARP1 inhibitors may be achieved through two possible molec-\\n\\nular pathways. The first one is to modulate the expression of pro-inflammation factors\\n\\nsuch as NF-B, AP-1, IL-6 and downstream cytokines and chemokines [37, 38, 39, 40].\\n\\nThe second possible pathway is to prevent the overactivation of PARP1 and thus avoid\\n\\nthe depletion of NAD+\\n\\nand ATP, and the consequent cellular energy failure and cell\\n\\ndeath caused by necrosis [37, 38, 39, 40]. (C). The potential antiviral effects of PARP1\\n\\ninhibitors through suppressing the ADP-ribosylation of viral proteins and interven-\\n\\ning the host-pathogen interactions, thus resulting in the inhibition of viral replica-\\n\\ntion [34, 35, 42, 43].\\n\\n38\\n\\nTable 1: The top list of drug candidates identified by the connectivity map analysis\\n\\nusing the gene expression profiles of the peripheral blood mononuclear cell (PBMC)\\n\\nsamples of ten SARS-CoV-infected patients [6]. The connectivity map score [5] of\\n\\n-90.0 was used as the cut-off threshold to determine the top list, i.e., only those drug\\n\\ncandidates with the connectivity scores of the query ranked to the top 10% of the\\n\\nreference perturbations were selected. Two PARP1 inhibitors (i.e., veriparib and PJ-\\n\\n34) were chosen into the top list (shown in bold).\\n\\nConnectivity Map Score Compound BRD ID Name Description\\n\\n-98.94 BRD-K87142802 Veliparib PARP inhibitor\\n\\n-95.37 BRD-A35338386 NECA Adenosine receptor agonist\\n\\n-95.26 BRD-K11853856 PJ-34 PARP inhibitor\\n\\n-92.96 BRD-A53952395 Prilocaine Local anesthetic\\n\\n-91.8 BRD-K32977963 Eugenol Androgen receptor antagonist\\n\\n-91.56 BRD-A09495397 Bicuculline GABA receptor antagonist\\n\\n-91.32 BRD-K82164249 Andarine Androgen receptor modulator\\n\\n39\\n\\nTable 2: Selected examples of the predicted drug candidates against SARS-CoV or\\n\\nMERS-CoV that can be validated by the literature evidences in a retrospective study.\\n\\nThe drug candidates were first predicted using our network based knowledge mining al-\\n\\ngorithm with a cut-off threshold of p-value < 0.05. Then the identified drug candidates\\n\\nwere validated using an automated relation extraction method from the large-scale\\n\\nliterature texts, followed by a minimum of manual checking.\\n\\nDrug name Virus Original targetsa\\n\\nOriginal indicationsb\\n\\nReferencesc\\n\\nChloroquine SARS-\\n\\nCoV\\n\\nFe(II)-protoporphyrin IX (Plasmodium\\n\\nfalciparum)\\n\\nMalaria [8, 82]\\n\\nGemcitabine SARS-\\n\\nRibonucleoside-diphosphate reductase\\n\\nlarge subunit (Human)\\n\\nCancer [10, 82]\\n\\nCyclosporine SARS-\\n\\nCalcineurin subunit B type 2 (Human) Prophylaxis of organ rejection, severe\\n\\nactive rheumatoid arthritis (RA)\\n\\n[12]\\n\\nIndomethacin SARS-\\n\\nProstaglandin G/H synthase 1 and 2\\n\\n(Human)\\n\\nSymptomatic management of rheuma-\\n\\ntoid arthritis\\n\\n[83]\\n\\nCurcumin SARS-\\n\\nPeroxisome proliferator-activated re-\\n\\nceptor gamma (Human)\\n\\nVarious pro-inflammatory diseases [84] [85]\\n\\nPJ-34 SARS-\\n\\nPoly-ADP-ribose polymerase 1 (Hu-\\n\\nman)\\n\\nExperimental allergic encephalomyeli-\\n\\ntis [86]\\n\\n[87]\\n\\nHesperetin SARS-\\n\\nSterol O-acyltransferase 1 (Human) Lowering cholesterol [88] [89]\\n\\nMiltefosine MERS-\\n\\nP-glycoprotein 1 (Human) Mucosal, cutaneous, visceral leishmani-\\n\\nasis\\n\\n[14]\\n\\nChlorpromazine MERS-\\n\\nDopamine D2 and D1 receptors, 5-\\n\\nhydroxytryptamine receptor 1A and\\n\\n2A, Alpha-1A and -1B adrenergic re-\\n\\nceptors, Histamine H1 receptor (Hu-\\n\\nSchizophrenia and other psychotic dis-\\n\\norders\\n\\n[10, 82]\\n\\nImatinib MERS-\\n\\nBCR-ABL fusion kinase (Human) Leukemia [82, 90]\\n\\na. The parenthesis indicates the organism of the target(s).\\n\\nb. Drug indications stand for the official indications approved by the FDA, obtained\\n\\nfrom DrugBank [17], unless other references are stated.\\n\\nc. References stand for the supporting literatures.\\n\\n40\\n\\nTable 3: Comparison of the tissue to plasma concentration ratios between CVL218\\n\\nand arbidol in rats. The concentrations of CVL218 over different tissues of rats were\\n\\nmeasured at the 180 min time point following 20 mg/kg oral administration. The\\n\\nconcentrations of arbidol over different tissues of rats at the 15 min time point following\\n\\n54 mg/kg oral administration were obtained from the literature [91, 92]. Means and\\n\\nstandard deviations are shown.\\n\\nTissue\\n\\nTissue to plasma concentration ratio\\n\\nCVL218 Arbidol\\n\\nLung 188.364 ± 28.467 0.553 ± 0.392\\n\\nSpleen 54.897 ± 6.250 0.110 ± 0.060\\n\\nLiver 46.780 ± 5.215 0.204 ± 0.062\\n\\nKidney 41.307 ± 5.391 0.055 ± 0.040\\n\\nStomach 22.133 ± 7.130 4.920 ± 2.159\\n\\nHeart 16.514 ± 1.348 0.028 ± 0.015\\n\\nBrain 9.728 ± 1.130 0.011 ± 0.002\\n\\n41\\n\\nSupplementary Materials\\n\\nDetailed docking results on the interactions between PARP1 inhibitors and the N-terminal\\n\\ndomain of the nucleocapsid protein of SARS-CoV-2\\n\\nWe noticed that the binding surface of HCoV-OC43-N-NTD with PJ-34 consists of\\n\\nthe N-terminal loop, 2 and 3 strands (Figure 5B left panel). The oxygen and nitrogen\\n\\natoms on the 6-phenanthridinone of PJ-34 form three hydrogen bonds with S64 (3.1\\n\\n°A), Y126 (3.0 °A) and F66 (water-mediated) of HCoV-OC43-N-NTD. In addition to\\n\\nthe hydrogen network, the aromatic ring of phenanthridinone on PJ-34 participates in\\n\\n-stacking with H104 on 2 strand and Y124 on 3 strand. Compared to CoV-OC43-\\n\\nN-NTD, the binding pocket of SARS-CoV-2-N-NTD encompassed by 2 strand, 3\\n\\nstrand and loops is approximately similar in structural compositions, but more spacious,\\n\\nwhich may facilitate to bind with larger molecules. As shown in the Figure 5B (middle\\n\\npanel), CVL218 can be reliably docked inside the pocket of SARS-CoV-2-N-NTD with\\n\\nkey residues including Y111 on 2 strand, R92 on 3 strand, as well as S51 and E118\\n\\non loops. Among them, Y111 forms a bifurcated hydrogen bond to the oxygen atom\\n\\nof the benzofuran ring and the nitrogen atom of the amide group on CVL218 with a\\n\\ndistance of 2.6 °A and 3.1 °A, respectively. In addition, R92 further stabilizes the CVL218\\n\\nmolecule by forming a hydrogen bond with the oxygen atom of the amide group on the\\n\\nbenzofuran ring. The nitrogen atom of the amine close to the benzene ring of CVL218\\n\\nalso forms a hydrogen bond of distance 2.8 °A with the side chain of E118. In addition to\\n\\nthe hydrogen network which plays an essential role in CVL218 binding, the hydrophobic\\n\\ninteractions involved by T49, Y109, and Y112 of SARS-CoV-2-N-NTD also contribute\\n\\nto the molecular interaction.\\n\\nThe binding surface of olaparib on SARS-CoV-2-N-NTD is similar but not exactly\\n\\nthe same to that of CVL218. The two carbonyl groups of olaparib form hydrogen\\n\\nbonds with residues S51 and R149 of SARS-CoV-2-N-NTD with distances 3.0 °A and\\n\\n3.3 °A, respectively. In addition, the residues around the binding surface (i.e., R88, R92,\\n\\n42\\n\\nY109, Y111, R149, P151) participate in the interaction with olaparib via hydrophobic\\n\\ninteractions.\\n\\n43\\n\\nFigure S1: Structures of PARP1 inhibitors mentioned in this study.\\n\\n44\\n\\nFigure S2: Tissue distribution characteristics of CVL218 in rats, with the highest\\n\\nconcentration in lung. The concentrations of CVL218 in different tissues were measured\\n\\nat the 3/6/8 h time points after 20 mg/kg oral administration to rats. With the\\n\\nextension of administration time, the concentration of CVL218 in each organ decreased\\n\\nin a time-dependent manner.\\n\\n45\\n\\nTable S1: The top list of perturbational classes identified by the connectivity map\\n\\nanalysis using the gene expression profiles of the peripheral blood mononuclear cell\\n\\n(PBMC) samples of ten SARS-CoV-infected patients [6].\\n\\nConnectivity map score Perturbational classes\\n\\n-40.84 PARP inhibitor\\n\\n-37.31 RNA Polymerase Enzymes LOF\\n\\n-37.27 DNA synthesis inhibitor\\n\\n-36.55 GABA receptor antagonist\\n\\n-29.62 MDM inhibitor\\n\\n46\\n\\nTable S2: Comparison of the tissue distributions of CVL218 and arbidol in rats,\\n\\nfollowing 20 mg/kg and 54 mg/kg oral administrations, respectively.\\n\\nDrugs\\n\\nDose Time\\n\\nLung Spleen Liver Kidney Stomach Heart Brain\\n\\n(mg/kg) (min)\\n\\nCVL218 20\\n\\n180 69318±10476 20202±2300 17215±1919 15201±1984 8145±2624 6077±496 3580±416\\n\\n360 18858±2365 6358±1058 2187±859 3903±594 1871±813 1390±292 998±220\\n\\n480 4183±847 1475±324 213±88 993±327 569±293 275±80 317±55\\n\\nArbidola\\n\\n54\\n\\n5 933±837 48±35 104±82 79±54 8210±5410 72±47 101±67\\n\\n15 2603±1848 519±281 963±290 259±190 23180±10170 132±69 50±10\\n\\n360 833±397 143±51 262±175 58±21 52750±3059 41±28 31±21\\n\\na. The concentrations of arbidol in different tissues of rats at 5/15/360 min time\\n\\npoints with 54 mg/kg oral administration were obtained from [92].\\n\\n47\\n\\nTable S3: Comparisons of pharmacokinetic parameters in rats between CVL218 and\\n\\narbidol following 20/40 mg/kg and 18/54 mg/kg oral administrations, respectively.\\n\\nDrugs Dose Gender Tmax Cmax AUC0-t AUC0- MRT0 -  t1/2\\n\\n(mg/kg) (h) (ng/mL) (ng·h/mL) (ng·h/mL) (h) (h)\\n\\nCVL218\\n\\nmale 4.0 (4.0~4.0) 234 ± 35 1070 ± 176 1111 ± 192 3.91 ± 0.19 1.19 ± 0.09\\n\\nfemale 3.0 (2.0~3.0) 502 ± 80 2196 ± 228 2222 ± 241 3.16 ± 0.41 1.1 ± 0.16\\n\\ntotal 3.5 (2.0~4.0) 368 ± 157 1633 ± 643 1666 ± 639 3.54 ± 0.50 1.15 ± 0.13\\n\\nmale 3.0 (2.0~4.0) 510 ± 259 2802 ± 967 2830 ± 983 4.51 ± 0.18 1.3 ± 0.33\\n\\nfemale 2.0 (2.0~3.0) 940 ± 117 5220 ± 1113 5242 ± 1115 4.05 ± 0.43 1.29 ± 0.21\\n\\ntotal 2.5 (2.0~4.0) 725 ± 296 4011 ± 1620 4036 ± 1620 4.28 ± 0.39 1.3 ± 0.24\\n\\n18 male 0.28 ± 0.11 1002 ± 298 1956 ± 895 2224 ± 1058 - 3.6 ± 1.2\\n\\n54 male 0.18 ± 0.06 4711 ± 2361 6790 ± 2749 7558 ± 2877 - 3.3 ± 0.7\\n\\na. The pharmacokinetic data of arbidol were obtained from [91].\\n\\n48\\n\\nTable S4: Toxicokinetic parameters of CVL218 in rats in a four-week toxicity study.\\n\\nToxicological parameters\\n\\nDay 1 Day 28\\n\\nGroup Gender Dose Tmax Cmax AUC0-24 Tmax Cmax AUC0-24\\n\\n(mg/kg) (h) (ng/mL) (h·ng/mL) (h) (ng/mL) (h·ng/mL)\\n\\nM 20\\n\\nMean 3.00 261 2373 3.00 147 1004\\n\\nSD 0.00 124 2000 0.00 61.0 431\\n\\nN 3 3 3 3 3 3\\n\\nF 20\\n\\nMean 3.00 314 1674 3.00 147 797\\n\\nSD 0.00 56.2 382 0.00 35.7 197\\n\\nM 60\\n\\nMean 5.00 513 6784 3.00 611 5610\\n\\nSD 0.00 119 1592 0.00 114 1343\\n\\nF 60\\n\\nMean 5.30 708 9092 2.30 453 4090\\n\\nSD 2.50 137 549 1.20 115 312\\n\\nM 160\\n\\nMean 6.00 659 9102 5.30 824 10253\\n\\nSD 1.70 77.1 1776 2.50 268 3008\\n\\nF 160\\n\\nMean 2.30 614 7605 3.00 629 6657\\n\\nSD 1.20 122 1056 2.00 213 4592\\n\\n49\\n\\nTable S5: Toxicokinetic parameters of CVL218 in monkeys in a four-week toxicity\\n\\nstudy.\\n\\nM 5\\n\\nMean 2.2 119 528 2.8 48 215\\n\\nSD 0.4 31.7 138.2 1.3 12.5 62.3\\n\\nN 5 5 5 5 5 5\\n\\nF 5\\n\\nMean 4 76 451 3.8 36 172\\n\\nSD 1.4 38.8 239.8 1.6 20.3 77.7\\n\\nMean 4 440 4838 5 239 2111\\n\\nSD 2.5 162.4 2086.4 0.0 91.1 1186.8\\n\\nMean 4.6 479 4963 4.6 322 2779\\n\\nSD 0.9 100.5 1189.5 0.9 125.4 1458\\n\\nM 80\\n\\nMean 3.4 1372 16924 6.8 1582 22912\\n\\nSD 0.9 617.4 8831.1 1.6 416.6 8859.6\\n\\nF 80\\n\\nMean 5.2 1389 19466 5.6 1403 18774\\n\\nSD 1.8 387.5 5535.4 2.5 489.6 6179.1\\n\\n50\\n\\nReferences\\n\\n[1] T. T. Ashburn, K. B. Thor, Drug repositioning: identifying and developing new\\n\\nuses for existing drugs, Nature reviews drug discovery 3 (8) (2004) 673\\xad683.\\n\\n[2] S. Pushpakom, F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper, A. Wells, A. Doig,\\n\\nT. Guilliams, J. Latimer, C. McNamee, et al., Drug repurposing: progress, chal-\\n\\nlenges and recommendations, Nature reviews drug discovery 18 (1) (2019) 41\\xad58.\\n\\n[3] Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, F. Cheng, Network-based drug\\n\\nrepurposing for human coronavirus, medRxiv.\\n\\n[4] L. Hong, J. Lin, J. Tao, J. Zeng, BERE: An accurate distantly supervised biomed-\\n\\n[5] A. Subramanian, R. Narayan, S. M. Corsello, D. D. Peck, T. E. Natoli, X. Lu,\\n\\nJ. Gould, J. F. Davis, A. A. Tubelli, J. K. Asiedu, et al., A next generation\\n\\nconnectivity map: L1000 platform and the first 1,000,000 profiles, Cell 171 (6)\\n\\n(2017) 1437\\xad1452.\\n\\n[6] R. Reghunathan, M. Jayapal, L.-Y. Hsu, H.-H. Chng, D. Tai, B. P. Leung, A. J.\\n\\nMelendez, Expression profile of immune response genes in patients with severe\\n\\nacute respiratory syndrome, BMC immunology 6 (1) (2005) 2.\\n\\n[7] P. Goel, V. Gerriets, Chloroquine, in: StatPearls [Internet], StatPearls Publishing,\\n\\n2019.\\n\\n[8] E. Keyaerts, L. Vijgen, P. Maes, J. Neyts, M. Van Ranst, In vitro inhibition of\\n\\nsevere acute respiratory syndrome coronavirus by chloroquine, Biochemical and\\n\\nbiophysical research communications 323 (1) (2004) 264\\xad268.\\n\\n[9] V. Oldfield, K. Wellington, Gemcitabine, American journal of cancer 4 (5) (2005)\\n\\n337\\xad344.\\n\\n51\\n\\n[10] J. Dyall, C. M. Coleman, B. J. Hart, T. Venkataraman, M. R. Holbrook, J. Kin-\\n\\ndrachuk, R. F. Johnson, G. G. Olinger, P. B. Jahrling, M. Laidlaw, et al., Re-\\n\\npurposing of clinically developed drugs for treatment of Middle East respiratory\\n\\nsyndrome coronavirus infection, Antimicrobial agents and chemotherapy 58 (8)\\n\\n(2014) 4885\\xad4893.\\n\\n[11] P. Forsythe, S. Paterson, Ciclosporin 10 years on: indications and efficacy, The\\n\\nveterinary record 174 (Suppl 2) (2014) 13.\\n\\n[12] S. Pfefferle, J. Sch¨opf, M. K¨ogl, C. C. Friedel, M. A. M¨uller, J. Carbajo-\\n\\nLozoya, T. Stellberger, E. von DallArmi, P. Herzog, S. Kallies, et al., The SARS-\\n\\ncoronavirus-host interactome: identification of cyclophilins as target for pan-\\n\\ncoronavirus inhibitors, PLoS pathogens 7 (10).\\n\\n[13] J. Berman, Miltefosine, an FDA-approved drug for the `orphan disease\\', leishma-\\n\\nniasis, Expert opinion on orphan drugs 3 (6) (2015) 727\\xad735.\\n\\n[14] J. Kindrachuk, B. Ork, B. J. Hart, S. Mazur, M. R. Holbrook, M. B. Frieman,\\n\\nD. Traynor, R. F. Johnson, J. Dyall, J. H. Kuhn, et al., Antiviral potential of\\n\\nERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respi-\\n\\nratory syndrome coronavirus infection as identified by temporal kinome analysis,\\n\\nAntimicrobial agents and chemotherapy 59 (2) (2015) 1088\\xad1099.\\n\\n[15] C. E. Adams, J. Rathbone, B. Thornley, M. Clarke, J. Borrill, K. Wahlbeck, A. G.\\n\\nAwad, Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years\\n\\nof randomised controlled trials, BMC medicine 3 (1) (2005) 15.\\n\\n[16] M. H. Cohen, G. Williams, J. R. Johnson, J. Duan, J. Gobburu, A. Rahman,\\n\\nK. Benson, J. Leighton, S. K. Kim, R. Wood, et al., Approval summary for ima-\\n\\ntinib mesylate capsules in the treatment of chronic myelogenous leukemia, Clinical\\n\\ncancer research 8 (5) (2002) 935\\xad942.\\n\\n52\\n\\n[17] D. S. Wishart, Y. D. Feunang, A. C. Guo, E. J. Lo, A. Marcu, J. R. Grant,\\n\\nT. Sajed, D. Johnson, C. Li, Z. Sayeeda, et al., DrugBank 5.0: a major update to\\n\\nthe DrugBank database for 2018, Nucleic acids research 46 (D1) (2018) D1074\\xad\\n\\nD1082.\\n\\n[18] P. Richardson, I. Griffin, C. Tucker, D. Smith, O. Oechsle, A. Phelan, J. Stebbing,\\n\\nBaricitinib as potential treatment for 2019-nCoV acute respiratory disease, The\\n\\nlancet.\\n\\n[19] L. Velazquez-Salinas, A. Verdugo-Rodriguez, L. L. Rodriguez, M. V. Borca, The\\n\\nrole of interleukin 6 during viral infections, Frontiers in microbiology 10 (2019)\\n\\n1057.\\n\\n[20] M. M. McFarland-Mancini, H. M. Funk, A. M. Paluch, M. Zhou, P. V. Giridhar,\\n\\nC. A. Mercer, S. C. Kozma, A. F. Drew, Differences in wound healing in mice with\\n\\ndeficiency of IL-6 versus IL-6 receptor, The journal of immunology 184 (12) (2010)\\n\\n7219\\xad7228.\\n\\n[21] G. A. Palumbo, C. Scisciani, N. Pediconi, L. Lupacchini, D. Alfalate, F. Guerrieri,\\n\\nL. Calvo, D. Salerno, S. Di Cocco, M. Levrero, et al., IL6 inhibits HBV transcrip-\\n\\ntion by targeting the epigenetic control of the nuclear cccdna minichromosome,\\n\\nPLoS one 10 (11).\\n\\n[22] L. Velazquez-Salinas, S. J. Pauszek, C. Stenfeldt, E. S. OHearn, J. M. Pacheco,\\n\\nM. V. Borca, A. Verdugo-Rodriguez, J. Arzt, L. L. Rodriguez, Increased virulence\\n\\nof an epidemic strain of vesicular stomatitis virus is associated with interference\\n\\nof the innate response in pigs, Frontiers in microbiology 9 (2018) 1891.\\n\\n[23] W. Wu, K. K. Dietze, K. Gibbert, K. S. Lang, M. Trilling, H. Yan, J. Wu, D. Yang,\\n\\nM. Lu, M. Roggendorf, et al., TLR ligand induced IL-6 counter-regulates the anti-\\n\\n53\\n\\nviral CD8+ T cell response during an acute retrovirus infection, Scientific reports\\n\\n5 (2015) 10501.\\n\\n[24] J. Zheng, Y. Shi, L. Xiong, W. Zhang, Y. Li, P. G. Gibson, J. L. Simpson, C. Zhang,\\n\\nJ. Lu, J. Sai, et al., The expression of IL-6, tNF-, and MCP-1 in respiratory viral\\n\\ninfection in acute exacerbations of chronic obstructive pulmonary disease, Journal\\n\\nof immunology research 2017.\\n\\n[25] Y. Zhou, B. Fu, X. Zheng, D. Wang, C. Zhao, Y. Qi, R. Sun, Z. Tian, X. Xu,\\n\\nH. Wei, Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+\\n\\nmonocytes in severe pulmonary syndrome patients of a new coronavirus, bioRxiv.\\n\\n[26] J.-j. Zhang, X. Dong, Y.-Y. Cao, Y.-d. Yuan, Y.-b. Yang, Y.-q. Yan, C. A. Akdis,\\n\\nY.-d. Gao, Clinical characteristics of 140 patients infected by SARS-CoV-2 in\\n\\nWuhan, China, Allergy.\\n\\n[27] B. Diao, C. Wang, Y. Tan, X. Chen, Y. Liu, L. Ning, L. Chen, M. Li, Y. Liu,\\n\\nG. Wang, et al., Reduction and functional exhaustion of T cells in patients with\\n\\ncoronavirus disease 2019 (COVID-19), medRxiv.\\n\\n[28] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu,\\n\\nX. Gu, et al., Clinical features of patients infected with 2019 novel coronavirus in\\n\\nWuhan, China, The lancet 395 (10223) (2020) 497\\xad506.\\n\\n[29] B. Li, F. Feng, G. Yang, A. Liu, N. Yang, Q. Jiang, H. Zhang, T. Wang, P. Li,\\n\\nY. Mao, et al., Immunoglobulin G/M and cytokines detections in continuous sera\\n\\nfrom patients with novel coronaviruses (2019-nCoV) infection, Available at SSRN\\n\\n3543609.\\n\\n[30] J.-X. He, M. Wang, X.-J. Huan, C.-H. Chen, S.-S. Song, Y.-Q. Wang, X.-M. Liao,\\n\\nC. Tan, Q. He, L.-J. Tong, et al., Novel PARP1/2 inhibitor mefuparib hydrochlo-\\n\\nride elicits potent in vitro and in vivo anticancer activity, characteristic of high\\n\\ntissue distribution, Oncotarget 8 (3) (2017) 4156.\\n\\n[31] S.-Y. Lin, C.-L. Liu, Y.-M. Chang, J. Zhao, S. Perlman, M.-H. Hou, Structural\\n\\nbasis for the identification of the N-terminal domain of coronavirus nucleocapsid\\n\\nprotein as an antiviral target, Journal of medicinal chemistry 57 (6) (2014) 2247\\xad\\n\\n2257.\\n\\n[32] C.-k. Chang, S. Jeyachandran, N.-J. Hu, C.-L. Liu, S.-Y. Lin, Y.-S. Wang, Y.-M.\\n\\nChang, M.-H. Hou, Structure-based virtual screening and experimental validation\\n\\nof the discovery of inhibitors targeted towards the human coronavirus nucleocapsid\\n\\nprotein, Molecular biosystems 12 (1) (2016) 59\\xad66.\\n\\n[33] A. Zumla, J. F. Chan, E. I. Azhar, D. S. Hui, K.-Y. Yuen, Coronavirusesdrug\\n\\ndiscovery and therapeutic options, Nature reviews drug discovery 15 (5) (2016)\\n\\n327.\\n\\n[34] C. V. D´ery, G. de Murcia, D. Lamarre, N. Morin, G. G. Poirier, J. Weber, Possi-\\n\\nble role of ADP-ribosylation of adenovirus core proteins in virus infection, Virus\\n\\nresearch 4 (4) (1986) 313\\xad329.\\n\\n[35] L. Liu, Z. Lear, D. J. Hughes, W. Wu, E.-m. Zhou, A. Whitehouse, H. Chen,\\n\\nJ. A. Hiscox, Resolution of the cellular proteome of the nucleocapsid protein from\\n\\na highly pathogenic isolate of porcine reproductive and respiratory syndrome virus\\n\\nidentifies PARP-1 as a cellular target whose interaction is critical for virus biology,\\n\\nVeterinary microbiology 176 (1-2) (2015) 109\\xad119.\\n\\n[36] I. Tempera, Z. Deng, C. Atanasiu, C.-J. Chen, M. D\\'Erme, P. M. Lieberman, Reg-\\n\\nulation of Epstein-Barr virus OriP replication by poly (ADP-ribose) polymerase\\n\\n1, Journal of virology 84 (10) (2010) 4988\\xad4997.\\n\\n55\\n\\n[37] C. B. Larmonier, K. W. Shehab, D. Laubitz, D. R. Jamwal, F. K. Ghishan, P. R.\\n\\nKiela, Transcriptional reprogramming and resistance to colonic mucosal injury\\n\\nin poly (ADP-ribose) polymerase 1 (PARP1)-deficient mice, Journal of biological\\n\\nchemistry 291 (17) (2016) 8918\\xad8930.\\n\\n[38] G. Li, P. Cunin, D. D. Di Wu, Y. Yang, Y. Okada, R. M. Plenge, P. A. Nigrovic,\\n\\nThe rheumatoid arthritis risk variant CCR6DNP regulates CCR6 via PARP-1,\\n\\nPLoS genetics 12 (9).\\n\\n[39] M. Scalia, C. Satriano, R. Greca, A. M. G. Stella, E. Rizzarelli, V. Spina-Purrello,\\n\\nPARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commit-\\n\\nment of human glioblastoma cells, Neurochemical research 38 (1) (2013) 50\\xad58.\\n\\n[40] V. Schreiber, F. Dantzer, J.-C. Ame, G. De Murcia, Poly (ADP-ribose): novel\\n\\nfunctions for an old molecule, Nature reviews molecular cell biology 7 (7) (2006)\\n\\n517\\xad528.\\n\\n[41] J. Markovi´c, N. Grdovi´c, S. Dini´c, T. Karan-Djurasevi´c, A. Uskokovi´c,\\n\\nJ. Arambasi´c, M. Mihailovi´c, S. Pavlovi´c, G. Poznanovi´c, M. Vidakovi´c, PARP-\\n\\n1 and YY1 are important novel regulators of CXCL12 gene transcription in rat\\n\\npancreatic beta cells, PLoS one 8 (3).\\n\\n[42] E. Bortz, L. Westera, J. Maamary, J. Steel, R. A. Albrecht, B. Manicassamy,\\n\\nG. Chase, L. Mart´inez-Sobrido, M. Schwemmle, A. Garc´ia-Sastre, Host-and strain-\\n\\nspecific regulation of influenza virus polymerase activity by interacting cellular\\n\\nproteins, MBio 2 (4) (2011) e00151\\xad11.\\n\\n[43] S. L. Grady, J. Hwang, L. Vastag, J. D. Rabinowitz, T. Shenk, Herpes simplex virus\\n\\n1 infection activates poly (ADP-ribose) polymerase and triggers the degradation of\\n\\npoly (ADP-ribose) glycohydrolase, Journal of virology 86 (15) (2012) 8259\\xad8268.\\n\\n56\\n\\n[44] C. Xia, J. J. Wolf, C. Sun, M. Xu, C. J. Studstill, J. Chen, H. Ngo, H. Zhu,\\n\\nB. Hahm, PARP1 enhances influenza A virus propagation by facilitating degrada-\\n\\ntion of host type I interferon receptor, Journal of virology.\\n\\n[45] N. J. Curtin, C. Szabo, Therapeutic applications of PARP inhibitors: anticancer\\n\\ntherapy and beyond, Molecular aspects of medicine 34 (6) (2013) 1217\\xad1256.\\n\\n[46] P. Jagtap, C. Szab´o, Poly (ADP-ribose) polymerase and the therapeutic effects of\\n\\nits inhibitors, Nature reviews drug discovery 4 (5) (2005) 421\\xad440.\\n\\n[47] G. E. Abdelkarim, K. Gertz, C. Harms, J. Katchanov, U. Dirnagl, C. Szabo,\\n\\nM. Endres, Protective effects of PJ34, a novel, potent inhibitor of poly (ADP-\\n\\nribose) polymerase (PARP) in in vitro and in vivo models of stroke, International\\n\\njournal of molecular medicine 7 (3) (2001) 255\\xad260.\\n\\n[48] M. I. Arshad, C. Piquet-Pellorce, A. Filliol, A. LHelgoualch, C. Lucas-Clerc,\\n\\nS. Jouan-Lanhouet, M.-T. Dimanche-Boitrel, M. Samson, The chemical inhibitors\\n\\nof cellular death, PJ34 and Necrostatin-1, down-regulate IL-33 expression in liver,\\n\\nJournal of molecular medicine 93 (8) (2015) 867\\xad878.\\n\\n[49] K. Kapoor, E. Singla, B. Sahu, A. S. Naura, PARP inhibitor, olaparib ameliorates\\n\\nacute lung and kidney injury upon intratracheal administration of LPS in mice,\\n\\nMolecular and cellular biochemistry 400 (1-2) (2015) 153\\xad162.\\n\\n[50] S. Pazzaglia, C. Pioli, Multifaceted role of PARP-1 in DNA repair and inflamma-\\n\\ntion: Pathological and therapeutic implications in cancer and non-cancer diseases,\\n\\nCells 9 (1) (2020) 41.\\n\\n[51] G. S. Sethi, V. Dharwal, A. S. Naura, Poly (ADP-ribose) polymerase-1 in lung\\n\\ninflammatory disorders: a review, Frontiers in immunology 8 (2017) 1172.\\n\\n[52] N. A. Berger, V. C. Besson, A. H. Boulares, A. B¨urkle, A. Chiarugi, R. S. Clark,\\n\\nN. J. Curtin, S. Cuzzocrea, T. M. Dawson, V. L. Dawson, et al., Opportunities\\n\\n57\\n\\nfor the repurposing of PARP inhibitors for the therapy of non-oncological diseases,\\n\\nBritish journal of pharmacology 175 (2) (2018) 192\\xad222.\\n\\n[53] S. Garc´ia, C. Conde, The role of poly (ADP-ribose) polymerase-1 in rheumatoid\\n\\narthritis, Mediators of inflammation 2015.\\n\\n[54] D. Mendez, A. Gaulton, A. P. Bento, J. Chambers, M. De Veij, E. F´elix, M. P.\\n\\nMagari~nos, J. F. Mosquera, P. Mutowo, M. Nowotka, et al., ChEMBL: towards\\n\\ndirect deposition of bioassay data, Nucleic acids research 47 (D1) (2019) D930\\xad\\n\\nD940.\\n\\n[55] Y. Wang, S. Zhang, F. Li, Y. Zhou, Y. Zhang, Z. Wang, R. Zhang, J. Zhu, Y. Ren,\\n\\nY. Tan, et al., Therapeutic target database 2020: enriched resource for facilitating\\n\\nresearch and early development of targeted therapeutics, Nucleic acids research\\n\\n48 (D1) (2020) D1031\\xadD1041.\\n\\n[56] A. J. Pawson, J. L. Sharman, H. E. Benson, E. Faccenda, S. P. Alexander, O. P.\\n\\nBuneman, A. P. Davenport, J. C. McGrath, J. A. Peters, C. Southan, et al., The\\n\\nIUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of\\n\\ndrug targets and their ligands, Nucleic acids research 42 (D1) (2014) D1098\\xadD1106.\\n\\n[57] M. K. Gilson, T. Liu, M. Baitaluk, G. Nicola, L. Hwang, J. Chong, BindingDB\\n\\nin 2015: a public database for medicinal chemistry, computational chemistry and\\n\\nsystems pharmacology, Nucleic acids research 44 (D1) (2016) D1045\\xadD1053.\\n\\n[58] R. Oughtred, C. Stark, B.-J. Breitkreutz, J. Rust, L. Boucher, C. Chang, N. Kolas,\\n\\nL. ODonnell, G. Leung, R. McAdam, et al., The BioGRID interaction database:\\n\\n2019 update, Nucleic acids research 47 (D1) (2019) D529\\xadD541.\\n\\n[59] D. Figeys, Mapping the human protein interactome, Cell research 18 (7) (2008)\\n\\n716\\xad724.\\n\\n58\\n\\n[60] M. J. Meyer, J. Das, X. Wang, H. Yu, INstruct: a database of high-quality 3D\\n\\nstructurally resolved protein interactome networks, Bioinformatics 29 (12) (2013)\\n\\n1577\\xad1579.\\n\\n[61] L. Licata, L. Briganti, D. Peluso, L. Perfetto, M. Iannuccelli, E. Galeota, F. Sacco,\\n\\nA. Palma, A. P. Nardozza, E. Santonico, et al., MINT, the molecular interaction\\n\\ndatabase: 2012 update, Nucleic acids research 40 (D1) (2012) D857\\xadD861.\\n\\n[62] M. J. Cowley, M. Pinese, K. S. Kassahn, N. Waddell, J. V. Pearson, S. M. Grim-\\n\\nmond, A. V. Biankin, S. Hautaniemi, J. Wu, PINA v2. 0: mining interactome\\n\\nmodules, Nucleic acids research 40 (D1) (2012) D862\\xadD865.\\n\\n[63] A. Ebrahim, J. A. Lerman, B. O. Palsson, D. R. Hyduke, COBRApy: COnstraints-\\n\\nbased reconstruction and analysis for python, BMC systems biology 7 (1) (2013)\\n\\n74.\\n\\n[64] K. Breuer, A. K. Foroushani, M. R. Laird, C. Chen, A. Sribnaia, R. Lo, G. L.\\n\\nWinsor, R. E. Hancock, F. S. Brinkman, D. J. Lynn, InnateDB: systems biology of\\n\\ninnate immunity and beyondrecent updates and continuing curation, Nucleic acids\\n\\nresearch 41 (D1) (2013) D1228\\xadD1233.\\n\\n[65] G. Landrum, et al., RDKit: Open-source cheminformatics.\\n\\n[66] UniProt: the universal protein knowledgebase, Nucleic acids research 45 (D1)\\n\\n(2017) D158\\xadD169.\\n\\n[67] M. Zhao, W.-P. Lee, E. P. Garrison, G. T. Marth, SSW library: an SIMD Smith-\\n\\nWaterman C/C++ library for use in genomic applications, PloS one 8 (12).\\n\\n[68] Y. Luo, X. Zhao, J. Zhou, J. Yang, Y. Zhang, W. Kuang, J. Peng, L. Chen, J. Zeng,\\n\\nA network integration approach for drug-target interaction prediction and compu-\\n\\ntational drug repositioning from heterogeneous information, Nature communica-\\n\\ntions 8 (1) (2017) 1\\xad13.\\n\\n59\\n\\n[69] F. Wan, L. Hong, A. Xiao, T. Jiang, J. Zeng, NeoDTI: neural integration of neigh-\\n\\nbor information from a heterogeneous network for discovering new drug\\xadtarget\\n\\ninteractions, Bioinformatics 35 (1) (2019) 104\\xad111.\\n\\n[70] J. Gilmer, S. S. Schoenholz, P. F. Riley, O. Vinyals, G. E. Dahl, Neural message\\n\\npassing for quantum chemistry, in: Proceedings of the 34th international conference\\n\\non machine learning-volume 70, JMLR. org, 2017, pp. 1263\\xad1272.\\n\\n[71] S. Rendle, C. Freudenthaler, Z. Gantner, L. Schmidt-Thieme, BPR: Bayesian per-\\n\\n[72] A. Vaswani, N. Shazeer, N. Parmar, J. Uszkoreit, L. Jones, A. N. Gomez, L. Kaiser,\\n\\nI. Polosukhin, Attention is all you need, in: Advances in neural information pro-\\n\\ncessing systems, 2017, pp. 5998\\xad6008.\\n\\n[73] K. Cho, B. Van Merri¨enboer, D. Bahdanau, Y. Bengio, On the properties\\n\\narXiv:1409.1259.\\n\\n[74] E. Jang, S. Gu, B. Poole, Categorical reparameterization with gumbel-softmax,\\n\\n[75] S. Riedel, L. Yao, A. McCallum, Modeling relations and their mentions without\\n\\nlabeled text, in: Joint european conference on machine learning and knowledge\\n\\ndiscovery in databases, Springer, 2010, pp. 148\\xad163.\\n\\n[76] R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang,\\n\\nN. Zhu, et al., Genomic characterisation and epidemiology of 2019 novel coron-\\n\\navirus: implications for virus origins and receptor binding, The lancet 395 (10224)\\n\\n(2020) 565\\xad574.\\n\\n60\\n\\n[77] S. F. Ahmed, A. A. Quadeer, M. R. McKay, Preliminary identification of potential\\n\\nvaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV\\n\\nimmunological studies, Viruses 12 (3) (2020) 254.\\n\\n[78] J. Xu, S. Zhao, T. Teng, A. E. Abdalla, W. Zhu, L. Xie, Y. Wang, X. Guo,\\n\\nSystematic comparison of two animal-to-human transmitted human coronaviruses:\\n\\nSARS-CoV-2 and SARS-CoV, Viruses 12 (2) (2020) 244.\\n\\n[79] G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell,\\n\\nA. J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective\\n\\nreceptor flexibility, Journal of computational chemistry 30 (16) (2009) 2785\\xad2791.\\n\\n[80] C. Zhang, W. Zheng, X. Huang, E. W. Bell, X. Zhou, Y. Zhang, Protein structure\\n\\nand sequence re-analysis of 2019-nCoV genome does not indicate snakes as its\\n\\nintermediate host or the unique similarity between its spike protein insertions and\\n\\n[81] R. C. Edgar, MUSCLE: multiple sequence alignment with high accuracy and high\\n\\nthroughput, Nucleic acids research 32 (5) (2004) 1792\\xad1797.\\n\\n[82] J. Dyall, R. Gross, J. Kindrachuk, R. F. Johnson, G. G. Olinger, L. E. Hensley,\\n\\nM. B. Frieman, P. B. Jahrling, Middle East respiratory syndrome and severe acute\\n\\nrespiratory syndrome: current therapeutic options and potential targets for novel\\n\\ntherapies, Drugs 77 (18) (2017) 1935\\xad1966.\\n\\n[83] K. Bhardwaj, How prepared are we to control severe acute respiratory syndrome\\n\\nin future, Am. J. Virol 2 (2013) 8\\xad19.\\n\\n[84] S. C. Gupta, S. Patchva, B. B. Aggarwal, Therapeutic roles of curcumin: lessons\\n\\nlearned from clinical trials, The AAPS journal 15 (1) (2013) 195\\xad218.\\n\\n[85] V. Mac´ias-Villamizar, R. Gonz´alez-Ascanio, Plantas de Santa Marta con posible\\n\\nactividad biol´ogica antimicrobiana, Duazary 16 (2) (2019) 414\\xad439.\\n\\n61\\n\\n[86] G. S. Scott, R. B. Kean, T. Mikheeva, M. J. Fabis, J. G. Mabley, C. Szabo, D. C.\\n\\nHooper, The therapeutic effects of PJ34 [N-(6-oxo-5, 6-dihydrophenanthridin-\\n\\n2-yl)-N, N-dimethylacetamide. HCl], a selective inhibitor of poly (ADP-ribose)\\n\\npolymerase, in experimental allergic encephalomyelitis are associated with im-\\n\\nmunomodulation, Journal of pharmacology and experimental therapeutics 310 (3)\\n\\n(2004) 1053\\xad1061.\\n\\n[87] S. J. Nicolino Jr, I. Chayut, Ambient audio transformation using transformation\\n\\naudio, uS Patent 8,280,068 (Oct. 2 2012).\\n\\n[88] H. K. Kim, T.-S. Jeong, M.-K. Lee, Y. B. Park, M.-S. Choi, Lipid-lowering efficacy\\n\\nof hesperetin metabolites in high-cholesterol fed rats, Clinica chimica acta 327 (1-2)\\n\\n(2003) 129\\xad137.\\n\\n[89] C.-W. Lin, F.-J. Tsai, C.-H. Tsai, C.-C. Lai, L. Wan, T.-Y. Ho, C.-C. Hsieh, P.-\\n\\nD. L. Chao, Anti-SARS coronavirus 3C-like protease effects of isatis indigotica root\\n\\nand plant-derived phenolic compounds, Antiviral research 68 (1) (2005) 36\\xad42.\\n\\n[90] J. S. Shin, E. Jung, M. Kim, R. S. Baric, Y. Y. Go, Saracatinib inhibits middle\\n\\neast respiratory syndrome-coronavirus replication in vitro, Viruses 10 (6) (2018)\\n\\n283.\\n\\n[91] X. LIU, Q.-g. ZHOU, H. LI, B.-c. CAI, X.-h. CHEN, K.-s. BI, Pharmacokinetics\\n\\nof arbidol hydrochloride in rats, Chinese pharmacological bulletin 28 (12) (2012)\\n\\n1747\\xad1750.\\n\\n[92] X. LIU, K. PEI, X.-h. CHEN, K.-s. BI, Distribution and excretion of arbidol hy-\\n\\ndrochloride in rats, Chinese journal of new drugs 22 (7) (2013) 829\\xad833.\\n\\n62\\n\\n\\n'"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "total_raw[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "total_sentence = ''\n",
    "for x in total_raw:\n",
    "    total_sentence+=x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200491"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(total_sentence.split())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def preprocess(txt):\n",
    "    b = txt.replace('i.e.','')\n",
    "\n",
    "    b = b.replace('-\\n\\n', '')\n",
    "    b = b.replace('\\n\\n', ' ')\n",
    "    b = b.replace('\\n', ' ')\n",
    "    \n",
    "    b = b.replace('\\n\\n', ' ')\n",
    "    b = b.replace('\\n', ' ')\n",
    "    b = b.replace('\\n\\n', ' ')\n",
    "    b = b.replace('\\n', ' ')\n",
    "    \n",
    "    b = b.replace('(', ' ')\n",
    "    b = b.replace(')', ' ')\n",
    "    b = b.replace(',', '')\n",
    "    \n",
    "    b = re.sub('[^\\#0-9A-Za-z-]', ' ',b)\n",
    "    b = re.sub(' +', ' ',b)\n",
    "    b= b.strip()\n",
    "\n",
    "    # print(b)\n",
    "#     b = b.lower()\n",
    "    if 'References' in b and len(b.split('References')[0])>15:\n",
    "        b = b.split('References')[0]\n",
    "    if 'Introduction' in b:\n",
    "        b = b.split('Introduction')[1]\n",
    "    if 'Abstract' in b:\n",
    "        b = b.split('Abstract')[1]\n",
    "    b = b.lower()    \n",
    "    b = b.replace('et al.','')\n",
    "    b = b.replace('table','')\n",
    "    b = b.replace('figure','')\n",
    "\n",
    "    return b"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' the outbreak of the pneumonia named covid-19 caused by the novel coronavirus sars-cov-2 2019-ncov has infected over 110000 people worldwide by 8th march 2020 apart from china other countries or regions including south korea iran and europe have reported a rapid increase in the number of covid-19 cases implying that this novel coronavirus has posed a global health threat under the current circumstance of the absence of the specific vaccines and medicines against sars-cov-2 it is urgent to discover effective therapies especially drugs to treat the resulting covid-19 disease and prevent the virus from further spreading considering that the development of a new drug generally takes years probably the best therapeutic shortcut is to apply the drug repositioning strategy finding the new uses of old drugs 1 2 3 to identify the potential antiviral effects against sars-cov-2 of existing drugs that have been approved for clinical use or to enter clinical trials those existing drugs with potent antiviral efficacy can be directly applied to treat covid-19 in a short time as their safety has been verified in principle in clinical trials in this study we applied a data-driven framework that combines both machine learning and statistical analysis methods to systematically integrate large-scale available coronavirus-related data and identify the drug candidates against sars-cov-2 from a set of over 6000 drug candidates mainly including approved investigational and experimental drugs our in silico screening process followed by experimental validation revealed that a poly-adp-ribose polymerase 1 parp1 inhibitor cvl218 currently in phase i clinical trial may serve as a potential drug candidate to treat covid-19 our in vitro assays demonstrated that cvl218 can exhibit effective inhibitory activity against sars-cov-2 replication in a dose-dependent manner and with no obvious cytopathic effect in addition we found that in human peripheral blood mononuclear cells pbmcs cvl218 is able to suppress the cpg-induced production of il-6 which has been reported previously to be of high relevance to the viral pathogenesis of covid-19 especially for those intensive care unit icu patients infected by sars-cov-2 further in vivo pharmacokinetic and toxicokinetic studies in rats and monkeys showed that cvl218 was highly distributed in the lung tissue and no apparent sign of toxicity was observed which makes it an appealing potential drug candidate for the treatment of the novel pneumonia caused by sars-cov-2 infection moreover our molecular docking study suggested that cvl218 may bind to the n-terminal domain of nucleocapsid n protein of sars-cov-2 providing a possible mode of its antiviral action against sars-cov-2 based on the data present in this study and previous known evidences reported in the literature we also discussed several putative mechanisms of the anti-sars-cov-2 effects for cvl218 or other parp1 inhibitors to be involved in the treatment of covid-19 overall our results indicated that the parp1 inhibitor cvl218 identified by our drug repositioning pipeline may serve as an effective therapeutic agent against covid-19 2 results 2 1 overview of our drug repositioning framework the overview of our data-driven drug repositioning framework is shown in  1a we first constructed a virus related knowledge graph consisting of drug-target interactions protein-protein interactions and similarity networks from publically available databases methods three different types of nodes drugs human targets and virus targets within the knowledge graph were connected through edges describing their interactions associations or similarities to establish bridges of information aggregation and knowledge mining we then applied a network-based knowledge mining algorithm to predict an initial list of drug candidates that can be potentially used to treat sars-cov-2 infection  1b and methods next we further narrowed down the list of drug candidates with the previously reported evidences of antiviral activities based on the text mining results from the large-scale literature texts which were derived through a deep learning based relation extraction method named bere 4  1c and methods followed by a minimum of manual checking after that we used the connectivity map analysis approach 5 with the gene expression profiles of ten sars-cov-infected patients 6 to further refine the list of drug candidates against sars-cov-2  1d  1  s1 and methods the above screening process revealed that a poly-adp-ribose polymerase 1 parp1 inhibitor pj-34 could potentially have the antiviral activities against sars-cov-2 2 2 validation of our network-based knowledge mining results to demonstrate that our computational pipeline for drug repositioning can yield reasonably accurate prediction results we also validated our network-based knowledge mining algorithm  1b using the retrospective data of the two coronaviruses that are closely related to sars-cov-2 and had been relatively well studied in the literature sars-cov and mers-cov with the aid of our developed text mining tool bere we found that many of the drugs that had been reported previously in the literature to have antiviral activities against the corresponding coronavirus were also among the top list of our predicted results  2 for example chloroquine an fda-approved drug for treating malaria 7 which was previously reported to exhibit micromolar anti-sars-cov activity in vitro 8 was also repurposed for targeting the same virus by our prediction framework gemcitabine which was originally approved for treating certain types of cancers 9 was also predicted for targeting sars-cov with validation by previous in vitro studies 10 cyclosporine a calcineurin inhibitor approved as an immunomodulatory drug 11 was observed to block the replication of sars-cov 12 and also successfully predicted by our approach among the predicted top list for mers-cov miltefosine which was approved for treating leishmaniasis 13 was previously identified to have anti-mers-cov activity 14 chlorpromazine and imatinib which were used for treating schizophrenia 15 and leukemia 16 respectively were also selected by our computational pipeline as anti-mers-cov drugs and can be validated by previous in vitro experiments 10 thus the above retrospective study illustrated that our computational framework is able to predict effective drug candidates against a specific coronavirus 2 3 cvl218 exhibits in vitro inhibitory activity against sars-cov-2 replication as pj-34 is still currently in the pre-clinical trial stage drugbank id db08348 17 we selected two parp1 inhibitors including olaparib and mefuparib hydrochloride cvl218  s1 that are currently fda-approved and at phase i clinical trial respectively for our initial study we first conducted a pilot experimental test in vitro methods on the anti-sars-cov-2 activities of olaparib cvl218 and several other related drugs  2a we found that both parp1 inhibitors olaparib and cvl218 exhibited inhibitory effects against sars-cov-2 replication nevertheless cvl218 showed a much higher inhibition rate than olaparib more specifically olaparib inhibited sars-cov-2 replication by 15 48 at a concentration of 3 2 m while cvl218 reached 35 16 reduction at a concentration of 3 m notably the antiviral efficacy of cvl218 even surpassed arbidol which is one of the standard treatments for covid-19 in the diagnosis and treatment protocol for novel coronavirus pneumonia trial version 6 promulgated by the chinese 351d7da8aefc2 files b218cfeb1bc54639af227f922bf6b817 pdf in particular arbidol inhibited sars-cov-2 replication by 21 73 at 3 m much lower than that of cvl218 at the same concentration  2a in contrast oseltamivir zanamivir drugs used for preventing influenza virus infection and baricitinib jak1 2 inhibitor which was recommended in 18 to treat covid-19 showed no inhibitory activities against sars-cov-2 at the concentration of 3 m or 3 2 m based on the above pilot experimental results we then chose cvl218 for subsequent experimental studies our further in vitro assays methods showed that cvl218 exhibited effective inhibitory activity against sars-cov-2 replication in a dose-dependent manner with an ec50 of 5 12 m  2b we also assessed the cytotoxicity of cvl218 by the cck8 assay methods and found that cvl218 had a cc50 of 91 05 m in vero e6 cells in addition immunofluorescence microscopy methods revealed that at 14 h post sars-cov-2 infection virus nucleoprotein np expression in the cvl218-treated cells demonstrated a dose-response relationship with the treated drug concentrations and was significantly lower upon cvl218 treatment compared with that in the dsmo treated cells  2c no obvious cytopathic effect was observed in the infected cells treated with cvl218 at 25 m to systematically assess the inhibitory activities of cvl218 against sars-cov2 we also performed a time-of-addition assay methods to determine at which stage cvl218 inhibits viral infection remdesivir which has entered the clinical trials for the treatment of covid-19 https clinicaltrials gov ct2 show nct0425765 6 was also tested in this assay for comparison in particular as compared to the dmso control group both cvl218 and remdesivir showed potent antiviral activities during the full-time procedure of the sars-cov-2 infection in vero e6 cells  2d the results of the time-of-addition assay indicated that cvl218 can partially work against the viral entry and significantly inhibit the replication of virus post-entry while the remdesivir can only function at the post-entry stage  2d 2e all together the results of these in vitro assays indicated that cvl218 can be further evaluated as a potential therapeutic agent for treating covid-19 2 4 cvl218 inhibits il-6 production in pbmcs induced by cpg-odn 1826 recently it has become evident that interleukin-6 il-6 is one of the most important cytokines during viral infection 19 and emerging clinical studies in humans and animals have linked the excessive synthesis of il-6 with the persistence of many viruses such as human immunodeficiency virus hiv 20 foot and mouth disease virus 21 and vesicular stomatitis virus vsv 22 in addition an in vivo study in the friend retrovirus fv mouse model showed that il-6 blockage can reduce viral loads and enhance virus-specific cd8 t-cell immunity 23 these findings supported a hypothesis that rapid production of il-6 might be a possible mechanism leading to the deleterious clinical manifestations in viral pathogenesis 24 recently published researches on the clinical characteristics of severe patients with sars-cov-2 infection showed that il-6 was significantly elevated especially in those icu patients which caused excessive activated immune response 25 26 27 28 29 the pathological role of il-6 in sarscov-2 infection indicated that il-6 blockade may provide a feasible therapy for the treatment of covid-19 to test whether cvl218 is able to regulate the il-6 production in vitro we stimulated the il-6 production of the peripheral blood mononuclear cells pmbcs by cpg-odn 1826 which is an effective stimulator of cytokines and chemokines incubation of pbmcs with 1 m cpg-odn 1826 for 6 h methods induced il-6 production by 40 when compared to untreated cells  3 in the presence of cvl218 the stimulatory effect of cpg-odn 1826 was counteracted further study showed that cvl218 inhibited the cpg-induced il-6 upregulation in a time- and dose-dependent manner  3 more specifically exposure with cvl218 at concentrations 1 m and 3 m for 12 h attenuated the cpg-induced il-6 production by 50 and 72 65 respectively these results provided an in vitro evidence to support cvl218 as a potential therapeutic agent for treating pro-inflammatory response caused by sars-cov-2 infection 2 5 cvl218 possesses good pharmacokinetic and toxicokinetic characteristics in animals 2 5 1 cvl218 has the highest tissue distribution in lung of rats we further performed in vivo pharmacokinetic and toxicokinetic evaluation of cvl218 in animals methods we first examined the concentrations of cvl218 over different tissues in rats at different time points post oral administration at different doses  s2 and  s2 which was also previously reported in 30 among seven tissues lung spleen liver kidney stomach heart and brain we observed that lung had the highest cvl218 concentration which was 188-fold higher compared to that of plasma  3 the observation that lung had the highest concentration of cvl218 was in line with the fact that the sars-cov-2 virus has the most pathological impact in lung with high viral loads which suggested that cvl218 has the potential to be used for the indications of the lung lesions caused by sars-cov-2 infection if its antiviral profile can be established in animal models and clinical trials furthermore we compared the pharmacokinetic data between cvl218 and arbidol a broad-spectrum antiviral drug commercialized in china since 2016 had been recommended to treat the sars-cov-2-infected patients by the chinese government we found that the pharmacokinetic parameters of cvl218 and arbidol were comparable with similar plasma concentrations and drug exposures  s3 arbidol was mostly distributed in stomach and plasma post administration in rats in contrast higher distributions of cvl218 in tissues especially in lung rather than plasma compared to those of arbidol indicated a superior pharmacokinetic profile of cvl218 which may render it as a better potential antiviral treatment of sars-cov-2 infection in lung 2 5 2 the toxicity study demonstrated a safety profile of cvl218 in rats in rats after being orally administrated 20 60 160 mg kg of cvl218 for 28 consecutive days and followed by 28 more days without drug administration methods we observed no significant difference in body weight of rats among different dosage and the control groups  4a we next conducted a toxicokinetic analysis of cvl218 in rats methods in particular rats were given cvl218 20 60 160 mg kg by oral gavage once a day for consecutive 28 days followed by 28 days without cvl218 administration to investigate the reversibility of the toxic effects of the compound and examine whether there is any potential delayed-onset toxicity of this drug in rats the results showed that the maximum tolerable dose mtd and the no-observed adverse effect level noael were 160 mg kg and 20 mg kg respectively the exposure of female rats to cvl218 auc0-24 was 7605 h ng ml in day 1 and 6657 h ng ml in day 28 while that of male rats auc0-24 was 9102 h ng ml in day 1 and 10253 h ng ml in day 28  s4 based on the toxicokinetic results from the repeated dose studies all rats survived after a 28-day treatment period and showed no apparent signs of toxicity 2 5 3 cvl218 exhibits a favorable safety profile in monkeys monkeys were administered cvl218 5 20 or 80 mg kg by nasogastric feeding tubes with a consecutive daily dosing schedule for 28 days followed by a 28-day recovery period methods only a slight decrease of body weight was observed in the highdose 80 mg kg group and all changes were reversed after a 28-day recovery period  4b demonstrating a favorable safety profile for cvl218 in monkeys further examination of the toxicokinetic data of cvl218 in monkeys showed that the increase of the exposure of cvl218 auc0-24 was approximately dose proportional and after consecutive 28 days of drug administration the accumulation was not apparent the exposure of female monkeys to cvl218 auc0-24 was 19466 h ng ml in day 1 and 18774 h ng ml in day 28  s5 while that of male monkeys auc0-24 was 16924 h ng ml in day 1 and 22912 h ng ml in day 28 the maximum tolerable dose mtd of cvl218 in monkeys was 80 mg kg and the dose of 5 mg kg was considered as the no-observed adverse effect level noael overall the above in vivo data showed that cvl218 possesses good pharmacokinetic and toxicokinetic characteristics in rats and monkeys and its high-level distribution in the therapeutically targeted tissue lung may greatly favor the treatment of sarscov-2 infection 2 6 molecular docking suggests the interactions between parp1 inhibitors and the nterminal domain of coronavirus nucleocapsid protein as the previous studies have reported that the parp1 inhibitor pj-34 can target the n-terminal domain ntd of the coronavirus nucleocapsid n protein to reduce its rna binding and thus impede viral replication 31 32 33 we speculated that olaparib and cvl218 may also interact with the n protein of sars-cov-2 to perform the similar antiviral function to test this hypothesis we conducted molecular docking to study the potential interactions between these two drugs and the n-ntd of sars-cov-2 methods the overall structure of hcov-oc43 another coronavirus phylogenetically closely related to sars-cov-2 and sars-cov-2 share similar compositions of secondary structure elements including five conserved strands and flexible loops  5a in addition their sequences covering the corresponding binding pocket regions are well conserved  5c thus their structures may provide common molecular features in terms of interactions with small molecules at this binding pocket therefore we also used the experimentally solved structure of hcov-oc43-n-ntd complexed with pj-34 as a reference to analyze our docking results our docking results more details can also be found in supplementary materials showed that both cvl218 and olaparib can bind to the n-ntd of sars-cov-2 around the same binding pocket as in the experimentally solved complex structure between pj34 and the corresponding protein of hcov-oc43 though with different binding poses  5b examination of docked structures indicated that cvl218 exhibits stronger binding ability than olaparib in terms of the hydrogen bond formation meanwhile the key residues s51 y109 and y111 participating in the binding with the drugs on sars-cov-2-n-ntd are also highly conserved among other viruses including sarscov hcov-oc43 mouse hepatitis virus mhv and infectious bronchitis virus ibv  5c suggesting that the n-ntds of different viruses most likely display similar binding behaviors for pj-34 cvl218 or other parp1 inhibitors overall our docking results indicated that cvl218 should be more effective in binding toward the nucleocapsid protein of sars-cov-2 compared to olaparib thus better beneficial to intervene the nucleocapsid-dependent assembly of viral genome and thus inhibit viral replication 3 discussion in this study we reported a top down data integration approach by combining both machine learning and statistical analysis techniques followed by web-lab experimental validation to identify potential drug candidates for treating sars-cov-2 infection we showed that the parp1 inhibitor cvl218 discovered by our in silico drug repurposing framework may have the therapeutic potential for the treatment of covid-19 although we mainly conducted in vitro assays to experimentally validate the anti-sarscov-2 effects of olaparib and cvl218 due to limited time it is natural to speculate that other parp1 inhibitors may also have antiviral activities against sars-cov-2 infection based on our computational prediction and experimental validation results based on the data present in this study and the previously known evidences reported in the literature we propose several potential mechanisms to help understand the involvement of parp1 inhibitors in the treatment of covid-19  6 first during the life cycle of the coronavirus parp1 inhibitors may inhibit the viral growth through suppressing viral replication and impeding the binding of the nucleocapsid protein to viral rnas 31 34 35 36 which can also be supported by our molecular docking results see section 2 6 second parp1 inhibitors have been previously reported to play a critical role in regulating inflammatory response by modulating the expression of pro-inflammatory factors such as nf-b ap-1 il-6 and downstream cytokines and chemokines 37 38 39 40 also it has been shown that the overactivation of parp1 promotes energy nad atp consumption and drives cell death exacerbating the inflammation response 37 38 39 41 parp1 inhibitors thus may repress the nf-b-mediated pro-inflammatory signals and reduce energy failure and subsequent cell death induced by necrosis thus providing a clinical potential for attenuating the cytokine storm and inflammatory response caused by sars-cov-2 infection third adp-ribosylation is a conserved post-translational modification on the nucleocapsid proteins across different coronavirus lineages implying that it may have an important regulatory role for the structure packing of viral genome several previous studies have demonstrated that parp1 is critical for viral replication 35 42 43 for example parp1 has been reported to interact with hemagglutinin ha of influenza a virus iav and promote its replication by triggering the degradation of host type i ifn 12 receptor 44 in addition the adp-ribosylation of adenoviral core proteins displays an antiviral defense mechanism 34 therefore intervening the adp-ribosylation mediated interplay between parp1 and viral proteins may be another important pathway for parp1 inhibitors to prevent sars-cov-2 infection of course to throughly understand the anti-sars-cov-2 roles of parp1 inhibitors more experimental studies and direct clinical evidences will be needed in the future considering the pro-inflammatory role of parp1 the therapeutic effects of parp1 inhibitors in inflammatory-mediated diseases have been extensively studied over past two decades 45 46 pj-34 the early generation parp1 inhibitor has been suggested in previous studies to have neuroprotective effects in stroke model and protect mice from necroptosis-associated liver injuries by repressing the il-33 expression 47 48 in addition the fda-approved parp1 inhibitor olaparib has been reported to protect against the lps lipopolysaccharide -induced acute lung and kidney injuries in a nf-b-dependent manner in mice 49 numerous pre-clinical studies demonstrated that parp1 inhibitors play an essential role in a range of inflammatory injuries and related diseases especially the lung inflammatory disorders including ards acute respiratory distress syndrome copd chronic obstructive pulmonary disease and asthma 40 46 50 51 all these studies suggest that parp1 inhibitors are of high relevance to the treatment of the novel pneumonia caused by sars-cov-2 infection possibly via their roles in modulating inflammatory response notably current pathological studies have shown that the severe patients infected by sars-cov-2 generally have higher plasma levels of il-2 il-6 il-10 tnf ifn- 25 27 28 29 implying a high risk of the inflammatory-associated cytokine storm after viral infection in addition reduction and functional exhaustion of t cells have also been observed in covid-19 patients 27 therefore blocking the overactive inflammatory response may be an effective strategy for the treatment of covid-19 particularly for those icu patients infected by sars-cov-2 recently tocilizumab a monoclonal anti13 body drug targeting il-6 has been recommended for the treatment of covid-19 in the diagnosis and treatment protocol for novel coronavirus pneumonia trial version 7 2003 46c9294a7dfe4cef80dc7f5912eb1989 files ce3e6945832a438eaae415350a8c e964 pdf which also highlights the vital role of anti-inflammatory response in current therapeutics against sars-cov-2 our in vitro study has showed that cvl218 can effectively inhibit the il-6 production induced by cpg in pbmcs  3 this finding indicates that cvl218 may also possess the il-6 specific anti-inflammatory effect that is applicable to those severe patients infected by sars-cov-2 parp1 inhibitors are originally used for targeting homologous recombination repair defects in cancers and mainly categorized as oncology drugs thus it would generally need more safety data to justify any repurposing of parp1 inhibitors for non-oncology indications fortunately there are numerous existing pre-clinical and clinical studies on repurposing parp1 inhibitors into non-oncological diseases including the aforementioned acute diseases e g acute respiratory distress syndrome ards stroke 52 and chronic diseases e g rheumatoid arthritis and vascular diseases 52 53 all these evidences indicate the possibility of repurposing parp1 inhibitors as a safe therapeutic agent to treat the current acute lung disease caused by sars-cov-2 infection in addition our pharmacokinetic and toxicokinetic data in rats and monkeys shown in our study indicate that cvl218 may have a relatively accep safety profile to be repositioned for the antiviral purpose moreover cvl218 has been approved to enter phase i clinical trial in 2017 by national medical products administration nmpa in china for cancer treatment the preliminary data from the phase i clinical trial have shown that cvl218 is well tolerated in ascending dose studies at doses as high as 1000 mg qd and 500 mg bid and no grade ii and above adverse events have been observed which indicates that cvl218 is also quite safe and well tolerated in human our pharmacokinetic examination in rats has shown that cvl218 has the highest 14 level distribution in the lung tissue 188-fold higher concentration compared to that in plasma such a tissue specific enrichment in lung may bring an extra advantage for cvl218 to be used for the anti-sars-cov-2 purpose as lung is the therapeutically targeted tissue for covid-19 moreover high level distribution in lung may also suggest that only low dosage is needed in order to ensure the therapeutic efficacy of cvl218 against sars-cov-2 which may further reduce the risk of adverse events thus cvl218 may have great potential to be repurposed as an effective therapeutic agent to combat sars-cov-2 and prevent future epidemic outbreak 15 4 methods 4 1 construction of the virus-related knowledge graph the virus-related knowledge graph was constructed for predicting the coronavirus related drugs in total seven networks were considered in the constructed knowledge graph  1b including a human target-drug interaction network a virus target-drug interaction network a human protein-protein interaction network a virus protein-human protein interaction network a drug molecular similarity network a human protein sequence similarity network and a virus protein sequence similarity network the human target-drug interaction network was derived from drugbank version 5 1 0 17 the virus target-drug interaction network was constructed from the integrated data from drugbank version 5 1 0 17 chembl release 26 54 ttd last update 11 nov 2019 55 iuphar bps release 13 nov 2019 56 bindinddb 57 and ghddi https ghddi-ailab github io targeting2019-nco v cov experiment data with a cut-off threshold of ic50 ec50 ki kd 10 m the human protein-protein interaction network and the virus protein-human protein interaction network were constructed from the integrated data from biogrid release 3 5 181 58 huri 59 instruct 60 mint 2012 update 61 pina v2 0 62 signalink v2 0 63 and innatedb 64 the drug molecular similarity network was obtained by calculating the tanimoto similarities from morgan fingerprints with a radius of 2 computed using the rdkit tool 65 the protein sequence similarity networks of both human and virus were obtained by calculating the smith-waterman similarities of the amino acid sequences derived from uniprot 66 using a sequence alignment software provided in 67 noted that we collected additional protein sequences of sars-cov-2 from uniprot 66 and added them into the corresponding networks for the final prediction those drugs without drug-target interactions or outside the drugbank database were removed from the corresponding networks we then constructed the virus-related knowledge graph by merging together all the nodes and edges of the 16 above seven networks  1b the constructed knowledge graph g v e is an undirected graph in which each node v v in the node set v belongs to one of the node types including drugs human proteins and virus proteins and each edge e e in the edge set e v v r belongs to one of the relation types from the relation type set r including two drug-target interactions two protein-protein interactions and three similarities 4 2 the network-based knowledge mining algorithm the initial list of drug candidates targeting sars-cov-2 was first screened using a network-based knowledge mining algorithm modified from our previous work 68 69 the goal was to capture the hidden virus-related feature information and accurately predict the potential drug candidates from the constructed knowledge graph which was realized through learning a network topology-preserving embedding for each node more specifically our model used a graph convolution algorithm 70 to gather and update feature information for each node in the constructed heterogeneous knowledge graph network from neighborhoods so that the network topology information can be fully exploited suppose that we perform t iterations of graph convolution at iteration 1 t t the message mt v passed to node v can be expressed as mt v rr unr v e uvr e auvrrelu w t r ht-1 u bt r 1 where avur stands for the weight for edge e u v r auvr avur u avur w t r rd d and bt r rd stand for the learnable parameters relu x max 0 x and nr v u u v u v u v r e denotes the set of adjacent nodes connected to v v through edges of type r r then the feature ht v of node v is updated by ht relu w t concat ht-1 v mt v ht-1 v bt relu w tconcat ht-1 v bt 2 2 17 where w t rd d rd stand for the learnable parameters and concat stands for the concatenation operation finally the confidence score suv of the relation r between node u and node v is derived from the learned node embeddings and the corresponding projection matrices that is suv ht u gr hr ht v 3 where gr hr rd k stand for the edge-type specific projection matrices we minimized the bayesian personalized ranking bpr loss 71 for drug-target interaction reconstruction by regarding those edges not in the edge set e as missing values rather than negative samples that is rr uvwxv uvr e wxr e - log suv - swx 4 where suv and swx stand for the confidence scores of the relation r between u and v and between w and x respectively and stands for the sigmoid activation function intuitively in the above loss function the confidence scores of the node pairs u v in the edge set u v r e were encouraged to be higher than those of unseen pairs w x w x r e we predicted the confidence scores under the relation of virus target-drug interactions for each virus target-drug pair using equation 3 then the confidence scores were averaged across all the proteins of a certain virus e g sars-cov mers-cov or sars-cov-2 and the corresponding p-values were obtained by z-test for each virus we selected those predictions with a p-value 0 05 as drug candidates 4 3 automated relation extraction from large-scale literature texts we used a deep learning based relation extraction method named bere 4 to extract the coronavirus related drugs from large-scale literature texts more specifically 18 the sentences mentioning the two entities of interest name or alias of a coronavirus or coronavirus target or name or alias of a drug were first collected using a dictionarybased name entity recognition method string matching for each pair of entities e1 e2 there are usually more than one sentence describing the underlying relations therefore we used a bag of sentences se1e2 denoting the set of all the sentences mentioning both e1 and e2 to predict the relation between these two entities we first encoded each sentence s se1e2 in a semantic and syntactic manner using a hybrid deep neural network h s rd including a self-attention module 72 a bidirectional gated recurrent unit gru module 73 and a gumbel tree-gru module 4 74 each sentence representation h s was then scored by a sentence-level attention module to indicate its contribution to the relation prediction that is s exp ws h s s se1e2 exp ws h s 5 where s r stands for the weight score and ws rd 1 stands for the learnable weight parameters finally the relation was predicted by a binary classifier based on the weighted sum of sentence representations that is re1e2 classifier sse1e2 s h s 6 where re1e2 stands for the probability of the relation of interest between entities e1 and e2 mentioned by the bag of sentences se1e2 the training corpus we used was curated automatically from nearly 20 million in detail the names or aliases of drugs or targets in sentences were first annotated by a dictionary-based named entity recognition method string matching in which the name dictionary was derived from drugbank version 5 1 0 17 with ambiguous names e g common words removed next the label for each bag of sentences co19 mentioning a drug-target pair of interest was annotated automatically by the known drug-target interactions in drugbank the unlabeled corpus that we used in this work for text-mining the coronavirus related drugs was obtained from approximately 2 2 million pmc full-text articles with entities of interest annotated using the aforementioned named entity recognition approach a coronavirus related drug was extracted as a hit candidate if the model found a bag of sentences describing a relation between this drug and a target in the coronavirus of interest 4 4 connectivity map analysis we used the transcriptome analysis approach to further filter the potential drug candidates for treating the covid-19 patients infected by sars-cov-2 due to the lack of gene expression data from the sars-cov-2 infected patients we used those from the sars-cov infected patients to screen the potential therapeutic drug candidates against covid-19 such a strategy is reasonable as sars-cov and sars-cov-2 are two closely related and highly similar coronavirus first the genome of sarscov-2 is phylogenetically close to that of sars-cov with about 79 of sequence identity 76 and the m membrane n nucleocapsid and e envelope proteins of these two coronaviruses have over 90 sequence similarities 77 in addition the pathogenic mechanisms of sars-cov-2 and sars-cov were highly similar 78 in particularly we collected the gene expression profiles of the peripheral blood mononuclear cells pbmcs from ten sars-cov infected patients geo gse1739 6 the raw gene expression values were first converted into logarithm scale and then the differential expression values z-scores were computed by comparing to those of healthy persons using the same protocol as described in 5 that is zinfected xinfected - median xhealthy c mad xhealthy 7 mad xhealthy median xhealthy - median xhealthy 8 20 where zinfected stands for the z-scores of the sars-cov infected patients xinfected and xhealthy stand for the gene expression values in logarithm scale of the infected and healthy persons respectively median stands for the median operation mad stands for the median absolute deviation operation and c 1 4826 is a constant for normalization the p-values for all the genes with measured expression values during the analysis were also computed based on the z-scores the up- and down-regulated genes were then identified using a cut-off threshold of p-value 10-10 we used the connectivity map cmap 5 which contains the cellular gene expression profiles under the perturbation of 2428 well annotated reference compounds to measure the associations of gene expression patterns between sars-cov infected patients and the reference compound-perturbed cells the connectivity map scores were computed based on the up- and down-regulated gene sets of sars-cov infected patients using the web tool https clue io query under the hypothesis that the gene expression pattern resulting from the perturbation by a therapeutic compound should be negatively correlated with that resulting from the coronavirus infection we selected those compounds that have significant negative connectivity map scores that is the list of drug candidates predicted to treat the coronavirus infected patients was obtained by selecting the compounds with the connectivity map scores -90 which was suggested by the original paper 5 4 5 cells and virus the african green monkey kidney vero e6 cell line was purchased from the cell resources center of shanghai institute of life science chinese academy of sciences shanghai china and cultured in dmem medium gibco invitrogen no 12430-054 containing 10 fetal bovine serum fbs gibco invitrogen at 37 c with 5 co2 atmosphere betacov js03 human 2020 epi isl 411953 a sars-cov-2 virus strain was isolated from nasopharyngeal swab of a 40-year old female confirmed as covid-19 case by reverse transcriptase polymerase chain reaction rt-pcr in december 2019 21 the virus was propagated in vero e6 cells and the viral titer was determined by the 50 tissue culture infective dose tcid50 based on microscopic observation of cytopathic effects all the in vitro sars-cov-2 infection experiments were performed in a biosafety level-3 bls-3 laboratory in jiangsu provincial center for diseases control and prevention jiangsu china 4 6 antiviral drugs potential antiviral drugs including zanamivir oseltamivir remdesivir baricitinib olaparib and arbidol were all provided by mce medchem express china the parp1 inhibitor mefuparib hydrochloride cvl218 with a purity of more than 99 0 was provided by convalife shanghai china 4 7 cytotoxicity test and virus infection assay the cytotoxicity of the tested drugs on vero e6 cells was determined by the cck8 assays beyotime china at 48 h post addition of the tested drugs 20 l cck8 was added to each well and incubated at 37 c for 1 h then optical density was measured at 450 nm the 50 cytotoxic concentration cc50 values were calculated using graphpad prism graphpad software usa vero e6 cells were seeded into 96-well plates with a density of 5 104 cells well for incubation in dmem medium supplemented with 10 fbs for 16 h in an incubator with 5 co2 at 37 c for cells to reach 80 confluent then cell culture medium of each well was removed and pbs was used to wash the cells once before evaluating the antiviral efficacy of the drugs four duplicated wells were made for each dose of drugs and the cells were pre-treated with different doses of antiviral drugs diluted by the cell maintenance solution 50 l per well for 1 h for the virus control and cell control wells cell medium containing dmso or only medium of 50 l per well was added next pre-treated or untreated cells in each well were infected with the virus with multiplicity of infection moi of 0 05 for 2 h after that the virus-drug mixture was removed and cells were further 22 cultured with fresh drug-containing medium at 37 c with 5 co2 atmosphere for 48 h then culture supernatant per well was harvested and inactivated at 56 c for 30 min to further extract and quantify viral rna 4 8 viral rna extraction and quantitative real-time pcr qrt-pcr viral rna was extracted from culture supernatant using the hp rna isolation kit roche according to the manufacturer s instructions rna was eluted in 30 l rnase-free water reverse transcription was performed with a sars-cov-2 nucleic acid detection kit biogerm china according to the manufacturer s instructions the pcr reaction system was cond as follows 6 l of qrt-pcr reaction solution 2 l of qrt-pcr enzyme mixture 2 l of primer probe and 2 5 l of template and the reaction was performed as follows 50 c for 10 min 95 c for 5 min followed by 40 cycles of 95 c for 10 s 55 c for 40 s the values of 2-ct were calculated according to the ct value measured from the pcr instrument to represent the relative virus copies of the drug group to the control group the virus replication inhibition rate was calculated as 1-2-ct 100 the dose-response curves were plotted according to viral rna copies and the drug concentrations using graphpad prism graphpad software usa 4 9 time-of-addition assay to facilitate the observation of the antiviral effects of drugs against sars-cov-2 at different timing relative high doses of the tested drugs cvl218 at 20 m and remdesivir at 10 m were used for the time-of-addition assay vero e6 cells with a density of 5 104 cells per well were treated with the tested drugs or dmso as controls at different stages of virus infection the cells were infected with virus at an moi of 0 05 the full-time treatment was to evaluate the maximum antiviral effects with the tested drugs in the cell culture medium during the whole experiment process which was consistent with the descriptions in the virus infection assay for the entry 23 treatment the tested drug was added to the cells for 1 h before virus infection and then cells were maintained in the drug-virus mixture for 2 h during the virus infection process after that the culture medium containing both virus and the tested drug was replaced with fresh culture medium till the end of the experiment for the postentry experiment virus was first added to the cells to allow infection for 2 h before the virus-containing supernatant was replaced with drug-containing medium until the end of the experiment at 14 h post infection the viral inhibition in the cell supernatants of the tested drug was quantified by qrt-pcr and calculated using the dmso group as reference 4 10 indirect immunofluorescence assay vero e6 cells were treated with cvl218 at 5 m 15 m and 25 m respectively following the same procedure of full-time treatment infected cells were fixed with 80 acetone in pbs and permeabilized with 0 5 triton x-100 and then blocked with 5 bsa in pbs buffer containing 0 05 tween 20 at room temperature for 30 min the cells were further incubated with a rabbit polyclonal antibody against a sars-cov nucleocapsid protein cambridgebio usa as primary antibody at a dilution of 1 200 for 2 h followed by incubation with the secondary alexa 488-labeled goat anti-rabbit antibody beyotime china at a dilution of 1 500 nuclei were stained with dapi beyotime china immunofluorescence was observed using fluorescence microscopy 4 11 western blot assay np expression in infected cells was analyzed by western blot protein samples were branes millipore usa before being blocked with 6 rapid block buff ii sangon biotech china at room temperature for 10 min the blot was probed with the antibody against the viral nucleocapsid protein cambridgebio usa and the horseradish peroxidase-conjugated goat anti-rabbit igg abcam usa as the primary and the 24 secondary antibodies respectively protein bands were detected by chemiluminescence using an ecl kit sangon biotech china 4 12 cpg-pdn1826 induced il-6 production in pbmcs peripheral blood mononuclear cells yicon china were cultured at 37 c at concentration 5 co2 atmospheric on a 96-well plate in rpmi1640 cell growth medium corning cat 10-040-cvr for stimulation pbmc cells were incubated with 1 m cpg-odn1826 invivogen cat tlrl-1826 to test whether cvl218 can inhibit il6 production 1 m and 3 m concentrations of cvl218 were added to cell culture medium for 6 and 12 h respectively the concentration of il-6 was determined by elisa using a commercial kit dakewe biotech cat 1110602 4 13 pharmacokinetics and toxicity study sprague-dawley rats were purchased from shanghai laboratory animal center china the animals were grouped and housed in wire cages with no more than six per cage under good laboratory conditions temperature 25 2 c relative humidity 50 20 and with dark and light cycle 12 h 12 h only healthy animals were used for experimental purpose the pharmacokinetics and biodistribution study in sprague-dawley rats was approved by center for drug safety evaluation and research shanghai institute of materia medica chinese academy of sciences a total of 144 sprague-dawley rats with each sex were used for toxicity study animals were randomly separated into four groups 18 sex group cvl218 was administered at doses of 20 40 60 and 160 mg kg for all the groups 20 rats 10 sex group were randomly selected and euthanized at day 28 and their sections of various tissues and organs were obtained and frozen ten 5 sex group animals were euthanized after a 28-day drug free period and their sections of tissues and organs were obtained and frozen six 3 sex group were euthanized after the blood-samples were obtained for pharmacokinetic and toxicity evaluation clinical symptoms mortality and the animals body 25 weight were examined serum 0 5 ml was collected to analyze toxicokinetics at different time points post drug administration the plasma concentration-time data were analyzed using a non-compartmental method phoenix version 1 3 usa to derive the pharmacokinetic parameters 4 14 biodistribution study thirty sprague-dawley rats were randomly divided into three time point groups 3 sex group at 3 6 and 8h after cvl218 administration animals were sacrificed and the brain heart lung liver spleen stomach and kidney tissues were collected tissue samples were washed in ice-cold saline blotted with paper towel to remove excess fluid and weighed tissue samples were fluid weighted and stored at -20 2 c until the determination of drug concentration by lc-ms-ms 4 15 toxicity study in cynomolgus monkeys healthy male and female cynomolgus monkeys aged 3 4 years were purchased from guangdong landau biotechnology china the animals were maintained in accordance with the guide for the care and use of laboratory animals cynomolgus monkey 5 sex group were selected using a computerized randomization procedure and administered cvl218 by nasogastric feeding at dose levels of 0 control 5 20 80 mg kg individual dose volumes were adjusted weekly based on body weight of monkeys the monkeys were observed twice daily for viability mortality and for any change in behavior reaction to treatment or ill-health electrocardiograms intraocular pressure rectal temperature and body weight were recorded for all the groups 2 3 of the animals were randomly selected and euthanized at day 28 the remaining animals were euthanized after a 28-day drug free period blood samples were taken before and at 0 5 1 2 4 8 and 24 h post-dose on days 1 and 28 of the treatment period pharmacokinetic evaluation was performed using a non-compartmental method phoenix version 1 3 usa and pharmacokinetic parameters were calculated 26 for individual monkeys 4 16 statistical analysis all data represent the means standard deviations sds of n values where n corresponds to the number of data points used the s were prepared using graphpad prism graphpad software usa the statistical significance was calculated by spss ver 12 and two values were considered significantly different if the p-value is 0 05 4 17 molecular docking the docking program autodock4 2 79 was used to model the molecular interactions between parp1 inhibitors cvl218 and olaparib to the n-terminal domain of the n protein of sars-cov-2 sars-cov-2-n-ntd the structure of sars-cov-2-n-ntd used for molecular docking was built from homology modeling 80 the autogrid program was used to generate a grid map with 60 60 60 points spaced equally at 0 375 a for evaluating the binding energies between the protein and the ligands 27 acknowledgement this work was supported in part by the national natural science foundation of china 61872216 81630103 31900862 jiangsu provincial emergency project on prevention and control of covid-19 epidemic be2020601 the nation science and technology major projects for major new drugs innovation and development 2018zx09711003004-0022019zx09301010 pudong new area science and technology development foundation pkx2019-s08 and the turing ai institute of nanjing and the zhongguancun haihua institute for frontier information technology the authors thank dr feixiong cheng for email communications on the connectivity map analysis 28 29 for discovering the potential drugs to treat the covid-19 disease a the overview of our drug screening pipeline the initial drug set for screening contains 6255 drug candidates mainly including 1786 approved drugs 1125 investigational drugs and 3290 experimental drugs the number of drug candidates after each filtering step is also shown b the network-based knowledge mining module seven individual networks containing three types of nodes drugs human targets and virus targets and the corresponding edges describing their interactions associations or similarities are first constructed based on the known chemical structures protein sequences and relations derived from publically available databases then a deep learning based method which learns and updates the feature representation of each node through information aggregation is used to predict the potential drug candidates against a specific coronavirus c the automated relation extraction module the structure of each sentence from the literature texts is first learned from the encoded word features using the gumbel tree gated recurrent unit technique 4 74 then the learned sequence structures as well as the corresponding encoded word features are fed into a relation classifier to automatically extract the relations between two entities from large-scale documents in the literature d the connectivity map cmap analysis module the transcriptome profiles of the peripheral blood mononuclear cell pbmc samples from the sars-cov infected patients and healthy persons are compared to derive the query gene expression signatures which are then correlated to the drug-perturbed cellular expression profiles in the connectivity map 5 to filter out the anti-sars-cov drug candidates 30 31 a the in vitro inhibition rates of multiple tested drugs on sars-cov-2 replication at individual concentrations b the concentration-dependent inhibition curve of cvl218 against sars-cov-2 replication and its cytotoxicity results c visualization of virus nucleoprotein np expression of the infected cells upon treatment of cvl218 at 14 h post the sars-cov-2 infection using fluorescence microscopy d time-ofaddition results on the inhibition of cvl218 and remdesivir against sars-cov-2 in vitro the viral inhibitory activities of cvl218 and remdesivir were measured at fulltime entry and post-entry stages respectively e virus np expression in the infected cells upon the treatment of cvl218 and remdesivir was analyzed by western blot 32  3 cvl218 attenuates the cpg-induced il-6 production in a time- and dosedependent manner 33  4 effects of cvl218 on body weight in rats a and monkeys b rats and monkeys were orally administered 20 60 160 mg kg and 5 20 80 mg kg of cvl218 respectively for 28 consecutive days and then followed by 28 more days without drug administration 34 35 cleocapsid protein n-ntd of sars-cov-2 complexed with parp1 inhibitors a overall complex structures of hcov-oc43-n-ntd the n-ntd of hcov-oc43 bound to pj-34 pdb id 4kxj and sars-cov-2-n-ntd the n-ntd of sarscov-2 bound to cvl218 and olaparib both modeled by autodock4 2 in ribbon view the structure of sars-cov-2-n-ntd that we used for docking simulation was derived from homology modeling 80 with residues ranging from 47 to 177 genbank qhd43423 b detailed molecular interactions between the coronavirus n-ntds and parp1 inhibitors left panel the experimentally solved complex structure of hcov-oc43-n-ntd cyan ribbon bound to pj-34 yellow sticks middle panel the modeled complex structure of sars-cov-2-n-ntd purple ribbon bound to cvl218 yellow sticks right panel the modeled complex structure of sars-cov-2-n-ntd purple ribbon bound to olaparib yellow sticks the key residues interacting with the inhibitors are shown as green sticks the hydrogen bonds are denoted as pink dashes c multiple sequence alignment performed using muscle 81 of the nntds among sars-cov-2 sars-cov hcov-oc43 mouse hepatitis virus mhv and infectious bronchitis virus ibv the virus names are listed on the left with available pdb codes shown in the parentheses the sequence of sars-cov-2-n-ntd was obtained from genbank qhd43423 secondary structure elements of hcov-oc43-n are depicted above the sequence alignment asterisks indicate the key residues interacting with the inhibitors the residues conserved among all five viruses are shaded in red the residues with the percentage of conservation larger than 50 are shaded in green and the similar residues are shaded in yellow 36 37 the covid-19 disease derived based on the data present in this study and the known antiviral activities of parp1 inhibitors previously reported in the literature a schematic diagram showing the possible antiviral mechanisms of parp1 inhibitors in the life cycle of coronavirus in human cells parp1 inhibitors have been previously reported in the literature to suppress viral replication and imped the binding of nucleocapsid protein to viral rnas thus preventing the virus infection 31 34 35 36 b potential protective effects of parp1 inhibitors in the treatment of covid-19 the antiinflammation effects of parp1 inhibitors may be achieved through two possible molecular pathways the first one is to modulate the expression of pro-inflammation factors such as nf-b ap-1 il-6 and downstream cytokines and chemokines 37 38 39 40 the second possible pathway is to prevent the overactivation of parp1 and thus avoid the depletion of nad and atp and the consequent cellular energy failure and cell death caused by necrosis 37 38 39 40 c the potential antiviral effects of parp1 inhibitors through suppressing the adp-ribosylation of viral proteins and intervening the host-pathogen interactions thus resulting in the inhibition of viral replication 34 35 42 43 38  1 the top list of drug candidates identified by the connectivity map analysis using the gene expression profiles of the peripheral blood mononuclear cell pbmc samples of ten sars-cov-infected patients 6 the connectivity map score 5 of -90 0 was used as the cut-off threshold to determine the top list only those drug candidates with the connectivity scores of the query ranked to the top 10 of the reference perturbations were selected two parp1 inhibitors veriparib and pj34 were chosen into the top list shown in bold connectivity map score compound brd id name description -98 94 brd-k87142802 veliparib parp inhibitor -95 37 brd-a35338386 neca adenosine receptor agonist -95 26 brd-k11853856 pj-34 parp inhibitor -92 96 brd-a53952395 prilocaine local anesthetic -91 8 brd-k32977963 eugenol androgen receptor antagonist -91 56 brd-a09495397 bicuculline gaba receptor antagonist -91 32 brd-k82164249 andarine androgen receptor modulator 39  2 selected examples of the predicted drug candidates against sars-cov or mers-cov that can be validated by the literature evidences in a retrospective study the drug candidates were first predicted using our network based knowledge mining algorithm with a cut-off threshold of p-value 0 05 then the identified drug candidates were validated using an automated relation extraction method from the large-scale literature texts followed by a minimum of manual checking drug name virus original targetsa original indicationsb '"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "k = preprocess(total_sentence)\n",
    "k"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "word_list1 = k.split()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\arbre\\AppData\\Local\\Continuum\\anaconda3\\lib\\site-packages\\ipykernel_launcher.py:2: TqdmDeprecationWarning: This function will be removed in tqdm==5.0.0\n",
      "Please use `tqdm.notebook.tqdm` instead of `tqdm.tqdm_notebook`\n",
      "  \n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "181e8dedc76c44a6a834de47a75c56b3",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, max=8658.0), HTML(value='')))"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "new_total = []\n",
    "for word in tqdm_notebook(word_list1):\n",
    "    if word[-1]=='s' and word[:-1] in word_list1:\n",
    "        new_total.append(word[:-1])\n",
    "    else:\n",
    "        new_total.append(word)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "word_list2 = [x for x in new_total if len(x)>=3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'the'"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "word_list2[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6672"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(word_list2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "total_sentence = ' '.join(word_list2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('no_plural_total_sentence.txt', 'w', encoding='utf-8') as f:\n",
    "    f.write(total_sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "# minn=3, maxn=5, dim=100, lr=0.05, epoch=5가 default\n",
    "\n",
    "dim=100\n",
    "lr=0.05\n",
    "epoch=15\n",
    "minn=3\n",
    "maxn=7\n",
    "\n",
    "model = fasttext.train_unsupervised('./no_plural_total_sentence.txt', model='skipgram', minn=minn, epoch=epoch)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### default로 5번 이상 등장하는 단어만 사용 "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['the',\n",
       " 'and',\n",
       " 'for',\n",
       " 'with',\n",
       " 'drug',\n",
       " 'that',\n",
       " 'were',\n",
       " 'are',\n",
       " 'cell',\n",
       " 'from',\n",
       " 'virus',\n",
       " 'protein',\n",
       " 'sars-cov-2',\n",
       " 'this',\n",
       " 'coronavirus',\n",
       " 'covid-19',\n",
       " 'treatment',\n",
       " 'infection',\n",
       " 'viral',\n",
       " 'inhibitor',\n",
       " 'human',\n",
       " 'patient',\n",
       " 'used',\n",
       " 'figure',\n",
       " 'antiviral',\n",
       " 'which',\n",
       " 'against',\n",
       " 'have',\n",
       " 'disease',\n",
       " 'protease',\n",
       " 'binding',\n",
       " 'using',\n",
       " 'clinical',\n",
       " 'sars-cov',\n",
       " '2019-ncov',\n",
       " 'doi',\n",
       " 'these',\n",
       " 'compound',\n",
       " 'target',\n",
       " 'data',\n",
       " 'also',\n",
       " 'chloroquine',\n",
       " 'structure',\n",
       " 'can',\n",
       " 'model',\n",
       " 'interaction',\n",
       " 'potential',\n",
       " 'effect',\n",
       " 'all',\n",
       " 'sar',\n",
       " 'respiratory',\n",
       " 'residue',\n",
       " 'china',\n",
       " 'result',\n",
       " 'two',\n",
       " 'study',\n",
       " 'other',\n",
       " 'mpro',\n",
       " 'activity',\n",
       " 'therapeutic',\n",
       " 'been',\n",
       " 'acid',\n",
       " 'not',\n",
       " 'our',\n",
       " 'table',\n",
       " 'rna',\n",
       " 'molecular',\n",
       " 'novel',\n",
       " 'agent',\n",
       " 'molecule',\n",
       " 'between',\n",
       " 'receptor',\n",
       " 'trial',\n",
       " 'analysis',\n",
       " 'sequence',\n",
       " 'may',\n",
       " 'both',\n",
       " 'replication',\n",
       " 'new',\n",
       " 'site',\n",
       " 'method',\n",
       " 'such',\n",
       " 'approved',\n",
       " 'host',\n",
       " 'gene',\n",
       " 'docking',\n",
       " 'their',\n",
       " 'into',\n",
       " 'inhibit',\n",
       " 'infected',\n",
       " 'than',\n",
       " 'shown',\n",
       " 'fig',\n",
       " 'one',\n",
       " 'wang',\n",
       " 'value',\n",
       " 'more',\n",
       " 'severe',\n",
       " 'inhibition',\n",
       " 'including',\n",
       " 'candidate',\n",
       " 'screening',\n",
       " 'based',\n",
       " 'could',\n",
       " 'after',\n",
       " 'vitro',\n",
       " 'available',\n",
       " 'lung',\n",
       " 'influenza',\n",
       " 'number',\n",
       " 'syndrome',\n",
       " 'time',\n",
       " 'concentration',\n",
       " 'use',\n",
       " 'each',\n",
       " 'spike',\n",
       " 'acute',\n",
       " 'further',\n",
       " 'day',\n",
       " 'reported',\n",
       " 'first',\n",
       " 'medicine',\n",
       " 'different',\n",
       " 'chemical',\n",
       " 'viruse',\n",
       " 'case',\n",
       " 'function',\n",
       " 'well',\n",
       " 'studies',\n",
       " 'airway',\n",
       " 'assay',\n",
       " 'active',\n",
       " 'expression',\n",
       " 'science',\n",
       " 'research',\n",
       " 'response',\n",
       " 'there',\n",
       " 'vaccine',\n",
       " 'repurposing',\n",
       " 'combination',\n",
       " '3clpro',\n",
       " 'journal',\n",
       " 'liu',\n",
       " 'effective',\n",
       " 'network',\n",
       " 'performed',\n",
       " 'pneumonia',\n",
       " 'group',\n",
       " 'development',\n",
       " 'control',\n",
       " 'information',\n",
       " 'chip',\n",
       " 'domain',\n",
       " 'ritonavir',\n",
       " 'ace2',\n",
       " 'then',\n",
       " 'through',\n",
       " 'entry',\n",
       " 'high',\n",
       " 'showed',\n",
       " 'found',\n",
       " 'under',\n",
       " 'review',\n",
       " 'remdesivir',\n",
       " 'mers-cov',\n",
       " 'zhang',\n",
       " 'cvl218',\n",
       " 'energy',\n",
       " 'mers',\n",
       " 'enzyme',\n",
       " 'however',\n",
       " 'set',\n",
       " 'efficacy',\n",
       " 'university',\n",
       " 'fda',\n",
       " 'patent',\n",
       " 'cov',\n",
       " 'med',\n",
       " 'surface',\n",
       " 'compared',\n",
       " 'most',\n",
       " 'coronaviruses',\n",
       " 'level',\n",
       " 'hcov',\n",
       " 'form',\n",
       " 'related',\n",
       " 'ligand',\n",
       " 'possible',\n",
       " 'discovery',\n",
       " 'chain',\n",
       " 'outbreak',\n",
       " 'only',\n",
       " 'top',\n",
       " 'rdrp',\n",
       " 'mechanism',\n",
       " 'wuhan',\n",
       " 'treat',\n",
       " 'red',\n",
       " 'amino',\n",
       " 'test',\n",
       " 'score',\n",
       " 'health',\n",
       " 'rbd',\n",
       " 'complex',\n",
       " 'author',\n",
       " 'system',\n",
       " 'prediction',\n",
       " 'potent',\n",
       " 'associated',\n",
       " 'but',\n",
       " 'targeting',\n",
       " 'interferon',\n",
       " 'known',\n",
       " 'three',\n",
       " 'key',\n",
       " 'will',\n",
       " 'role',\n",
       " 'learning',\n",
       " 'hydroxychloroquine',\n",
       " 'database',\n",
       " 'respectively',\n",
       " 'similar',\n",
       " 'library',\n",
       " 'experimental',\n",
       " 'type',\n",
       " 'show',\n",
       " 'line',\n",
       " 'those',\n",
       " 'state',\n",
       " 'identified',\n",
       " 'calculated',\n",
       " 'several',\n",
       " 'qtc',\n",
       " 'caused',\n",
       " 'obtained',\n",
       " 'chen',\n",
       " 'thus',\n",
       " 'vero',\n",
       " 'during',\n",
       " 'when',\n",
       " 'among',\n",
       " 'national',\n",
       " 'yang',\n",
       " 'reference',\n",
       " 'lopinavir',\n",
       " 'predicted',\n",
       " 'they',\n",
       " 'calculation',\n",
       " 'over',\n",
       " 'action',\n",
       " 'sars-',\n",
       " 'therapy',\n",
       " 'profile',\n",
       " 'hiv',\n",
       " 'polymerase',\n",
       " 'signature',\n",
       " 'selected',\n",
       " 'positive',\n",
       " 'addition',\n",
       " 'lead',\n",
       " 'who',\n",
       " 'containing',\n",
       " 'design',\n",
       " 'medium',\n",
       " 'region',\n",
       " 'clq',\n",
       " 'treated',\n",
       " 'side',\n",
       " 'global',\n",
       " 'bond',\n",
       " 'bind',\n",
       " 'pathway',\n",
       " 'pandemic',\n",
       " 'current',\n",
       " 'immune',\n",
       " 'work',\n",
       " 'virtual',\n",
       " 'same',\n",
       " 'application',\n",
       " 'tested',\n",
       " 'cytokine',\n",
       " 'mean',\n",
       " 'usa',\n",
       " 'article',\n",
       " 'should',\n",
       " 'specific',\n",
       " 'ganglioside',\n",
       " 'since',\n",
       " 'main',\n",
       " 'atv',\n",
       " 'chinese',\n",
       " 'although',\n",
       " 'some',\n",
       " 'ebola',\n",
       " 'multiple',\n",
       " 'recently',\n",
       " 'any',\n",
       " 'according',\n",
       " 'hydrogen',\n",
       " 'favipiravir',\n",
       " 'hospital',\n",
       " 'february',\n",
       " 'total',\n",
       " 'various',\n",
       " 'virol',\n",
       " 'report',\n",
       " 'prevent',\n",
       " 'death',\n",
       " 'while',\n",
       " 'modification',\n",
       " 'added',\n",
       " 'significant',\n",
       " 'hepatitis',\n",
       " 'provide',\n",
       " 'functional',\n",
       " 'small',\n",
       " 'experiment',\n",
       " 'rate',\n",
       " 'cellular',\n",
       " 'dose',\n",
       " 'http',\n",
       " 'infectious',\n",
       " 'free',\n",
       " 'il-6',\n",
       " 'developed',\n",
       " 'process',\n",
       " 'within',\n",
       " 'nature',\n",
       " 'channel',\n",
       " 'without',\n",
       " 'highly',\n",
       " 'structural',\n",
       " 'culture',\n",
       " 'given',\n",
       " 'existing',\n",
       " 'peptide',\n",
       " 'atom',\n",
       " 'arbidol',\n",
       " 'production',\n",
       " 'negative',\n",
       " 'risk',\n",
       " 'symptom',\n",
       " 'institute',\n",
       " 'activities',\n",
       " 'crystal',\n",
       " 'chem',\n",
       " 'term',\n",
       " 'arginine',\n",
       " 'chemistry',\n",
       " 'rapid',\n",
       " 'medical',\n",
       " 'derivative',\n",
       " 'deep',\n",
       " 'blue',\n",
       " 'hcv',\n",
       " 'clq-oh',\n",
       " 'approach',\n",
       " 'disulfide',\n",
       " 'comparison',\n",
       " 'due',\n",
       " 'heparin',\n",
       " 'list',\n",
       " 'huang',\n",
       " 'membrane',\n",
       " 'interest',\n",
       " 'middle',\n",
       " 'pdb',\n",
       " 'ic50',\n",
       " 'because',\n",
       " 'clinically',\n",
       " 'feb',\n",
       " 'oseltamivir',\n",
       " 'h1n1',\n",
       " 'modeling',\n",
       " 'supplementary',\n",
       " 'distribution',\n",
       " 'previously',\n",
       " 'cycle',\n",
       " 'sample',\n",
       " 'corresponding',\n",
       " 'indicate',\n",
       " 'antibodies',\n",
       " 'currently',\n",
       " 'published',\n",
       " 'where',\n",
       " 'emerged',\n",
       " 'zhou',\n",
       " 'identification',\n",
       " 'increase',\n",
       " 'range',\n",
       " 'condition',\n",
       " 'determined',\n",
       " 'indicated',\n",
       " 'medicinal',\n",
       " 'dataset',\n",
       " 'being',\n",
       " 'strategy',\n",
       " 'east',\n",
       " 'point',\n",
       " 'administration',\n",
       " 'animal',\n",
       " 'might',\n",
       " 'before',\n",
       " 'change',\n",
       " 'van',\n",
       " 'phase',\n",
       " 'biological',\n",
       " 'toxicity',\n",
       " 'important',\n",
       " 'need',\n",
       " 'significantly',\n",
       " 'example',\n",
       " 'enrichment',\n",
       " 'here',\n",
       " 'tissue',\n",
       " 'covalent',\n",
       " 'identify',\n",
       " 'lower',\n",
       " '3cl',\n",
       " 'tcm',\n",
       " 'represent',\n",
       " 'factor',\n",
       " 'green',\n",
       " 'considered',\n",
       " 'observed',\n",
       " 'previous',\n",
       " 'sci',\n",
       " 'described',\n",
       " 'repositioning',\n",
       " 'fda-approved',\n",
       " 'genome',\n",
       " 'collected',\n",
       " 'four',\n",
       " 'lopinavir/ritonavir',\n",
       " 'confirmed',\n",
       " 'option',\n",
       " 'strain',\n",
       " 'increased',\n",
       " 'properties',\n",
       " 'therefore',\n",
       " 'had',\n",
       " 'infect',\n",
       " 'safety',\n",
       " 'block',\n",
       " 'prevention',\n",
       " 'center',\n",
       " 'nucleotide',\n",
       " 'simulation',\n",
       " 'laboratory',\n",
       " 'vivo',\n",
       " 'world',\n",
       " 'via',\n",
       " 'moi',\n",
       " 'cancer',\n",
       " 'suggest',\n",
       " 'present',\n",
       " 'applied',\n",
       " 'danoprevir',\n",
       " 'dynamic',\n",
       " 'recent',\n",
       " 'treating',\n",
       " 'sialic',\n",
       " 'material',\n",
       " 'plate',\n",
       " 'parp1',\n",
       " 'out',\n",
       " 'fragment',\n",
       " 'cov-2',\n",
       " 'march',\n",
       " 'ec50',\n",
       " 'finding',\n",
       " 'individual',\n",
       " 'them',\n",
       " 'extended',\n",
       " 'hit',\n",
       " 'proteome',\n",
       " '1016/j',\n",
       " 'spread',\n",
       " 'department',\n",
       " 'blood',\n",
       " 'nat',\n",
       " 'step',\n",
       " 'restraint',\n",
       " 'antibody',\n",
       " 'inflammatory',\n",
       " 'order',\n",
       " 'evaluation',\n",
       " 'antimicrob',\n",
       " 'rat',\n",
       " 'version',\n",
       " 'contain',\n",
       " 'mrna',\n",
       " 'next',\n",
       " 'demonstrated',\n",
       " 'year',\n",
       " 'support',\n",
       " 'effort',\n",
       " 'per',\n",
       " 'life',\n",
       " 'algorithm',\n",
       " 'shanghai',\n",
       " 'higher',\n",
       " 'derived',\n",
       " 'conserved',\n",
       " 'glycoprotein',\n",
       " 'biorxiv',\n",
       " 'about',\n",
       " 'initial',\n",
       " 'nucleic',\n",
       " 'standard',\n",
       " 'computational',\n",
       " 'zhao',\n",
       " 'another',\n",
       " 'potentially',\n",
       " 'ntd',\n",
       " 'emerging',\n",
       " 'beijing',\n",
       " 'validation',\n",
       " 'involved',\n",
       " 'gov',\n",
       " 'evidence',\n",
       " 'technology',\n",
       " 'reduce',\n",
       " 'preparation',\n",
       " 'interactome',\n",
       " 'solution',\n",
       " 'difference',\n",
       " 'curve',\n",
       " 'plus',\n",
       " 'gm1',\n",
       " 'resource',\n",
       " 'many',\n",
       " 'biology',\n",
       " 'stage',\n",
       " 'reaction',\n",
       " 'would',\n",
       " 'inhibitory',\n",
       " 'made',\n",
       " 'presence',\n",
       " 'measured',\n",
       " 'induced',\n",
       " 'large',\n",
       " 'inhibiting',\n",
       " 'least',\n",
       " 'min',\n",
       " 'pocket',\n",
       " 'still',\n",
       " 'position',\n",
       " 'prior',\n",
       " 'clinicaltrials',\n",
       " 'homology',\n",
       " 'disulfiram',\n",
       " 'international',\n",
       " 'now',\n",
       " 'very',\n",
       " 'medication',\n",
       " 'yellow',\n",
       " 'screen',\n",
       " 'low',\n",
       " 'arb',\n",
       " 'revealed',\n",
       " 'plpro',\n",
       " 'identity',\n",
       " 'ribavirin',\n",
       " 'area',\n",
       " 'common',\n",
       " 'defined',\n",
       " 'affinity',\n",
       " 'zhu',\n",
       " 'software',\n",
       " 'promising',\n",
       " 'lancet',\n",
       " 'cytotoxicity',\n",
       " 'section',\n",
       " 'primary',\n",
       " 'literature',\n",
       " 'synthesis',\n",
       " 'supernatant',\n",
       " 'clin',\n",
       " 'pose',\n",
       " 'ability',\n",
       " 'inhibited',\n",
       " 'critical',\n",
       " 'biol',\n",
       " 'program',\n",
       " 'pharmacokinetic',\n",
       " 'therapies',\n",
       " 'manuscript',\n",
       " 'right',\n",
       " 'feature',\n",
       " 'early',\n",
       " 'epidemic',\n",
       " 'sofosbuvir',\n",
       " 'along',\n",
       " 'plasma',\n",
       " 'representation',\n",
       " 'make',\n",
       " 'rt-pcr',\n",
       " 'graph',\n",
       " 'force',\n",
       " 'additional',\n",
       " 'peer',\n",
       " 'develop',\n",
       " 'showing',\n",
       " 'proteinase',\n",
       " 'essential',\n",
       " 'see',\n",
       " 'rev',\n",
       " 'targeted',\n",
       " 'cheng',\n",
       " 'like',\n",
       " 'network-based',\n",
       " 'generated',\n",
       " 'effectively',\n",
       " '2019-ncov/sars-cov-2',\n",
       " 'mice',\n",
       " 'less',\n",
       " 'formation',\n",
       " 'received',\n",
       " 'even',\n",
       " 'map',\n",
       " 'people',\n",
       " 'able',\n",
       " 'machine',\n",
       " 'tion',\n",
       " 'online',\n",
       " 'water',\n",
       " 'bound',\n",
       " 'include',\n",
       " 'rank',\n",
       " 'polyprotein',\n",
       " 'signaling',\n",
       " 'likely',\n",
       " 'provided',\n",
       " 'act',\n",
       " 'ifn-',\n",
       " 'characteristic',\n",
       " 'nebulization',\n",
       " 'relative',\n",
       " 'titer',\n",
       " 'already',\n",
       " 'predict',\n",
       " 'motif',\n",
       " 'rapidly',\n",
       " 'incubated',\n",
       " 'limited',\n",
       " 'and/or',\n",
       " 'together',\n",
       " 'hydrochloride',\n",
       " 'major',\n",
       " 'chemother',\n",
       " 'pharmaceutical',\n",
       " 'buffer',\n",
       " 'second',\n",
       " 'search',\n",
       " 'analyse',\n",
       " 'required',\n",
       " 'lpv',\n",
       " 'oral',\n",
       " 'lee',\n",
       " 'good',\n",
       " 'plos',\n",
       " 'interact',\n",
       " 'complexes',\n",
       " 'parameter',\n",
       " 'mar',\n",
       " 'efficient',\n",
       " 'spectrum',\n",
       " 'tract',\n",
       " 'whether',\n",
       " 'boosted',\n",
       " 'thiol',\n",
       " 'newly',\n",
       " 'specifically',\n",
       " 'urgent',\n",
       " 'organization',\n",
       " 'serum',\n",
       " 'training',\n",
       " 'cc50',\n",
       " 'fep-abfe',\n",
       " 'analogue',\n",
       " 'bank',\n",
       " 'cleavage',\n",
       " 'name',\n",
       " 'transmission',\n",
       " 'heart',\n",
       " 'testing',\n",
       " 'either',\n",
       " 'qrt-pcr',\n",
       " 'substrate',\n",
       " 'cardiovascular',\n",
       " 'epithelial',\n",
       " 'epithelium',\n",
       " 'systematic',\n",
       " 'part',\n",
       " 'neutrophil',\n",
       " 'release',\n",
       " 'presented',\n",
       " 'mortality',\n",
       " 'broad-spectrum',\n",
       " 'inflammation',\n",
       " 'particle',\n",
       " 'future',\n",
       " 'chronic',\n",
       " 'discussion',\n",
       " 'repurposed',\n",
       " 'suggested',\n",
       " 'abstract',\n",
       " 'drug-target',\n",
       " 'toremifene',\n",
       " 'stick',\n",
       " 'toward',\n",
       " 'listed',\n",
       " 'ifn',\n",
       " 'protocol',\n",
       " 'above',\n",
       " 'hours',\n",
       " 'non-covalent',\n",
       " 'expected',\n",
       " 'fever',\n",
       " 'general',\n",
       " 'kit',\n",
       " 'traditional',\n",
       " 'mock',\n",
       " 'evaluated',\n",
       " 'identifier',\n",
       " 'px-12',\n",
       " 'worldwide',\n",
       " 'furthermore',\n",
       " 'potency',\n",
       " 'alignment',\n",
       " 'kcal/mol',\n",
       " 'alone',\n",
       " 'sirna',\n",
       " 'dna',\n",
       " 'scientific',\n",
       " 'disclose',\n",
       " 'absence',\n",
       " 'designed',\n",
       " 'better',\n",
       " 'analyzed',\n",
       " 'angiotensin',\n",
       " 'around',\n",
       " 'organ',\n",
       " 'mild',\n",
       " 'knowledge',\n",
       " 'unit',\n",
       " 'end',\n",
       " 'natural',\n",
       " 'growth',\n",
       " 'genomic',\n",
       " 'similarity',\n",
       " 'cultured',\n",
       " 'until',\n",
       " 'measure',\n",
       " 'experienced',\n",
       " 'cep',\n",
       " 'glo1',\n",
       " 'conclusion',\n",
       " 'image',\n",
       " 'energies',\n",
       " 'shi',\n",
       " 'affinities',\n",
       " 'ifn-2b',\n",
       " 'glide',\n",
       " 'included',\n",
       " 'cat',\n",
       " 'conformation',\n",
       " 'accuracy',\n",
       " 'evaluate',\n",
       " 'prepared',\n",
       " 'especially',\n",
       " 'vascular',\n",
       " 'dipyridamole',\n",
       " '3c-like',\n",
       " 'kim',\n",
       " 'alternative',\n",
       " 'phosphate',\n",
       " '//clinicaltrials',\n",
       " 'introduction',\n",
       " 'anti-inflammatory',\n",
       " 'require',\n",
       " 'cysteine',\n",
       " 'improved',\n",
       " 'province',\n",
       " 'cao',\n",
       " 'view',\n",
       " 'malaria',\n",
       " 'approaches',\n",
       " 'fusion',\n",
       " 'reduced',\n",
       " 'density',\n",
       " 'engl',\n",
       " 'administered',\n",
       " 'fold',\n",
       " 'thank',\n",
       " 'h3n2',\n",
       " 'india',\n",
       " 'activation',\n",
       " 'class',\n",
       " 'secondary',\n",
       " 'nucleocapsid',\n",
       " 'school',\n",
       " 'decreased',\n",
       " 'mol',\n",
       " 'supported',\n",
       " 'anti-',\n",
       " 'inc',\n",
       " 'drugbank',\n",
       " 'whereas',\n",
       " 'share',\n",
       " 'ring',\n",
       " 'metabolism',\n",
       " 'relevant',\n",
       " 'cause',\n",
       " 'adding',\n",
       " 'content',\n",
       " 'antimalarial',\n",
       " 'origin',\n",
       " 'mg/kg',\n",
       " 'pulmonary',\n",
       " 'unknown',\n",
       " 'public',\n",
       " 'bat',\n",
       " 'pangolin',\n",
       " 'processes',\n",
       " 'outcome',\n",
       " 'atv/rtv',\n",
       " 'play',\n",
       " 'date',\n",
       " 'anti-viral',\n",
       " 'care',\n",
       " 'describe',\n",
       " 'mode',\n",
       " 'flow',\n",
       " 'taken',\n",
       " 'silico',\n",
       " 'long',\n",
       " 'pcr',\n",
       " 'repurposable',\n",
       " 'environment',\n",
       " 'exposure',\n",
       " 'did',\n",
       " 'proposed',\n",
       " 'rabbani',\n",
       " 'access',\n",
       " 'hypertension',\n",
       " 'update',\n",
       " 'attachment',\n",
       " 'manufacturer',\n",
       " 'selective',\n",
       " 'american',\n",
       " 'virology',\n",
       " 'monkey',\n",
       " 'pathogenic',\n",
       " 'processing',\n",
       " 'sodium',\n",
       " 'hong',\n",
       " 'internet',\n",
       " 'period',\n",
       " 'participants',\n",
       " 'five',\n",
       " 'approximately',\n",
       " 'weight',\n",
       " 'validated',\n",
       " 'jan',\n",
       " 'reverse',\n",
       " 'bethesda',\n",
       " 'final',\n",
       " 'strand',\n",
       " 'post-infection',\n",
       " 'perturbation',\n",
       " 'assessment',\n",
       " 'strong',\n",
       " 'antibiotic',\n",
       " 'united',\n",
       " 'reward',\n",
       " 'background',\n",
       " 'covid19',\n",
       " 'zika',\n",
       " 'consistent',\n",
       " 'virion',\n",
       " 'structure-based',\n",
       " 'panel',\n",
       " 'investigation',\n",
       " 'few',\n",
       " 'median',\n",
       " 'hiv-1',\n",
       " 'clearance',\n",
       " 'wei',\n",
       " 'division',\n",
       " 'viability',\n",
       " 'improve',\n",
       " 'thornalley',\n",
       " 'suggesting',\n",
       " 'methylglyoxal',\n",
       " 'grant',\n",
       " 'moreover',\n",
       " 'named',\n",
       " 'resulting',\n",
       " 'responsible',\n",
       " 'normal',\n",
       " 'directly',\n",
       " 'additionally',\n",
       " 'open',\n",
       " 'angiotensin-converting',\n",
       " 'impact',\n",
       " 'useful',\n",
       " 'detail',\n",
       " 'rna-dependent',\n",
       " 'collection',\n",
       " 'www',\n",
       " 'cpe',\n",
       " 'framework',\n",
       " 'note',\n",
       " 'node',\n",
       " 'clinic',\n",
       " 'ing',\n",
       " 'challenge',\n",
       " 'emergency',\n",
       " 'equilibrium',\n",
       " 'field',\n",
       " 'ggo',\n",
       " 'increasing',\n",
       " 'isolate',\n",
       " 'moderate',\n",
       " 'com',\n",
       " 'january',\n",
       " 'funding',\n",
       " 'relation',\n",
       " 'error',\n",
       " 'white',\n",
       " 'reveal',\n",
       " 'family',\n",
       " 'catalytic',\n",
       " 'file',\n",
       " 'high-throughput',\n",
       " 'combined',\n",
       " 'int',\n",
       " 'melatonin',\n",
       " 'appropriate',\n",
       " 'established',\n",
       " 'left',\n",
       " 'independent',\n",
       " 'ranked',\n",
       " 'non-structural',\n",
       " 'particularly',\n",
       " 'raoult',\n",
       " 'tool',\n",
       " 'envelope',\n",
       " 'chan',\n",
       " '6lu7',\n",
       " 'close',\n",
       " 'media',\n",
       " 'past',\n",
       " 'reduction',\n",
       " 'body',\n",
       " 'chembiochem',\n",
       " 'fit',\n",
       " 'competing',\n",
       " 'countries',\n",
       " 'assess',\n",
       " 'proc',\n",
       " 'extracted',\n",
       " 'formed',\n",
       " 'gao',\n",
       " 'nucleoprotein',\n",
       " 'yet',\n",
       " 'preclinical',\n",
       " 'mol-1',\n",
       " 'modified',\n",
       " 'detailed',\n",
       " 'greater',\n",
       " 'edu',\n",
       " 'correlation',\n",
       " 'bar',\n",
       " 'insight',\n",
       " 'connectivity',\n",
       " 'determine',\n",
       " 'strategies',\n",
       " 'pro-',\n",
       " 'six',\n",
       " 'tang',\n",
       " 'temperature',\n",
       " 'monoclonal',\n",
       " 'help',\n",
       " 'core',\n",
       " 'needed',\n",
       " 'kong',\n",
       " 'lack',\n",
       " 'injection',\n",
       " 'preliminary',\n",
       " 'bioinformatic',\n",
       " 'xiao',\n",
       " 'recombinant',\n",
       " 'accession',\n",
       " 'marseille',\n",
       " 'exhibited',\n",
       " 'scoring',\n",
       " 'considering',\n",
       " ...]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "model.get_words()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3614"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# model.save_model('./34_paper_total.bin')\n",
    "# len(model.get_words())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Warning : `load_model` does not return WordVectorModel or SupervisedModel any more, but a `FastText` object which is very similar.\n"
     ]
    }
   ],
   "source": [
    "model = fasttext.load_model('./litcovid/litcovid_fasttext_0623.bin')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "word_list = model.get_words()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['covid-19',\n",
       " 'sars-cov-2',\n",
       " 'drug',\n",
       " 'coronavirus',\n",
       " 'treatment',\n",
       " 'disease',\n",
       " 'clinical',\n",
       " 'infection',\n",
       " 'virus',\n",
       " 'respiratory',\n",
       " 'pandemic',\n",
       " 'viral',\n",
       " 'severe',\n",
       " 'potential',\n",
       " 'antiviral',\n",
       " 'health',\n",
       " 'study',\n",
       " 'novel',\n",
       " 'acute',\n",
       " 'studies',\n",
       " 'syndrome',\n",
       " 'effective',\n",
       " 'also',\n",
       " 'hydroxychloroquine',\n",
       " 'human',\n",
       " 'new',\n",
       " 'data',\n",
       " 'therapeutic',\n",
       " 'available',\n",
       " 'protein',\n",
       " 'trial',\n",
       " 'binding',\n",
       " 'china',\n",
       " 'current',\n",
       " 'including',\n",
       " 'using',\n",
       " 'care',\n",
       " 'however',\n",
       " 'two',\n",
       " 'group',\n",
       " 'high',\n",
       " 'review',\n",
       " 'world',\n",
       " 'outbreak',\n",
       " 'approved',\n",
       " 'development',\n",
       " 'global',\n",
       " 'therapy',\n",
       " 'currently',\n",
       " 'efficacy',\n",
       " 'hcq',\n",
       " 'associated',\n",
       " 'control',\n",
       " 'risk',\n",
       " 'need',\n",
       " 'reported',\n",
       " 'based',\n",
       " 'chloroquine',\n",
       " 'evidence',\n",
       " 'sars-cov',\n",
       " 'several',\n",
       " 'remdesivir',\n",
       " 'research',\n",
       " 'safety',\n",
       " 'patient',\n",
       " 'target',\n",
       " 'protease',\n",
       " 'specific',\n",
       " 'spread',\n",
       " 'first',\n",
       " 'molecular',\n",
       " 'main',\n",
       " 'vaccine',\n",
       " 'analysis',\n",
       " 'activity',\n",
       " 'hospital',\n",
       " 'rna',\n",
       " 'wuhan',\n",
       " 'among',\n",
       " 'one',\n",
       " 'possible',\n",
       " 'receptor',\n",
       " 'mortality',\n",
       " 'well',\n",
       " 'known',\n",
       " 'provide',\n",
       " 'replication',\n",
       " 'medicine',\n",
       " 'due',\n",
       " 'time',\n",
       " 'repurposing',\n",
       " '2019-ncov',\n",
       " 'number',\n",
       " 'treat',\n",
       " 'different',\n",
       " 'cell',\n",
       " 'system',\n",
       " 'present',\n",
       " 'many',\n",
       " 'identified',\n",
       " 'pro',\n",
       " 'since',\n",
       " 'vitro',\n",
       " 'infected',\n",
       " 'pneumonia',\n",
       " 'lung',\n",
       " 'immune',\n",
       " 'compared',\n",
       " 'screening',\n",
       " 'showed',\n",
       " 'worldwide',\n",
       " 'public',\n",
       " 'host',\n",
       " 'design',\n",
       " 'found',\n",
       " 'management',\n",
       " 'docking',\n",
       " 'promising',\n",
       " 'chinese',\n",
       " 'december',\n",
       " 'coronaviruses',\n",
       " 'protocol',\n",
       " 'strategies',\n",
       " 'therapies',\n",
       " 'participants',\n",
       " 'important',\n",
       " 'sars',\n",
       " 'mg',\n",
       " 'response',\n",
       " 'people',\n",
       " 'viruses',\n",
       " 'active',\n",
       " 'recent',\n",
       " 'countries',\n",
       " 'developed',\n",
       " 'medical',\n",
       " 'rapidly',\n",
       " 'confirmed',\n",
       " 'significant',\n",
       " 'adverse',\n",
       " 'thus',\n",
       " 'structure',\n",
       " 'enzyme',\n",
       " 'rate',\n",
       " 'role',\n",
       " 'dose',\n",
       " 'information',\n",
       " 'combination',\n",
       " 'azithromycin',\n",
       " 'might',\n",
       " 'total',\n",
       " 'case',\n",
       " 'needed',\n",
       " 'performed',\n",
       " 'addition',\n",
       " 'rapid',\n",
       " 'prevention',\n",
       " 'key',\n",
       " 'higher',\n",
       " 'identify',\n",
       " 'years',\n",
       " 'lopinavir',\n",
       " 'plasma',\n",
       " 'considered',\n",
       " 'although',\n",
       " 'angiotensin',\n",
       " 'approach',\n",
       " 'acid',\n",
       " 'related',\n",
       " 'three',\n",
       " 'emergency',\n",
       " 'prevent',\n",
       " 'test',\n",
       " 'administration',\n",
       " 'randomized',\n",
       " 'discovery',\n",
       " 'effect',\n",
       " 'background',\n",
       " 'april',\n",
       " 'cq',\n",
       " 'major',\n",
       " 'ritonavir',\n",
       " 'article',\n",
       " 'urgent',\n",
       " 'march',\n",
       " 'day',\n",
       " 'ongoing',\n",
       " 'strategy',\n",
       " 'future',\n",
       " 'cytokine',\n",
       " 'spike',\n",
       " 'similar',\n",
       " 'suggest',\n",
       " 'expression',\n",
       " 'infectious',\n",
       " 'properties',\n",
       " 'without',\n",
       " 'highly',\n",
       " 'critical',\n",
       " 'cardiovascular',\n",
       " 'liver',\n",
       " 'increase',\n",
       " 'measures',\n",
       " 'therefore',\n",
       " 'various',\n",
       " 'additional',\n",
       " 'severity',\n",
       " 'epidemic',\n",
       " 'population',\n",
       " 'cardiac',\n",
       " 'existing',\n",
       " 'recently',\n",
       " 'given',\n",
       " 'include',\n",
       " 'diagnosis',\n",
       " 'multiple',\n",
       " 'primary',\n",
       " 'treating',\n",
       " 'approaches',\n",
       " 'findings',\n",
       " 'course',\n",
       " 'injury',\n",
       " 'age',\n",
       " 'likely',\n",
       " 'early',\n",
       " 'standard',\n",
       " 'previously',\n",
       " 'transmission',\n",
       " 'potentially',\n",
       " 'serious',\n",
       " 'positive',\n",
       " 'structural',\n",
       " 'ras',\n",
       " 'fever',\n",
       " 'model',\n",
       " 'order',\n",
       " 'mpro',\n",
       " 'inhibitor',\n",
       " 'death',\n",
       " 'natural',\n",
       " 'rdrp',\n",
       " 'cause',\n",
       " 'efforts',\n",
       " 'develop',\n",
       " 'women',\n",
       " 'still',\n",
       " 'literature',\n",
       " 'especially',\n",
       " 'reduce',\n",
       " 'even',\n",
       " 'middle',\n",
       " 'within',\n",
       " 'traditional',\n",
       " 'inhibition',\n",
       " 'healthcare',\n",
       " 'criteria',\n",
       " 'mers-cov',\n",
       " 'site',\n",
       " 'inhibit',\n",
       " 'outcome',\n",
       " 'full',\n",
       " 'respectively',\n",
       " 'yet',\n",
       " 'date',\n",
       " 'lack',\n",
       " 'emerged',\n",
       " 'community',\n",
       " 'large',\n",
       " 'according',\n",
       " 'particularly',\n",
       " 'significantly',\n",
       " 'anti-inflammatory',\n",
       " 'published',\n",
       " 'recommended',\n",
       " 'clinically',\n",
       " 'daily',\n",
       " 'result',\n",
       " 'across',\n",
       " 'tested',\n",
       " 'distress',\n",
       " 'database',\n",
       " 'demonstrated',\n",
       " 'sequence',\n",
       " 'become',\n",
       " 'regarding',\n",
       " 'scientific',\n",
       " 'entry',\n",
       " 'inflammatory',\n",
       " 'essential',\n",
       " 'anti-viral',\n",
       " 'conclusion',\n",
       " 'situation',\n",
       " 'diabetes',\n",
       " 'polymerase',\n",
       " 'medication',\n",
       " 'following',\n",
       " 'agent',\n",
       " 'favipiravir',\n",
       " 'targeting',\n",
       " 'mechanism',\n",
       " 'events',\n",
       " 'ratio',\n",
       " 'characteristics',\n",
       " 'storm',\n",
       " 'predicted',\n",
       " 'organization',\n",
       " 'support',\n",
       " 'alone',\n",
       " 'limited',\n",
       " 'international',\n",
       " 'help',\n",
       " 'cough',\n",
       " 'randomised',\n",
       " 'failure',\n",
       " 'children',\n",
       " 'affinity',\n",
       " 'common',\n",
       " 'illness',\n",
       " 'already',\n",
       " 'attention',\n",
       " 'monitoring',\n",
       " 'period',\n",
       " 'intervention',\n",
       " 'controlled',\n",
       " 'low',\n",
       " 'sample',\n",
       " 'report',\n",
       " 'around',\n",
       " 'causing',\n",
       " 'objective',\n",
       " 'safe',\n",
       " 'negative',\n",
       " 'evaluation',\n",
       " 'interaction',\n",
       " 'experimental',\n",
       " 'lower',\n",
       " 'treated',\n",
       " 'vs',\n",
       " 'responsible',\n",
       " 'virtual',\n",
       " 'single',\n",
       " 'good',\n",
       " 'level',\n",
       " 'ci',\n",
       " 'find',\n",
       " 'work',\n",
       " 'manifestations',\n",
       " 'ii',\n",
       " 'complex',\n",
       " 'intensive',\n",
       " 'action',\n",
       " 'crisis',\n",
       " 'pulmonary',\n",
       " 'ards',\n",
       " 'observed',\n",
       " 'east',\n",
       " 'emerging',\n",
       " 'better',\n",
       " 'involved',\n",
       " 'file',\n",
       " 'energy',\n",
       " 'mild',\n",
       " 'national',\n",
       " 'hospitalized',\n",
       " 'qt',\n",
       " 'inflammation',\n",
       " 'chronic',\n",
       " 'systemic',\n",
       " 'evaluate',\n",
       " 'search',\n",
       " 'method',\n",
       " 'via',\n",
       " 'interest',\n",
       " 'knowledge',\n",
       " 'status',\n",
       " 'laboratory',\n",
       " 'testing',\n",
       " 'lead',\n",
       " 'us',\n",
       " 'hours',\n",
       " 'established',\n",
       " 'widely',\n",
       " 'prolongation',\n",
       " 'small',\n",
       " 'secondary',\n",
       " 'features',\n",
       " 'network',\n",
       " 'residues',\n",
       " 'impact',\n",
       " 'previous',\n",
       " 'cov',\n",
       " 'threat',\n",
       " 'heart',\n",
       " 'conducted',\n",
       " 'tcm',\n",
       " 'mers',\n",
       " 'pathogenesis',\n",
       " 'pregnancy',\n",
       " 'surface',\n",
       " 'randomization',\n",
       " 'pregnant',\n",
       " 'either',\n",
       " 'bind',\n",
       " 'domain',\n",
       " 'summarize',\n",
       " 'corona',\n",
       " 'general',\n",
       " 'vivo',\n",
       " 'less',\n",
       " 'compound',\n",
       " 'combat',\n",
       " 'improvement',\n",
       " 'potent',\n",
       " 'furthermore',\n",
       " 'underlying',\n",
       " 'placebo',\n",
       " 'interval',\n",
       " 'followed',\n",
       " 'exposure',\n",
       " 'paper',\n",
       " 'screened',\n",
       " 'history',\n",
       " 'angiotensin-converting',\n",
       " 'named',\n",
       " 'candidate',\n",
       " 'complications',\n",
       " 'despite',\n",
       " 'side',\n",
       " 'blood',\n",
       " 'mainly',\n",
       " 'cancer',\n",
       " 'four',\n",
       " 'assess',\n",
       " 'influenza',\n",
       " 'molecule',\n",
       " 'discuss',\n",
       " 'least',\n",
       " 'like',\n",
       " 'relevant',\n",
       " 'animal',\n",
       " 'computational',\n",
       " 'revealed',\n",
       " 'range',\n",
       " 'identification',\n",
       " 'guidelines',\n",
       " 'toxicity',\n",
       " 'concern',\n",
       " 'led',\n",
       " 'cellular',\n",
       " 'experience',\n",
       " 'taking',\n",
       " 'production',\n",
       " '3cl',\n",
       " 'increasing',\n",
       " 'particular',\n",
       " 'factor',\n",
       " 'type',\n",
       " 'serum',\n",
       " 'registered',\n",
       " 'last',\n",
       " 'genome',\n",
       " 'understanding',\n",
       " 'activities',\n",
       " 'size',\n",
       " 'challenge',\n",
       " 'absence',\n",
       " 'best',\n",
       " 'life',\n",
       " 'moreover',\n",
       " 'investigation',\n",
       " 'repositioning',\n",
       " 'oxygen',\n",
       " 'recommendations',\n",
       " 'end',\n",
       " 'ivermectin',\n",
       " 'critically',\n",
       " 'gov',\n",
       " 'targeted',\n",
       " 'direct',\n",
       " 'damage',\n",
       " 'pcr',\n",
       " 'pharmaceutical',\n",
       " 'suggested',\n",
       " 'herein',\n",
       " 'prophylaxis',\n",
       " 'combined',\n",
       " 'central',\n",
       " 'contact',\n",
       " 'selected',\n",
       " 'simulation',\n",
       " 'fda',\n",
       " 'de',\n",
       " 'initial',\n",
       " 'administered',\n",
       " 'aimed',\n",
       " 'old',\n",
       " 'tissue',\n",
       " 'much',\n",
       " 'clinicaltrials',\n",
       " 'process',\n",
       " 'whether',\n",
       " 'applied',\n",
       " 'center',\n",
       " 'overall',\n",
       " 'renal',\n",
       " 'obtained',\n",
       " 'terms',\n",
       " 'mol',\n",
       " 'resulted',\n",
       " 'block',\n",
       " 'made',\n",
       " 'food',\n",
       " 'pathogenic',\n",
       " 'association',\n",
       " 'far',\n",
       " 'strong',\n",
       " 'library',\n",
       " 'concentration',\n",
       " 'tocilizumab',\n",
       " 'efficient',\n",
       " 'chemical',\n",
       " 'suggesting',\n",
       " 'analyses',\n",
       " 'recruitment',\n",
       " 'disorders',\n",
       " 'series',\n",
       " 'silico',\n",
       " 'benefit',\n",
       " 'proven',\n",
       " 'propose',\n",
       " 'cpz',\n",
       " 'decrease',\n",
       " 'appropriate',\n",
       " 'blockers',\n",
       " 'globally',\n",
       " 'considering',\n",
       " 'organ',\n",
       " 'supply',\n",
       " 'symptomatic',\n",
       " 'reporting',\n",
       " 'form',\n",
       " 'admission',\n",
       " 'context',\n",
       " 'effectiveness',\n",
       " 'antimalarial',\n",
       " 'pharmacological',\n",
       " 'incidence',\n",
       " 'hubei',\n",
       " 'services',\n",
       " 'newly',\n",
       " 'receive',\n",
       " 'importance',\n",
       " 'off-label',\n",
       " 'suitable',\n",
       " 'state',\n",
       " 'developing',\n",
       " 'md',\n",
       " 'anti-sars-cov-2',\n",
       " 'reaction',\n",
       " 'setting',\n",
       " 'receiving',\n",
       " 'province',\n",
       " 'progression',\n",
       " 'function',\n",
       " 'hypertension',\n",
       " 'broad-spectrum',\n",
       " 'biological',\n",
       " 'morbidity',\n",
       " 'authors',\n",
       " 'tool',\n",
       " 'ill',\n",
       " 'prescription',\n",
       " 'cycle',\n",
       " 'protective',\n",
       " 'close',\n",
       " 'spreading',\n",
       " 'describe',\n",
       " 'focus',\n",
       " 'recovery',\n",
       " 'resulting',\n",
       " 'unit',\n",
       " 'version',\n",
       " 'synthesis',\n",
       " 'membrane',\n",
       " 'often',\n",
       " 'pharmacists',\n",
       " 'score',\n",
       " 'every',\n",
       " 'make',\n",
       " 'useful',\n",
       " 'arm',\n",
       " 'amino',\n",
       " 'professionals',\n",
       " 'pathway',\n",
       " 'gene',\n",
       " 'unprecedented',\n",
       " 'ability',\n",
       " 'mean',\n",
       " 'nucleic',\n",
       " 'malaria',\n",
       " 'rbd',\n",
       " 'option',\n",
       " 'family',\n",
       " 'kcal',\n",
       " 'comparison',\n",
       " 'along',\n",
       " 'dosage',\n",
       " 'antibodies',\n",
       " 'contain',\n",
       " 'diagnosed',\n",
       " 'reduction',\n",
       " 'inclusion',\n",
       " 'dosing',\n",
       " 'kg',\n",
       " 'functional',\n",
       " 'et',\n",
       " 'onset',\n",
       " 'declared',\n",
       " 'hence',\n",
       " 'application',\n",
       " 'investigational',\n",
       " 'improve',\n",
       " 'january',\n",
       " 'glycoprotein',\n",
       " 'admitted',\n",
       " 'assessed',\n",
       " 'stage',\n",
       " 'immunity',\n",
       " 'material',\n",
       " 'innate',\n",
       " 'kidney',\n",
       " 'interferon',\n",
       " 'epidemiology',\n",
       " 'show',\n",
       " 'median',\n",
       " 'conserved',\n",
       " 'social',\n",
       " 'greater',\n",
       " 'reviewed',\n",
       " 'release',\n",
       " 'profile',\n",
       " 'exclusion',\n",
       " 'represent',\n",
       " 'leading',\n",
       " 'physicians',\n",
       " 'hypothesis',\n",
       " 'screen',\n",
       " 'cohort',\n",
       " 'comorbidities',\n",
       " 'chain',\n",
       " 'pubmed',\n",
       " 'nitazoxanide',\n",
       " 'consideration',\n",
       " 'ventilation',\n",
       " 'fda-approved',\n",
       " 'prior',\n",
       " 'melatonin',\n",
       " 'phase',\n",
       " 'serve',\n",
       " 'systematic',\n",
       " 'beneficial',\n",
       " 'remain',\n",
       " 'communicated',\n",
       " 'stress',\n",
       " 'approximately',\n",
       " 'free',\n",
       " 'long',\n",
       " 'orally',\n",
       " 'prediction',\n",
       " 'preclinical',\n",
       " 'investigate',\n",
       " 'providing',\n",
       " 'searched',\n",
       " 'regulatory',\n",
       " 'elderly',\n",
       " 'pediatric',\n",
       " 'icu',\n",
       " 'alternative',\n",
       " 'progress',\n",
       " 'collected',\n",
       " 'supportive',\n",
       " 'studied',\n",
       " 'il-6',\n",
       " 'february',\n",
       " 'clinicians',\n",
       " 'workers',\n",
       " 'stability',\n",
       " 'ribavirin',\n",
       " 'take',\n",
       " 'registration',\n",
       " 'presented',\n",
       " 'crucial',\n",
       " 'ramaswamy',\n",
       " 'way',\n",
       " 'comparator',\n",
       " 'identifying',\n",
       " 'certain',\n",
       " 'urgently',\n",
       " 'burden',\n",
       " 'proportion',\n",
       " 'randomisation',\n",
       " 'continue',\n",
       " 'normal',\n",
       " 'commonly',\n",
       " 'gastrointestinal',\n",
       " 'presence',\n",
       " 'practice',\n",
       " 'called',\n",
       " 'focused',\n",
       " 'unique',\n",
       " 'summary',\n",
       " 'sarma',\n",
       " 'asymptomatic',\n",
       " 'great',\n",
       " 'rhizoma',\n",
       " 'expressed',\n",
       " 'access',\n",
       " 'seven',\n",
       " 'rna-dependent',\n",
       " 'hiv',\n",
       " 'radix',\n",
       " 'university',\n",
       " 'mechanical',\n",
       " 'six',\n",
       " 'oral',\n",
       " 'antibiotics',\n",
       " 'informed',\n",
       " 'rheumatic',\n",
       " 'highest',\n",
       " 'prolonged',\n",
       " 'per',\n",
       " 'defined',\n",
       " 'elevated',\n",
       " 'covid',\n",
       " 'peptide',\n",
       " 'involvement',\n",
       " 'require',\n",
       " 'interventional',\n",
       " 'availability',\n",
       " 'arbs',\n",
       " 'ms',\n",
       " 'convalescent',\n",
       " 'top',\n",
       " 'whole',\n",
       " 'understand',\n",
       " 'activation',\n",
       " 'introduction',\n",
       " 'open',\n",
       " 'biology',\n",
       " 'vitamin',\n",
       " 'blinded',\n",
       " 'expected',\n",
       " 'lesions',\n",
       " 'country',\n",
       " 'website',\n",
       " 'regimen',\n",
       " 'validated',\n",
       " 'economic',\n",
       " 'consent',\n",
       " 'products',\n",
       " 'estimated',\n",
       " 'fpv',\n",
       " 'tract',\n",
       " 'second',\n",
       " 'city',\n",
       " 'team',\n",
       " 'distribution',\n",
       " 'late',\n",
       " 'eligible',\n",
       " 'explore',\n",
       " 'society',\n",
       " 'fatigue',\n",
       " 'strain',\n",
       " 'fatal',\n",
       " 'dysfunction',\n",
       " 'ligand',\n",
       " 'guide',\n",
       " 'variety',\n",
       " 'twice',\n",
       " 'subjects',\n",
       " 'obesity',\n",
       " 'accessible',\n",
       " 'elements',\n",
       " 'life-threatening',\n",
       " 'allocation',\n",
       " 'past',\n",
       " 'must',\n",
       " 'ec50',\n",
       " 'chest',\n",
       " 'scientists',\n",
       " 'delivery',\n",
       " 'purpose',\n",
       " 'cov-2',\n",
       " 'affected',\n",
       " 'view',\n",
       " 'list',\n",
       " 'umifenovir',\n",
       " 'tmprss2',\n",
       " 'ace-2',\n",
       " 'unknown',\n",
       " 'load',\n",
       " 'cutaneous',\n",
       " 'reducing',\n",
       " 'together',\n",
       " 'cost',\n",
       " 'epidemiological',\n",
       " 'long-term',\n",
       " 'differences',\n",
       " 'skin',\n",
       " 'recipients',\n",
       " 'modeling',\n",
       " 'necessary',\n",
       " 'additionally',\n",
       " 'five',\n",
       " 'expert',\n",
       " 'effectively',\n",
       " 'discussed',\n",
       " 'metabolism',\n",
       " 'resistance',\n",
       " 'pharmacokinetic',\n",
       " 'transplant',\n",
       " 'able',\n",
       " 'staff',\n",
       " 'compassionate',\n",
       " 'familiar',\n",
       " 'exhibited',\n",
       " 'limit',\n",
       " 'nucleocapsid',\n",
       " 'aspects',\n",
       " 'rational',\n",
       " 'field',\n",
       " 'region',\n",
       " 'pharmacy',\n",
       " 'ensure',\n",
       " 'offer',\n",
       " 'affect',\n",
       " 'homology',\n",
       " 'carried',\n",
       " 'contribute',\n",
       " 'play',\n",
       " 'recognition',\n",
       " 'maximum',\n",
       " 'detected',\n",
       " 'guidance',\n",
       " 'set',\n",
       " 'successful',\n",
       " 'body',\n",
       " 'drug-induced',\n",
       " 'short',\n",
       " 'hospitalization',\n",
       " 'nasopharyngeal',\n",
       " 'fusion',\n",
       " 'point',\n",
       " 'determine',\n",
       " 'throughout',\n",
       " 'extensive',\n",
       " 'stay',\n",
       " 'quickly',\n",
       " 'specifically',\n",
       " 'preliminary',\n",
       " 'fight',\n",
       " 'analyze',\n",
       " 'recommend',\n",
       " 'area',\n",
       " 'species',\n",
       " 'scale',\n",
       " 'persons',\n",
       " 'mutation',\n",
       " 'another',\n",
       " 'diagnostic',\n",
       " 'duration',\n",
       " 'facilitate',\n",
       " 'rights',\n",
       " 'shortage',\n",
       " 'susceptible',\n",
       " 'optimal',\n",
       " 'men',\n",
       " 'enrolled',\n",
       " 'facing',\n",
       " 'mtor',\n",
       " 'globe',\n",
       " 'efficiency',\n",
       " 's-protein',\n",
       " 'unclear',\n",
       " 'at1r',\n",
       " 'fatality',\n",
       " 'prospective',\n",
       " 'light',\n",
       " 'successfully',\n",
       " 'contagious',\n",
       " 'special',\n",
       " 'fibrosis',\n",
       " 'adrs',\n",
       " 'ml',\n",
       " 'linked',\n",
       " 'pathogen',\n",
       " 'markers',\n",
       " 'odds',\n",
       " 'prophylactic',\n",
       " 'involving',\n",
       " 'aes',\n",
       " 'retrospective',\n",
       " 'assessment',\n",
       " 'broad',\n",
       " 'complete',\n",
       " 'ebola',\n",
       " 'concomitant',\n",
       " 'highlight',\n",
       " 'decades',\n",
       " 'alveolar',\n",
       " 'researchers',\n",
       " 'sofosbuvir',\n",
       " 'parameters',\n",
       " 'neurological',\n",
       " 'letter',\n",
       " 'generated',\n",
       " 'stable',\n",
       " 'united',\n",
       " 'crystal',\n",
       " 'emergence',\n",
       " 'started',\n",
       " 'vulnerable',\n",
       " 'indicate',\n",
       " 'innovative',\n",
       " 'docked',\n",
       " 'devastating',\n",
       " 'warranted',\n",
       " 'symptom',\n",
       " 'capacity',\n",
       " 'allocated',\n",
       " 'value',\n",
       " 'covid19',\n",
       " 'recombinant',\n",
       " 'masking',\n",
       " 'upon',\n",
       " 'technology',\n",
       " 'components',\n",
       " 'blinding',\n",
       " 'market',\n",
       " 'consider',\n",
       " 'anti-covid-19',\n",
       " 'unfortunately',\n",
       " 'seen',\n",
       " 'died',\n",
       " 'dissemination',\n",
       " 'infectivity',\n",
       " 'th',\n",
       " 'attached',\n",
       " 'resources',\n",
       " 'thousands',\n",
       " 'basis',\n",
       " 'older',\n",
       " 'requiring',\n",
       " 'baseline',\n",
       " 'rcts',\n",
       " 'protected',\n",
       " 'formed',\n",
       " 'specimens',\n",
       " 'appear',\n",
       " 'ace',\n",
       " 'classes',\n",
       " 'processing',\n",
       " 'proper',\n",
       " 'initiated',\n",
       " 'widespread',\n",
       " 'suspected',\n",
       " 'prevalence',\n",
       " 'platform',\n",
       " 'besides',\n",
       " 'microm',\n",
       " 'intravenous',\n",
       " 'preventing',\n",
       " 'expediting',\n",
       " 'protect',\n",
       " 'cure',\n",
       " 'causative',\n",
       " 'adult',\n",
       " 'versus',\n",
       " 'calculated',\n",
       " 'sars-cov-1',\n",
       " 'software',\n",
       " 'recruited',\n",
       " 'affecting',\n",
       " 'huge',\n",
       " 'fact',\n",
       " 'month',\n",
       " 'ranging',\n",
       " 'oxygenation',\n",
       " 'antibody',\n",
       " 'closely',\n",
       " 'spectrum',\n",
       " 'strongly',\n",
       " 'envelope',\n",
       " 'index',\n",
       " 'coronavirus-2',\n",
       " 'experiments',\n",
       " 'prognosis',\n",
       " 'characterized',\n",
       " 'systematically',\n",
       " 'designed',\n",
       " ...]"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[x for x in word_list if x[:-1] not in word_list]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "word_list = [x for x in word_list if x!='doi']\n",
    "word_list = [x for x in word_list if x!='1016/j']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1447"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(word_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['covid-19',\n",
       " 'sars-cov-2',\n",
       " 'patients',\n",
       " 'drug',\n",
       " 'coronavirus',\n",
       " 'drugs',\n",
       " 'treatment',\n",
       " 'disease',\n",
       " 'clinical',\n",
       " 'infection',\n",
       " 'virus',\n",
       " 'respiratory',\n",
       " 'pandemic',\n",
       " 'viral',\n",
       " 'severe',\n",
       " 'potential',\n",
       " 'antiviral',\n",
       " 'health',\n",
       " 'study',\n",
       " 'trials',\n",
       " 'use',\n",
       " 'novel',\n",
       " 'used',\n",
       " 'acute',\n",
       " 'studies',\n",
       " 'syndrome',\n",
       " 'effective',\n",
       " 'also',\n",
       " 'hydroxychloroquine',\n",
       " 'human',\n",
       " 'new',\n",
       " 'data',\n",
       " 'therapeutic',\n",
       " 'results',\n",
       " 'available',\n",
       " 'protein',\n",
       " 'trial',\n",
       " 'binding',\n",
       " 'china',\n",
       " 'current',\n",
       " 'ace2',\n",
       " 'effects',\n",
       " 'caused',\n",
       " 'including',\n",
       " 'using',\n",
       " 'care',\n",
       " 'cases',\n",
       " 'however',\n",
       " 'two',\n",
       " 'group',\n",
       " 'high',\n",
       " 'review',\n",
       " 'world',\n",
       " 'outbreak',\n",
       " 'approved',\n",
       " 'development',\n",
       " 'global',\n",
       " 'therapy',\n",
       " 'currently',\n",
       " 'efficacy',\n",
       " 'hcq',\n",
       " 'associated',\n",
       " 'compounds',\n",
       " 'control',\n",
       " 'cells',\n",
       " 'risk',\n",
       " 'need',\n",
       " 'reported',\n",
       " 'based',\n",
       " 'chloroquine',\n",
       " 'evidence',\n",
       " 'sars-cov',\n",
       " 'several',\n",
       " 'remdesivir',\n",
       " 'inhibitors',\n",
       " 'research',\n",
       " 'diseases',\n",
       " 'safety',\n",
       " 'patient',\n",
       " 'target',\n",
       " 'protease',\n",
       " 'specific',\n",
       " 'spread',\n",
       " 'first',\n",
       " 'molecular',\n",
       " 'main',\n",
       " 'vaccine',\n",
       " 'analysis',\n",
       " 'activity',\n",
       " 'hospital',\n",
       " 'rna',\n",
       " 'wuhan',\n",
       " 'days',\n",
       " 'among',\n",
       " 'infections',\n",
       " 'symptoms',\n",
       " 'one',\n",
       " 'possible',\n",
       " 'receptor',\n",
       " 'mortality',\n",
       " 'treatments',\n",
       " 'well',\n",
       " 'known',\n",
       " 'provide',\n",
       " 'replication',\n",
       " 'medicine',\n",
       " 'methods',\n",
       " 'due',\n",
       " 'time',\n",
       " 'repurposing',\n",
       " '2019-ncov',\n",
       " 'number',\n",
       " 'treat',\n",
       " 'different',\n",
       " 'cell',\n",
       " 'system',\n",
       " 'present',\n",
       " 'many',\n",
       " 'identified',\n",
       " 'pro',\n",
       " 'proteins',\n",
       " 'since',\n",
       " 'outcomes',\n",
       " 'vitro',\n",
       " 'infected',\n",
       " 'pneumonia',\n",
       " 'lung',\n",
       " 'immune',\n",
       " 'targets',\n",
       " 'compared',\n",
       " 'screening',\n",
       " 'agents',\n",
       " 'showed',\n",
       " 'worldwide',\n",
       " 'public',\n",
       " 'host',\n",
       " 'design',\n",
       " 'found',\n",
       " 'management',\n",
       " 'docking',\n",
       " 'promising',\n",
       " 'chinese',\n",
       " 'december',\n",
       " 'coronaviruses',\n",
       " 'protocol',\n",
       " 'strategies',\n",
       " 'therapies',\n",
       " 'participants',\n",
       " 'important',\n",
       " 'sars',\n",
       " 'mg',\n",
       " 'response',\n",
       " 'people',\n",
       " 'viruses',\n",
       " 'molecules',\n",
       " 'active',\n",
       " 'recent',\n",
       " 'countries',\n",
       " 'developed',\n",
       " 'medical',\n",
       " 'vaccines',\n",
       " 'rapidly',\n",
       " 'confirmed',\n",
       " 'significant',\n",
       " 'adverse',\n",
       " 'thus',\n",
       " 'structure',\n",
       " 'enzyme',\n",
       " 'rate',\n",
       " 'role',\n",
       " 'dose',\n",
       " 'information',\n",
       " 'combination',\n",
       " 'azithromycin',\n",
       " 'might',\n",
       " 'total',\n",
       " 'case',\n",
       " 'increased',\n",
       " 'needed',\n",
       " 'performed',\n",
       " 'addition',\n",
       " 'rapid',\n",
       " 'prevention',\n",
       " 'key',\n",
       " 'higher',\n",
       " 'identify',\n",
       " 'years',\n",
       " 'lopinavir',\n",
       " 'plasma',\n",
       " 'considered',\n",
       " 'included',\n",
       " 'although',\n",
       " 'angiotensin',\n",
       " 'approach',\n",
       " 'acid',\n",
       " 'related',\n",
       " 'three',\n",
       " 'emergency',\n",
       " 'prevent',\n",
       " 'test',\n",
       " 'administration',\n",
       " 'randomized',\n",
       " 'discovery',\n",
       " 'effect',\n",
       " 'background',\n",
       " 'april',\n",
       " 'cq',\n",
       " 'major',\n",
       " 'mechanisms',\n",
       " 'shown',\n",
       " 'ritonavir',\n",
       " 'article',\n",
       " 'urgent',\n",
       " 'march',\n",
       " 'day',\n",
       " 'ongoing',\n",
       " 'strategy',\n",
       " 'reports',\n",
       " 'future',\n",
       " 'cytokine',\n",
       " 'spike',\n",
       " 'repurposed',\n",
       " 'interactions',\n",
       " 'similar',\n",
       " 'suggest',\n",
       " 'expression',\n",
       " 'infectious',\n",
       " 'properties',\n",
       " 'without',\n",
       " 'highly',\n",
       " 'critical',\n",
       " 'cardiovascular',\n",
       " 'liver',\n",
       " 'increase',\n",
       " 'measures',\n",
       " 'therefore',\n",
       " 'various',\n",
       " 'therapeutics',\n",
       " 'additional',\n",
       " 'severity',\n",
       " 'epidemic',\n",
       " 'candidates',\n",
       " 'population',\n",
       " 'cardiac',\n",
       " 'existing',\n",
       " 'recently',\n",
       " 'given',\n",
       " 'include',\n",
       " 'diagnosis',\n",
       " 'multiple',\n",
       " 'primary',\n",
       " 'treating',\n",
       " 'approaches',\n",
       " 'deaths',\n",
       " 'findings',\n",
       " 'course',\n",
       " 'injury',\n",
       " 'age',\n",
       " 'likely',\n",
       " 'early',\n",
       " 'proposed',\n",
       " 'standard',\n",
       " 'previously',\n",
       " 'transmission',\n",
       " 'potentially',\n",
       " 'serious',\n",
       " 'positive',\n",
       " 'structural',\n",
       " 'ras',\n",
       " 'conclusions',\n",
       " 'fever',\n",
       " 'model',\n",
       " 'order',\n",
       " 'mpro',\n",
       " 'inhibitor',\n",
       " 'death',\n",
       " 'natural',\n",
       " 'rdrp',\n",
       " 'levels',\n",
       " 'cause',\n",
       " 'efforts',\n",
       " 'develop',\n",
       " 'women',\n",
       " 'still',\n",
       " 'literature',\n",
       " 'especially',\n",
       " 'reduce',\n",
       " 'even',\n",
       " 'medications',\n",
       " 'middle',\n",
       " 'within',\n",
       " 'traditional',\n",
       " 'inhibition',\n",
       " 'healthcare',\n",
       " 'criteria',\n",
       " 'mers-cov',\n",
       " 'site',\n",
       " 'inhibit',\n",
       " 'outcome',\n",
       " 'full',\n",
       " 'respectively',\n",
       " 'yet',\n",
       " 'date',\n",
       " 'lack',\n",
       " 'groups',\n",
       " 'emerged',\n",
       " 'community',\n",
       " 'large',\n",
       " 'according',\n",
       " 'particularly',\n",
       " 'significantly',\n",
       " 'anti-inflammatory',\n",
       " 'published',\n",
       " 'recommended',\n",
       " 'clinically',\n",
       " 'conditions',\n",
       " 'daily',\n",
       " 'result',\n",
       " 'qtc',\n",
       " 'across',\n",
       " 'tested',\n",
       " 'distress',\n",
       " 'database',\n",
       " 'required',\n",
       " 'demonstrated',\n",
       " 'sequence',\n",
       " 'become',\n",
       " 'regarding',\n",
       " 'scientific',\n",
       " 'entry',\n",
       " 'inflammatory',\n",
       " 'essential',\n",
       " 'anti-viral',\n",
       " 'conclusion',\n",
       " 'situation',\n",
       " 'diabetes',\n",
       " 'polymerase',\n",
       " 'medication',\n",
       " 'following',\n",
       " 'agent',\n",
       " 'favipiravir',\n",
       " 'targeting',\n",
       " 'mechanism',\n",
       " 'events',\n",
       " 'ratio',\n",
       " 'antivirals',\n",
       " 'characteristics',\n",
       " 'storm',\n",
       " 'medicines',\n",
       " 'predicted',\n",
       " 'organization',\n",
       " 'support',\n",
       " 'covs',\n",
       " 'alone',\n",
       " 'options',\n",
       " 'limited',\n",
       " 'international',\n",
       " 'help',\n",
       " 'cough',\n",
       " 'randomised',\n",
       " 'failure',\n",
       " 'children',\n",
       " 'affinity',\n",
       " 'taken',\n",
       " 'common',\n",
       " 'illness',\n",
       " 'already',\n",
       " 'humans',\n",
       " 'attention',\n",
       " 'monitoring',\n",
       " 'period',\n",
       " 'intervention',\n",
       " 'controlled',\n",
       " 'low',\n",
       " 'sample',\n",
       " 'report',\n",
       " 'around',\n",
       " 'causing',\n",
       " 'objective',\n",
       " 'safe',\n",
       " 'negative',\n",
       " 'evaluation',\n",
       " 'interaction',\n",
       " 'experimental',\n",
       " 'lower',\n",
       " 'treated',\n",
       " 'vs',\n",
       " 'responsible',\n",
       " 'virtual',\n",
       " 'single',\n",
       " 'good',\n",
       " 'level',\n",
       " 'ci',\n",
       " 'individuals',\n",
       " 'find',\n",
       " 'work',\n",
       " 'manifestations',\n",
       " 'ii',\n",
       " 'complex',\n",
       " 'models',\n",
       " 'intensive',\n",
       " 'action',\n",
       " 'crisis',\n",
       " 'pulmonary',\n",
       " 'ards',\n",
       " 'observed',\n",
       " 'east',\n",
       " 'evaluated',\n",
       " 'emerging',\n",
       " 'better',\n",
       " 'involved',\n",
       " 'file',\n",
       " 'energy',\n",
       " 'mild',\n",
       " 'national',\n",
       " 'hospitalized',\n",
       " 'qt',\n",
       " 'inflammation',\n",
       " 'chronic',\n",
       " 'systemic',\n",
       " 'evaluate',\n",
       " 'search',\n",
       " 'method',\n",
       " 'via',\n",
       " 'interest',\n",
       " 'knowledge',\n",
       " 'status',\n",
       " 'laboratory',\n",
       " 'testing',\n",
       " 'dynamics',\n",
       " 'lead',\n",
       " 'us',\n",
       " 'hours',\n",
       " 'established',\n",
       " 'widely',\n",
       " 'prolongation',\n",
       " 'small',\n",
       " 'secondary',\n",
       " 'systems',\n",
       " 'features',\n",
       " 'network',\n",
       " 'residues',\n",
       " 'impact',\n",
       " 'previous',\n",
       " 'cov',\n",
       " 'threat',\n",
       " 'heart',\n",
       " 'conducted',\n",
       " 'tcm',\n",
       " 'mers',\n",
       " 'pathogenesis',\n",
       " 'pregnancy',\n",
       " 'surface',\n",
       " 'randomization',\n",
       " 'concentrations',\n",
       " 'pregnant',\n",
       " 'either',\n",
       " 'bind',\n",
       " 'domain',\n",
       " 'aim',\n",
       " 'summarize',\n",
       " 'corona',\n",
       " 'general',\n",
       " 'vivo',\n",
       " 'less',\n",
       " 'compound',\n",
       " 'combat',\n",
       " 'improvement',\n",
       " 'potent',\n",
       " 'furthermore',\n",
       " 'changes',\n",
       " 'underlying',\n",
       " 'simulations',\n",
       " 'interventions',\n",
       " 'placebo',\n",
       " 'interval',\n",
       " 'followed',\n",
       " 'exposure',\n",
       " 'paper',\n",
       " 'screened',\n",
       " 'history',\n",
       " 'angiotensin-converting',\n",
       " 'named',\n",
       " 'candidate',\n",
       " 'complications',\n",
       " 'despite',\n",
       " 'side',\n",
       " 'blood',\n",
       " 'mainly',\n",
       " 'cancer',\n",
       " 'four',\n",
       " 'assess',\n",
       " 'influenza',\n",
       " 'molecule',\n",
       " 'discuss',\n",
       " 'least',\n",
       " 'like',\n",
       " 'relevant',\n",
       " 'animal',\n",
       " 'computational']"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "word_list[:500]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['ensure',\n",
       " 'offer',\n",
       " 'affect',\n",
       " 'homology',\n",
       " 'carried',\n",
       " 'contribute',\n",
       " 'types',\n",
       " 'play',\n",
       " 'recognition',\n",
       " 'maximum',\n",
       " 'detected',\n",
       " 'guidance',\n",
       " 'set',\n",
       " 'successful',\n",
       " 'body',\n",
       " 'drug-induced',\n",
       " 'short',\n",
       " 'hospitalization',\n",
       " 'nasopharyngeal',\n",
       " 'iii',\n",
       " 'fusion',\n",
       " 'point',\n",
       " 'determine',\n",
       " 'throughout',\n",
       " 'extensive',\n",
       " 'determined',\n",
       " 'stay',\n",
       " 'highlights',\n",
       " 'quickly',\n",
       " 'specifically',\n",
       " 'preliminary',\n",
       " 'fight',\n",
       " 'analyze',\n",
       " 'recommend',\n",
       " 'area',\n",
       " 'species',\n",
       " 'scale',\n",
       " 'persons',\n",
       " 'mutation',\n",
       " 'another',\n",
       " 'diagnostic',\n",
       " 'duration',\n",
       " 'plays',\n",
       " 'seems',\n",
       " 'facilitate',\n",
       " 'rights',\n",
       " 'shortage',\n",
       " 'susceptible',\n",
       " 'optimal',\n",
       " 'costs',\n",
       " 'men',\n",
       " 'enrolled',\n",
       " 'facing',\n",
       " 'mtor',\n",
       " 'globe',\n",
       " 'efficiency',\n",
       " 's-protein',\n",
       " 'unclear',\n",
       " 'at1r',\n",
       " 'issues',\n",
       " 'fatality',\n",
       " 'prospective',\n",
       " 'light',\n",
       " 'successfully',\n",
       " 'contagious',\n",
       " 'special',\n",
       " 'fibrosis',\n",
       " 'adrs',\n",
       " 'applications',\n",
       " 'ml',\n",
       " 'binds',\n",
       " 'linked',\n",
       " 'pathogen',\n",
       " 'markers',\n",
       " 'appears',\n",
       " 'odds',\n",
       " 'prophylactic',\n",
       " 'regimens',\n",
       " 'involving',\n",
       " 'aes',\n",
       " 'etc',\n",
       " 'continues',\n",
       " 'retrospective',\n",
       " 'assessment',\n",
       " 'broad',\n",
       " 'complete',\n",
       " 'ebola',\n",
       " 'concomitant',\n",
       " 'highlight',\n",
       " 'centers',\n",
       " 'decades',\n",
       " 'alveolar',\n",
       " 'researchers',\n",
       " 'sofosbuvir',\n",
       " 'parameters',\n",
       " 'neurological',\n",
       " 'letter',\n",
       " 'points',\n",
       " 'generated',\n",
       " 'stable',\n",
       " 'increases',\n",
       " 'united',\n",
       " 'crystal',\n",
       " 'emergence',\n",
       " 'started',\n",
       " 'vulnerable',\n",
       " 'indicate',\n",
       " 'innovative',\n",
       " 'docked',\n",
       " 'indicated',\n",
       " 'devastating',\n",
       " 'warranted',\n",
       " 'symptom',\n",
       " 'capacity',\n",
       " 'allocated',\n",
       " 'value',\n",
       " 'covid19',\n",
       " 'recombinant',\n",
       " 'masking',\n",
       " 'upon',\n",
       " 'technology',\n",
       " 'components',\n",
       " 'blinding',\n",
       " 'market',\n",
       " 'consider',\n",
       " 'anti-covid-19',\n",
       " 'unfortunately',\n",
       " 'seen',\n",
       " 'died',\n",
       " 'dissemination',\n",
       " 'infectivity',\n",
       " 'th',\n",
       " 'attached',\n",
       " 'resources',\n",
       " 'acids',\n",
       " 'later',\n",
       " 'thousands',\n",
       " 'improved',\n",
       " 'basis',\n",
       " 'older',\n",
       " 'requiring',\n",
       " 'baseline',\n",
       " 'rcts',\n",
       " 'protected',\n",
       " 'formed',\n",
       " 'specimens',\n",
       " 'appear',\n",
       " 'ace',\n",
       " 'classes',\n",
       " 'affects',\n",
       " 'processing',\n",
       " 'proper',\n",
       " 'initiated',\n",
       " 'widespread',\n",
       " 'suspected',\n",
       " 'prevalence',\n",
       " 'platform',\n",
       " 'besides',\n",
       " 'microm',\n",
       " 'intravenous',\n",
       " 'preventing',\n",
       " 'expediting',\n",
       " 'protect',\n",
       " 'cure',\n",
       " 'causative',\n",
       " 'adult',\n",
       " 'versus',\n",
       " 'makes',\n",
       " 'calculated',\n",
       " 'sars-cov-1',\n",
       " 'software',\n",
       " 'presents',\n",
       " 'recruited',\n",
       " 'affecting',\n",
       " 'huge',\n",
       " 'considerations',\n",
       " 'fact',\n",
       " 'month',\n",
       " 'ranging',\n",
       " 'oxygenation',\n",
       " 'antibody',\n",
       " 'closely',\n",
       " 'spectrum',\n",
       " 'strongly',\n",
       " 'envelope',\n",
       " 'index',\n",
       " 'coronavirus-2',\n",
       " 'experiments',\n",
       " 'prognosis',\n",
       " 'characterized',\n",
       " 'combinations',\n",
       " 'systematically',\n",
       " 'designed',\n",
       " 'pharmacology',\n",
       " 'listed',\n",
       " 'formatting',\n",
       " 'raised',\n",
       " 'eliminated',\n",
       " 'change',\n",
       " 'line',\n",
       " 'conduct',\n",
       " 'adjusted',\n",
       " 'rt-pcr',\n",
       " 'fighting',\n",
       " 'others',\n",
       " 'identity',\n",
       " 'initially',\n",
       " 'clearance',\n",
       " 'discharge',\n",
       " 'uses',\n",
       " 'rds',\n",
       " 'detailed',\n",
       " 'members',\n",
       " 'signaling',\n",
       " 'forms',\n",
       " 'mitigate',\n",
       " 'formulation',\n",
       " 'pathogens',\n",
       " 'address',\n",
       " 'share',\n",
       " 'reference',\n",
       " 'values',\n",
       " 'pharmacovigilance',\n",
       " 'third',\n",
       " 'means',\n",
       " 'improving',\n",
       " 'seem',\n",
       " 'issue',\n",
       " 'autoimmune',\n",
       " 'cov-19',\n",
       " 'sequences',\n",
       " 'beta',\n",
       " 'establish',\n",
       " 'problems',\n",
       " 'regions',\n",
       " 'continuous',\n",
       " 'mass',\n",
       " 'derived',\n",
       " '-7',\n",
       " 'roles',\n",
       " 'week',\n",
       " 'immediate',\n",
       " 'located',\n",
       " 'obese',\n",
       " 'created',\n",
       " 'majority',\n",
       " 'home',\n",
       " 'decreased',\n",
       " 'wide',\n",
       " 'extracted',\n",
       " 'derivatives',\n",
       " 'overview',\n",
       " 'promote',\n",
       " 'statins',\n",
       " 'cannot',\n",
       " 'consistent',\n",
       " 'evaluating',\n",
       " 'vital',\n",
       " 'lipid',\n",
       " 'statistical',\n",
       " 'kinase',\n",
       " 'interleukin',\n",
       " 'lethal',\n",
       " 'loss',\n",
       " 'deadly',\n",
       " 'ligands',\n",
       " 'ventricular',\n",
       " 'examined',\n",
       " 'measured',\n",
       " 'significance',\n",
       " 'pre-existing',\n",
       " 'exposed',\n",
       " 'stem',\n",
       " 'high-quality',\n",
       " 'registry',\n",
       " 'participate',\n",
       " 'towards',\n",
       " 'namely',\n",
       " 'limitations',\n",
       " 'predict',\n",
       " 'place',\n",
       " 'similarity',\n",
       " 'healthy',\n",
       " 'finally',\n",
       " 'allow',\n",
       " 'clozapine',\n",
       " 'interestingly',\n",
       " 'calculations',\n",
       " 'profiles',\n",
       " 'possibly',\n",
       " 'hepatic',\n",
       " 'immunosuppressive',\n",
       " 'signal',\n",
       " 'relatively',\n",
       " 'facilities',\n",
       " 'spain',\n",
       " 'problem',\n",
       " 'follow',\n",
       " 'modern',\n",
       " 'arbidol',\n",
       " 'excluded',\n",
       " 'nuclear',\n",
       " 'x-ray',\n",
       " 'undertaken',\n",
       " 'endocytosis',\n",
       " 'meet',\n",
       " 'personal',\n",
       " 'associates',\n",
       " 'helicase',\n",
       " 'local',\n",
       " 'hospitalisation',\n",
       " '3d',\n",
       " 'pocket',\n",
       " 'dual',\n",
       " 'accurate',\n",
       " 'selection',\n",
       " 'regard',\n",
       " 'assay',\n",
       " 'solution',\n",
       " 'enveloped',\n",
       " 'antimicrobial',\n",
       " 'immunomodulatory',\n",
       " 'frequent',\n",
       " 'zoonotic',\n",
       " 'swab',\n",
       " 'neutralizing',\n",
       " 'transcription',\n",
       " 'attractive',\n",
       " 'records',\n",
       " 'reserved',\n",
       " 'originated',\n",
       " 'cmax',\n",
       " 'asari',\n",
       " 'pathologies',\n",
       " 'percentage',\n",
       " 'government',\n",
       " 'consecutive',\n",
       " 'medicinal',\n",
       " 'structure-based',\n",
       " 'asthma',\n",
       " 'avoid',\n",
       " 'consensus',\n",
       " 'monoclonal',\n",
       " 'half',\n",
       " 'mdi',\n",
       " 'famotidine',\n",
       " 'scores',\n",
       " 'utilized',\n",
       " 'states',\n",
       " 'none',\n",
       " 'inactivation',\n",
       " 'starting',\n",
       " 'plus',\n",
       " 'though',\n",
       " 'induced',\n",
       " 'diverse',\n",
       " 'reached',\n",
       " 'demand',\n",
       " 'ct',\n",
       " 'copyright',\n",
       " 'individual',\n",
       " 'class',\n",
       " 'impairment',\n",
       " 'till',\n",
       " 'distancing',\n",
       " 'abnormal',\n",
       " 'substances',\n",
       " 'nature',\n",
       " 'appeared',\n",
       " 'nucleotide',\n",
       " 'advances',\n",
       " 'converting',\n",
       " 'bound',\n",
       " 'comparable',\n",
       " 'rationale',\n",
       " 'relationship',\n",
       " 'typical',\n",
       " 'hits',\n",
       " 'inhibited',\n",
       " 'putative',\n",
       " 'indicating',\n",
       " 'deficiency',\n",
       " 'complexes',\n",
       " 'controlling',\n",
       " 'western',\n",
       " 'graphene',\n",
       " 'subsequent',\n",
       " 'weight',\n",
       " 'vaccination',\n",
       " 'presenting',\n",
       " 'discovered',\n",
       " 'isolation',\n",
       " 'phosphate',\n",
       " 'environment',\n",
       " 'rapamycin',\n",
       " 'maintain',\n",
       " 'basic',\n",
       " 'usually',\n",
       " 'primarily',\n",
       " 'catalytic',\n",
       " 'condition',\n",
       " 'tomography',\n",
       " 'validation',\n",
       " 'produce',\n",
       " 'exist',\n",
       " 'proteasome',\n",
       " 'importantly',\n",
       " 'stop',\n",
       " 'capable',\n",
       " 'embase',\n",
       " 'containment',\n",
       " 'massive',\n",
       " 'numerous',\n",
       " 'core',\n",
       " 'opportunity',\n",
       " 'hand',\n",
       " 'dynamic',\n",
       " 'document',\n",
       " 'insights',\n",
       " 'choice',\n",
       " 'little',\n",
       " 'authorities',\n",
       " 'moderate',\n",
       " 'ai',\n",
       " 'druggable',\n",
       " 'assigned',\n",
       " 'alleviate',\n",
       " 'occur',\n",
       " 'intubation',\n",
       " 'nasal',\n",
       " 'containing',\n",
       " 'regulation',\n",
       " 'approval',\n",
       " 'ang',\n",
       " 'heat',\n",
       " 'source',\n",
       " 'sufficient',\n",
       " 'unbound',\n",
       " 'induce',\n",
       " 'observation',\n",
       " 'tools',\n",
       " 'parallel',\n",
       " 'proliferation',\n",
       " 'pathophysiology',\n",
       " 'evolving',\n",
       " 'hot',\n",
       " 'prescriptions',\n",
       " 'act',\n",
       " 'colchicine',\n",
       " 'hydrophobic',\n",
       " '-2',\n",
       " 'decoction',\n",
       " 'arms',\n",
       " 'tissues',\n",
       " 'aceis',\n",
       " 'length',\n",
       " 'repurpose',\n",
       " 'timely',\n",
       " 'processes',\n",
       " 'part',\n",
       " 'comprehensive',\n",
       " 'titers',\n",
       " 'animals',\n",
       " 'utility',\n",
       " 'well-known',\n",
       " 'hydrogen',\n",
       " 'quot',\n",
       " 'metformin',\n",
       " 'quarantine',\n",
       " 'pain',\n",
       " 'priority',\n",
       " 'pattern',\n",
       " 'drug-drug',\n",
       " 'consequences',\n",
       " 'detection',\n",
       " 'outside',\n",
       " 'immunological',\n",
       " 'whereas',\n",
       " 'wi-n',\n",
       " 'lpv',\n",
       " 'reliable',\n",
       " 'iv',\n",
       " 'hundred',\n",
       " 'overdose',\n",
       " 'modernization',\n",
       " 'procedures',\n",
       " 'multicenter',\n",
       " 'pointes',\n",
       " 'india',\n",
       " 'bacterial',\n",
       " '3c-like',\n",
       " 'telephone',\n",
       " 'synthetic',\n",
       " 'ascorbic',\n",
       " 'assays',\n",
       " 'turn',\n",
       " 'populations',\n",
       " 'science',\n",
       " 'room',\n",
       " 'hypothesize']"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "word_list[-500:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "total_raw = [preprocess(x) for x in total_raw]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "N = len(total_raw) # 총 문서의 수\n",
    "\n",
    "def tf(t, d):\n",
    "    return d.count(t)\n",
    "\n",
    "def idf(t):\n",
    "    df = 0\n",
    "    for doc in total_raw:\n",
    "        df += t in doc\n",
    "    return np.log(N/(df + 1))\n",
    "\n",
    "def tfidf(t, d):\n",
    "    return tf(t,d)* idf(t)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "N"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>covid-19</th>\n",
       "      <th>sars-cov-2</th>\n",
       "      <th>patients</th>\n",
       "      <th>drug</th>\n",
       "      <th>coronavirus</th>\n",
       "      <th>drugs</th>\n",
       "      <th>treatment</th>\n",
       "      <th>disease</th>\n",
       "      <th>clinical</th>\n",
       "      <th>infection</th>\n",
       "      <th>...</th>\n",
       "      <th>3c-like</th>\n",
       "      <th>telephone</th>\n",
       "      <th>synthetic</th>\n",
       "      <th>ascorbic</th>\n",
       "      <th>assays</th>\n",
       "      <th>turn</th>\n",
       "      <th>populations</th>\n",
       "      <th>science</th>\n",
       "      <th>room</th>\n",
       "      <th>hypothesize</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>26</td>\n",
       "      <td>75</td>\n",
       "      <td>19</td>\n",
       "      <td>119</td>\n",
       "      <td>27</td>\n",
       "      <td>37</td>\n",
       "      <td>25</td>\n",
       "      <td>13</td>\n",
       "      <td>20</td>\n",
       "      <td>32</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>6</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>5</td>\n",
       "      <td>37</td>\n",
       "      <td>1</td>\n",
       "      <td>25</td>\n",
       "      <td>4</td>\n",
       "      <td>13</td>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>42</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>14</td>\n",
       "      <td>19</td>\n",
       "      <td>10</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>5</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>12</td>\n",
       "      <td>43</td>\n",
       "      <td>7</td>\n",
       "      <td>19</td>\n",
       "      <td>1</td>\n",
       "      <td>9</td>\n",
       "      <td>8</td>\n",
       "      <td>9</td>\n",
       "      <td>18</td>\n",
       "      <td>16</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>45</td>\n",
       "      <td>11</td>\n",
       "      <td>35</td>\n",
       "      <td>28</td>\n",
       "      <td>54</td>\n",
       "      <td>8</td>\n",
       "      <td>53</td>\n",
       "      <td>15</td>\n",
       "      <td>102</td>\n",
       "      <td>25</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 1447 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   covid-19  sars-cov-2  patients  drug  coronavirus  drugs  treatment  \\\n",
       "0        26          75        19   119           27     37         25   \n",
       "1         5          37         1    25            4     13          4   \n",
       "2        42           0         0    14           19     10          0   \n",
       "3        12          43         7    19            1      9          8   \n",
       "4        45          11        35    28           54      8         53   \n",
       "\n",
       "   disease  clinical  infection     ...       3c-like  telephone  synthetic  \\\n",
       "0       13        20         32     ...             0          0          0   \n",
       "1        4         1          3     ...             1          0          1   \n",
       "2        0         3          5     ...             0          0          0   \n",
       "3        9        18         16     ...             0          0          0   \n",
       "4       15       102         25     ...             0          0          0   \n",
       "\n",
       "   ascorbic  assays  turn  populations  science  room  hypothesize  \n",
       "0         0       5     0            0        6     2            0  \n",
       "1         0       0     0            0        0     0            0  \n",
       "2         0       0     2            0        3     0            0  \n",
       "3         0       4     0            0        5     1            0  \n",
       "4         1       0     0            0        2     0            0  \n",
       "\n",
       "[5 rows x 1447 columns]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result = []\n",
    "for i in range(N): # 각 문서에 대해서 아래 명령을 수행\n",
    "    result.append([])\n",
    "    d = total_raw[i]\n",
    "    for j in range(len(word_list)):\n",
    "        t = word_list[j]        \n",
    "        result[-1].append(tf(t, d))\n",
    "\n",
    "tf_ = pd.DataFrame(result, columns = word_list)\n",
    "tf_.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "tf_ = tf_.loc[:, (tf_ != 0).any(axis=0)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(34, 1388)"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tf_.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>IDF</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>covid-19</th>\n",
       "      <td>0.092373</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>sars-cov-2</th>\n",
       "      <td>0.194156</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>patients</th>\n",
       "      <td>0.194156</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>drug</th>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>coronavirus</th>\n",
       "      <td>-0.028988</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                  IDF\n",
       "covid-19     0.092373\n",
       "sars-cov-2   0.194156\n",
       "patients     0.194156\n",
       "drug         0.000000\n",
       "coronavirus -0.028988"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result = []\n",
    "for j in range(len(word_list)):\n",
    "    t = word_list[j]\n",
    "    result.append(idf(t))\n",
    "\n",
    "idf_ = pd.DataFrame(result, index = word_list, columns = [\"IDF\"])\n",
    "idf_.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "idf_ = idf_.loc[:, (idf_ != 0).any(axis=0)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(1447, 1)"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "idf_.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>covid-19</th>\n",
       "      <th>sars-cov-2</th>\n",
       "      <th>patients</th>\n",
       "      <th>drug</th>\n",
       "      <th>coronavirus</th>\n",
       "      <th>drugs</th>\n",
       "      <th>treatment</th>\n",
       "      <th>disease</th>\n",
       "      <th>clinical</th>\n",
       "      <th>infection</th>\n",
       "      <th>...</th>\n",
       "      <th>3c-like</th>\n",
       "      <th>telephone</th>\n",
       "      <th>synthetic</th>\n",
       "      <th>ascorbic</th>\n",
       "      <th>assays</th>\n",
       "      <th>turn</th>\n",
       "      <th>populations</th>\n",
       "      <th>science</th>\n",
       "      <th>room</th>\n",
       "      <th>hypothesize</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2.401706</td>\n",
       "      <td>14.561701</td>\n",
       "      <td>3.688964</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.782663</td>\n",
       "      <td>1.104560</td>\n",
       "      <td>2.309333</td>\n",
       "      <td>2.067841</td>\n",
       "      <td>1.212492</td>\n",
       "      <td>0.955295</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.207269</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>3.160901</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>0.388089</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.636259</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>...</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3.879679</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.550763</td>\n",
       "      <td>0.298530</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.774606</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1.108480</td>\n",
       "      <td>8.348709</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>0.738987</td>\n",
       "      <td>1.431582</td>\n",
       "      <td>1.091243</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.165815</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.954332</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4.156799</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>6.795461</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-1.565327</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>4.895786</td>\n",
       "      <td>2.385970</td>\n",
       "      <td>6.183711</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.833213</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.781733</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>1.939840</td>\n",
       "      <td>1.164936</td>\n",
       "      <td>1.164936</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>0.831360</td>\n",
       "      <td>0.954388</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.781733</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.184747</td>\n",
       "      <td>3.106496</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>0.447794</td>\n",
       "      <td>0.461867</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.328383</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.124362</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>1.939840</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.057975</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.848745</td>\n",
       "      <td>0.208971</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.774606</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2.309333</td>\n",
       "      <td>3.300652</td>\n",
       "      <td>15.726637</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>6.004266</td>\n",
       "      <td>1.590647</td>\n",
       "      <td>1.273117</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>9.125333</td>\n",
       "      <td>1.941560</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>1.462795</td>\n",
       "      <td>1.570346</td>\n",
       "      <td>1.908776</td>\n",
       "      <td>2.667483</td>\n",
       "      <td>2.298678</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>6.248723</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.736064</td>\n",
       "      <td>4.741351</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>2.718184</td>\n",
       "      <td>0.776624</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.447794</td>\n",
       "      <td>0.184747</td>\n",
       "      <td>0.636259</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.328383</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>0.184747</td>\n",
       "      <td>3.106496</td>\n",
       "      <td>0.970780</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.289875</td>\n",
       "      <td>0.835883</td>\n",
       "      <td>5.080533</td>\n",
       "      <td>2.067841</td>\n",
       "      <td>0.606246</td>\n",
       "      <td>0.806030</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>29.960926</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>1.385600</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>4.077276</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.787306</td>\n",
       "      <td>3.817553</td>\n",
       "      <td>0.909369</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>6.420198</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.970780</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.260888</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.795323</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>7.112746</td>\n",
       "      <td>5.436368</td>\n",
       "      <td>7.766241</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.289875</td>\n",
       "      <td>0.895589</td>\n",
       "      <td>6.189012</td>\n",
       "      <td>5.249135</td>\n",
       "      <td>2.182486</td>\n",
       "      <td>0.716471</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.280132</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>0.092373</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>1.553248</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>1.731472</td>\n",
       "      <td>1.847466</td>\n",
       "      <td>2.385970</td>\n",
       "      <td>1.030619</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>6.248723</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>3.494808</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.840639</td>\n",
       "      <td>0.119412</td>\n",
       "      <td>0.831360</td>\n",
       "      <td>0.954388</td>\n",
       "      <td>0.363748</td>\n",
       "      <td>0.298530</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.086963</td>\n",
       "      <td>0.806030</td>\n",
       "      <td>0.554240</td>\n",
       "      <td>0.318129</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.160901</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.289875</td>\n",
       "      <td>0.417941</td>\n",
       "      <td>0.092373</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>...</td>\n",
       "      <td>3.469202</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>4.077276</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.231900</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>0.554240</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.545622</td>\n",
       "      <td>0.119412</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>2.524028</td>\n",
       "      <td>1.164936</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.057975</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>0.184747</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.303123</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.927601</td>\n",
       "      <td>0.597059</td>\n",
       "      <td>1.108480</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.242498</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.124362</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>1.747404</td>\n",
       "      <td>0.582468</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.608738</td>\n",
       "      <td>1.253824</td>\n",
       "      <td>0.646613</td>\n",
       "      <td>0.795323</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>...</td>\n",
       "      <td>5.203803</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>1.477973</td>\n",
       "      <td>1.553248</td>\n",
       "      <td>0.970780</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-1.565327</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>0.646613</td>\n",
       "      <td>1.908776</td>\n",
       "      <td>0.545622</td>\n",
       "      <td>0.358236</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.954332</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>3.883120</td>\n",
       "      <td>0.776624</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.260888</td>\n",
       "      <td>1.552354</td>\n",
       "      <td>1.108480</td>\n",
       "      <td>4.294747</td>\n",
       "      <td>0.545622</td>\n",
       "      <td>1.343383</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>5.630524</td>\n",
       "      <td>0.388312</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.347850</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>0.184747</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.242498</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>2.216960</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.795323</td>\n",
       "      <td>0.848745</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>...</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.082908</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.299529</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>1.553248</td>\n",
       "      <td>0.388312</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>0.646613</td>\n",
       "      <td>0.954388</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.092373</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.173925</td>\n",
       "      <td>0.119412</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.661910</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>0.092373</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.463801</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>0.738987</td>\n",
       "      <td>0.318129</td>\n",
       "      <td>0.666871</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>4.618666</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>4.077276</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.463801</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>1.016107</td>\n",
       "      <td>1.908776</td>\n",
       "      <td>0.484997</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>0.831360</td>\n",
       "      <td>11.843517</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>-0.231900</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>0.923733</td>\n",
       "      <td>1.272518</td>\n",
       "      <td>0.484997</td>\n",
       "      <td>0.208971</td>\n",
       "      <td>...</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.517797</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>34 rows × 1447 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    covid-19  sars-cov-2   patients  drug  coronavirus     drugs  treatment  \\\n",
       "0   2.401706   14.561701   3.688964   0.0    -0.782663  1.104560   2.309333   \n",
       "1   0.461867    7.183773   0.194156   0.0    -0.115950  0.388089   0.369493   \n",
       "2   3.879679    0.000000   0.000000   0.0    -0.550763  0.298530   0.000000   \n",
       "3   1.108480    8.348709   1.359092   0.0    -0.028988  0.268677   0.738987   \n",
       "4   4.156799    2.135716   6.795461   0.0    -1.565327  0.238824   4.895786   \n",
       "5   1.939840    1.164936   1.164936   0.0    -0.202913  0.149265   0.831360   \n",
       "6   0.184747    3.106496   0.194156   0.0    -0.115950  0.447794   0.461867   \n",
       "7   1.939840    0.194156   1.359092   0.0    -0.057975  0.238824   0.369493   \n",
       "8   2.309333    3.300652  15.726637   0.0    -0.376838  0.179118   6.004266   \n",
       "9   0.554240    9.125333   1.941560   0.0    -0.202913  1.462795   1.570346   \n",
       "10  0.554240    2.718184   0.776624   0.0    -0.028988  0.447794   0.184747   \n",
       "11  0.184747    3.106496   0.970780   0.0    -0.289875  0.835883   5.080533   \n",
       "12  1.385600    2.135716   4.077276   0.0    -0.202913  0.000000   3.787306   \n",
       "13  0.000000    0.000000   0.970780   0.0    -0.376838  0.029853   0.369493   \n",
       "14  0.277120    1.359092   0.000000   0.0    -0.260888  0.059706   0.000000   \n",
       "15  7.112746    5.436368   7.766241   0.0    -0.289875  0.895589   6.189012   \n",
       "16  0.092373    7.183773   1.553248   0.0    -0.376838  1.731472   1.847466   \n",
       "17  0.554240    3.494808   1.359092   0.0    -0.840639  0.119412   0.831360   \n",
       "18  0.000000    0.000000   0.194156   0.0    -0.086963  0.806030   0.554240   \n",
       "19  0.000000    0.000000   0.000000   0.0    -0.289875  0.417941   0.092373   \n",
       "20  0.277120    4.077276   0.194156   0.0    -0.231900  0.477647   0.554240   \n",
       "21  0.554240    2.524028   1.164936   0.0    -0.057975  0.059706   0.184747   \n",
       "22  0.277120    0.000000   0.000000   0.0    -0.927601  0.597059   1.108480   \n",
       "23  0.554240    1.747404   0.582468   0.0    -0.608738  1.253824   0.646613   \n",
       "24  1.477973    1.553248   0.970780   0.0    -1.565327  0.179118   0.646613   \n",
       "25  0.461867    3.883120   0.776624   0.0    -0.260888  1.552354   1.108480   \n",
       "26  0.277120    5.630524   0.388312   0.0    -0.347850  0.268677   0.184747   \n",
       "27  2.216960    0.000000   0.000000   0.0    -0.028988  0.238824   0.369493   \n",
       "28  0.000000    0.000000   0.000000   0.0    -0.028988  0.000000   0.000000   \n",
       "29  0.461867    1.553248   0.388312   0.0    -0.202913  0.029853   0.646613   \n",
       "30  0.092373    7.183773   0.194156   0.0    -0.173925  0.119412   0.000000   \n",
       "31  0.092373    0.194156   1.359092   0.0    -0.463801  0.089559   0.738987   \n",
       "32  4.618666    2.135716   4.077276   0.0    -0.463801  0.179118   1.016107   \n",
       "33  0.831360   11.843517   0.000000   0.0    -0.231900  0.477647   0.923733   \n",
       "\n",
       "     disease  clinical  infection     ...        3c-like  telephone  \\\n",
       "0   2.067841  1.212492   0.955295     ...       0.000000        0.0   \n",
       "1   0.636259  0.060625   0.089559     ...       1.734601        0.0   \n",
       "2   0.000000  0.181874   0.149265     ...       0.000000        0.0   \n",
       "3   1.431582  1.091243   0.477647     ...       0.000000        0.0   \n",
       "4   2.385970  6.183711   0.746324     ...       0.000000        0.0   \n",
       "5   0.954388  0.181874   0.268677     ...       0.000000        0.0   \n",
       "6   0.159065  0.000000   0.328383     ...       0.000000        0.0   \n",
       "7   0.000000  0.848745   0.208971     ...       0.000000        0.0   \n",
       "8   1.590647  1.273117   0.179118     ...       0.000000        0.0   \n",
       "9   1.908776  2.667483   2.298678     ...       0.000000        0.0   \n",
       "10  0.636259  0.181874   0.328383     ...       0.000000        0.0   \n",
       "11  2.067841  0.606246   0.806030     ...       0.000000        0.0   \n",
       "12  3.817553  0.909369   0.179118     ...       0.000000        0.0   \n",
       "13  0.000000  0.060625   0.149265     ...       0.000000        0.0   \n",
       "14  0.795323  0.000000   0.000000     ...       0.000000        0.0   \n",
       "15  5.249135  2.182486   0.716471     ...       0.000000        0.0   \n",
       "16  2.385970  1.030619   0.746324     ...       0.000000        0.0   \n",
       "17  0.954388  0.363748   0.298530     ...       0.000000        0.0   \n",
       "18  0.318129  0.060625   0.059706     ...       0.000000        0.0   \n",
       "19  0.159065  0.060625   0.089559     ...       3.469202        0.0   \n",
       "20  0.159065  0.545622   0.119412     ...       0.000000        0.0   \n",
       "21  0.159065  0.303123   0.029853     ...       0.000000        0.0   \n",
       "22  0.159065  0.242498   0.746324     ...       0.000000        0.0   \n",
       "23  0.795323  0.181874   0.029853     ...       5.203803        0.0   \n",
       "24  1.908776  0.545622   0.358236     ...       0.000000        0.0   \n",
       "25  4.294747  0.545622   1.343383     ...       0.000000        0.0   \n",
       "26  0.000000  0.242498   0.149265     ...       0.000000        0.0   \n",
       "27  0.795323  0.848745   0.059706     ...       1.734601        0.0   \n",
       "28  0.000000  0.000000   0.000000     ...       0.000000        0.0   \n",
       "29  0.954388  0.060625   0.238824     ...       0.000000        0.0   \n",
       "30  0.000000  0.060625   0.059706     ...       0.000000        0.0   \n",
       "31  0.318129  0.666871   0.238824     ...       0.000000        0.0   \n",
       "32  1.908776  0.484997   0.238824     ...       0.000000        0.0   \n",
       "33  1.272518  0.484997   0.208971     ...       1.734601        0.0   \n",
       "\n",
       "    synthetic  ascorbic    assays      turn  populations   science      room  \\\n",
       "0    0.000000  0.000000  5.207269  0.000000     0.000000  2.345198  3.160901   \n",
       "1    2.140066  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "2    0.000000  0.000000  0.000000  1.774606     0.000000  1.172599  0.000000   \n",
       "3    0.000000  0.000000  4.165815  0.000000     0.000000  1.954332  1.580450   \n",
       "4    0.000000  2.833213  0.000000  0.000000     0.000000  0.781733  0.000000   \n",
       "5    0.000000  0.000000  0.000000  0.000000     0.000000  0.781733  0.000000   \n",
       "6    0.000000  0.000000  3.124362  0.000000     0.000000  0.000000  0.000000   \n",
       "7    0.000000  0.000000  0.000000  1.774606     0.000000  1.172599  0.000000   \n",
       "8    0.000000  0.000000  0.000000  0.887303     0.000000  1.172599  0.000000   \n",
       "9    0.000000  0.000000  6.248723  0.000000     0.000000  2.736064  4.741351   \n",
       "10   0.000000  0.000000  1.041454  0.000000     0.000000  0.390866  0.000000   \n",
       "11  29.960926  0.000000  1.041454  0.887303     2.140066  0.000000  0.000000   \n",
       "12   0.000000  0.000000  1.041454  0.887303     6.420198  0.390866  0.000000   \n",
       "13   0.000000  0.000000  0.000000  0.000000     0.000000  0.390866  1.580450   \n",
       "14   0.000000  0.000000  0.000000  0.887303     0.000000  0.390866  0.000000   \n",
       "15   4.280132  0.000000  0.000000  0.000000     0.000000  2.345198  0.000000   \n",
       "16   0.000000  0.000000  6.248723  0.000000     0.000000  0.000000  0.000000   \n",
       "17   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "18   0.000000  0.000000  0.000000  0.887303     0.000000  0.000000  0.000000   \n",
       "19   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "20   0.000000  0.000000  0.000000  0.887303     0.000000  0.390866  0.000000   \n",
       "21   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "22   0.000000  0.000000  3.124362  0.887303     0.000000  2.345198  1.580450   \n",
       "23   0.000000  0.000000  0.000000  0.000000     0.000000  0.390866  0.000000   \n",
       "24   0.000000  0.000000  0.000000  0.887303     0.000000  1.954332  0.000000   \n",
       "25   0.000000  0.000000  0.000000  0.887303     2.140066  0.390866  0.000000   \n",
       "26   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "27   0.000000  0.000000  2.082908  0.000000     0.000000  4.299529  0.000000   \n",
       "28   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "29   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "30   0.000000  0.000000  0.000000  2.661910     0.000000  0.390866  1.580450   \n",
       "31   0.000000  0.000000  0.000000  0.000000     0.000000  1.172599  0.000000   \n",
       "32   0.000000  0.000000  0.000000  0.887303     0.000000  0.000000  0.000000   \n",
       "33   0.000000  0.000000  1.041454  0.000000     0.000000  3.517797  0.000000   \n",
       "\n",
       "    hypothesize  \n",
       "0      0.000000  \n",
       "1      0.000000  \n",
       "2      0.000000  \n",
       "3      0.000000  \n",
       "4      0.000000  \n",
       "5      0.000000  \n",
       "6      0.000000  \n",
       "7      0.000000  \n",
       "8      0.000000  \n",
       "9      0.000000  \n",
       "10     0.000000  \n",
       "11     0.000000  \n",
       "12     0.000000  \n",
       "13     0.000000  \n",
       "14     0.000000  \n",
       "15     1.580450  \n",
       "16     0.000000  \n",
       "17     0.000000  \n",
       "18     3.160901  \n",
       "19     0.000000  \n",
       "20     0.000000  \n",
       "21     0.000000  \n",
       "22     0.000000  \n",
       "23     1.580450  \n",
       "24     0.000000  \n",
       "25     0.000000  \n",
       "26     1.580450  \n",
       "27     0.000000  \n",
       "28     0.000000  \n",
       "29     0.000000  \n",
       "30     0.000000  \n",
       "31     1.580450  \n",
       "32     1.580450  \n",
       "33     0.000000  \n",
       "\n",
       "[34 rows x 1447 columns]"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result = []\n",
    "for i in range(N):\n",
    "    result.append([])\n",
    "    d = total_raw[i]\n",
    "    for j in range(len(word_list)):\n",
    "        t = word_list[j]\n",
    "\n",
    "        result[-1].append(tfidf(t,d))\n",
    "\n",
    "tfidf_ = pd.DataFrame(result, columns = word_list)\n",
    "tfidf_"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "tfidf_ = tfidf_.loc[:, (tfidf_ != 0).any(axis=0)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>covid-19</th>\n",
       "      <th>sars-cov-2</th>\n",
       "      <th>patients</th>\n",
       "      <th>coronavirus</th>\n",
       "      <th>drugs</th>\n",
       "      <th>treatment</th>\n",
       "      <th>disease</th>\n",
       "      <th>clinical</th>\n",
       "      <th>infection</th>\n",
       "      <th>virus</th>\n",
       "      <th>...</th>\n",
       "      <th>bacterial</th>\n",
       "      <th>3c-like</th>\n",
       "      <th>synthetic</th>\n",
       "      <th>ascorbic</th>\n",
       "      <th>assays</th>\n",
       "      <th>turn</th>\n",
       "      <th>populations</th>\n",
       "      <th>science</th>\n",
       "      <th>room</th>\n",
       "      <th>hypothesize</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2.401706</td>\n",
       "      <td>14.561701</td>\n",
       "      <td>3.688964</td>\n",
       "      <td>-0.782663</td>\n",
       "      <td>1.104560</td>\n",
       "      <td>2.309333</td>\n",
       "      <td>2.067841</td>\n",
       "      <td>1.212492</td>\n",
       "      <td>0.955295</td>\n",
       "      <td>-2.550903</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.207269</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>3.160901</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>0.388089</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.636259</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>-0.318863</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3.879679</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.550763</td>\n",
       "      <td>0.298530</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>-1.101526</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.774606</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1.108480</td>\n",
       "      <td>8.348709</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>0.738987</td>\n",
       "      <td>1.431582</td>\n",
       "      <td>1.091243</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>-0.811651</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.165815</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.954332</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4.156799</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>6.795461</td>\n",
       "      <td>-1.565327</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>4.895786</td>\n",
       "      <td>2.385970</td>\n",
       "      <td>6.183711</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>-2.116090</td>\n",
       "      <td>...</td>\n",
       "      <td>2.447551</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.833213</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.781733</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 1374 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   covid-19  sars-cov-2  patients  coronavirus     drugs  treatment   disease  \\\n",
       "0  2.401706   14.561701  3.688964    -0.782663  1.104560   2.309333  2.067841   \n",
       "1  0.461867    7.183773  0.194156    -0.115950  0.388089   0.369493  0.636259   \n",
       "2  3.879679    0.000000  0.000000    -0.550763  0.298530   0.000000  0.000000   \n",
       "3  1.108480    8.348709  1.359092    -0.028988  0.268677   0.738987  1.431582   \n",
       "4  4.156799    2.135716  6.795461    -1.565327  0.238824   4.895786  2.385970   \n",
       "\n",
       "   clinical  infection     virus     ...       bacterial   3c-like  synthetic  \\\n",
       "0  1.212492   0.955295 -2.550903     ...        0.000000  0.000000   0.000000   \n",
       "1  0.060625   0.089559 -0.318863     ...        0.000000  1.734601   2.140066   \n",
       "2  0.181874   0.149265 -1.101526     ...        0.000000  0.000000   0.000000   \n",
       "3  1.091243   0.477647 -0.811651     ...        0.000000  0.000000   0.000000   \n",
       "4  6.183711   0.746324 -2.116090     ...        2.447551  0.000000   0.000000   \n",
       "\n",
       "   ascorbic    assays      turn  populations   science      room  hypothesize  \n",
       "0  0.000000  5.207269  0.000000          0.0  2.345198  3.160901          0.0  \n",
       "1  0.000000  0.000000  0.000000          0.0  0.000000  0.000000          0.0  \n",
       "2  0.000000  0.000000  1.774606          0.0  1.172599  0.000000          0.0  \n",
       "3  0.000000  4.165815  0.000000          0.0  1.954332  1.580450          0.0  \n",
       "4  2.833213  0.000000  0.000000          0.0  0.781733  0.000000          0.0  \n",
       "\n",
       "[5 rows x 1374 columns]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tfidf_.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "tfidf_.index = list(range(1,35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>covid-19</th>\n",
       "      <th>sars-cov-2</th>\n",
       "      <th>patients</th>\n",
       "      <th>coronavirus</th>\n",
       "      <th>drugs</th>\n",
       "      <th>treatment</th>\n",
       "      <th>disease</th>\n",
       "      <th>clinical</th>\n",
       "      <th>infection</th>\n",
       "      <th>virus</th>\n",
       "      <th>...</th>\n",
       "      <th>bacterial</th>\n",
       "      <th>3c-like</th>\n",
       "      <th>synthetic</th>\n",
       "      <th>ascorbic</th>\n",
       "      <th>assays</th>\n",
       "      <th>turn</th>\n",
       "      <th>populations</th>\n",
       "      <th>science</th>\n",
       "      <th>room</th>\n",
       "      <th>hypothesize</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2.401706</td>\n",
       "      <td>14.561701</td>\n",
       "      <td>3.688964</td>\n",
       "      <td>-0.782663</td>\n",
       "      <td>1.104560</td>\n",
       "      <td>2.309333</td>\n",
       "      <td>2.067841</td>\n",
       "      <td>1.212492</td>\n",
       "      <td>0.955295</td>\n",
       "      <td>-2.550903</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.207269</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>3.160901</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>0.388089</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.636259</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>-0.318863</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3.879679</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.550763</td>\n",
       "      <td>0.298530</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>-1.101526</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.774606</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1.108480</td>\n",
       "      <td>8.348709</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>0.738987</td>\n",
       "      <td>1.431582</td>\n",
       "      <td>1.091243</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>-0.811651</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.165815</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.954332</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>4.156799</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>6.795461</td>\n",
       "      <td>-1.565327</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>4.895786</td>\n",
       "      <td>2.385970</td>\n",
       "      <td>6.183711</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>-2.116090</td>\n",
       "      <td>...</td>\n",
       "      <td>2.447551</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.833213</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.781733</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 1374 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   covid-19  sars-cov-2  patients  coronavirus     drugs  treatment   disease  \\\n",
       "1  2.401706   14.561701  3.688964    -0.782663  1.104560   2.309333  2.067841   \n",
       "2  0.461867    7.183773  0.194156    -0.115950  0.388089   0.369493  0.636259   \n",
       "3  3.879679    0.000000  0.000000    -0.550763  0.298530   0.000000  0.000000   \n",
       "4  1.108480    8.348709  1.359092    -0.028988  0.268677   0.738987  1.431582   \n",
       "5  4.156799    2.135716  6.795461    -1.565327  0.238824   4.895786  2.385970   \n",
       "\n",
       "   clinical  infection     virus     ...       bacterial   3c-like  synthetic  \\\n",
       "1  1.212492   0.955295 -2.550903     ...        0.000000  0.000000   0.000000   \n",
       "2  0.060625   0.089559 -0.318863     ...        0.000000  1.734601   2.140066   \n",
       "3  0.181874   0.149265 -1.101526     ...        0.000000  0.000000   0.000000   \n",
       "4  1.091243   0.477647 -0.811651     ...        0.000000  0.000000   0.000000   \n",
       "5  6.183711   0.746324 -2.116090     ...        2.447551  0.000000   0.000000   \n",
       "\n",
       "   ascorbic    assays      turn  populations   science      room  hypothesize  \n",
       "1  0.000000  5.207269  0.000000          0.0  2.345198  3.160901          0.0  \n",
       "2  0.000000  0.000000  0.000000          0.0  0.000000  0.000000          0.0  \n",
       "3  0.000000  0.000000  1.774606          0.0  1.172599  0.000000          0.0  \n",
       "4  0.000000  4.165815  0.000000          0.0  1.954332  1.580450          0.0  \n",
       "5  2.833213  0.000000  0.000000          0.0  0.781733  0.000000          0.0  \n",
       "\n",
       "[5 rows x 1374 columns]"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tfidf_.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "total_a = []\n",
    "total_b = []\n",
    "\n",
    "for doc_num in range(1, N+1):\n",
    "    a = [] \n",
    "    b = [] \n",
    "    \n",
    "    tfidf_dic = {}\n",
    "    for x in tfidf_.columns:\n",
    "#         print(x, tfidf_.loc[doc_num][x])\n",
    "        tfidf_dic[x] = tfidf_.loc[doc_num][x]\n",
    "    tfidf_sorted = sorted(tfidf_dic.items(), key=operator.itemgetter(1), reverse=True)\n",
    "    \n",
    "    for x in tfidf_sorted[:150]:\n",
    "        a.append(x[0])\n",
    "        b.append(x[1])\n",
    "    \n",
    "    total_a.append(a)\n",
    "    total_b.append(b)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(total_a)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "new_df = pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "for x in range(1, N+1):\n",
    "    new_df[x] = total_a[x-1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>10</th>\n",
       "      <th>...</th>\n",
       "      <th>25</th>\n",
       "      <th>26</th>\n",
       "      <th>27</th>\n",
       "      <th>28</th>\n",
       "      <th>29</th>\n",
       "      <th>30</th>\n",
       "      <th>31</th>\n",
       "      <th>32</th>\n",
       "      <th>33</th>\n",
       "      <th>34</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>network</td>\n",
       "      <td>3cl</td>\n",
       "      <td>rdrp</td>\n",
       "      <td>lpv</td>\n",
       "      <td>clinicaltrials</td>\n",
       "      <td>india</td>\n",
       "      <td>hydroxychloroquine</td>\n",
       "      <td>calculations</td>\n",
       "      <td>ritonavir</td>\n",
       "      <td>influenza</td>\n",
       "      <td>...</td>\n",
       "      <td>vaccine</td>\n",
       "      <td>nature</td>\n",
       "      <td>energy</td>\n",
       "      <td>mpro</td>\n",
       "      <td>ii</td>\n",
       "      <td>outbreaks</td>\n",
       "      <td>rbd</td>\n",
       "      <td>2019-ncov</td>\n",
       "      <td>qt</td>\n",
       "      <td>mg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>il-6</td>\n",
       "      <td>docking</td>\n",
       "      <td>sofosbuvir</td>\n",
       "      <td>cq</td>\n",
       "      <td>participants</td>\n",
       "      <td>convalescent</td>\n",
       "      <td>chloroquine</td>\n",
       "      <td>ligand</td>\n",
       "      <td>february</td>\n",
       "      <td>lung</td>\n",
       "      <td>...</td>\n",
       "      <td>modern</td>\n",
       "      <td>expression</td>\n",
       "      <td>domain</td>\n",
       "      <td>leads</td>\n",
       "      <td>iii</td>\n",
       "      <td>estimated</td>\n",
       "      <td>surface</td>\n",
       "      <td>favipiravir</td>\n",
       "      <td>qtc</td>\n",
       "      <td>residues</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>tissue</td>\n",
       "      <td>state</td>\n",
       "      <td>mdi</td>\n",
       "      <td>storm</td>\n",
       "      <td>gov</td>\n",
       "      <td>plasma</td>\n",
       "      <td>assay</td>\n",
       "      <td>simulations</td>\n",
       "      <td>experience</td>\n",
       "      <td>responses</td>\n",
       "      <td>...</td>\n",
       "      <td>vaccines</td>\n",
       "      <td>genes</td>\n",
       "      <td>acid</td>\n",
       "      <td>pocket</td>\n",
       "      <td>environment</td>\n",
       "      <td>conserved</td>\n",
       "      <td>change</td>\n",
       "      <td>glycoprotein</td>\n",
       "      <td>risk</td>\n",
       "      <td>rbd</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>healthy</td>\n",
       "      <td>forms</td>\n",
       "      <td>docking</td>\n",
       "      <td>cytokine</td>\n",
       "      <td>trials</td>\n",
       "      <td>services</td>\n",
       "      <td>rdrp</td>\n",
       "      <td>simulation</td>\n",
       "      <td>areas</td>\n",
       "      <td>relevant</td>\n",
       "      <td>...</td>\n",
       "      <td>responses</td>\n",
       "      <td>profiles</td>\n",
       "      <td>acids</td>\n",
       "      <td>assay</td>\n",
       "      <td>proliferation</td>\n",
       "      <td>worldwide</td>\n",
       "      <td>binds</td>\n",
       "      <td>enzymes</td>\n",
       "      <td>hydroxychloroquine</td>\n",
       "      <td>peptide</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>expression</td>\n",
       "      <td>environment</td>\n",
       "      <td>ribavirin</td>\n",
       "      <td>il-6</td>\n",
       "      <td>medicine</td>\n",
       "      <td>quarantine</td>\n",
       "      <td>screen</td>\n",
       "      <td>ligands</td>\n",
       "      <td>pcr</td>\n",
       "      <td>recruitment</td>\n",
       "      <td>...</td>\n",
       "      <td>neutralizing</td>\n",
       "      <td>profile</td>\n",
       "      <td>residues</td>\n",
       "      <td>screening</td>\n",
       "      <td>cellular</td>\n",
       "      <td>ribavirin</td>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>options</td>\n",
       "      <td>cardiac</td>\n",
       "      <td>sites</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>kg</td>\n",
       "      <td>core</td>\n",
       "      <td>newly</td>\n",
       "      <td>mpro</td>\n",
       "      <td>tcm</td>\n",
       "      <td>april</td>\n",
       "      <td>concentrations</td>\n",
       "      <td>strain</td>\n",
       "      <td>day</td>\n",
       "      <td>tmprss2</td>\n",
       "      <td>...</td>\n",
       "      <td>united</td>\n",
       "      <td>prediction</td>\n",
       "      <td>ace-2</td>\n",
       "      <td>virtual</td>\n",
       "      <td>type</td>\n",
       "      <td>efficiency</td>\n",
       "      <td>cov-2</td>\n",
       "      <td>interferon</td>\n",
       "      <td>interval</td>\n",
       "      <td>background</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>animals</td>\n",
       "      <td>experience</td>\n",
       "      <td>residues</td>\n",
       "      <td>cells</td>\n",
       "      <td>medicines</td>\n",
       "      <td>antibodies</td>\n",
       "      <td>prior</td>\n",
       "      <td>energy</td>\n",
       "      <td>nasal</td>\n",
       "      <td>way</td>\n",
       "      <td>...</td>\n",
       "      <td>peptide</td>\n",
       "      <td>score</td>\n",
       "      <td>interaction</td>\n",
       "      <td>screen</td>\n",
       "      <td>reaction</td>\n",
       "      <td>bacterial</td>\n",
       "      <td>domain</td>\n",
       "      <td>protease</td>\n",
       "      <td>chloroquine</td>\n",
       "      <td>domain</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>pharmacokinetic</td>\n",
       "      <td>structure</td>\n",
       "      <td>nucleotide</td>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>trial</td>\n",
       "      <td>antibody</td>\n",
       "      <td>cells</td>\n",
       "      <td>mpro</td>\n",
       "      <td>interferon</td>\n",
       "      <td>cells</td>\n",
       "      <td>...</td>\n",
       "      <td>length</td>\n",
       "      <td>comparison</td>\n",
       "      <td>amino</td>\n",
       "      <td>residues</td>\n",
       "      <td>reduction</td>\n",
       "      <td>chloroquine</td>\n",
       "      <td>bind</td>\n",
       "      <td>ec50</td>\n",
       "      <td>medication</td>\n",
       "      <td>kg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>lung</td>\n",
       "      <td>score</td>\n",
       "      <td>additionally</td>\n",
       "      <td>dynamic</td>\n",
       "      <td>library</td>\n",
       "      <td>pubmed</td>\n",
       "      <td>phosphate</td>\n",
       "      <td>virtual</td>\n",
       "      <td>rt-pcr</td>\n",
       "      <td>vivo</td>\n",
       "      <td>...</td>\n",
       "      <td>antibody</td>\n",
       "      <td>samples</td>\n",
       "      <td>glycoprotein</td>\n",
       "      <td>inactivation</td>\n",
       "      <td>dynamic</td>\n",
       "      <td>causing</td>\n",
       "      <td>spectrum</td>\n",
       "      <td>initiated</td>\n",
       "      <td>medications</td>\n",
       "      <td>amino</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>nucleocapsid</td>\n",
       "      <td>molecule</td>\n",
       "      <td>covs</td>\n",
       "      <td>assay</td>\n",
       "      <td>arbidol</td>\n",
       "      <td>rights</td>\n",
       "      <td>reduction</td>\n",
       "      <td>signaling</td>\n",
       "      <td>receiving</td>\n",
       "      <td>-7</td>\n",
       "      <td>...</td>\n",
       "      <td>states</td>\n",
       "      <td>sample</td>\n",
       "      <td>simulations</td>\n",
       "      <td>chain</td>\n",
       "      <td>targeted</td>\n",
       "      <td>named</td>\n",
       "      <td>basic</td>\n",
       "      <td>trials</td>\n",
       "      <td>azithromycin</td>\n",
       "      <td>susceptible</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>mainly</td>\n",
       "      <td>accessible</td>\n",
       "      <td>cov-2</td>\n",
       "      <td>repositioning</td>\n",
       "      <td>spain</td>\n",
       "      <td>production</td>\n",
       "      <td>free</td>\n",
       "      <td>swab</td>\n",
       "      <td>cytokine</td>\n",
       "      <td>...</td>\n",
       "      <td>society</td>\n",
       "      <td>file</td>\n",
       "      <td>located</td>\n",
       "      <td>domain</td>\n",
       "      <td>sites</td>\n",
       "      <td>efficacy</td>\n",
       "      <td>secondary</td>\n",
       "      <td>cq</td>\n",
       "      <td>monitoring</td>\n",
       "      <td>functional</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>issue</td>\n",
       "      <td>library</td>\n",
       "      <td>emerged</td>\n",
       "      <td>cellular</td>\n",
       "      <td>hydroxychloroquine</td>\n",
       "      <td>repurposed</td>\n",
       "      <td>treated</td>\n",
       "      <td>molecules</td>\n",
       "      <td>days</td>\n",
       "      <td>tissue</td>\n",
       "      <td>...</td>\n",
       "      <td>application</td>\n",
       "      <td>core</td>\n",
       "      <td>membrane</td>\n",
       "      <td>determined</td>\n",
       "      <td>activities</td>\n",
       "      <td>region</td>\n",
       "      <td>pharmaceutical</td>\n",
       "      <td>existing</td>\n",
       "      <td>prolongation</td>\n",
       "      <td>increase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>literature</td>\n",
       "      <td>molecules</td>\n",
       "      <td>region</td>\n",
       "      <td>alone</td>\n",
       "      <td>chloroquine</td>\n",
       "      <td>prophylaxis</td>\n",
       "      <td>toxicity</td>\n",
       "      <td>distribution</td>\n",
       "      <td>lung</td>\n",
       "      <td>cytokines</td>\n",
       "      <td>...</td>\n",
       "      <td>immune</td>\n",
       "      <td>predict</td>\n",
       "      <td>plasma</td>\n",
       "      <td>crystal</td>\n",
       "      <td>strategy</td>\n",
       "      <td>transmission</td>\n",
       "      <td>decrease</td>\n",
       "      <td>option</td>\n",
       "      <td>drug-induced</td>\n",
       "      <td>inactivation</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>issues</td>\n",
       "      <td>structures</td>\n",
       "      <td>strain</td>\n",
       "      <td>levels</td>\n",
       "      <td>ritonavir</td>\n",
       "      <td>social</td>\n",
       "      <td>greater</td>\n",
       "      <td>assay</td>\n",
       "      <td>history</td>\n",
       "      <td>cmax</td>\n",
       "      <td>...</td>\n",
       "      <td>protect</td>\n",
       "      <td>processes</td>\n",
       "      <td>interestingly</td>\n",
       "      <td>catalytic</td>\n",
       "      <td>types</td>\n",
       "      <td>asymptomatic</td>\n",
       "      <td>changes</td>\n",
       "      <td>agents</td>\n",
       "      <td>pointes</td>\n",
       "      <td>cellular</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>tissues</td>\n",
       "      <td>unique</td>\n",
       "      <td>kcal</td>\n",
       "      <td>region</td>\n",
       "      <td>vitamin</td>\n",
       "      <td>risks</td>\n",
       "      <td>concentration</td>\n",
       "      <td>docking</td>\n",
       "      <td>discharge</td>\n",
       "      <td>covid19</td>\n",
       "      <td>...</td>\n",
       "      <td>release</td>\n",
       "      <td>ec50</td>\n",
       "      <td>surface</td>\n",
       "      <td>lead</td>\n",
       "      <td>demand</td>\n",
       "      <td>team</td>\n",
       "      <td>amino</td>\n",
       "      <td>helicase</td>\n",
       "      <td>heart</td>\n",
       "      <td>acid</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>cov-2</td>\n",
       "      <td>pocket</td>\n",
       "      <td>hand</td>\n",
       "      <td>lungs</td>\n",
       "      <td>2019-ncov</td>\n",
       "      <td>compassionate</td>\n",
       "      <td>determined</td>\n",
       "      <td>system</td>\n",
       "      <td>cough</td>\n",
       "      <td>different</td>\n",
       "      <td>...</td>\n",
       "      <td>unit</td>\n",
       "      <td>induce</td>\n",
       "      <td>estimated</td>\n",
       "      <td>structure</td>\n",
       "      <td>special</td>\n",
       "      <td>autoimmune</td>\n",
       "      <td>binding</td>\n",
       "      <td>hiv</td>\n",
       "      <td>status</td>\n",
       "      <td>sequence</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>weight</td>\n",
       "      <td>play</td>\n",
       "      <td>complexes</td>\n",
       "      <td>ml</td>\n",
       "      <td>interferon</td>\n",
       "      <td>critically</td>\n",
       "      <td>control</td>\n",
       "      <td>stem</td>\n",
       "      <td>lungs</td>\n",
       "      <td>articles</td>\n",
       "      <td>...</td>\n",
       "      <td>fusion</td>\n",
       "      <td>induced</td>\n",
       "      <td>modeling</td>\n",
       "      <td>parallel</td>\n",
       "      <td>appropriate</td>\n",
       "      <td>reached</td>\n",
       "      <td>reducing</td>\n",
       "      <td>fever</td>\n",
       "      <td>baseline</td>\n",
       "      <td>due</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>animal</td>\n",
       "      <td>lead</td>\n",
       "      <td>ligands</td>\n",
       "      <td>dynamics</td>\n",
       "      <td>md</td>\n",
       "      <td>distancing</td>\n",
       "      <td>started</td>\n",
       "      <td>systems</td>\n",
       "      <td>area</td>\n",
       "      <td>organ</td>\n",
       "      <td>...</td>\n",
       "      <td>angiotensin</td>\n",
       "      <td>drug-induced</td>\n",
       "      <td>simulation</td>\n",
       "      <td>docking</td>\n",
       "      <td>relatively</td>\n",
       "      <td>epidemic</td>\n",
       "      <td>background</td>\n",
       "      <td>ribavirin</td>\n",
       "      <td>personal</td>\n",
       "      <td>resistance</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>dose</td>\n",
       "      <td>defined</td>\n",
       "      <td>structure</td>\n",
       "      <td>ec50</td>\n",
       "      <td>favipiravir</td>\n",
       "      <td>repurpose</td>\n",
       "      <td>seen</td>\n",
       "      <td>signal</td>\n",
       "      <td>enrolled</td>\n",
       "      <td>issue</td>\n",
       "      <td>...</td>\n",
       "      <td>recombinant</td>\n",
       "      <td>hot</td>\n",
       "      <td>bind</td>\n",
       "      <td>science</td>\n",
       "      <td>2019-ncov</td>\n",
       "      <td>already</td>\n",
       "      <td>observed</td>\n",
       "      <td>rna-dependent</td>\n",
       "      <td>exposure</td>\n",
       "      <td>environment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>score</td>\n",
       "      <td>network</td>\n",
       "      <td>score</td>\n",
       "      <td>consistent</td>\n",
       "      <td>hospital</td>\n",
       "      <td>globally</td>\n",
       "      <td>alone</td>\n",
       "      <td>molecule</td>\n",
       "      <td>hospital</td>\n",
       "      <td>cell</td>\n",
       "      <td>...</td>\n",
       "      <td>body</td>\n",
       "      <td>median</td>\n",
       "      <td>molecules</td>\n",
       "      <td>design</td>\n",
       "      <td>proteins</td>\n",
       "      <td>cycle</td>\n",
       "      <td>expression</td>\n",
       "      <td>remdesivir</td>\n",
       "      <td>individuals</td>\n",
       "      <td>expression</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>day</td>\n",
       "      <td>design</td>\n",
       "      <td>february</td>\n",
       "      <td>cell</td>\n",
       "      <td>pneumonia</td>\n",
       "      <td>cure</td>\n",
       "      <td>rt-pcr</td>\n",
       "      <td>leads</td>\n",
       "      <td>negative</td>\n",
       "      <td>hours</td>\n",
       "      <td>...</td>\n",
       "      <td>response</td>\n",
       "      <td>greater</td>\n",
       "      <td>lipid</td>\n",
       "      <td>conserved</td>\n",
       "      <td>contagious</td>\n",
       "      <td>symptomatic</td>\n",
       "      <td>bound</td>\n",
       "      <td>interventions</td>\n",
       "      <td>antimalarial</td>\n",
       "      <td>host</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>median</td>\n",
       "      <td>compound</td>\n",
       "      <td>modeling</td>\n",
       "      <td>included</td>\n",
       "      <td>cost</td>\n",
       "      <td>body</td>\n",
       "      <td>performed</td>\n",
       "      <td>screen</td>\n",
       "      <td>patients</td>\n",
       "      <td>levels</td>\n",
       "      <td>...</td>\n",
       "      <td>outbreaks</td>\n",
       "      <td>change</td>\n",
       "      <td>complex</td>\n",
       "      <td>forms</td>\n",
       "      <td>calculations</td>\n",
       "      <td>quickly</td>\n",
       "      <td>second</td>\n",
       "      <td>iii</td>\n",
       "      <td>ventricular</td>\n",
       "      <td>sars-cov-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>scores</td>\n",
       "      <td>generated</td>\n",
       "      <td>surface</td>\n",
       "      <td>individuals</td>\n",
       "      <td>lopinavir</td>\n",
       "      <td>population</td>\n",
       "      <td>determine</td>\n",
       "      <td>screening</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>chloroquine</td>\n",
       "      <td>...</td>\n",
       "      <td>innovative</td>\n",
       "      <td>concentration</td>\n",
       "      <td>region</td>\n",
       "      <td>inhibition</td>\n",
       "      <td>cancer</td>\n",
       "      <td>majority</td>\n",
       "      <td>length</td>\n",
       "      <td>trial</td>\n",
       "      <td>light</td>\n",
       "      <td>cov-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>knowledge</td>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>presented</td>\n",
       "      <td>pathogenic</td>\n",
       "      <td>chinese</td>\n",
       "      <td>exposure</td>\n",
       "      <td>previously</td>\n",
       "      <td>inflammatory</td>\n",
       "      <td>median</td>\n",
       "      <td>clearance</td>\n",
       "      <td>...</td>\n",
       "      <td>state</td>\n",
       "      <td>summarized</td>\n",
       "      <td>side</td>\n",
       "      <td>located</td>\n",
       "      <td>local</td>\n",
       "      <td>government</td>\n",
       "      <td>alone</td>\n",
       "      <td>intravenous</td>\n",
       "      <td>hours</td>\n",
       "      <td>activation</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>assay</td>\n",
       "      <td>structure-based</td>\n",
       "      <td>interaction</td>\n",
       "      <td>another</td>\n",
       "      <td>traditional</td>\n",
       "      <td>immune</td>\n",
       "      <td>collected</td>\n",
       "      <td>selected</td>\n",
       "      <td>plus</td>\n",
       "      <td>arbidol</td>\n",
       "      <td>...</td>\n",
       "      <td>induced</td>\n",
       "      <td>expressed</td>\n",
       "      <td>binding</td>\n",
       "      <td>order</td>\n",
       "      <td>applications</td>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>acids</td>\n",
       "      <td>plus</td>\n",
       "      <td>factors</td>\n",
       "      <td>prevalence</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>inflammatory</td>\n",
       "      <td>reaction</td>\n",
       "      <td>conserved</td>\n",
       "      <td>highlight</td>\n",
       "      <td>efficacy</td>\n",
       "      <td>reserved</td>\n",
       "      <td>pcr</td>\n",
       "      <td>cytokine</td>\n",
       "      <td>decreased</td>\n",
       "      <td>titers</td>\n",
       "      <td>...</td>\n",
       "      <td>mers-cov</td>\n",
       "      <td>selected</td>\n",
       "      <td>rbd</td>\n",
       "      <td>biology</td>\n",
       "      <td>mechanism</td>\n",
       "      <td>vitro</td>\n",
       "      <td>accessible</td>\n",
       "      <td>nature</td>\n",
       "      <td>therapies</td>\n",
       "      <td>acids</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>nuclear</td>\n",
       "      <td>bind</td>\n",
       "      <td>chain</td>\n",
       "      <td>docking</td>\n",
       "      <td>caused</td>\n",
       "      <td>purpose</td>\n",
       "      <td>assays</td>\n",
       "      <td>repositioning</td>\n",
       "      <td>chest</td>\n",
       "      <td>clinically</td>\n",
       "      <td>...</td>\n",
       "      <td>spike</td>\n",
       "      <td>point</td>\n",
       "      <td>basic</td>\n",
       "      <td>bind</td>\n",
       "      <td>general</td>\n",
       "      <td>december</td>\n",
       "      <td>continuous</td>\n",
       "      <td>pain</td>\n",
       "      <td>measures</td>\n",
       "      <td>metabolism</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>core</td>\n",
       "      <td>cov-2</td>\n",
       "      <td>site</td>\n",
       "      <td>times</td>\n",
       "      <td>march</td>\n",
       "      <td>epidemic</td>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>responses</td>\n",
       "      <td>lopinavir</td>\n",
       "      <td>liver</td>\n",
       "      <td>...</td>\n",
       "      <td>pharmaceutical</td>\n",
       "      <td>different</td>\n",
       "      <td>whether</td>\n",
       "      <td>structure-based</td>\n",
       "      <td>herein</td>\n",
       "      <td>focused</td>\n",
       "      <td>parallel</td>\n",
       "      <td>influenza</td>\n",
       "      <td>induced</td>\n",
       "      <td>proteins</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>docking</td>\n",
       "      <td>binding</td>\n",
       "      <td>covid</td>\n",
       "      <td>enzymes</td>\n",
       "      <td>costs</td>\n",
       "      <td>deaths</td>\n",
       "      <td>compounds</td>\n",
       "      <td>cytokines</td>\n",
       "      <td>patient</td>\n",
       "      <td>later</td>\n",
       "      <td>...</td>\n",
       "      <td>february</td>\n",
       "      <td>toxicity</td>\n",
       "      <td>sars-cov-2</td>\n",
       "      <td>compound</td>\n",
       "      <td>reactions</td>\n",
       "      <td>cov-2</td>\n",
       "      <td>presence</td>\n",
       "      <td>intervention</td>\n",
       "      <td>individual</td>\n",
       "      <td>concentration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>cells</td>\n",
       "      <td>leads</td>\n",
       "      <td>vs</td>\n",
       "      <td>highlights</td>\n",
       "      <td>national</td>\n",
       "      <td>impact</td>\n",
       "      <td>normal</td>\n",
       "      <td>inhibitory</td>\n",
       "      <td>decrease</td>\n",
       "      <td>antibody</td>\n",
       "      <td>...</td>\n",
       "      <td>induce</td>\n",
       "      <td>candidates</td>\n",
       "      <td>bound</td>\n",
       "      <td>chinese</td>\n",
       "      <td>mechanical</td>\n",
       "      <td>showed</td>\n",
       "      <td>kg</td>\n",
       "      <td>preclinical</td>\n",
       "      <td>death</td>\n",
       "      <td>site</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>30 rows × 34 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 1                2             3            4   \\\n",
       "0           network              3cl          rdrp          lpv   \n",
       "1              il-6          docking    sofosbuvir           cq   \n",
       "2            tissue            state           mdi        storm   \n",
       "3           healthy            forms       docking     cytokine   \n",
       "4        expression      environment     ribavirin         il-6   \n",
       "5                kg             core         newly         mpro   \n",
       "6           animals       experience      residues        cells   \n",
       "7   pharmacokinetic        structure    nucleotide   sars-cov-2   \n",
       "8              lung            score  additionally      dynamic   \n",
       "9      nucleocapsid         molecule          covs        assay   \n",
       "10       sars-cov-2           mainly    accessible        cov-2   \n",
       "11            issue          library       emerged     cellular   \n",
       "12       literature        molecules        region        alone   \n",
       "13           issues       structures        strain       levels   \n",
       "14          tissues           unique          kcal       region   \n",
       "15            cov-2           pocket          hand        lungs   \n",
       "16           weight             play     complexes           ml   \n",
       "17           animal             lead       ligands     dynamics   \n",
       "18             dose          defined     structure         ec50   \n",
       "19            score          network         score   consistent   \n",
       "20              day           design      february         cell   \n",
       "21           median         compound      modeling     included   \n",
       "22           scores        generated       surface  individuals   \n",
       "23        knowledge       sars-cov-2     presented   pathogenic   \n",
       "24            assay  structure-based   interaction      another   \n",
       "25     inflammatory         reaction     conserved    highlight   \n",
       "26          nuclear             bind         chain      docking   \n",
       "27             core            cov-2          site        times   \n",
       "28          docking          binding         covid      enzymes   \n",
       "29            cells            leads            vs   highlights   \n",
       "\n",
       "                    5              6                   7              8   \\\n",
       "0       clinicaltrials          india  hydroxychloroquine   calculations   \n",
       "1         participants   convalescent         chloroquine         ligand   \n",
       "2                  gov         plasma               assay    simulations   \n",
       "3               trials       services                rdrp     simulation   \n",
       "4             medicine     quarantine              screen        ligands   \n",
       "5                  tcm          april      concentrations         strain   \n",
       "6            medicines     antibodies               prior         energy   \n",
       "7                trial       antibody               cells           mpro   \n",
       "8              library         pubmed           phosphate        virtual   \n",
       "9              arbidol         rights           reduction      signaling   \n",
       "10       repositioning          spain          production           free   \n",
       "11  hydroxychloroquine     repurposed             treated      molecules   \n",
       "12         chloroquine    prophylaxis            toxicity   distribution   \n",
       "13           ritonavir         social             greater          assay   \n",
       "14             vitamin          risks       concentration        docking   \n",
       "15           2019-ncov  compassionate          determined         system   \n",
       "16          interferon     critically             control           stem   \n",
       "17                  md     distancing             started        systems   \n",
       "18         favipiravir      repurpose                seen         signal   \n",
       "19            hospital       globally               alone       molecule   \n",
       "20           pneumonia           cure              rt-pcr          leads   \n",
       "21                cost           body           performed         screen   \n",
       "22           lopinavir     population           determine      screening   \n",
       "23             chinese       exposure          previously   inflammatory   \n",
       "24         traditional         immune           collected       selected   \n",
       "25            efficacy       reserved                 pcr       cytokine   \n",
       "26              caused        purpose              assays  repositioning   \n",
       "27               march       epidemic          sars-cov-2      responses   \n",
       "28               costs         deaths           compounds      cytokines   \n",
       "29            national         impact              normal     inhibitory   \n",
       "\n",
       "              9            10      ...                    25             26  \\\n",
       "0      ritonavir    influenza      ...               vaccine         nature   \n",
       "1       february         lung      ...                modern     expression   \n",
       "2     experience    responses      ...              vaccines          genes   \n",
       "3          areas     relevant      ...             responses       profiles   \n",
       "4            pcr  recruitment      ...          neutralizing        profile   \n",
       "5            day      tmprss2      ...                united     prediction   \n",
       "6          nasal          way      ...               peptide          score   \n",
       "7     interferon        cells      ...                length     comparison   \n",
       "8         rt-pcr         vivo      ...              antibody        samples   \n",
       "9      receiving           -7      ...                states         sample   \n",
       "10          swab     cytokine      ...               society           file   \n",
       "11          days       tissue      ...           application           core   \n",
       "12          lung    cytokines      ...                immune        predict   \n",
       "13       history         cmax      ...               protect      processes   \n",
       "14     discharge      covid19      ...               release           ec50   \n",
       "15         cough    different      ...                  unit         induce   \n",
       "16         lungs     articles      ...                fusion        induced   \n",
       "17          area        organ      ...           angiotensin   drug-induced   \n",
       "18      enrolled        issue      ...           recombinant            hot   \n",
       "19      hospital         cell      ...                  body         median   \n",
       "20      negative        hours      ...              response        greater   \n",
       "21      patients       levels      ...             outbreaks         change   \n",
       "22  hypertension  chloroquine      ...            innovative  concentration   \n",
       "23        median    clearance      ...                 state     summarized   \n",
       "24          plus      arbidol      ...               induced      expressed   \n",
       "25     decreased       titers      ...              mers-cov       selected   \n",
       "26         chest   clinically      ...                 spike          point   \n",
       "27     lopinavir        liver      ...        pharmaceutical      different   \n",
       "28       patient        later      ...              february       toxicity   \n",
       "29      decrease     antibody      ...                induce     candidates   \n",
       "\n",
       "               27               28             29            30  \\\n",
       "0          energy             mpro             ii     outbreaks   \n",
       "1          domain            leads            iii     estimated   \n",
       "2            acid           pocket    environment     conserved   \n",
       "3           acids            assay  proliferation     worldwide   \n",
       "4        residues        screening       cellular     ribavirin   \n",
       "5           ace-2          virtual           type    efficiency   \n",
       "6     interaction           screen       reaction     bacterial   \n",
       "7           amino         residues      reduction   chloroquine   \n",
       "8    glycoprotein     inactivation        dynamic       causing   \n",
       "9     simulations            chain       targeted         named   \n",
       "10        located           domain          sites      efficacy   \n",
       "11       membrane       determined     activities        region   \n",
       "12         plasma          crystal       strategy  transmission   \n",
       "13  interestingly        catalytic          types  asymptomatic   \n",
       "14        surface             lead         demand          team   \n",
       "15      estimated        structure        special    autoimmune   \n",
       "16       modeling         parallel    appropriate       reached   \n",
       "17     simulation          docking     relatively      epidemic   \n",
       "18           bind          science      2019-ncov       already   \n",
       "19      molecules           design       proteins         cycle   \n",
       "20          lipid        conserved     contagious   symptomatic   \n",
       "21        complex            forms   calculations       quickly   \n",
       "22         region       inhibition         cancer      majority   \n",
       "23           side          located          local    government   \n",
       "24        binding            order   applications    sars-cov-2   \n",
       "25            rbd          biology      mechanism         vitro   \n",
       "26          basic             bind        general      december   \n",
       "27        whether  structure-based         herein       focused   \n",
       "28     sars-cov-2         compound      reactions         cov-2   \n",
       "29          bound          chinese     mechanical        showed   \n",
       "\n",
       "                31             32                  33             34  \n",
       "0              rbd      2019-ncov                  qt             mg  \n",
       "1          surface    favipiravir                 qtc       residues  \n",
       "2           change   glycoprotein                risk            rbd  \n",
       "3            binds        enzymes  hydroxychloroquine        peptide  \n",
       "4       sars-cov-2        options             cardiac          sites  \n",
       "5            cov-2     interferon            interval     background  \n",
       "6           domain       protease         chloroquine         domain  \n",
       "7             bind           ec50          medication             kg  \n",
       "8         spectrum      initiated         medications          amino  \n",
       "9            basic         trials        azithromycin    susceptible  \n",
       "10       secondary             cq          monitoring     functional  \n",
       "11  pharmaceutical       existing        prolongation       increase  \n",
       "12        decrease         option        drug-induced   inactivation  \n",
       "13         changes         agents             pointes       cellular  \n",
       "14           amino       helicase               heart           acid  \n",
       "15         binding            hiv              status       sequence  \n",
       "16        reducing          fever            baseline            due  \n",
       "17      background      ribavirin            personal     resistance  \n",
       "18        observed  rna-dependent            exposure    environment  \n",
       "19      expression     remdesivir         individuals     expression  \n",
       "20           bound  interventions        antimalarial           host  \n",
       "21          second            iii         ventricular     sars-cov-2  \n",
       "22          length          trial               light          cov-2  \n",
       "23           alone    intravenous               hours     activation  \n",
       "24           acids           plus             factors     prevalence  \n",
       "25      accessible         nature           therapies          acids  \n",
       "26      continuous           pain            measures     metabolism  \n",
       "27        parallel      influenza             induced       proteins  \n",
       "28        presence   intervention          individual  concentration  \n",
       "29              kg    preclinical               death           site  \n",
       "\n",
       "[30 rows x 34 columns]"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_df.head(30)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "new_df.to_excel('34_paper_tf_idf_updated.xlsx', encoding='utf-8-sig')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "def doc2vec(list_):\n",
    "    sent_vec = []\n",
    "    for word in list_:\n",
    "        sent_vec.append(model.get_word_vector(word))\n",
    "    sent_vec = np.sum(sent_vec, axis=1)\n",
    "    return sent_vec"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc2vec_list = []\n",
    "for x in range(1, N+1):\n",
    "    doc2vec_list.append(doc2vec(new_df[x].values))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc2vec_list = np.array(doc2vec_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(34, 150)"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc2vec_list.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([ 1.0379071e+01, -2.4630480e+00,  7.5931807e+00,  6.8816376e+00,\n",
       "        9.1409225e+00, -6.0930672e+00,  1.7363100e+00,  4.8915645e-01,\n",
       "        5.4964066e+00, -2.1096449e+00,  1.1700504e+00,  1.1224647e+01,\n",
       "       -1.0622038e+00,  1.0066730e+01,  3.7106009e+00,  6.5075998e+00,\n",
       "        7.4277115e+00,  8.6608267e-01, -6.4782519e+00,  8.0875959e+00,\n",
       "       -5.7486024e+00,  6.8812776e+00, -2.3188219e+00,  3.1759703e-01,\n",
       "        1.1441100e+01,  4.3653506e-01, -1.4552817e+00,  6.7932510e+00,\n",
       "        2.8590035e+00,  2.2511325e+00,  2.3247256e+00,  1.1659303e+00,\n",
       "       -8.3778483e-01,  6.8245096e+00,  6.0704684e+00, -5.3422122e+00,\n",
       "       -5.7872281e+00, -4.3962226e+00, -7.9997163e+00,  2.4229841e+00,\n",
       "       -3.3188553e+00,  1.1882868e+00,  6.7260581e-01,  4.1351066e+00,\n",
       "        5.6675777e+00,  2.8961391e+00,  1.3552924e+00,  4.7775617e+00,\n",
       "       -6.7995298e-01,  1.0762869e+01,  6.6902795e+00,  3.0388136e+00,\n",
       "       -7.1036792e-01,  3.3871679e+00,  3.9533505e+00, -4.2353487e-01,\n",
       "        7.8366647e+00,  3.5643404e+00, -3.1629400e+00,  3.4292550e+00,\n",
       "        4.8787742e+00, -1.3939396e+00,  5.1797304e+00,  5.8210711e+00,\n",
       "        1.0812521e+00,  6.3409653e+00,  1.7779535e+00,  4.4008484e+00,\n",
       "        5.6854498e-01,  4.6763939e-01,  4.4287791e+00,  4.1538434e+00,\n",
       "       -3.6979091e-01,  6.3037887e+00, -5.5421157e+00, -1.6434532e+00,\n",
       "       -4.6013457e-01, -2.9849771e-01, -7.9509530e+00,  1.3921881e+00,\n",
       "        2.7625008e+00,  2.0914543e+00,  5.1908698e+00,  4.2641001e+00,\n",
       "        2.2992146e+00, -3.0964002e-01,  3.6025848e+00,  1.2418408e+00,\n",
       "       -1.2728774e+01, -5.1240551e-01, -3.0709743e-01,  1.3491932e+00,\n",
       "        4.8943624e+00,  9.0784305e-01, -2.8182764e+00,  7.3315935e+00,\n",
       "       -1.3784262e+00,  9.9299479e+00,  4.6158018e+00, -2.9442389e+00,\n",
       "       -5.4747462e-03, -1.2616593e+00,  2.6524370e+00, -5.8498774e+00,\n",
       "       -2.2530675e+00,  2.6838493e+00,  6.9307899e-01, -5.3347621e+00,\n",
       "       -1.0050516e+01, -4.4272394e+00,  7.0294595e+00, -4.2156277e+00,\n",
       "        4.7451715e+00, -1.0088143e+00,  2.3187706e+00, -1.8245137e+00,\n",
       "        1.3208449e+00,  4.3553386e+00, -1.3981913e+00,  1.8565416e-02,\n",
       "       -1.3714725e+00, -2.7011377e-01,  4.3080025e+00,  6.5320230e+00,\n",
       "       -1.2703016e+00, -7.5386858e-01,  2.3936915e+00,  3.9523035e-01,\n",
       "       -3.2622921e+00, -3.1174128e+00,  2.3322170e+00, -3.8314125e-01,\n",
       "        5.0615996e-01, -7.1974683e+00, -1.1317840e-01,  8.9016843e-01,\n",
       "       -5.1709729e-01,  1.7357166e+00,  2.7434967e+00, -3.4354657e-01,\n",
       "        3.3921132e+00,  5.1021290e-01,  1.1764141e+00,  3.5388215e+00,\n",
       "        2.5593596e+00,  1.0319652e+01,  7.2700977e+00,  6.1533489e+00,\n",
       "        1.3803670e+00, -1.9253774e+00], dtype=float32)"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc2vec_list[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### 각 document 마다 (150, 100)의 벡터 형태로 embedding "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### 150은 각 doc 별 tfidf 상위 150단어 "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.metrics.pairwise import cosine_similarity"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0.23129748]], dtype=float32)"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cosine_similarity(doc2vec_list[0].reshape(1,-1), doc2vec_list[1].reshape(1,-1))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0.05507124]], dtype=float32)"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cosine_similarity(doc2vec_list[5].reshape(1,-1), doc2vec_list[0].reshape(1,-1))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "m = []\n",
    "for x in range(N):\n",
    "    n = []\n",
    "    for y in range(N):\n",
    "        n.append(cosine_similarity(doc2vec_list[x].reshape(1,-1), doc2vec_list[y].reshape(1,-1))[0][0])\n",
    "    m.append(n)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "cos_df = pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: []\n",
       "Index: []"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cos_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [],
   "source": [
    "for x in range(N):\n",
    "    cos_df[x+1] = m[x]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "cos_df.index = list(range(1,35))\n",
    "cos_df.columns = list(range(1,35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>10</th>\n",
       "      <th>...</th>\n",
       "      <th>25</th>\n",
       "      <th>26</th>\n",
       "      <th>27</th>\n",
       "      <th>28</th>\n",
       "      <th>29</th>\n",
       "      <th>30</th>\n",
       "      <th>31</th>\n",
       "      <th>32</th>\n",
       "      <th>33</th>\n",
       "      <th>34</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.231297</td>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.058290</td>\n",
       "      <td>-0.019313</td>\n",
       "      <td>0.055071</td>\n",
       "      <td>0.298865</td>\n",
       "      <td>0.081741</td>\n",
       "      <td>0.050880</td>\n",
       "      <td>0.121065</td>\n",
       "      <td>...</td>\n",
       "      <td>0.124348</td>\n",
       "      <td>0.163235</td>\n",
       "      <td>0.158082</td>\n",
       "      <td>0.181133</td>\n",
       "      <td>0.288083</td>\n",
       "      <td>0.092794</td>\n",
       "      <td>0.185628</td>\n",
       "      <td>0.144161</td>\n",
       "      <td>0.005380</td>\n",
       "      <td>0.145754</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.231297</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>0.168359</td>\n",
       "      <td>0.302533</td>\n",
       "      <td>0.283711</td>\n",
       "      <td>0.167143</td>\n",
       "      <td>0.113720</td>\n",
       "      <td>...</td>\n",
       "      <td>0.317686</td>\n",
       "      <td>0.249315</td>\n",
       "      <td>0.244756</td>\n",
       "      <td>0.328094</td>\n",
       "      <td>0.400561</td>\n",
       "      <td>0.103856</td>\n",
       "      <td>0.365101</td>\n",
       "      <td>0.219111</td>\n",
       "      <td>0.140468</td>\n",
       "      <td>0.268175</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.076830</td>\n",
       "      <td>-0.064591</td>\n",
       "      <td>0.254749</td>\n",
       "      <td>0.190225</td>\n",
       "      <td>0.172798</td>\n",
       "      <td>...</td>\n",
       "      <td>0.115676</td>\n",
       "      <td>0.146782</td>\n",
       "      <td>-0.029606</td>\n",
       "      <td>0.163706</td>\n",
       "      <td>0.072575</td>\n",
       "      <td>0.043145</td>\n",
       "      <td>0.234544</td>\n",
       "      <td>-0.039937</td>\n",
       "      <td>0.059261</td>\n",
       "      <td>0.265866</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.058290</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>0.161103</td>\n",
       "      <td>0.084728</td>\n",
       "      <td>0.259842</td>\n",
       "      <td>0.014458</td>\n",
       "      <td>0.086001</td>\n",
       "      <td>...</td>\n",
       "      <td>-0.039929</td>\n",
       "      <td>0.239550</td>\n",
       "      <td>0.215339</td>\n",
       "      <td>0.134585</td>\n",
       "      <td>0.205383</td>\n",
       "      <td>0.094626</td>\n",
       "      <td>0.159678</td>\n",
       "      <td>0.144439</td>\n",
       "      <td>0.054221</td>\n",
       "      <td>0.203177</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>-0.019313</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.016522</td>\n",
       "      <td>0.046765</td>\n",
       "      <td>-0.015356</td>\n",
       "      <td>0.004066</td>\n",
       "      <td>0.048524</td>\n",
       "      <td>...</td>\n",
       "      <td>-0.074344</td>\n",
       "      <td>-0.008325</td>\n",
       "      <td>0.069442</td>\n",
       "      <td>-0.056780</td>\n",
       "      <td>-0.029405</td>\n",
       "      <td>-0.172705</td>\n",
       "      <td>-0.066141</td>\n",
       "      <td>-0.066380</td>\n",
       "      <td>0.102173</td>\n",
       "      <td>-0.045759</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 34 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         1         2         3         4         5         6         7   \\\n",
       "1  1.000000  0.231297  0.065869  0.058290 -0.019313  0.055071  0.298865   \n",
       "2  0.231297  1.000000  0.164515  0.273920 -0.163867  0.168359  0.302533   \n",
       "3  0.065869  0.164515  1.000000  0.030626 -0.127232  0.076830 -0.064591   \n",
       "4  0.058290  0.273920  0.030626  1.000000  0.028030  0.161103  0.084728   \n",
       "5 -0.019313 -0.163867 -0.127232  0.028030  1.000000 -0.016522  0.046765   \n",
       "\n",
       "         8         9         10    ...           25        26        27  \\\n",
       "1  0.081741  0.050880  0.121065    ...     0.124348  0.163235  0.158082   \n",
       "2  0.283711  0.167143  0.113720    ...     0.317686  0.249315  0.244756   \n",
       "3  0.254749  0.190225  0.172798    ...     0.115676  0.146782 -0.029606   \n",
       "4  0.259842  0.014458  0.086001    ...    -0.039929  0.239550  0.215339   \n",
       "5 -0.015356  0.004066  0.048524    ...    -0.074344 -0.008325  0.069442   \n",
       "\n",
       "         28        29        30        31        32        33        34  \n",
       "1  0.181133  0.288083  0.092794  0.185628  0.144161  0.005380  0.145754  \n",
       "2  0.328094  0.400561  0.103856  0.365101  0.219111  0.140468  0.268175  \n",
       "3  0.163706  0.072575  0.043145  0.234544 -0.039937  0.059261  0.265866  \n",
       "4  0.134585  0.205383  0.094626  0.159678  0.144439  0.054221  0.203177  \n",
       "5 -0.056780 -0.029405 -0.172705 -0.066141 -0.066380  0.102173 -0.045759  \n",
       "\n",
       "[5 rows x 34 columns]"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cos_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>10</th>\n",
       "      <th>...</th>\n",
       "      <th>25</th>\n",
       "      <th>26</th>\n",
       "      <th>27</th>\n",
       "      <th>28</th>\n",
       "      <th>29</th>\n",
       "      <th>30</th>\n",
       "      <th>31</th>\n",
       "      <th>32</th>\n",
       "      <th>33</th>\n",
       "      <th>34</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.231297</td>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.058290</td>\n",
       "      <td>-0.019313</td>\n",
       "      <td>0.055071</td>\n",
       "      <td>0.298865</td>\n",
       "      <td>0.081741</td>\n",
       "      <td>0.050880</td>\n",
       "      <td>0.121065</td>\n",
       "      <td>...</td>\n",
       "      <td>0.124348</td>\n",
       "      <td>0.163235</td>\n",
       "      <td>0.158082</td>\n",
       "      <td>0.181133</td>\n",
       "      <td>0.288083</td>\n",
       "      <td>0.092794</td>\n",
       "      <td>0.185628</td>\n",
       "      <td>0.144161</td>\n",
       "      <td>0.005380</td>\n",
       "      <td>0.145754</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.231297</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>0.168359</td>\n",
       "      <td>0.302533</td>\n",
       "      <td>0.283711</td>\n",
       "      <td>0.167143</td>\n",
       "      <td>0.113720</td>\n",
       "      <td>...</td>\n",
       "      <td>0.317686</td>\n",
       "      <td>0.249315</td>\n",
       "      <td>0.244756</td>\n",
       "      <td>0.328094</td>\n",
       "      <td>0.400561</td>\n",
       "      <td>0.103856</td>\n",
       "      <td>0.365101</td>\n",
       "      <td>0.219111</td>\n",
       "      <td>0.140468</td>\n",
       "      <td>0.268175</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.076830</td>\n",
       "      <td>-0.064591</td>\n",
       "      <td>0.254749</td>\n",
       "      <td>0.190225</td>\n",
       "      <td>0.172798</td>\n",
       "      <td>...</td>\n",
       "      <td>0.115676</td>\n",
       "      <td>0.146782</td>\n",
       "      <td>-0.029606</td>\n",
       "      <td>0.163706</td>\n",
       "      <td>0.072575</td>\n",
       "      <td>0.043145</td>\n",
       "      <td>0.234544</td>\n",
       "      <td>-0.039937</td>\n",
       "      <td>0.059261</td>\n",
       "      <td>0.265866</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.058290</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>0.161103</td>\n",
       "      <td>0.084728</td>\n",
       "      <td>0.259842</td>\n",
       "      <td>0.014458</td>\n",
       "      <td>0.086001</td>\n",
       "      <td>...</td>\n",
       "      <td>-0.039929</td>\n",
       "      <td>0.239550</td>\n",
       "      <td>0.215339</td>\n",
       "      <td>0.134585</td>\n",
       "      <td>0.205383</td>\n",
       "      <td>0.094626</td>\n",
       "      <td>0.159678</td>\n",
       "      <td>0.144439</td>\n",
       "      <td>0.054221</td>\n",
       "      <td>0.203177</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>-0.019313</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.016522</td>\n",
       "      <td>0.046765</td>\n",
       "      <td>-0.015356</td>\n",
       "      <td>0.004066</td>\n",
       "      <td>0.048524</td>\n",
       "      <td>...</td>\n",
       "      <td>-0.074344</td>\n",
       "      <td>-0.008325</td>\n",
       "      <td>0.069442</td>\n",
       "      <td>-0.056780</td>\n",
       "      <td>-0.029405</td>\n",
       "      <td>-0.172705</td>\n",
       "      <td>-0.066141</td>\n",
       "      <td>-0.066380</td>\n",
       "      <td>0.102173</td>\n",
       "      <td>-0.045759</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.055071</td>\n",
       "      <td>0.168359</td>\n",
       "      <td>0.076830</td>\n",
       "      <td>0.161103</td>\n",
       "      <td>-0.016522</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.075521</td>\n",
       "      <td>0.142143</td>\n",
       "      <td>0.193062</td>\n",
       "      <td>0.072850</td>\n",
       "      <td>...</td>\n",
       "      <td>0.143456</td>\n",
       "      <td>0.102159</td>\n",
       "      <td>0.192513</td>\n",
       "      <td>0.093202</td>\n",
       "      <td>0.119560</td>\n",
       "      <td>0.151886</td>\n",
       "      <td>0.035962</td>\n",
       "      <td>0.100289</td>\n",
       "      <td>-0.010641</td>\n",
       "      <td>0.313789</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>0.298865</td>\n",
       "      <td>0.302533</td>\n",
       "      <td>-0.064591</td>\n",
       "      <td>0.084728</td>\n",
       "      <td>0.046765</td>\n",
       "      <td>0.075521</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.176210</td>\n",
       "      <td>0.048967</td>\n",
       "      <td>0.128083</td>\n",
       "      <td>...</td>\n",
       "      <td>0.133786</td>\n",
       "      <td>0.214904</td>\n",
       "      <td>0.158772</td>\n",
       "      <td>0.125200</td>\n",
       "      <td>0.233753</td>\n",
       "      <td>-0.007819</td>\n",
       "      <td>0.168046</td>\n",
       "      <td>0.221606</td>\n",
       "      <td>0.005159</td>\n",
       "      <td>0.046504</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>0.081741</td>\n",
       "      <td>0.283711</td>\n",
       "      <td>0.254749</td>\n",
       "      <td>0.259842</td>\n",
       "      <td>-0.015356</td>\n",
       "      <td>0.142143</td>\n",
       "      <td>0.176210</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.088855</td>\n",
       "      <td>0.339105</td>\n",
       "      <td>...</td>\n",
       "      <td>0.226559</td>\n",
       "      <td>0.240244</td>\n",
       "      <td>0.207780</td>\n",
       "      <td>0.288166</td>\n",
       "      <td>0.283431</td>\n",
       "      <td>-0.005587</td>\n",
       "      <td>0.266753</td>\n",
       "      <td>0.154125</td>\n",
       "      <td>0.047907</td>\n",
       "      <td>0.196631</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>0.050880</td>\n",
       "      <td>0.167143</td>\n",
       "      <td>0.190225</td>\n",
       "      <td>0.014458</td>\n",
       "      <td>0.004066</td>\n",
       "      <td>0.193062</td>\n",
       "      <td>0.048967</td>\n",
       "      <td>0.088855</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.086335</td>\n",
       "      <td>...</td>\n",
       "      <td>0.084337</td>\n",
       "      <td>0.103068</td>\n",
       "      <td>0.117690</td>\n",
       "      <td>0.141619</td>\n",
       "      <td>0.077829</td>\n",
       "      <td>-0.093685</td>\n",
       "      <td>0.193870</td>\n",
       "      <td>-0.063637</td>\n",
       "      <td>0.053103</td>\n",
       "      <td>0.211752</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.121065</td>\n",
       "      <td>0.113720</td>\n",
       "      <td>0.172798</td>\n",
       "      <td>0.086001</td>\n",
       "      <td>0.048524</td>\n",
       "      <td>0.072850</td>\n",
       "      <td>0.128083</td>\n",
       "      <td>0.339105</td>\n",
       "      <td>-0.086335</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>...</td>\n",
       "      <td>0.236249</td>\n",
       "      <td>0.210963</td>\n",
       "      <td>0.136911</td>\n",
       "      <td>0.261479</td>\n",
       "      <td>0.242289</td>\n",
       "      <td>-0.041338</td>\n",
       "      <td>0.201240</td>\n",
       "      <td>-0.001629</td>\n",
       "      <td>0.157727</td>\n",
       "      <td>0.074777</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>-0.017714</td>\n",
       "      <td>0.143385</td>\n",
       "      <td>0.154351</td>\n",
       "      <td>0.299998</td>\n",
       "      <td>0.052768</td>\n",
       "      <td>0.045258</td>\n",
       "      <td>-0.034573</td>\n",
       "      <td>0.200004</td>\n",
       "      <td>0.187460</td>\n",
       "      <td>0.139939</td>\n",
       "      <td>...</td>\n",
       "      <td>0.074934</td>\n",
       "      <td>0.205511</td>\n",
       "      <td>0.128390</td>\n",
       "      <td>0.219803</td>\n",
       "      <td>0.166906</td>\n",
       "      <td>-0.009510</td>\n",
       "      <td>0.072732</td>\n",
       "      <td>0.053302</td>\n",
       "      <td>0.060894</td>\n",
       "      <td>0.224745</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>0.090746</td>\n",
       "      <td>0.272458</td>\n",
       "      <td>0.258385</td>\n",
       "      <td>0.242838</td>\n",
       "      <td>0.032546</td>\n",
       "      <td>0.048919</td>\n",
       "      <td>0.051618</td>\n",
       "      <td>0.257476</td>\n",
       "      <td>0.152552</td>\n",
       "      <td>0.192923</td>\n",
       "      <td>...</td>\n",
       "      <td>0.202175</td>\n",
       "      <td>0.208951</td>\n",
       "      <td>0.215667</td>\n",
       "      <td>0.172584</td>\n",
       "      <td>0.158460</td>\n",
       "      <td>-0.022365</td>\n",
       "      <td>0.192056</td>\n",
       "      <td>0.017305</td>\n",
       "      <td>0.169414</td>\n",
       "      <td>0.117850</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>0.137045</td>\n",
       "      <td>0.158494</td>\n",
       "      <td>-0.001768</td>\n",
       "      <td>0.024502</td>\n",
       "      <td>-0.082011</td>\n",
       "      <td>0.151125</td>\n",
       "      <td>0.058614</td>\n",
       "      <td>0.028347</td>\n",
       "      <td>0.091298</td>\n",
       "      <td>0.104138</td>\n",
       "      <td>...</td>\n",
       "      <td>0.027356</td>\n",
       "      <td>0.050050</td>\n",
       "      <td>0.027336</td>\n",
       "      <td>0.111930</td>\n",
       "      <td>0.055918</td>\n",
       "      <td>0.100567</td>\n",
       "      <td>0.001916</td>\n",
       "      <td>0.123836</td>\n",
       "      <td>-0.060468</td>\n",
       "      <td>0.252181</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>0.132741</td>\n",
       "      <td>0.234365</td>\n",
       "      <td>0.275718</td>\n",
       "      <td>0.100823</td>\n",
       "      <td>-0.025042</td>\n",
       "      <td>0.024520</td>\n",
       "      <td>0.266535</td>\n",
       "      <td>0.309100</td>\n",
       "      <td>0.133893</td>\n",
       "      <td>0.257692</td>\n",
       "      <td>...</td>\n",
       "      <td>0.260861</td>\n",
       "      <td>0.264244</td>\n",
       "      <td>0.219171</td>\n",
       "      <td>0.183122</td>\n",
       "      <td>0.204197</td>\n",
       "      <td>-0.079143</td>\n",
       "      <td>0.198989</td>\n",
       "      <td>0.185249</td>\n",
       "      <td>0.059410</td>\n",
       "      <td>0.155889</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>0.270691</td>\n",
       "      <td>0.317535</td>\n",
       "      <td>0.181697</td>\n",
       "      <td>0.206648</td>\n",
       "      <td>-0.098275</td>\n",
       "      <td>0.194779</td>\n",
       "      <td>0.236407</td>\n",
       "      <td>0.303881</td>\n",
       "      <td>0.167131</td>\n",
       "      <td>0.268551</td>\n",
       "      <td>...</td>\n",
       "      <td>0.195201</td>\n",
       "      <td>0.289369</td>\n",
       "      <td>0.400601</td>\n",
       "      <td>0.292267</td>\n",
       "      <td>0.395746</td>\n",
       "      <td>0.100289</td>\n",
       "      <td>0.225039</td>\n",
       "      <td>0.260701</td>\n",
       "      <td>0.125557</td>\n",
       "      <td>0.269022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>-0.045149</td>\n",
       "      <td>-0.007777</td>\n",
       "      <td>-0.047224</td>\n",
       "      <td>0.020141</td>\n",
       "      <td>0.010517</td>\n",
       "      <td>0.132037</td>\n",
       "      <td>0.113191</td>\n",
       "      <td>0.136252</td>\n",
       "      <td>0.040168</td>\n",
       "      <td>-0.018488</td>\n",
       "      <td>...</td>\n",
       "      <td>0.043359</td>\n",
       "      <td>0.051846</td>\n",
       "      <td>-0.025101</td>\n",
       "      <td>0.055884</td>\n",
       "      <td>0.000392</td>\n",
       "      <td>-0.035567</td>\n",
       "      <td>0.048703</td>\n",
       "      <td>0.103241</td>\n",
       "      <td>-0.038202</td>\n",
       "      <td>0.100845</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>0.100358</td>\n",
       "      <td>0.300339</td>\n",
       "      <td>0.094073</td>\n",
       "      <td>0.164856</td>\n",
       "      <td>0.013194</td>\n",
       "      <td>0.041638</td>\n",
       "      <td>0.121134</td>\n",
       "      <td>0.311772</td>\n",
       "      <td>0.042635</td>\n",
       "      <td>0.223358</td>\n",
       "      <td>...</td>\n",
       "      <td>0.211601</td>\n",
       "      <td>0.242571</td>\n",
       "      <td>0.193467</td>\n",
       "      <td>0.195947</td>\n",
       "      <td>0.283689</td>\n",
       "      <td>-0.018320</td>\n",
       "      <td>0.108554</td>\n",
       "      <td>-0.015052</td>\n",
       "      <td>0.292868</td>\n",
       "      <td>0.203139</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>0.107239</td>\n",
       "      <td>0.238500</td>\n",
       "      <td>0.076736</td>\n",
       "      <td>0.186204</td>\n",
       "      <td>-0.045489</td>\n",
       "      <td>0.193957</td>\n",
       "      <td>0.059147</td>\n",
       "      <td>0.227068</td>\n",
       "      <td>-0.017300</td>\n",
       "      <td>0.099241</td>\n",
       "      <td>...</td>\n",
       "      <td>0.223210</td>\n",
       "      <td>0.055842</td>\n",
       "      <td>0.120995</td>\n",
       "      <td>0.168918</td>\n",
       "      <td>0.227482</td>\n",
       "      <td>0.020453</td>\n",
       "      <td>0.113469</td>\n",
       "      <td>0.027196</td>\n",
       "      <td>0.010731</td>\n",
       "      <td>0.156155</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>0.158246</td>\n",
       "      <td>0.192932</td>\n",
       "      <td>0.151736</td>\n",
       "      <td>0.195696</td>\n",
       "      <td>0.017797</td>\n",
       "      <td>0.129658</td>\n",
       "      <td>0.079941</td>\n",
       "      <td>0.244671</td>\n",
       "      <td>0.013216</td>\n",
       "      <td>0.126369</td>\n",
       "      <td>...</td>\n",
       "      <td>0.130315</td>\n",
       "      <td>0.220274</td>\n",
       "      <td>0.148490</td>\n",
       "      <td>0.231832</td>\n",
       "      <td>0.181748</td>\n",
       "      <td>-0.010906</td>\n",
       "      <td>0.254832</td>\n",
       "      <td>0.044762</td>\n",
       "      <td>0.083175</td>\n",
       "      <td>0.097739</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>-0.088408</td>\n",
       "      <td>0.153199</td>\n",
       "      <td>0.126975</td>\n",
       "      <td>0.129019</td>\n",
       "      <td>0.058423</td>\n",
       "      <td>0.094837</td>\n",
       "      <td>0.027974</td>\n",
       "      <td>0.143561</td>\n",
       "      <td>0.052735</td>\n",
       "      <td>0.196288</td>\n",
       "      <td>...</td>\n",
       "      <td>0.225538</td>\n",
       "      <td>0.145799</td>\n",
       "      <td>0.033281</td>\n",
       "      <td>0.072919</td>\n",
       "      <td>0.034996</td>\n",
       "      <td>-0.009259</td>\n",
       "      <td>0.084532</td>\n",
       "      <td>0.001876</td>\n",
       "      <td>0.217904</td>\n",
       "      <td>0.197544</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>0.123733</td>\n",
       "      <td>0.239491</td>\n",
       "      <td>0.112038</td>\n",
       "      <td>0.107437</td>\n",
       "      <td>-0.157204</td>\n",
       "      <td>0.197821</td>\n",
       "      <td>0.051098</td>\n",
       "      <td>0.164966</td>\n",
       "      <td>-0.000306</td>\n",
       "      <td>0.110194</td>\n",
       "      <td>...</td>\n",
       "      <td>0.063112</td>\n",
       "      <td>0.163645</td>\n",
       "      <td>0.140799</td>\n",
       "      <td>0.258101</td>\n",
       "      <td>0.154051</td>\n",
       "      <td>0.093902</td>\n",
       "      <td>0.100144</td>\n",
       "      <td>0.076863</td>\n",
       "      <td>0.153935</td>\n",
       "      <td>0.238476</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>0.239593</td>\n",
       "      <td>0.315955</td>\n",
       "      <td>0.134811</td>\n",
       "      <td>0.052380</td>\n",
       "      <td>-0.109882</td>\n",
       "      <td>0.136943</td>\n",
       "      <td>0.317797</td>\n",
       "      <td>0.334644</td>\n",
       "      <td>0.071909</td>\n",
       "      <td>0.224188</td>\n",
       "      <td>...</td>\n",
       "      <td>0.269890</td>\n",
       "      <td>0.346415</td>\n",
       "      <td>0.165297</td>\n",
       "      <td>0.316277</td>\n",
       "      <td>0.243542</td>\n",
       "      <td>0.132188</td>\n",
       "      <td>0.244902</td>\n",
       "      <td>0.008299</td>\n",
       "      <td>0.161652</td>\n",
       "      <td>0.220335</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>0.216014</td>\n",
       "      <td>0.314191</td>\n",
       "      <td>0.192691</td>\n",
       "      <td>0.222751</td>\n",
       "      <td>-0.097145</td>\n",
       "      <td>0.040756</td>\n",
       "      <td>0.068366</td>\n",
       "      <td>0.228696</td>\n",
       "      <td>-0.030098</td>\n",
       "      <td>0.155276</td>\n",
       "      <td>...</td>\n",
       "      <td>0.255545</td>\n",
       "      <td>0.343526</td>\n",
       "      <td>0.194341</td>\n",
       "      <td>0.245517</td>\n",
       "      <td>0.167493</td>\n",
       "      <td>0.100540</td>\n",
       "      <td>0.111737</td>\n",
       "      <td>0.139508</td>\n",
       "      <td>0.071148</td>\n",
       "      <td>0.202421</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>0.087176</td>\n",
       "      <td>0.148152</td>\n",
       "      <td>0.252261</td>\n",
       "      <td>0.107210</td>\n",
       "      <td>-0.002205</td>\n",
       "      <td>0.058429</td>\n",
       "      <td>0.114613</td>\n",
       "      <td>0.154443</td>\n",
       "      <td>0.064202</td>\n",
       "      <td>0.077505</td>\n",
       "      <td>...</td>\n",
       "      <td>0.139093</td>\n",
       "      <td>0.082416</td>\n",
       "      <td>0.250200</td>\n",
       "      <td>0.198064</td>\n",
       "      <td>0.156323</td>\n",
       "      <td>0.028019</td>\n",
       "      <td>0.087621</td>\n",
       "      <td>0.160530</td>\n",
       "      <td>0.101771</td>\n",
       "      <td>0.192524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>0.124348</td>\n",
       "      <td>0.317686</td>\n",
       "      <td>0.115676</td>\n",
       "      <td>-0.039929</td>\n",
       "      <td>-0.074344</td>\n",
       "      <td>0.143456</td>\n",
       "      <td>0.133786</td>\n",
       "      <td>0.226559</td>\n",
       "      <td>0.084337</td>\n",
       "      <td>0.236249</td>\n",
       "      <td>...</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.246913</td>\n",
       "      <td>0.200249</td>\n",
       "      <td>0.242660</td>\n",
       "      <td>0.151708</td>\n",
       "      <td>0.241589</td>\n",
       "      <td>0.122659</td>\n",
       "      <td>0.162770</td>\n",
       "      <td>0.196408</td>\n",
       "      <td>0.164206</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>0.163235</td>\n",
       "      <td>0.249315</td>\n",
       "      <td>0.146782</td>\n",
       "      <td>0.239550</td>\n",
       "      <td>-0.008325</td>\n",
       "      <td>0.102159</td>\n",
       "      <td>0.214904</td>\n",
       "      <td>0.240244</td>\n",
       "      <td>0.103068</td>\n",
       "      <td>0.210963</td>\n",
       "      <td>...</td>\n",
       "      <td>0.246913</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.243000</td>\n",
       "      <td>0.220480</td>\n",
       "      <td>0.265362</td>\n",
       "      <td>0.013241</td>\n",
       "      <td>0.214885</td>\n",
       "      <td>0.183110</td>\n",
       "      <td>0.159444</td>\n",
       "      <td>0.227234</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>0.158082</td>\n",
       "      <td>0.244756</td>\n",
       "      <td>-0.029606</td>\n",
       "      <td>0.215339</td>\n",
       "      <td>0.069442</td>\n",
       "      <td>0.192513</td>\n",
       "      <td>0.158772</td>\n",
       "      <td>0.207780</td>\n",
       "      <td>0.117690</td>\n",
       "      <td>0.136911</td>\n",
       "      <td>...</td>\n",
       "      <td>0.200249</td>\n",
       "      <td>0.243000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.187517</td>\n",
       "      <td>0.161334</td>\n",
       "      <td>0.080408</td>\n",
       "      <td>0.080120</td>\n",
       "      <td>0.285077</td>\n",
       "      <td>0.057834</td>\n",
       "      <td>0.147561</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>0.181133</td>\n",
       "      <td>0.328094</td>\n",
       "      <td>0.163706</td>\n",
       "      <td>0.134585</td>\n",
       "      <td>-0.056780</td>\n",
       "      <td>0.093202</td>\n",
       "      <td>0.125200</td>\n",
       "      <td>0.288166</td>\n",
       "      <td>0.141619</td>\n",
       "      <td>0.261479</td>\n",
       "      <td>...</td>\n",
       "      <td>0.242660</td>\n",
       "      <td>0.220480</td>\n",
       "      <td>0.187517</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.169237</td>\n",
       "      <td>0.087062</td>\n",
       "      <td>0.207930</td>\n",
       "      <td>0.099492</td>\n",
       "      <td>0.029027</td>\n",
       "      <td>0.118481</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>0.288083</td>\n",
       "      <td>0.400561</td>\n",
       "      <td>0.072575</td>\n",
       "      <td>0.205383</td>\n",
       "      <td>-0.029405</td>\n",
       "      <td>0.119560</td>\n",
       "      <td>0.233753</td>\n",
       "      <td>0.283431</td>\n",
       "      <td>0.077829</td>\n",
       "      <td>0.242289</td>\n",
       "      <td>...</td>\n",
       "      <td>0.151708</td>\n",
       "      <td>0.265362</td>\n",
       "      <td>0.161334</td>\n",
       "      <td>0.169237</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.039089</td>\n",
       "      <td>0.315618</td>\n",
       "      <td>0.122392</td>\n",
       "      <td>0.158943</td>\n",
       "      <td>0.251346</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.092794</td>\n",
       "      <td>0.103856</td>\n",
       "      <td>0.043145</td>\n",
       "      <td>0.094626</td>\n",
       "      <td>-0.172705</td>\n",
       "      <td>0.151886</td>\n",
       "      <td>-0.007819</td>\n",
       "      <td>-0.005587</td>\n",
       "      <td>-0.093685</td>\n",
       "      <td>-0.041338</td>\n",
       "      <td>...</td>\n",
       "      <td>0.241589</td>\n",
       "      <td>0.013241</td>\n",
       "      <td>0.080408</td>\n",
       "      <td>0.087062</td>\n",
       "      <td>0.039089</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.152726</td>\n",
       "      <td>-0.039400</td>\n",
       "      <td>0.069477</td>\n",
       "      <td>0.012725</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>0.185628</td>\n",
       "      <td>0.365101</td>\n",
       "      <td>0.234544</td>\n",
       "      <td>0.159678</td>\n",
       "      <td>-0.066141</td>\n",
       "      <td>0.035962</td>\n",
       "      <td>0.168046</td>\n",
       "      <td>0.266753</td>\n",
       "      <td>0.193870</td>\n",
       "      <td>0.201240</td>\n",
       "      <td>...</td>\n",
       "      <td>0.122659</td>\n",
       "      <td>0.214885</td>\n",
       "      <td>0.080120</td>\n",
       "      <td>0.207930</td>\n",
       "      <td>0.315618</td>\n",
       "      <td>-0.152726</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.028414</td>\n",
       "      <td>0.134884</td>\n",
       "      <td>0.144587</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>0.144161</td>\n",
       "      <td>0.219111</td>\n",
       "      <td>-0.039937</td>\n",
       "      <td>0.144439</td>\n",
       "      <td>-0.066380</td>\n",
       "      <td>0.100289</td>\n",
       "      <td>0.221606</td>\n",
       "      <td>0.154125</td>\n",
       "      <td>-0.063637</td>\n",
       "      <td>-0.001629</td>\n",
       "      <td>...</td>\n",
       "      <td>0.162770</td>\n",
       "      <td>0.183110</td>\n",
       "      <td>0.285077</td>\n",
       "      <td>0.099492</td>\n",
       "      <td>0.122392</td>\n",
       "      <td>-0.039400</td>\n",
       "      <td>0.028414</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.026660</td>\n",
       "      <td>0.134684</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>0.005380</td>\n",
       "      <td>0.140468</td>\n",
       "      <td>0.059261</td>\n",
       "      <td>0.054221</td>\n",
       "      <td>0.102173</td>\n",
       "      <td>-0.010641</td>\n",
       "      <td>0.005159</td>\n",
       "      <td>0.047907</td>\n",
       "      <td>0.053103</td>\n",
       "      <td>0.157727</td>\n",
       "      <td>...</td>\n",
       "      <td>0.196408</td>\n",
       "      <td>0.159444</td>\n",
       "      <td>0.057834</td>\n",
       "      <td>0.029027</td>\n",
       "      <td>0.158943</td>\n",
       "      <td>0.069477</td>\n",
       "      <td>0.134884</td>\n",
       "      <td>-0.026660</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.003157</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>0.145754</td>\n",
       "      <td>0.268175</td>\n",
       "      <td>0.265866</td>\n",
       "      <td>0.203177</td>\n",
       "      <td>-0.045759</td>\n",
       "      <td>0.313789</td>\n",
       "      <td>0.046504</td>\n",
       "      <td>0.196631</td>\n",
       "      <td>0.211752</td>\n",
       "      <td>0.074777</td>\n",
       "      <td>...</td>\n",
       "      <td>0.164206</td>\n",
       "      <td>0.227234</td>\n",
       "      <td>0.147561</td>\n",
       "      <td>0.118481</td>\n",
       "      <td>0.251346</td>\n",
       "      <td>0.012725</td>\n",
       "      <td>0.144587</td>\n",
       "      <td>0.134684</td>\n",
       "      <td>-0.003157</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>34 rows × 34 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          1         2         3         4         5         6         7   \\\n",
       "1   1.000000  0.231297  0.065869  0.058290 -0.019313  0.055071  0.298865   \n",
       "2   0.231297  1.000000  0.164515  0.273920 -0.163867  0.168359  0.302533   \n",
       "3   0.065869  0.164515  1.000000  0.030626 -0.127232  0.076830 -0.064591   \n",
       "4   0.058290  0.273920  0.030626  1.000000  0.028030  0.161103  0.084728   \n",
       "5  -0.019313 -0.163867 -0.127232  0.028030  1.000000 -0.016522  0.046765   \n",
       "6   0.055071  0.168359  0.076830  0.161103 -0.016522  1.000000  0.075521   \n",
       "7   0.298865  0.302533 -0.064591  0.084728  0.046765  0.075521  1.000000   \n",
       "8   0.081741  0.283711  0.254749  0.259842 -0.015356  0.142143  0.176210   \n",
       "9   0.050880  0.167143  0.190225  0.014458  0.004066  0.193062  0.048967   \n",
       "10  0.121065  0.113720  0.172798  0.086001  0.048524  0.072850  0.128083   \n",
       "11 -0.017714  0.143385  0.154351  0.299998  0.052768  0.045258 -0.034573   \n",
       "12  0.090746  0.272458  0.258385  0.242838  0.032546  0.048919  0.051618   \n",
       "13  0.137045  0.158494 -0.001768  0.024502 -0.082011  0.151125  0.058614   \n",
       "14  0.132741  0.234365  0.275718  0.100823 -0.025042  0.024520  0.266535   \n",
       "15  0.270691  0.317535  0.181697  0.206648 -0.098275  0.194779  0.236407   \n",
       "16 -0.045149 -0.007777 -0.047224  0.020141  0.010517  0.132037  0.113191   \n",
       "17  0.100358  0.300339  0.094073  0.164856  0.013194  0.041638  0.121134   \n",
       "18  0.107239  0.238500  0.076736  0.186204 -0.045489  0.193957  0.059147   \n",
       "19  0.158246  0.192932  0.151736  0.195696  0.017797  0.129658  0.079941   \n",
       "20 -0.088408  0.153199  0.126975  0.129019  0.058423  0.094837  0.027974   \n",
       "21  0.123733  0.239491  0.112038  0.107437 -0.157204  0.197821  0.051098   \n",
       "22  0.239593  0.315955  0.134811  0.052380 -0.109882  0.136943  0.317797   \n",
       "23  0.216014  0.314191  0.192691  0.222751 -0.097145  0.040756  0.068366   \n",
       "24  0.087176  0.148152  0.252261  0.107210 -0.002205  0.058429  0.114613   \n",
       "25  0.124348  0.317686  0.115676 -0.039929 -0.074344  0.143456  0.133786   \n",
       "26  0.163235  0.249315  0.146782  0.239550 -0.008325  0.102159  0.214904   \n",
       "27  0.158082  0.244756 -0.029606  0.215339  0.069442  0.192513  0.158772   \n",
       "28  0.181133  0.328094  0.163706  0.134585 -0.056780  0.093202  0.125200   \n",
       "29  0.288083  0.400561  0.072575  0.205383 -0.029405  0.119560  0.233753   \n",
       "30  0.092794  0.103856  0.043145  0.094626 -0.172705  0.151886 -0.007819   \n",
       "31  0.185628  0.365101  0.234544  0.159678 -0.066141  0.035962  0.168046   \n",
       "32  0.144161  0.219111 -0.039937  0.144439 -0.066380  0.100289  0.221606   \n",
       "33  0.005380  0.140468  0.059261  0.054221  0.102173 -0.010641  0.005159   \n",
       "34  0.145754  0.268175  0.265866  0.203177 -0.045759  0.313789  0.046504   \n",
       "\n",
       "          8         9         10    ...           25        26        27  \\\n",
       "1   0.081741  0.050880  0.121065    ...     0.124348  0.163235  0.158082   \n",
       "2   0.283711  0.167143  0.113720    ...     0.317686  0.249315  0.244756   \n",
       "3   0.254749  0.190225  0.172798    ...     0.115676  0.146782 -0.029606   \n",
       "4   0.259842  0.014458  0.086001    ...    -0.039929  0.239550  0.215339   \n",
       "5  -0.015356  0.004066  0.048524    ...    -0.074344 -0.008325  0.069442   \n",
       "6   0.142143  0.193062  0.072850    ...     0.143456  0.102159  0.192513   \n",
       "7   0.176210  0.048967  0.128083    ...     0.133786  0.214904  0.158772   \n",
       "8   1.000000  0.088855  0.339105    ...     0.226559  0.240244  0.207780   \n",
       "9   0.088855  1.000000 -0.086335    ...     0.084337  0.103068  0.117690   \n",
       "10  0.339105 -0.086335  1.000000    ...     0.236249  0.210963  0.136911   \n",
       "11  0.200004  0.187460  0.139939    ...     0.074934  0.205511  0.128390   \n",
       "12  0.257476  0.152552  0.192923    ...     0.202175  0.208951  0.215667   \n",
       "13  0.028347  0.091298  0.104138    ...     0.027356  0.050050  0.027336   \n",
       "14  0.309100  0.133893  0.257692    ...     0.260861  0.264244  0.219171   \n",
       "15  0.303881  0.167131  0.268551    ...     0.195201  0.289369  0.400601   \n",
       "16  0.136252  0.040168 -0.018488    ...     0.043359  0.051846 -0.025101   \n",
       "17  0.311772  0.042635  0.223358    ...     0.211601  0.242571  0.193467   \n",
       "18  0.227068 -0.017300  0.099241    ...     0.223210  0.055842  0.120995   \n",
       "19  0.244671  0.013216  0.126369    ...     0.130315  0.220274  0.148490   \n",
       "20  0.143561  0.052735  0.196288    ...     0.225538  0.145799  0.033281   \n",
       "21  0.164966 -0.000306  0.110194    ...     0.063112  0.163645  0.140799   \n",
       "22  0.334644  0.071909  0.224188    ...     0.269890  0.346415  0.165297   \n",
       "23  0.228696 -0.030098  0.155276    ...     0.255545  0.343526  0.194341   \n",
       "24  0.154443  0.064202  0.077505    ...     0.139093  0.082416  0.250200   \n",
       "25  0.226559  0.084337  0.236249    ...     1.000000  0.246913  0.200249   \n",
       "26  0.240244  0.103068  0.210963    ...     0.246913  1.000000  0.243000   \n",
       "27  0.207780  0.117690  0.136911    ...     0.200249  0.243000  1.000000   \n",
       "28  0.288166  0.141619  0.261479    ...     0.242660  0.220480  0.187517   \n",
       "29  0.283431  0.077829  0.242289    ...     0.151708  0.265362  0.161334   \n",
       "30 -0.005587 -0.093685 -0.041338    ...     0.241589  0.013241  0.080408   \n",
       "31  0.266753  0.193870  0.201240    ...     0.122659  0.214885  0.080120   \n",
       "32  0.154125 -0.063637 -0.001629    ...     0.162770  0.183110  0.285077   \n",
       "33  0.047907  0.053103  0.157727    ...     0.196408  0.159444  0.057834   \n",
       "34  0.196631  0.211752  0.074777    ...     0.164206  0.227234  0.147561   \n",
       "\n",
       "          28        29        30        31        32        33        34  \n",
       "1   0.181133  0.288083  0.092794  0.185628  0.144161  0.005380  0.145754  \n",
       "2   0.328094  0.400561  0.103856  0.365101  0.219111  0.140468  0.268175  \n",
       "3   0.163706  0.072575  0.043145  0.234544 -0.039937  0.059261  0.265866  \n",
       "4   0.134585  0.205383  0.094626  0.159678  0.144439  0.054221  0.203177  \n",
       "5  -0.056780 -0.029405 -0.172705 -0.066141 -0.066380  0.102173 -0.045759  \n",
       "6   0.093202  0.119560  0.151886  0.035962  0.100289 -0.010641  0.313789  \n",
       "7   0.125200  0.233753 -0.007819  0.168046  0.221606  0.005159  0.046504  \n",
       "8   0.288166  0.283431 -0.005587  0.266753  0.154125  0.047907  0.196631  \n",
       "9   0.141619  0.077829 -0.093685  0.193870 -0.063637  0.053103  0.211752  \n",
       "10  0.261479  0.242289 -0.041338  0.201240 -0.001629  0.157727  0.074777  \n",
       "11  0.219803  0.166906 -0.009510  0.072732  0.053302  0.060894  0.224745  \n",
       "12  0.172584  0.158460 -0.022365  0.192056  0.017305  0.169414  0.117850  \n",
       "13  0.111930  0.055918  0.100567  0.001916  0.123836 -0.060468  0.252181  \n",
       "14  0.183122  0.204197 -0.079143  0.198989  0.185249  0.059410  0.155889  \n",
       "15  0.292267  0.395746  0.100289  0.225039  0.260701  0.125557  0.269022  \n",
       "16  0.055884  0.000392 -0.035567  0.048703  0.103241 -0.038202  0.100845  \n",
       "17  0.195947  0.283689 -0.018320  0.108554 -0.015052  0.292868  0.203139  \n",
       "18  0.168918  0.227482  0.020453  0.113469  0.027196  0.010731  0.156155  \n",
       "19  0.231832  0.181748 -0.010906  0.254832  0.044762  0.083175  0.097739  \n",
       "20  0.072919  0.034996 -0.009259  0.084532  0.001876  0.217904  0.197544  \n",
       "21  0.258101  0.154051  0.093902  0.100144  0.076863  0.153935  0.238476  \n",
       "22  0.316277  0.243542  0.132188  0.244902  0.008299  0.161652  0.220335  \n",
       "23  0.245517  0.167493  0.100540  0.111737  0.139508  0.071148  0.202421  \n",
       "24  0.198064  0.156323  0.028019  0.087621  0.160530  0.101771  0.192524  \n",
       "25  0.242660  0.151708  0.241589  0.122659  0.162770  0.196408  0.164206  \n",
       "26  0.220480  0.265362  0.013241  0.214885  0.183110  0.159444  0.227234  \n",
       "27  0.187517  0.161334  0.080408  0.080120  0.285077  0.057834  0.147561  \n",
       "28  1.000000  0.169237  0.087062  0.207930  0.099492  0.029027  0.118481  \n",
       "29  0.169237  1.000000  0.039089  0.315618  0.122392  0.158943  0.251346  \n",
       "30  0.087062  0.039089  1.000000 -0.152726 -0.039400  0.069477  0.012725  \n",
       "31  0.207930  0.315618 -0.152726  1.000000  0.028414  0.134884  0.144587  \n",
       "32  0.099492  0.122392 -0.039400  0.028414  1.000000 -0.026660  0.134684  \n",
       "33  0.029027  0.158943  0.069477  0.134884 -0.026660  1.000000 -0.003157  \n",
       "34  0.118481  0.251346  0.012725  0.144587  0.134684 -0.003157  1.000000  \n",
       "\n",
       "[34 rows x 34 columns]"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cos_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "7"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cos_df[1].sort_values(ascending=False).keys()[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1.0000003576278687,\n",
       " 1.000000238418579,\n",
       " 1.0000001192092896,\n",
       " 1.0,\n",
       " 0.9999999403953552,\n",
       " 0.9999998211860657,\n",
       " 0.4006013572216034,\n",
       " 0.40056055784225464,\n",
       " 0.395746111869812,\n",
       " 0.3780534267425537,\n",
       " 0.36510059237480164,\n",
       " 0.34641459584236145,\n",
       " 0.3435259461402893,\n",
       " 0.33910518884658813,\n",
       " 0.338845431804657,\n",
       " 0.3346439599990845,\n",
       " 0.3335384130477905,\n",
       " 0.3280940651893616,\n",
       " 0.32422471046447754,\n",
       " 0.31779706478118896,\n",
       " 0.3176860809326172,\n",
       " 0.3175346255302429,\n",
       " 0.31627655029296875,\n",
       " 0.3159550428390503,\n",
       " 0.315618097782135,\n",
       " 0.3141908049583435,\n",
       " 0.3137894868850708,\n",
       " 0.31177228689193726,\n",
       " 0.3091001808643341,\n",
       " 0.3083761930465698,\n",
       " 0.30388063192367554,\n",
       " 0.3025328814983368,\n",
       " 0.3003387451171875,\n",
       " 0.29999828338623047,\n",
       " 0.2988654375076294,\n",
       " 0.2957431375980377,\n",
       " 0.292868435382843,\n",
       " 0.2922665476799011,\n",
       " 0.2893688976764679,\n",
       " 0.28816550970077515,\n",
       " 0.2880832552909851,\n",
       " 0.28507745265960693,\n",
       " 0.2837110161781311,\n",
       " 0.283689022064209,\n",
       " 0.2834733724594116,\n",
       " 0.28343063592910767,\n",
       " 0.2757182717323303,\n",
       " 0.27391988039016724,\n",
       " 0.2737148404121399,\n",
       " 0.273483544588089,\n",
       " 0.2724577784538269,\n",
       " 0.27171647548675537,\n",
       " 0.27069103717803955,\n",
       " 0.2698897123336792,\n",
       " 0.26902222633361816,\n",
       " 0.2685505747795105,\n",
       " 0.26827192306518555,\n",
       " 0.26817548274993896,\n",
       " 0.26675301790237427,\n",
       " 0.26653534173965454,\n",
       " 0.26586589217185974,\n",
       " 0.2653615474700928,\n",
       " 0.2642436623573303,\n",
       " 0.2614785134792328,\n",
       " 0.2608606219291687,\n",
       " 0.2607005834579468,\n",
       " 0.25984227657318115,\n",
       " 0.2583848834037781,\n",
       " 0.258101224899292,\n",
       " 0.25769174098968506,\n",
       " 0.2575069069862366,\n",
       " 0.2574756443500519,\n",
       " 0.25554487109184265,\n",
       " 0.2548319697380066,\n",
       " 0.2547493875026703,\n",
       " 0.25226080417633057,\n",
       " 0.2521813213825226,\n",
       " 0.251345694065094,\n",
       " 0.25020015239715576,\n",
       " 0.2493152618408203,\n",
       " 0.2482774257659912,\n",
       " 0.24691250920295715,\n",
       " 0.24551650881767273,\n",
       " 0.24490182101726532,\n",
       " 0.24475562572479248,\n",
       " 0.2446707785129547,\n",
       " 0.24435818195343018,\n",
       " 0.24354183673858643,\n",
       " 0.2434930056333542,\n",
       " 0.2429996132850647,\n",
       " 0.24283796548843384,\n",
       " 0.24266019463539124,\n",
       " 0.2425708770751953,\n",
       " 0.24228891730308533,\n",
       " 0.24158944189548492,\n",
       " 0.24024376273155212,\n",
       " 0.2395927906036377,\n",
       " 0.23955003917217255,\n",
       " 0.23949143290519714,\n",
       " 0.23850049078464508,\n",
       " 0.23847612738609314,\n",
       " 0.23640698194503784,\n",
       " 0.23624858260154724,\n",
       " 0.23457461595535278,\n",
       " 0.2345442920923233,\n",
       " 0.2343646138906479,\n",
       " 0.23375304043293,\n",
       " 0.23183247447013855,\n",
       " 0.23129747807979584,\n",
       " 0.22939759492874146,\n",
       " 0.22869551181793213,\n",
       " 0.22748202085494995,\n",
       " 0.22723430395126343,\n",
       " 0.22706787288188934,\n",
       " 0.22655850648880005,\n",
       " 0.22553792595863342,\n",
       " 0.2250392585992813,\n",
       " 0.22474521398544312,\n",
       " 0.2241877317428589,\n",
       " 0.22335831820964813,\n",
       " 0.2232104241847992,\n",
       " 0.2227509319782257,\n",
       " 0.22160600125789642,\n",
       " 0.22073718905448914,\n",
       " 0.2204800546169281,\n",
       " 0.22033506631851196,\n",
       " 0.22027379274368286,\n",
       " 0.21980339288711548,\n",
       " 0.21917077898979187,\n",
       " 0.21911077201366425,\n",
       " 0.21790409088134766,\n",
       " 0.21601352095603943,\n",
       " 0.21588748693466187,\n",
       " 0.21566736698150635,\n",
       " 0.21557947993278503,\n",
       " 0.21533851325511932,\n",
       " 0.21490412950515747,\n",
       " 0.21488529443740845,\n",
       " 0.21381133794784546,\n",
       " 0.21320205926895142,\n",
       " 0.21175150573253632,\n",
       " 0.211600661277771,\n",
       " 0.21132107079029083,\n",
       " 0.21096311509609222,\n",
       " 0.20895105600357056,\n",
       " 0.20793002843856812,\n",
       " 0.207780122756958,\n",
       " 0.20664827525615692,\n",
       " 0.20551133155822754,\n",
       " 0.20538318157196045,\n",
       " 0.2041972577571869,\n",
       " 0.20317688584327698,\n",
       " 0.2031385749578476,\n",
       " 0.20242133736610413,\n",
       " 0.20217491686344147,\n",
       " 0.2012403905391693,\n",
       " 0.20024864375591278,\n",
       " 0.20000356435775757,\n",
       " 0.19898931682109833,\n",
       " 0.19806361198425293,\n",
       " 0.19782111048698425,\n",
       " 0.19773010909557343,\n",
       " 0.1975436806678772,\n",
       " 0.1966305673122406,\n",
       " 0.19640789926052094,\n",
       " 0.19628816843032837,\n",
       " 0.19594745337963104,\n",
       " 0.19569607079029083,\n",
       " 0.1952008157968521,\n",
       " 0.19477863609790802,\n",
       " 0.19437620043754578,\n",
       " 0.19434109330177307,\n",
       " 0.19395685195922852,\n",
       " 0.19387026131153107,\n",
       " 0.19346684217453003,\n",
       " 0.19306214153766632,\n",
       " 0.1929321140050888,\n",
       " 0.19292284548282623,\n",
       " 0.1926913559436798,\n",
       " 0.192524254322052,\n",
       " 0.19251254200935364,\n",
       " 0.1920560598373413,\n",
       " 0.19202780723571777,\n",
       " 0.19022519886493683,\n",
       " 0.18790078163146973,\n",
       " 0.18751715123653412,\n",
       " 0.18745958805084229,\n",
       " 0.18620353937149048,\n",
       " 0.1856282353401184,\n",
       " 0.1852487325668335,\n",
       " 0.183121919631958,\n",
       " 0.18310962617397308,\n",
       " 0.18243557214736938,\n",
       " 0.18174836039543152,\n",
       " 0.1816970258951187,\n",
       " 0.1811329424381256,\n",
       " 0.17782607674598694,\n",
       " 0.17620962858200073,\n",
       " 0.17470481991767883,\n",
       " 0.17429715394973755,\n",
       " 0.17279817163944244,\n",
       " 0.17258359491825104,\n",
       " 0.16941428184509277,\n",
       " 0.169236958026886,\n",
       " 0.16902096569538116,\n",
       " 0.16891831159591675,\n",
       " 0.16860301792621613,\n",
       " 0.16835948824882507,\n",
       " 0.16823320090770721,\n",
       " 0.16823121905326843,\n",
       " 0.16804559528827667,\n",
       " 0.16782483458518982,\n",
       " 0.16749264299869537,\n",
       " 0.16714319586753845,\n",
       " 0.16713106632232666,\n",
       " 0.16690593957901,\n",
       " 0.1664549708366394,\n",
       " 0.1652972251176834,\n",
       " 0.16496627032756805,\n",
       " 0.16485589742660522,\n",
       " 0.16451458632946014,\n",
       " 0.16423290967941284,\n",
       " 0.16420572996139526,\n",
       " 0.1637060046195984,\n",
       " 0.16364465653896332,\n",
       " 0.1632346510887146,\n",
       " 0.1627696454524994,\n",
       " 0.16165177524089813,\n",
       " 0.16133414208889008,\n",
       " 0.16110293567180634,\n",
       " 0.16053040325641632,\n",
       " 0.15967795252799988,\n",
       " 0.15966354310512543,\n",
       " 0.15964438021183014,\n",
       " 0.15944352746009827,\n",
       " 0.15894289314746857,\n",
       " 0.15877164900302887,\n",
       " 0.15849418938159943,\n",
       " 0.15845976769924164,\n",
       " 0.1582459658384323,\n",
       " 0.15808182954788208,\n",
       " 0.15772730112075806,\n",
       " 0.1563231647014618,\n",
       " 0.15615499019622803,\n",
       " 0.15588906407356262,\n",
       " 0.155276358127594,\n",
       " 0.1544426530599594,\n",
       " 0.1543508619070053,\n",
       " 0.15412461757659912,\n",
       " 0.15405148267745972,\n",
       " 0.15393543243408203,\n",
       " 0.1531985104084015,\n",
       " 0.15255209803581238,\n",
       " 0.15188626945018768,\n",
       " 0.1517355591058731,\n",
       " 0.15170793235301971,\n",
       " 0.15112517774105072,\n",
       " 0.14962178468704224,\n",
       " 0.14849019050598145,\n",
       " 0.14815223217010498,\n",
       " 0.1475989818572998,\n",
       " 0.1475609987974167,\n",
       " 0.1467818170785904,\n",
       " 0.1459982991218567,\n",
       " 0.14579857885837555,\n",
       " 0.1457538604736328,\n",
       " 0.1457062065601349,\n",
       " 0.1445866823196411,\n",
       " 0.14443853497505188,\n",
       " 0.1441609412431717,\n",
       " 0.14356067776679993,\n",
       " 0.1434560865163803,\n",
       " 0.1433849036693573,\n",
       " 0.142142653465271,\n",
       " 0.1416187882423401,\n",
       " 0.1413256824016571,\n",
       " 0.14079943299293518,\n",
       " 0.14046844840049744,\n",
       " 0.13993868231773376,\n",
       " 0.1395075023174286,\n",
       " 0.1390925496816635,\n",
       " 0.13775482773780823,\n",
       " 0.13764718174934387,\n",
       " 0.1370450109243393,\n",
       " 0.13694298267364502,\n",
       " 0.13691136240959167,\n",
       " 0.1362515091896057,\n",
       " 0.1348838210105896,\n",
       " 0.13481086492538452,\n",
       " 0.1346842646598816,\n",
       " 0.13458511233329773,\n",
       " 0.13420018553733826,\n",
       " 0.1338931918144226,\n",
       " 0.1337856948375702,\n",
       " 0.13274119794368744,\n",
       " 0.13218849897384644,\n",
       " 0.13203725218772888,\n",
       " 0.13031543791294098,\n",
       " 0.1296578347682953,\n",
       " 0.12901918590068817,\n",
       " 0.12839016318321228,\n",
       " 0.12808313965797424,\n",
       " 0.12697476148605347,\n",
       " 0.126369446516037,\n",
       " 0.1261439323425293,\n",
       " 0.1255568116903305,\n",
       " 0.12519994378089905,\n",
       " 0.12434831261634827,\n",
       " 0.12383612990379333,\n",
       " 0.12373277544975281,\n",
       " 0.12265920639038086,\n",
       " 0.12239202857017517,\n",
       " 0.12113353610038757,\n",
       " 0.12106522172689438,\n",
       " 0.12099461257457733,\n",
       " 0.12067530304193497,\n",
       " 0.11956039071083069,\n",
       " 0.11848053336143494,\n",
       " 0.11785005033016205,\n",
       " 0.11768956482410431,\n",
       " 0.11567584425210953,\n",
       " 0.11476865410804749,\n",
       " 0.1146131306886673,\n",
       " 0.11372042447328568,\n",
       " 0.1134694293141365,\n",
       " 0.11319111287593842,\n",
       " 0.1120377779006958,\n",
       " 0.1119295135140419,\n",
       " 0.11173730343580246,\n",
       " 0.11019397526979446,\n",
       " 0.10991445183753967,\n",
       " 0.10855375975370407,\n",
       " 0.10743659734725952,\n",
       " 0.10723932087421417,\n",
       " 0.10721021890640259,\n",
       " 0.10698382556438446,\n",
       " 0.1041383370757103,\n",
       " 0.10385581851005554,\n",
       " 0.10324080288410187,\n",
       " 0.10306831449270248,\n",
       " 0.1021944135427475,\n",
       " 0.10217303037643433,\n",
       " 0.10215936601161957,\n",
       " 0.10177136212587357,\n",
       " 0.10084453225135803,\n",
       " 0.10082300007343292,\n",
       " 0.10056706517934799,\n",
       " 0.10053981840610504,\n",
       " 0.1003580242395401,\n",
       " 0.10028910636901855,\n",
       " 0.10028853267431259,\n",
       " 0.10014411062002182,\n",
       " 0.09949220716953278,\n",
       " 0.09924133867025375,\n",
       " 0.0977388471364975,\n",
       " 0.09540440887212753,\n",
       " 0.09483672678470612,\n",
       " 0.09462568163871765,\n",
       " 0.09407256543636322,\n",
       " 0.09390221536159515,\n",
       " 0.09320159256458282,\n",
       " 0.0927935391664505,\n",
       " 0.09129785746335983,\n",
       " 0.09074628353118896,\n",
       " 0.09057962149381638,\n",
       " 0.08972582966089249,\n",
       " 0.08885498344898224,\n",
       " 0.08762091398239136,\n",
       " 0.08717633038759232,\n",
       " 0.0870620459318161,\n",
       " 0.08600051701068878,\n",
       " 0.08472824841737747,\n",
       " 0.0846366435289383,\n",
       " 0.08453201502561569,\n",
       " 0.08433655649423599,\n",
       " 0.08359543234109879,\n",
       " 0.08317530155181885,\n",
       " 0.0829414427280426,\n",
       " 0.08241577446460724,\n",
       " 0.08199144899845123,\n",
       " 0.08186798542737961,\n",
       " 0.08174076676368713,\n",
       " 0.08136546611785889,\n",
       " 0.08040783554315567,\n",
       " 0.08011972904205322,\n",
       " 0.07994051277637482,\n",
       " 0.07866240292787552,\n",
       " 0.07782881706953049,\n",
       " 0.07750530540943146,\n",
       " 0.077338308095932,\n",
       " 0.07686281204223633,\n",
       " 0.07682967185974121,\n",
       " 0.07673582434654236,\n",
       " 0.07552079856395721,\n",
       " 0.07493437826633453,\n",
       " 0.07477745413780212,\n",
       " 0.07291850447654724,\n",
       " 0.07285010069608688,\n",
       " 0.07273180037736893,\n",
       " 0.07257478684186935,\n",
       " 0.07190904021263123,\n",
       " 0.07114841043949127,\n",
       " 0.069923534989357,\n",
       " 0.06947669386863708,\n",
       " 0.06944163143634796,\n",
       " 0.06836573034524918,\n",
       " 0.0676702931523323,\n",
       " 0.06719616800546646,\n",
       " 0.06586873531341553,\n",
       " 0.06420234590768814,\n",
       " 0.06311237812042236,\n",
       " 0.06089431792497635,\n",
       " 0.0594099722802639,\n",
       " 0.05926069617271423,\n",
       " 0.05914672464132309,\n",
       " 0.05912856012582779,\n",
       " 0.058613769710063934,\n",
       " 0.05842933431267738,\n",
       " 0.058422841131687164,\n",
       " 0.058289654552936554,\n",
       " 0.057833798229694366,\n",
       " 0.05701179802417755,\n",
       " 0.055918075144290924,\n",
       " 0.055884283035993576,\n",
       " 0.05584186315536499,\n",
       " 0.05507124215364456,\n",
       " 0.05422072485089302,\n",
       " 0.053302351385354996,\n",
       " 0.05310283601284027,\n",
       " 0.05276799947023392,\n",
       " 0.0527346208691597,\n",
       " 0.05238023400306702,\n",
       " 0.05184583365917206,\n",
       " 0.05161844938993454,\n",
       " 0.05138660967350006,\n",
       " 0.0510982945561409,\n",
       " 0.05088018253445625,\n",
       " 0.050050243735313416,\n",
       " 0.048967137932777405,\n",
       " 0.04891917109489441,\n",
       " 0.04870288074016571,\n",
       " 0.04855673387646675,\n",
       " 0.04852446913719177,\n",
       " 0.04790724813938141,\n",
       " 0.047609612345695496,\n",
       " 0.046765197068452835,\n",
       " 0.04650396481156349,\n",
       " 0.04617171734571457,\n",
       " 0.04525751248002052,\n",
       " 0.04476170986890793,\n",
       " 0.04335924983024597,\n",
       " 0.04314541444182396,\n",
       " 0.042634740471839905,\n",
       " 0.04163823649287224,\n",
       " 0.04075616970658302,\n",
       " 0.04016779363155365,\n",
       " 0.03908869996666908,\n",
       " 0.035961903631687164,\n",
       " 0.03508324921131134,\n",
       " 0.03499568626284599,\n",
       " 0.034668102860450745,\n",
       " 0.033280521631240845,\n",
       " 0.03306291252374649,\n",
       " 0.03254564106464386,\n",
       " 0.030625684186816216,\n",
       " 0.029027150943875313,\n",
       " 0.028414294123649597,\n",
       " 0.02834748476743698,\n",
       " 0.02803048864006996,\n",
       " 0.028019048273563385,\n",
       " 0.02797362580895424,\n",
       " 0.027356203645467758,\n",
       " 0.027335528284311295,\n",
       " 0.027196165174245834,\n",
       " 0.024520425125956535,\n",
       " 0.02450193278491497,\n",
       " 0.023578837513923645,\n",
       " 0.02191638946533203,\n",
       " 0.02045261859893799,\n",
       " 0.020141080021858215,\n",
       " 0.017994090914726257,\n",
       " 0.01779748871922493,\n",
       " 0.01779501885175705,\n",
       " 0.017304599285125732,\n",
       " 0.014457538723945618,\n",
       " 0.013241222128272057,\n",
       " 0.01321648433804512,\n",
       " 0.013193666934967041,\n",
       " 0.012725068256258965,\n",
       " 0.010731471702456474,\n",
       " 0.010516839101910591,\n",
       " 0.008504532277584076,\n",
       " 0.0082986019551754,\n",
       " 0.005380237475037575,\n",
       " 0.005158711224794388,\n",
       " 0.004066143184900284,\n",
       " 0.001916147768497467,\n",
       " 0.0018762145191431046,\n",
       " 0.0003916751593351364,\n",
       " 6.099045276641846e-05,\n",
       " -0.0003063492476940155,\n",
       " -0.0016291886568069458,\n",
       " -0.0017684921622276306,\n",
       " -0.0019200220704078674,\n",
       " -0.0022050607949495316,\n",
       " -0.00315745547413826,\n",
       " -0.005586832761764526,\n",
       " -0.0077277421951293945,\n",
       " -0.007777012884616852,\n",
       " -0.007819082587957382,\n",
       " -0.008325016126036644,\n",
       " -0.00925939530134201,\n",
       " -0.009510472416877747,\n",
       " -0.010641418397426605,\n",
       " -0.010905757546424866,\n",
       " -0.015051867812871933,\n",
       " -0.015356224030256271,\n",
       " -0.01652214117348194,\n",
       " -0.017299817875027657,\n",
       " -0.017714284360408783,\n",
       " -0.018320463597774506,\n",
       " -0.018487686291337013,\n",
       " -0.01931300014257431,\n",
       " -0.022365447133779526,\n",
       " -0.025041721761226654,\n",
       " -0.025101283565163612,\n",
       " -0.026659686118364334,\n",
       " -0.029404588043689728,\n",
       " -0.029605675488710403,\n",
       " -0.030098285526037216,\n",
       " -0.0345727764070034,\n",
       " -0.035566747188568115,\n",
       " -0.03820236399769783,\n",
       " -0.03940034657716751,\n",
       " -0.039928920567035675,\n",
       " -0.03993670642375946,\n",
       " -0.041337981820106506,\n",
       " -0.04514949768781662,\n",
       " -0.045489292591810226,\n",
       " -0.04575871676206589,\n",
       " -0.04708365350961685,\n",
       " -0.0472235269844532,\n",
       " -0.05678039789199829,\n",
       " -0.06043538078665733,\n",
       " -0.06046779453754425,\n",
       " -0.06363661587238312,\n",
       " -0.06459127366542816,\n",
       " -0.06614109873771667,\n",
       " -0.06638016551733017,\n",
       " -0.0725749284029007,\n",
       " -0.07348562031984329,\n",
       " -0.07434429228305817,\n",
       " -0.07914334535598755,\n",
       " -0.0820111408829689,\n",
       " -0.08633458614349365,\n",
       " -0.08840811252593994,\n",
       " -0.09368538856506348,\n",
       " -0.0971449762582779,\n",
       " -0.09827543050050735,\n",
       " -0.09908995032310486,\n",
       " -0.10988180339336395,\n",
       " -0.1206657737493515,\n",
       " -0.12723177671432495,\n",
       " -0.152725949883461,\n",
       " -0.15720435976982117,\n",
       " -0.16386735439300537,\n",
       " -0.17270532250404358]"
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sorted(list(set(cos_df.values.flatten())), reverse=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_most_similar(doc_num):\n",
    "    return cos_df[doc_num].sort_values(ascending=False).keys()[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "similar_list = []\n",
    "\n",
    "for x in range(1,35):\n",
    "    similar_list.append(get_most_similar(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[7,\n",
       " 29,\n",
       " 14,\n",
       " 11,\n",
       " 33,\n",
       " 34,\n",
       " 22,\n",
       " 10,\n",
       " 34,\n",
       " 8,\n",
       " 4,\n",
       " 15,\n",
       " 21,\n",
       " 17,\n",
       " 27,\n",
       " 8,\n",
       " 22,\n",
       " 22,\n",
       " 22,\n",
       " 17,\n",
       " 28,\n",
       " 17,\n",
       " 26,\n",
       " 14,\n",
       " 2,\n",
       " 22,\n",
       " 15,\n",
       " 2,\n",
       " 2,\n",
       " 25,\n",
       " 2,\n",
       " 27,\n",
       " 17,\n",
       " 6]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "similar_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(similar_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [],
   "source": [
    "title_list = ['A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19',\n",
    "'AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2',\n",
    "'Anti-HCV, nucleotide inhibitors, repurposing against COVID-19',\n",
    "'Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production',\n",
    "'Clinical trials on drug repositioning for COVID-19 treatment',\n",
    "'Convalescent plasmaA possible treatment of COVID-19 in India',\n",
    "'FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro',\n",
    "'FEP-based screening prompts drug repositioning against COVID-19',\n",
    "'First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients',\n",
    "'Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics',\n",
    "'Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs',\n",
    "'In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication',\n",
    "'Interferon-a2b treatment for COVID-19',\n",
    "'Learning from the Past Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV',\n",
    "'Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets',\n",
    "'Molecular mechanism of action of repurposed drugs and traditional Chinese medicine used for the treatment of patients infected with COVID-19 A systematic review',\n",
    "'Network-based drug repurposing for novel coronavirus 2019-nCoVSARS-CoV-2',\n",
    "'New insights on the antiviral effects of chloroquine against coronavirus what to expect for COVID-19',\n",
    "'Potentially highly potent drugs for 2019-nCoV',\n",
    "'Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model',\n",
    "'Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates',\n",
    "'Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds',\n",
    "'Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model',\n",
    "'Repurposing Therapeutics for COVID-19Rapid Prediction of Commercially available drugs through Machine Learning and Docking',\n",
    "'Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases',\n",
    "'Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19',\n",
    "'Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection',\n",
    "'Structure of Mpro from COVID-19 virus and discovery of its inhibitors',\n",
    "'Targeted Oxidation Strategy (TOS) for Potential Inhibition of Coronaviruses by Disulfiram - a 70-Year Old Anti-Alcoholism Drug',\n",
    "'Teicoplanin an alternative drug for the treatment of COVID-19',\n",
    "'The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1',\n",
    "'Therapeutic options for the 2019 novel coronavirus (2019-nCoV)',\n",
    "'Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)',\n",
    "'Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity - opportunity for repurposed chemotherapy of COVID-19 infection']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19'"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "title_list[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(title_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "target doc title : <A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19>\n",
      "most similar doc title: <FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro>\n",
      "target doc_id : 1\n",
      "most similar doc_id : 7\n",
      "cosine similarity : 0.2988654375076294\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2>\n",
      "most similar doc title: <Targeted Oxidation Strategy (TOS) for Potential Inhibition of Coronaviruses by Disulfiram - a 70-Year Old Anti-Alcoholism Drug>\n",
      "target doc_id : 2\n",
      "most similar doc_id : 29\n",
      "cosine similarity : 0.40056055784225464\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Anti-HCV, nucleotide inhibitors, repurposing against COVID-19>\n",
      "most similar doc title: <Learning from the Past Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV>\n",
      "target doc_id : 3\n",
      "most similar doc_id : 14\n",
      "cosine similarity : 0.2757182717323303\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production>\n",
      "most similar doc title: <Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs>\n",
      "target doc_id : 4\n",
      "most similar doc_id : 11\n",
      "cosine similarity : 0.29999828338623047\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Clinical trials on drug repositioning for COVID-19 treatment>\n",
      "most similar doc title: <Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)>\n",
      "target doc_id : 5\n",
      "most similar doc_id : 33\n",
      "cosine similarity : 0.10217303037643433\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Convalescent plasmaA possible treatment of COVID-19 in India>\n",
      "most similar doc title: <Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity - opportunity for repurposed chemotherapy of COVID-19 infection>\n",
      "target doc_id : 6\n",
      "most similar doc_id : 34\n",
      "cosine similarity : 0.3137894868850708\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro>\n",
      "most similar doc title: <Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds>\n",
      "target doc_id : 7\n",
      "most similar doc_id : 22\n",
      "cosine similarity : 0.31779706478118896\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <FEP-based screening prompts drug repositioning against COVID-19>\n",
      "most similar doc title: <Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics>\n",
      "target doc_id : 8\n",
      "most similar doc_id : 10\n",
      "cosine similarity : 0.33910518884658813\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients>\n",
      "most similar doc title: <Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity - opportunity for repurposed chemotherapy of COVID-19 infection>\n",
      "target doc_id : 9\n",
      "most similar doc_id : 34\n",
      "cosine similarity : 0.21175150573253632\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics>\n",
      "most similar doc title: <FEP-based screening prompts drug repositioning against COVID-19>\n",
      "target doc_id : 10\n",
      "most similar doc_id : 8\n",
      "cosine similarity : 0.33910518884658813\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs>\n",
      "most similar doc title: <Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production>\n",
      "target doc_id : 11\n",
      "most similar doc_id : 4\n",
      "cosine similarity : 0.29999828338623047\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication>\n",
      "most similar doc title: <Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets>\n",
      "target doc_id : 12\n",
      "most similar doc_id : 15\n",
      "cosine similarity : 0.3083761930465698\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Interferon-a2b treatment for COVID-19>\n",
      "most similar doc title: <Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates>\n",
      "target doc_id : 13\n",
      "most similar doc_id : 21\n",
      "cosine similarity : 0.2575069069862366\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Learning from the Past Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV>\n",
      "most similar doc title: <Network-based drug repurposing for novel coronavirus 2019-nCoVSARS-CoV-2>\n",
      "target doc_id : 14\n",
      "most similar doc_id : 17\n",
      "cosine similarity : 0.32422471046447754\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets>\n",
      "most similar doc title: <Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection>\n",
      "target doc_id : 15\n",
      "most similar doc_id : 27\n",
      "cosine similarity : 0.4006013572216034\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Molecular mechanism of action of repurposed drugs and traditional Chinese medicine used for the treatment of patients infected with COVID-19 A systematic review>\n",
      "most similar doc title: <FEP-based screening prompts drug repositioning against COVID-19>\n",
      "target doc_id : 16\n",
      "most similar doc_id : 8\n",
      "cosine similarity : 0.1362515091896057\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Network-based drug repurposing for novel coronavirus 2019-nCoVSARS-CoV-2>\n",
      "most similar doc title: <Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds>\n",
      "target doc_id : 17\n",
      "most similar doc_id : 22\n",
      "cosine similarity : 0.3780534267425537\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <New insights on the antiviral effects of chloroquine against coronavirus what to expect for COVID-19>\n",
      "most similar doc title: <Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds>\n",
      "target doc_id : 18\n",
      "most similar doc_id : 22\n",
      "cosine similarity : 0.2737148404121399\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Potentially highly potent drugs for 2019-nCoV>\n",
      "most similar doc title: <Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds>\n",
      "target doc_id : 19\n",
      "most similar doc_id : 22\n",
      "cosine similarity : 0.338845431804657\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model>\n",
      "most similar doc title: <Network-based drug repurposing for novel coronavirus 2019-nCoVSARS-CoV-2>\n",
      "target doc_id : 20\n",
      "most similar doc_id : 17\n",
      "cosine similarity : 0.273483544588089\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates>\n",
      "most similar doc title: <Structure of Mpro from COVID-19 virus and discovery of its inhibitors>\n",
      "target doc_id : 21\n",
      "most similar doc_id : 28\n",
      "cosine similarity : 0.258101224899292\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds>\n",
      "most similar doc title: <Network-based drug repurposing for novel coronavirus 2019-nCoVSARS-CoV-2>\n",
      "target doc_id : 22\n",
      "most similar doc_id : 17\n",
      "cosine similarity : 0.3780534267425537\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model>\n",
      "most similar doc title: <Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19>\n",
      "target doc_id : 23\n",
      "most similar doc_id : 26\n",
      "cosine similarity : 0.3435259461402893\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Repurposing Therapeutics for COVID-19Rapid Prediction of Commercially available drugs through Machine Learning and Docking>\n",
      "most similar doc title: <Learning from the Past Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV>\n",
      "target doc_id : 24\n",
      "most similar doc_id : 14\n",
      "cosine similarity : 0.2834733724594116\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases>\n",
      "most similar doc title: <AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2>\n",
      "target doc_id : 25\n",
      "most similar doc_id : 2\n",
      "cosine similarity : 0.3176860809326172\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19>\n",
      "most similar doc title: <Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds>\n",
      "target doc_id : 26\n",
      "most similar doc_id : 22\n",
      "cosine similarity : 0.34641459584236145\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection>\n",
      "most similar doc title: <Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets>\n",
      "target doc_id : 27\n",
      "most similar doc_id : 15\n",
      "cosine similarity : 0.4006013572216034\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Structure of Mpro from COVID-19 virus and discovery of its inhibitors>\n",
      "most similar doc title: <AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2>\n",
      "target doc_id : 28\n",
      "most similar doc_id : 2\n",
      "cosine similarity : 0.3280940651893616\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Targeted Oxidation Strategy (TOS) for Potential Inhibition of Coronaviruses by Disulfiram - a 70-Year Old Anti-Alcoholism Drug>\n",
      "most similar doc title: <AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2>\n",
      "target doc_id : 29\n",
      "most similar doc_id : 2\n",
      "cosine similarity : 0.40056055784225464\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Teicoplanin an alternative drug for the treatment of COVID-19>\n",
      "most similar doc title: <Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases>\n",
      "target doc_id : 30\n",
      "most similar doc_id : 25\n",
      "cosine similarity : 0.24158944189548492\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1>\n",
      "most similar doc title: <AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2>\n",
      "target doc_id : 31\n",
      "most similar doc_id : 2\n",
      "cosine similarity : 0.36510059237480164\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Therapeutic options for the 2019 novel coronavirus (2019-nCoV)>\n",
      "most similar doc title: <Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection>\n",
      "target doc_id : 32\n",
      "most similar doc_id : 27\n",
      "cosine similarity : 0.28507745265960693\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)>\n",
      "most similar doc title: <Network-based drug repurposing for novel coronavirus 2019-nCoVSARS-CoV-2>\n",
      "target doc_id : 33\n",
      "most similar doc_id : 17\n",
      "cosine similarity : 0.292868435382843\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n",
      "target doc title : <Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity - opportunity for repurposed chemotherapy of COVID-19 infection>\n",
      "most similar doc title: <Convalescent plasmaA possible treatment of COVID-19 in India>\n",
      "target doc_id : 34\n",
      "most similar doc_id : 6\n",
      "cosine similarity : 0.3137894868850708\n",
      "\n",
      "----------------------------------------------------------------------------------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for x in range(34):\n",
    "    \n",
    "    print('target doc title : <{}>'.format(title_list[x]))\n",
    "    print('most similar doc title: <{}>'.format(title_list[similar_list[x]-1]))\n",
    "    \n",
    "#     print('<{}>is most similar to <{}>'.format(x, title_list[similar_list[k]-1]))\n",
    "    print('target doc_id :', x+1)\n",
    "    print('most similar doc_id :', similar_list[x])\n",
    "    print('cosine similarity :', cos_df[x+1].sort_values(ascending=False).values[1])\n",
    "#     print(x+1, similar_list[x], cos_df[x+1].sort_values(ascending=False).values[1])\n",
    "    print()\n",
    "    print('-'*100)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "cos_df['most_similar'] = similar_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>10</th>\n",
       "      <th>...</th>\n",
       "      <th>26</th>\n",
       "      <th>27</th>\n",
       "      <th>28</th>\n",
       "      <th>29</th>\n",
       "      <th>30</th>\n",
       "      <th>31</th>\n",
       "      <th>32</th>\n",
       "      <th>33</th>\n",
       "      <th>34</th>\n",
       "      <th>most_similar</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.231297</td>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.058290</td>\n",
       "      <td>-0.019313</td>\n",
       "      <td>0.055071</td>\n",
       "      <td>0.298865</td>\n",
       "      <td>0.081741</td>\n",
       "      <td>0.050880</td>\n",
       "      <td>0.121065</td>\n",
       "      <td>...</td>\n",
       "      <td>0.163235</td>\n",
       "      <td>0.158082</td>\n",
       "      <td>0.181133</td>\n",
       "      <td>0.288083</td>\n",
       "      <td>0.092794</td>\n",
       "      <td>0.185628</td>\n",
       "      <td>0.144161</td>\n",
       "      <td>0.005380</td>\n",
       "      <td>0.145754</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.231297</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>0.168359</td>\n",
       "      <td>0.302533</td>\n",
       "      <td>0.283711</td>\n",
       "      <td>0.167143</td>\n",
       "      <td>0.113720</td>\n",
       "      <td>...</td>\n",
       "      <td>0.249315</td>\n",
       "      <td>0.244756</td>\n",
       "      <td>0.328094</td>\n",
       "      <td>0.400561</td>\n",
       "      <td>0.103856</td>\n",
       "      <td>0.365101</td>\n",
       "      <td>0.219111</td>\n",
       "      <td>0.140468</td>\n",
       "      <td>0.268175</td>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.076830</td>\n",
       "      <td>-0.064591</td>\n",
       "      <td>0.254749</td>\n",
       "      <td>0.190225</td>\n",
       "      <td>0.172798</td>\n",
       "      <td>...</td>\n",
       "      <td>0.146782</td>\n",
       "      <td>-0.029606</td>\n",
       "      <td>0.163706</td>\n",
       "      <td>0.072575</td>\n",
       "      <td>0.043145</td>\n",
       "      <td>0.234544</td>\n",
       "      <td>-0.039937</td>\n",
       "      <td>0.059261</td>\n",
       "      <td>0.265866</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.058290</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>0.161103</td>\n",
       "      <td>0.084728</td>\n",
       "      <td>0.259842</td>\n",
       "      <td>0.014458</td>\n",
       "      <td>0.086001</td>\n",
       "      <td>...</td>\n",
       "      <td>0.239550</td>\n",
       "      <td>0.215339</td>\n",
       "      <td>0.134585</td>\n",
       "      <td>0.205383</td>\n",
       "      <td>0.094626</td>\n",
       "      <td>0.159678</td>\n",
       "      <td>0.144439</td>\n",
       "      <td>0.054221</td>\n",
       "      <td>0.203177</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>-0.019313</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.016522</td>\n",
       "      <td>0.046765</td>\n",
       "      <td>-0.015356</td>\n",
       "      <td>0.004066</td>\n",
       "      <td>0.048524</td>\n",
       "      <td>...</td>\n",
       "      <td>-0.008325</td>\n",
       "      <td>0.069442</td>\n",
       "      <td>-0.056780</td>\n",
       "      <td>-0.029405</td>\n",
       "      <td>-0.172705</td>\n",
       "      <td>-0.066141</td>\n",
       "      <td>-0.066380</td>\n",
       "      <td>0.102173</td>\n",
       "      <td>-0.045759</td>\n",
       "      <td>33</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          1         2         3         4         5         6         7  \\\n",
       "1  1.000000  0.231297  0.065869  0.058290 -0.019313  0.055071  0.298865   \n",
       "2  0.231297  1.000000  0.164515  0.273920 -0.163867  0.168359  0.302533   \n",
       "3  0.065869  0.164515  1.000000  0.030626 -0.127232  0.076830 -0.064591   \n",
       "4  0.058290  0.273920  0.030626  1.000000  0.028030  0.161103  0.084728   \n",
       "5 -0.019313 -0.163867 -0.127232  0.028030  1.000000 -0.016522  0.046765   \n",
       "\n",
       "          8         9        10      ...             26        27        28  \\\n",
       "1  0.081741  0.050880  0.121065      ...       0.163235  0.158082  0.181133   \n",
       "2  0.283711  0.167143  0.113720      ...       0.249315  0.244756  0.328094   \n",
       "3  0.254749  0.190225  0.172798      ...       0.146782 -0.029606  0.163706   \n",
       "4  0.259842  0.014458  0.086001      ...       0.239550  0.215339  0.134585   \n",
       "5 -0.015356  0.004066  0.048524      ...      -0.008325  0.069442 -0.056780   \n",
       "\n",
       "         29        30        31        32        33        34  most_similar  \n",
       "1  0.288083  0.092794  0.185628  0.144161  0.005380  0.145754             7  \n",
       "2  0.400561  0.103856  0.365101  0.219111  0.140468  0.268175            29  \n",
       "3  0.072575  0.043145  0.234544 -0.039937  0.059261  0.265866            14  \n",
       "4  0.205383  0.094626  0.159678  0.144439  0.054221  0.203177            11  \n",
       "5 -0.029405 -0.172705 -0.066141 -0.066380  0.102173 -0.045759            33  \n",
       "\n",
       "[5 rows x 35 columns]"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cos_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "cos_df.to_excel('./34_paper_cos_sim_updated.xlsx')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "from sklearn.decomposition import PCA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "pca = PCA(n_components = 2)\n",
    "principalComponents = pca.fit_transform(doc2vec_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "principalDf = pd.DataFrame(data = principalComponents\n",
    "             , columns = ['principal component 1', 'principal component 2'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "labels = list(range(1,35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PathCollection at 0x20af66058c8>"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.scatter(principalDf['principal component 1'], principalDf['principal component 2'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>covid-19</th>\n",
       "      <th>sars-cov-2</th>\n",
       "      <th>patients</th>\n",
       "      <th>coronavirus</th>\n",
       "      <th>drugs</th>\n",
       "      <th>treatment</th>\n",
       "      <th>disease</th>\n",
       "      <th>clinical</th>\n",
       "      <th>infection</th>\n",
       "      <th>virus</th>\n",
       "      <th>...</th>\n",
       "      <th>bacterial</th>\n",
       "      <th>3c-like</th>\n",
       "      <th>synthetic</th>\n",
       "      <th>ascorbic</th>\n",
       "      <th>assays</th>\n",
       "      <th>turn</th>\n",
       "      <th>populations</th>\n",
       "      <th>science</th>\n",
       "      <th>room</th>\n",
       "      <th>hypothesize</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2.401706</td>\n",
       "      <td>14.561701</td>\n",
       "      <td>3.688964</td>\n",
       "      <td>-0.782663</td>\n",
       "      <td>1.104560</td>\n",
       "      <td>2.309333</td>\n",
       "      <td>2.067841</td>\n",
       "      <td>1.212492</td>\n",
       "      <td>0.955295</td>\n",
       "      <td>-2.550903</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.207269</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>3.160901</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>0.388089</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.636259</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>-0.318863</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3.879679</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.550763</td>\n",
       "      <td>0.298530</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>-1.101526</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.774606</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1.108480</td>\n",
       "      <td>8.348709</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>0.738987</td>\n",
       "      <td>1.431582</td>\n",
       "      <td>1.091243</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>-0.811651</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.165815</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.954332</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>4.156799</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>6.795461</td>\n",
       "      <td>-1.565327</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>4.895786</td>\n",
       "      <td>2.385970</td>\n",
       "      <td>6.183711</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>-2.116090</td>\n",
       "      <td>...</td>\n",
       "      <td>2.447551</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.833213</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.781733</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>1.939840</td>\n",
       "      <td>1.164936</td>\n",
       "      <td>1.164936</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>0.831360</td>\n",
       "      <td>0.954388</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.781733</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>0.184747</td>\n",
       "      <td>3.106496</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>0.447794</td>\n",
       "      <td>0.461867</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.328383</td>\n",
       "      <td>-0.347850</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.124362</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>1.939840</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>-0.057975</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.848745</td>\n",
       "      <td>0.208971</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.774606</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2.309333</td>\n",
       "      <td>3.300652</td>\n",
       "      <td>15.726637</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>6.004266</td>\n",
       "      <td>1.590647</td>\n",
       "      <td>1.273117</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>-0.637726</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>9.125333</td>\n",
       "      <td>1.941560</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>1.462795</td>\n",
       "      <td>1.570346</td>\n",
       "      <td>1.908776</td>\n",
       "      <td>2.667483</td>\n",
       "      <td>2.298678</td>\n",
       "      <td>-3.826355</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>6.248723</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.736064</td>\n",
       "      <td>4.741351</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>2.718184</td>\n",
       "      <td>0.776624</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.447794</td>\n",
       "      <td>0.184747</td>\n",
       "      <td>0.636259</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.328383</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>0.184747</td>\n",
       "      <td>3.106496</td>\n",
       "      <td>0.970780</td>\n",
       "      <td>-0.289875</td>\n",
       "      <td>0.835883</td>\n",
       "      <td>5.080533</td>\n",
       "      <td>2.067841</td>\n",
       "      <td>0.606246</td>\n",
       "      <td>0.806030</td>\n",
       "      <td>-1.855202</td>\n",
       "      <td>...</td>\n",
       "      <td>28.146835</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>29.960926</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>1.385600</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>4.077276</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.787306</td>\n",
       "      <td>3.817553</td>\n",
       "      <td>0.909369</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>-0.318863</td>\n",
       "      <td>...</td>\n",
       "      <td>1.223775</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>6.420198</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.970780</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>-0.927601</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.260888</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.795323</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.898614</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>7.112746</td>\n",
       "      <td>5.436368</td>\n",
       "      <td>7.766241</td>\n",
       "      <td>-0.289875</td>\n",
       "      <td>0.895589</td>\n",
       "      <td>6.189012</td>\n",
       "      <td>5.249135</td>\n",
       "      <td>2.182486</td>\n",
       "      <td>0.716471</td>\n",
       "      <td>-1.855202</td>\n",
       "      <td>...</td>\n",
       "      <td>1.223775</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.280132</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>0.092373</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>1.553248</td>\n",
       "      <td>-0.376838</td>\n",
       "      <td>1.731472</td>\n",
       "      <td>1.847466</td>\n",
       "      <td>2.385970</td>\n",
       "      <td>1.030619</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>-1.855202</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>6.248723</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>3.494808</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>-0.840639</td>\n",
       "      <td>0.119412</td>\n",
       "      <td>0.831360</td>\n",
       "      <td>0.954388</td>\n",
       "      <td>0.363748</td>\n",
       "      <td>0.298530</td>\n",
       "      <td>-2.145078</td>\n",
       "      <td>...</td>\n",
       "      <td>1.223775</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.086963</td>\n",
       "      <td>0.806030</td>\n",
       "      <td>0.554240</td>\n",
       "      <td>0.318129</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>-0.173925</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.160901</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.289875</td>\n",
       "      <td>0.417941</td>\n",
       "      <td>0.092373</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>-0.318863</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.469202</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>4.077276</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.231900</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>0.554240</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.545622</td>\n",
       "      <td>0.119412</td>\n",
       "      <td>-0.405826</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>2.524028</td>\n",
       "      <td>1.164936</td>\n",
       "      <td>-0.057975</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>0.184747</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.303123</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>-0.115950</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.927601</td>\n",
       "      <td>0.597059</td>\n",
       "      <td>1.108480</td>\n",
       "      <td>0.159065</td>\n",
       "      <td>0.242498</td>\n",
       "      <td>0.746324</td>\n",
       "      <td>-1.362414</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.124362</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.345198</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>0.554240</td>\n",
       "      <td>1.747404</td>\n",
       "      <td>0.582468</td>\n",
       "      <td>-0.608738</td>\n",
       "      <td>1.253824</td>\n",
       "      <td>0.646613</td>\n",
       "      <td>0.795323</td>\n",
       "      <td>0.181874</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>-0.898614</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.203803</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>1.477973</td>\n",
       "      <td>1.553248</td>\n",
       "      <td>0.970780</td>\n",
       "      <td>-1.565327</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>0.646613</td>\n",
       "      <td>1.908776</td>\n",
       "      <td>0.545622</td>\n",
       "      <td>0.358236</td>\n",
       "      <td>-2.145078</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.954332</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>3.883120</td>\n",
       "      <td>0.776624</td>\n",
       "      <td>-0.260888</td>\n",
       "      <td>1.552354</td>\n",
       "      <td>1.108480</td>\n",
       "      <td>4.294747</td>\n",
       "      <td>0.545622</td>\n",
       "      <td>1.343383</td>\n",
       "      <td>-0.927601</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>2.140066</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>0.277120</td>\n",
       "      <td>5.630524</td>\n",
       "      <td>0.388312</td>\n",
       "      <td>-0.347850</td>\n",
       "      <td>0.268677</td>\n",
       "      <td>0.184747</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.242498</td>\n",
       "      <td>0.149265</td>\n",
       "      <td>-0.637726</td>\n",
       "      <td>...</td>\n",
       "      <td>1.223775</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>2.216960</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>0.369493</td>\n",
       "      <td>0.795323</td>\n",
       "      <td>0.848745</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>-0.869626</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.082908</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>4.299529</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.028988</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.144938</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.461867</td>\n",
       "      <td>1.553248</td>\n",
       "      <td>0.388312</td>\n",
       "      <td>-0.202913</td>\n",
       "      <td>0.029853</td>\n",
       "      <td>0.646613</td>\n",
       "      <td>0.954388</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>-0.492788</td>\n",
       "      <td>...</td>\n",
       "      <td>2.447551</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>0.092373</td>\n",
       "      <td>7.183773</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>-0.173925</td>\n",
       "      <td>0.119412</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.060625</td>\n",
       "      <td>0.059706</td>\n",
       "      <td>-0.231900</td>\n",
       "      <td>...</td>\n",
       "      <td>1.223775</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>2.661910</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.390866</td>\n",
       "      <td>1.580450</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>0.092373</td>\n",
       "      <td>0.194156</td>\n",
       "      <td>1.359092</td>\n",
       "      <td>-0.463801</td>\n",
       "      <td>0.089559</td>\n",
       "      <td>0.738987</td>\n",
       "      <td>0.318129</td>\n",
       "      <td>0.666871</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>-0.811651</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.172599</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>4.618666</td>\n",
       "      <td>2.135716</td>\n",
       "      <td>4.077276</td>\n",
       "      <td>-0.463801</td>\n",
       "      <td>0.179118</td>\n",
       "      <td>1.016107</td>\n",
       "      <td>1.908776</td>\n",
       "      <td>0.484997</td>\n",
       "      <td>0.238824</td>\n",
       "      <td>-0.521776</td>\n",
       "      <td>...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.887303</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.580450</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>0.831360</td>\n",
       "      <td>11.843517</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>-0.231900</td>\n",
       "      <td>0.477647</td>\n",
       "      <td>0.923733</td>\n",
       "      <td>1.272518</td>\n",
       "      <td>0.484997</td>\n",
       "      <td>0.208971</td>\n",
       "      <td>-1.043551</td>\n",
       "      <td>...</td>\n",
       "      <td>1.223775</td>\n",
       "      <td>1.734601</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.041454</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>3.517797</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>34 rows × 1374 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    covid-19  sars-cov-2   patients  coronavirus     drugs  treatment  \\\n",
       "1   2.401706   14.561701   3.688964    -0.782663  1.104560   2.309333   \n",
       "2   0.461867    7.183773   0.194156    -0.115950  0.388089   0.369493   \n",
       "3   3.879679    0.000000   0.000000    -0.550763  0.298530   0.000000   \n",
       "4   1.108480    8.348709   1.359092    -0.028988  0.268677   0.738987   \n",
       "5   4.156799    2.135716   6.795461    -1.565327  0.238824   4.895786   \n",
       "6   1.939840    1.164936   1.164936    -0.202913  0.149265   0.831360   \n",
       "7   0.184747    3.106496   0.194156    -0.115950  0.447794   0.461867   \n",
       "8   1.939840    0.194156   1.359092    -0.057975  0.238824   0.369493   \n",
       "9   2.309333    3.300652  15.726637    -0.376838  0.179118   6.004266   \n",
       "10  0.554240    9.125333   1.941560    -0.202913  1.462795   1.570346   \n",
       "11  0.554240    2.718184   0.776624    -0.028988  0.447794   0.184747   \n",
       "12  0.184747    3.106496   0.970780    -0.289875  0.835883   5.080533   \n",
       "13  1.385600    2.135716   4.077276    -0.202913  0.000000   3.787306   \n",
       "14  0.000000    0.000000   0.970780    -0.376838  0.029853   0.369493   \n",
       "15  0.277120    1.359092   0.000000    -0.260888  0.059706   0.000000   \n",
       "16  7.112746    5.436368   7.766241    -0.289875  0.895589   6.189012   \n",
       "17  0.092373    7.183773   1.553248    -0.376838  1.731472   1.847466   \n",
       "18  0.554240    3.494808   1.359092    -0.840639  0.119412   0.831360   \n",
       "19  0.000000    0.000000   0.194156    -0.086963  0.806030   0.554240   \n",
       "20  0.000000    0.000000   0.000000    -0.289875  0.417941   0.092373   \n",
       "21  0.277120    4.077276   0.194156    -0.231900  0.477647   0.554240   \n",
       "22  0.554240    2.524028   1.164936    -0.057975  0.059706   0.184747   \n",
       "23  0.277120    0.000000   0.000000    -0.927601  0.597059   1.108480   \n",
       "24  0.554240    1.747404   0.582468    -0.608738  1.253824   0.646613   \n",
       "25  1.477973    1.553248   0.970780    -1.565327  0.179118   0.646613   \n",
       "26  0.461867    3.883120   0.776624    -0.260888  1.552354   1.108480   \n",
       "27  0.277120    5.630524   0.388312    -0.347850  0.268677   0.184747   \n",
       "28  2.216960    0.000000   0.000000    -0.028988  0.238824   0.369493   \n",
       "29  0.000000    0.000000   0.000000    -0.028988  0.000000   0.000000   \n",
       "30  0.461867    1.553248   0.388312    -0.202913  0.029853   0.646613   \n",
       "31  0.092373    7.183773   0.194156    -0.173925  0.119412   0.000000   \n",
       "32  0.092373    0.194156   1.359092    -0.463801  0.089559   0.738987   \n",
       "33  4.618666    2.135716   4.077276    -0.463801  0.179118   1.016107   \n",
       "34  0.831360   11.843517   0.000000    -0.231900  0.477647   0.923733   \n",
       "\n",
       "     disease  clinical  infection     virus     ...       bacterial   3c-like  \\\n",
       "1   2.067841  1.212492   0.955295 -2.550903     ...        0.000000  0.000000   \n",
       "2   0.636259  0.060625   0.089559 -0.318863     ...        0.000000  1.734601   \n",
       "3   0.000000  0.181874   0.149265 -1.101526     ...        0.000000  0.000000   \n",
       "4   1.431582  1.091243   0.477647 -0.811651     ...        0.000000  0.000000   \n",
       "5   2.385970  6.183711   0.746324 -2.116090     ...        2.447551  0.000000   \n",
       "6   0.954388  0.181874   0.268677 -0.376838     ...        0.000000  0.000000   \n",
       "7   0.159065  0.000000   0.328383 -0.347850     ...        0.000000  0.000000   \n",
       "8   0.000000  0.848745   0.208971 -0.202913     ...        0.000000  0.000000   \n",
       "9   1.590647  1.273117   0.179118 -0.637726     ...        0.000000  0.000000   \n",
       "10  1.908776  2.667483   2.298678 -3.826355     ...        0.000000  0.000000   \n",
       "11  0.636259  0.181874   0.328383 -0.115950     ...        0.000000  0.000000   \n",
       "12  2.067841  0.606246   0.806030 -1.855202     ...       28.146835  0.000000   \n",
       "13  3.817553  0.909369   0.179118 -0.318863     ...        1.223775  0.000000   \n",
       "14  0.000000  0.060625   0.149265 -0.927601     ...        0.000000  0.000000   \n",
       "15  0.795323  0.000000   0.000000 -0.898614     ...        0.000000  0.000000   \n",
       "16  5.249135  2.182486   0.716471 -1.855202     ...        1.223775  0.000000   \n",
       "17  2.385970  1.030619   0.746324 -1.855202     ...        0.000000  0.000000   \n",
       "18  0.954388  0.363748   0.298530 -2.145078     ...        1.223775  0.000000   \n",
       "19  0.318129  0.060625   0.059706 -0.173925     ...        0.000000  0.000000   \n",
       "20  0.159065  0.060625   0.089559 -0.318863     ...        0.000000  3.469202   \n",
       "21  0.159065  0.545622   0.119412 -0.405826     ...        0.000000  0.000000   \n",
       "22  0.159065  0.303123   0.029853 -0.115950     ...        0.000000  0.000000   \n",
       "23  0.159065  0.242498   0.746324 -1.362414     ...        0.000000  0.000000   \n",
       "24  0.795323  0.181874   0.029853 -0.898614     ...        0.000000  5.203803   \n",
       "25  1.908776  0.545622   0.358236 -2.145078     ...        0.000000  0.000000   \n",
       "26  4.294747  0.545622   1.343383 -0.927601     ...        0.000000  0.000000   \n",
       "27  0.000000  0.242498   0.149265 -0.637726     ...        1.223775  0.000000   \n",
       "28  0.795323  0.848745   0.059706 -0.869626     ...        0.000000  1.734601   \n",
       "29  0.000000  0.000000   0.000000 -0.144938     ...        0.000000  0.000000   \n",
       "30  0.954388  0.060625   0.238824 -0.492788     ...        2.447551  0.000000   \n",
       "31  0.000000  0.060625   0.059706 -0.231900     ...        1.223775  0.000000   \n",
       "32  0.318129  0.666871   0.238824 -0.811651     ...        0.000000  0.000000   \n",
       "33  1.908776  0.484997   0.238824 -0.521776     ...        0.000000  0.000000   \n",
       "34  1.272518  0.484997   0.208971 -1.043551     ...        1.223775  1.734601   \n",
       "\n",
       "    synthetic  ascorbic    assays      turn  populations   science      room  \\\n",
       "1    0.000000  0.000000  5.207269  0.000000     0.000000  2.345198  3.160901   \n",
       "2    2.140066  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "3    0.000000  0.000000  0.000000  1.774606     0.000000  1.172599  0.000000   \n",
       "4    0.000000  0.000000  4.165815  0.000000     0.000000  1.954332  1.580450   \n",
       "5    0.000000  2.833213  0.000000  0.000000     0.000000  0.781733  0.000000   \n",
       "6    0.000000  0.000000  0.000000  0.000000     0.000000  0.781733  0.000000   \n",
       "7    0.000000  0.000000  3.124362  0.000000     0.000000  0.000000  0.000000   \n",
       "8    0.000000  0.000000  0.000000  1.774606     0.000000  1.172599  0.000000   \n",
       "9    0.000000  0.000000  0.000000  0.887303     0.000000  1.172599  0.000000   \n",
       "10   0.000000  0.000000  6.248723  0.000000     0.000000  2.736064  4.741351   \n",
       "11   0.000000  0.000000  1.041454  0.000000     0.000000  0.390866  0.000000   \n",
       "12  29.960926  0.000000  1.041454  0.887303     2.140066  0.000000  0.000000   \n",
       "13   0.000000  0.000000  1.041454  0.887303     6.420198  0.390866  0.000000   \n",
       "14   0.000000  0.000000  0.000000  0.000000     0.000000  0.390866  1.580450   \n",
       "15   0.000000  0.000000  0.000000  0.887303     0.000000  0.390866  0.000000   \n",
       "16   4.280132  0.000000  0.000000  0.000000     0.000000  2.345198  0.000000   \n",
       "17   0.000000  0.000000  6.248723  0.000000     0.000000  0.000000  0.000000   \n",
       "18   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "19   0.000000  0.000000  0.000000  0.887303     0.000000  0.000000  0.000000   \n",
       "20   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "21   0.000000  0.000000  0.000000  0.887303     0.000000  0.390866  0.000000   \n",
       "22   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "23   0.000000  0.000000  3.124362  0.887303     0.000000  2.345198  1.580450   \n",
       "24   0.000000  0.000000  0.000000  0.000000     0.000000  0.390866  0.000000   \n",
       "25   0.000000  0.000000  0.000000  0.887303     0.000000  1.954332  0.000000   \n",
       "26   0.000000  0.000000  0.000000  0.887303     2.140066  0.390866  0.000000   \n",
       "27   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "28   0.000000  0.000000  2.082908  0.000000     0.000000  4.299529  0.000000   \n",
       "29   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "30   0.000000  0.000000  0.000000  0.000000     0.000000  0.000000  0.000000   \n",
       "31   0.000000  0.000000  0.000000  2.661910     0.000000  0.390866  1.580450   \n",
       "32   0.000000  0.000000  0.000000  0.000000     0.000000  1.172599  0.000000   \n",
       "33   0.000000  0.000000  0.000000  0.887303     0.000000  0.000000  0.000000   \n",
       "34   0.000000  0.000000  1.041454  0.000000     0.000000  3.517797  0.000000   \n",
       "\n",
       "    hypothesize  \n",
       "1      0.000000  \n",
       "2      0.000000  \n",
       "3      0.000000  \n",
       "4      0.000000  \n",
       "5      0.000000  \n",
       "6      0.000000  \n",
       "7      0.000000  \n",
       "8      0.000000  \n",
       "9      0.000000  \n",
       "10     0.000000  \n",
       "11     0.000000  \n",
       "12     0.000000  \n",
       "13     0.000000  \n",
       "14     0.000000  \n",
       "15     0.000000  \n",
       "16     1.580450  \n",
       "17     0.000000  \n",
       "18     0.000000  \n",
       "19     3.160901  \n",
       "20     0.000000  \n",
       "21     0.000000  \n",
       "22     0.000000  \n",
       "23     0.000000  \n",
       "24     1.580450  \n",
       "25     0.000000  \n",
       "26     0.000000  \n",
       "27     1.580450  \n",
       "28     0.000000  \n",
       "29     0.000000  \n",
       "30     0.000000  \n",
       "31     0.000000  \n",
       "32     1.580450  \n",
       "33     1.580450  \n",
       "34     0.000000  \n",
       "\n",
       "[34 rows x 1374 columns]"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tfidf_"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [],
   "source": [
    "tfidf_.to_excel('./tfidf테이블.xlsx', encoding='utf-8-sig')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>10</th>\n",
       "      <th>...</th>\n",
       "      <th>26</th>\n",
       "      <th>27</th>\n",
       "      <th>28</th>\n",
       "      <th>29</th>\n",
       "      <th>30</th>\n",
       "      <th>31</th>\n",
       "      <th>32</th>\n",
       "      <th>33</th>\n",
       "      <th>34</th>\n",
       "      <th>most_similar</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.231297</td>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.058290</td>\n",
       "      <td>-0.019313</td>\n",
       "      <td>0.055071</td>\n",
       "      <td>0.298865</td>\n",
       "      <td>0.081741</td>\n",
       "      <td>0.050880</td>\n",
       "      <td>0.121065</td>\n",
       "      <td>...</td>\n",
       "      <td>0.163235</td>\n",
       "      <td>0.158082</td>\n",
       "      <td>0.181133</td>\n",
       "      <td>0.288083</td>\n",
       "      <td>0.092794</td>\n",
       "      <td>0.185628</td>\n",
       "      <td>0.144161</td>\n",
       "      <td>0.005380</td>\n",
       "      <td>0.145754</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.231297</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>0.168359</td>\n",
       "      <td>0.302533</td>\n",
       "      <td>0.283711</td>\n",
       "      <td>0.167143</td>\n",
       "      <td>0.113720</td>\n",
       "      <td>...</td>\n",
       "      <td>0.249315</td>\n",
       "      <td>0.244756</td>\n",
       "      <td>0.328094</td>\n",
       "      <td>0.400561</td>\n",
       "      <td>0.103856</td>\n",
       "      <td>0.365101</td>\n",
       "      <td>0.219111</td>\n",
       "      <td>0.140468</td>\n",
       "      <td>0.268175</td>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.065869</td>\n",
       "      <td>0.164515</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.076830</td>\n",
       "      <td>-0.064591</td>\n",
       "      <td>0.254749</td>\n",
       "      <td>0.190225</td>\n",
       "      <td>0.172798</td>\n",
       "      <td>...</td>\n",
       "      <td>0.146782</td>\n",
       "      <td>-0.029606</td>\n",
       "      <td>0.163706</td>\n",
       "      <td>0.072575</td>\n",
       "      <td>0.043145</td>\n",
       "      <td>0.234544</td>\n",
       "      <td>-0.039937</td>\n",
       "      <td>0.059261</td>\n",
       "      <td>0.265866</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.058290</td>\n",
       "      <td>0.273920</td>\n",
       "      <td>0.030626</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>0.161103</td>\n",
       "      <td>0.084728</td>\n",
       "      <td>0.259842</td>\n",
       "      <td>0.014458</td>\n",
       "      <td>0.086001</td>\n",
       "      <td>...</td>\n",
       "      <td>0.239550</td>\n",
       "      <td>0.215339</td>\n",
       "      <td>0.134585</td>\n",
       "      <td>0.205383</td>\n",
       "      <td>0.094626</td>\n",
       "      <td>0.159678</td>\n",
       "      <td>0.144439</td>\n",
       "      <td>0.054221</td>\n",
       "      <td>0.203177</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>-0.019313</td>\n",
       "      <td>-0.163867</td>\n",
       "      <td>-0.127232</td>\n",
       "      <td>0.028030</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.016522</td>\n",
       "      <td>0.046765</td>\n",
       "      <td>-0.015356</td>\n",
       "      <td>0.004066</td>\n",
       "      <td>0.048524</td>\n",
       "      <td>...</td>\n",
       "      <td>-0.008325</td>\n",
       "      <td>0.069442</td>\n",
       "      <td>-0.056780</td>\n",
       "      <td>-0.029405</td>\n",
       "      <td>-0.172705</td>\n",
       "      <td>-0.066141</td>\n",
       "      <td>-0.066380</td>\n",
       "      <td>0.102173</td>\n",
       "      <td>-0.045759</td>\n",
       "      <td>33</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.055071</td>\n",
       "      <td>0.168359</td>\n",
       "      <td>0.076830</td>\n",
       "      <td>0.161103</td>\n",
       "      <td>-0.016522</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.075521</td>\n",
       "      <td>0.142143</td>\n",
       "      <td>0.193062</td>\n",
       "      <td>0.072850</td>\n",
       "      <td>...</td>\n",
       "      <td>0.102159</td>\n",
       "      <td>0.192513</td>\n",
       "      <td>0.093202</td>\n",
       "      <td>0.119560</td>\n",
       "      <td>0.151886</td>\n",
       "      <td>0.035962</td>\n",
       "      <td>0.100289</td>\n",
       "      <td>-0.010641</td>\n",
       "      <td>0.313789</td>\n",
       "      <td>34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>0.298865</td>\n",
       "      <td>0.302533</td>\n",
       "      <td>-0.064591</td>\n",
       "      <td>0.084728</td>\n",
       "      <td>0.046765</td>\n",
       "      <td>0.075521</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.176210</td>\n",
       "      <td>0.048967</td>\n",
       "      <td>0.128083</td>\n",
       "      <td>...</td>\n",
       "      <td>0.214904</td>\n",
       "      <td>0.158772</td>\n",
       "      <td>0.125200</td>\n",
       "      <td>0.233753</td>\n",
       "      <td>-0.007819</td>\n",
       "      <td>0.168046</td>\n",
       "      <td>0.221606</td>\n",
       "      <td>0.005159</td>\n",
       "      <td>0.046504</td>\n",
       "      <td>22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>0.081741</td>\n",
       "      <td>0.283711</td>\n",
       "      <td>0.254749</td>\n",
       "      <td>0.259842</td>\n",
       "      <td>-0.015356</td>\n",
       "      <td>0.142143</td>\n",
       "      <td>0.176210</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.088855</td>\n",
       "      <td>0.339105</td>\n",
       "      <td>...</td>\n",
       "      <td>0.240244</td>\n",
       "      <td>0.207780</td>\n",
       "      <td>0.288166</td>\n",
       "      <td>0.283431</td>\n",
       "      <td>-0.005587</td>\n",
       "      <td>0.266753</td>\n",
       "      <td>0.154125</td>\n",
       "      <td>0.047907</td>\n",
       "      <td>0.196631</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>0.050880</td>\n",
       "      <td>0.167143</td>\n",
       "      <td>0.190225</td>\n",
       "      <td>0.014458</td>\n",
       "      <td>0.004066</td>\n",
       "      <td>0.193062</td>\n",
       "      <td>0.048967</td>\n",
       "      <td>0.088855</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.086335</td>\n",
       "      <td>...</td>\n",
       "      <td>0.103068</td>\n",
       "      <td>0.117690</td>\n",
       "      <td>0.141619</td>\n",
       "      <td>0.077829</td>\n",
       "      <td>-0.093685</td>\n",
       "      <td>0.193870</td>\n",
       "      <td>-0.063637</td>\n",
       "      <td>0.053103</td>\n",
       "      <td>0.211752</td>\n",
       "      <td>34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.121065</td>\n",
       "      <td>0.113720</td>\n",
       "      <td>0.172798</td>\n",
       "      <td>0.086001</td>\n",
       "      <td>0.048524</td>\n",
       "      <td>0.072850</td>\n",
       "      <td>0.128083</td>\n",
       "      <td>0.339105</td>\n",
       "      <td>-0.086335</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>...</td>\n",
       "      <td>0.210963</td>\n",
       "      <td>0.136911</td>\n",
       "      <td>0.261479</td>\n",
       "      <td>0.242289</td>\n",
       "      <td>-0.041338</td>\n",
       "      <td>0.201240</td>\n",
       "      <td>-0.001629</td>\n",
       "      <td>0.157727</td>\n",
       "      <td>0.074777</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>-0.017714</td>\n",
       "      <td>0.143385</td>\n",
       "      <td>0.154351</td>\n",
       "      <td>0.299998</td>\n",
       "      <td>0.052768</td>\n",
       "      <td>0.045258</td>\n",
       "      <td>-0.034573</td>\n",
       "      <td>0.200004</td>\n",
       "      <td>0.187460</td>\n",
       "      <td>0.139939</td>\n",
       "      <td>...</td>\n",
       "      <td>0.205511</td>\n",
       "      <td>0.128390</td>\n",
       "      <td>0.219803</td>\n",
       "      <td>0.166906</td>\n",
       "      <td>-0.009510</td>\n",
       "      <td>0.072732</td>\n",
       "      <td>0.053302</td>\n",
       "      <td>0.060894</td>\n",
       "      <td>0.224745</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>0.090746</td>\n",
       "      <td>0.272458</td>\n",
       "      <td>0.258385</td>\n",
       "      <td>0.242838</td>\n",
       "      <td>0.032546</td>\n",
       "      <td>0.048919</td>\n",
       "      <td>0.051618</td>\n",
       "      <td>0.257476</td>\n",
       "      <td>0.152552</td>\n",
       "      <td>0.192923</td>\n",
       "      <td>...</td>\n",
       "      <td>0.208951</td>\n",
       "      <td>0.215667</td>\n",
       "      <td>0.172584</td>\n",
       "      <td>0.158460</td>\n",
       "      <td>-0.022365</td>\n",
       "      <td>0.192056</td>\n",
       "      <td>0.017305</td>\n",
       "      <td>0.169414</td>\n",
       "      <td>0.117850</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>0.137045</td>\n",
       "      <td>0.158494</td>\n",
       "      <td>-0.001768</td>\n",
       "      <td>0.024502</td>\n",
       "      <td>-0.082011</td>\n",
       "      <td>0.151125</td>\n",
       "      <td>0.058614</td>\n",
       "      <td>0.028347</td>\n",
       "      <td>0.091298</td>\n",
       "      <td>0.104138</td>\n",
       "      <td>...</td>\n",
       "      <td>0.050050</td>\n",
       "      <td>0.027336</td>\n",
       "      <td>0.111930</td>\n",
       "      <td>0.055918</td>\n",
       "      <td>0.100567</td>\n",
       "      <td>0.001916</td>\n",
       "      <td>0.123836</td>\n",
       "      <td>-0.060468</td>\n",
       "      <td>0.252181</td>\n",
       "      <td>21</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>0.132741</td>\n",
       "      <td>0.234365</td>\n",
       "      <td>0.275718</td>\n",
       "      <td>0.100823</td>\n",
       "      <td>-0.025042</td>\n",
       "      <td>0.024520</td>\n",
       "      <td>0.266535</td>\n",
       "      <td>0.309100</td>\n",
       "      <td>0.133893</td>\n",
       "      <td>0.257692</td>\n",
       "      <td>...</td>\n",
       "      <td>0.264244</td>\n",
       "      <td>0.219171</td>\n",
       "      <td>0.183122</td>\n",
       "      <td>0.204197</td>\n",
       "      <td>-0.079143</td>\n",
       "      <td>0.198989</td>\n",
       "      <td>0.185249</td>\n",
       "      <td>0.059410</td>\n",
       "      <td>0.155889</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>0.270691</td>\n",
       "      <td>0.317535</td>\n",
       "      <td>0.181697</td>\n",
       "      <td>0.206648</td>\n",
       "      <td>-0.098275</td>\n",
       "      <td>0.194779</td>\n",
       "      <td>0.236407</td>\n",
       "      <td>0.303881</td>\n",
       "      <td>0.167131</td>\n",
       "      <td>0.268551</td>\n",
       "      <td>...</td>\n",
       "      <td>0.289369</td>\n",
       "      <td>0.400601</td>\n",
       "      <td>0.292267</td>\n",
       "      <td>0.395746</td>\n",
       "      <td>0.100289</td>\n",
       "      <td>0.225039</td>\n",
       "      <td>0.260701</td>\n",
       "      <td>0.125557</td>\n",
       "      <td>0.269022</td>\n",
       "      <td>27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>-0.045149</td>\n",
       "      <td>-0.007777</td>\n",
       "      <td>-0.047224</td>\n",
       "      <td>0.020141</td>\n",
       "      <td>0.010517</td>\n",
       "      <td>0.132037</td>\n",
       "      <td>0.113191</td>\n",
       "      <td>0.136252</td>\n",
       "      <td>0.040168</td>\n",
       "      <td>-0.018488</td>\n",
       "      <td>...</td>\n",
       "      <td>0.051846</td>\n",
       "      <td>-0.025101</td>\n",
       "      <td>0.055884</td>\n",
       "      <td>0.000392</td>\n",
       "      <td>-0.035567</td>\n",
       "      <td>0.048703</td>\n",
       "      <td>0.103241</td>\n",
       "      <td>-0.038202</td>\n",
       "      <td>0.100845</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>0.100358</td>\n",
       "      <td>0.300339</td>\n",
       "      <td>0.094073</td>\n",
       "      <td>0.164856</td>\n",
       "      <td>0.013194</td>\n",
       "      <td>0.041638</td>\n",
       "      <td>0.121134</td>\n",
       "      <td>0.311772</td>\n",
       "      <td>0.042635</td>\n",
       "      <td>0.223358</td>\n",
       "      <td>...</td>\n",
       "      <td>0.242571</td>\n",
       "      <td>0.193467</td>\n",
       "      <td>0.195947</td>\n",
       "      <td>0.283689</td>\n",
       "      <td>-0.018320</td>\n",
       "      <td>0.108554</td>\n",
       "      <td>-0.015052</td>\n",
       "      <td>0.292868</td>\n",
       "      <td>0.203139</td>\n",
       "      <td>22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>0.107239</td>\n",
       "      <td>0.238500</td>\n",
       "      <td>0.076736</td>\n",
       "      <td>0.186204</td>\n",
       "      <td>-0.045489</td>\n",
       "      <td>0.193957</td>\n",
       "      <td>0.059147</td>\n",
       "      <td>0.227068</td>\n",
       "      <td>-0.017300</td>\n",
       "      <td>0.099241</td>\n",
       "      <td>...</td>\n",
       "      <td>0.055842</td>\n",
       "      <td>0.120995</td>\n",
       "      <td>0.168918</td>\n",
       "      <td>0.227482</td>\n",
       "      <td>0.020453</td>\n",
       "      <td>0.113469</td>\n",
       "      <td>0.027196</td>\n",
       "      <td>0.010731</td>\n",
       "      <td>0.156155</td>\n",
       "      <td>22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>0.158246</td>\n",
       "      <td>0.192932</td>\n",
       "      <td>0.151736</td>\n",
       "      <td>0.195696</td>\n",
       "      <td>0.017797</td>\n",
       "      <td>0.129658</td>\n",
       "      <td>0.079941</td>\n",
       "      <td>0.244671</td>\n",
       "      <td>0.013216</td>\n",
       "      <td>0.126369</td>\n",
       "      <td>...</td>\n",
       "      <td>0.220274</td>\n",
       "      <td>0.148490</td>\n",
       "      <td>0.231832</td>\n",
       "      <td>0.181748</td>\n",
       "      <td>-0.010906</td>\n",
       "      <td>0.254832</td>\n",
       "      <td>0.044762</td>\n",
       "      <td>0.083175</td>\n",
       "      <td>0.097739</td>\n",
       "      <td>22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>-0.088408</td>\n",
       "      <td>0.153199</td>\n",
       "      <td>0.126975</td>\n",
       "      <td>0.129019</td>\n",
       "      <td>0.058423</td>\n",
       "      <td>0.094837</td>\n",
       "      <td>0.027974</td>\n",
       "      <td>0.143561</td>\n",
       "      <td>0.052735</td>\n",
       "      <td>0.196288</td>\n",
       "      <td>...</td>\n",
       "      <td>0.145799</td>\n",
       "      <td>0.033281</td>\n",
       "      <td>0.072919</td>\n",
       "      <td>0.034996</td>\n",
       "      <td>-0.009259</td>\n",
       "      <td>0.084532</td>\n",
       "      <td>0.001876</td>\n",
       "      <td>0.217904</td>\n",
       "      <td>0.197544</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>0.123733</td>\n",
       "      <td>0.239491</td>\n",
       "      <td>0.112038</td>\n",
       "      <td>0.107437</td>\n",
       "      <td>-0.157204</td>\n",
       "      <td>0.197821</td>\n",
       "      <td>0.051098</td>\n",
       "      <td>0.164966</td>\n",
       "      <td>-0.000306</td>\n",
       "      <td>0.110194</td>\n",
       "      <td>...</td>\n",
       "      <td>0.163645</td>\n",
       "      <td>0.140799</td>\n",
       "      <td>0.258101</td>\n",
       "      <td>0.154051</td>\n",
       "      <td>0.093902</td>\n",
       "      <td>0.100144</td>\n",
       "      <td>0.076863</td>\n",
       "      <td>0.153935</td>\n",
       "      <td>0.238476</td>\n",
       "      <td>28</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>0.239593</td>\n",
       "      <td>0.315955</td>\n",
       "      <td>0.134811</td>\n",
       "      <td>0.052380</td>\n",
       "      <td>-0.109882</td>\n",
       "      <td>0.136943</td>\n",
       "      <td>0.317797</td>\n",
       "      <td>0.334644</td>\n",
       "      <td>0.071909</td>\n",
       "      <td>0.224188</td>\n",
       "      <td>...</td>\n",
       "      <td>0.346415</td>\n",
       "      <td>0.165297</td>\n",
       "      <td>0.316277</td>\n",
       "      <td>0.243542</td>\n",
       "      <td>0.132188</td>\n",
       "      <td>0.244902</td>\n",
       "      <td>0.008299</td>\n",
       "      <td>0.161652</td>\n",
       "      <td>0.220335</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>0.216014</td>\n",
       "      <td>0.314191</td>\n",
       "      <td>0.192691</td>\n",
       "      <td>0.222751</td>\n",
       "      <td>-0.097145</td>\n",
       "      <td>0.040756</td>\n",
       "      <td>0.068366</td>\n",
       "      <td>0.228696</td>\n",
       "      <td>-0.030098</td>\n",
       "      <td>0.155276</td>\n",
       "      <td>...</td>\n",
       "      <td>0.343526</td>\n",
       "      <td>0.194341</td>\n",
       "      <td>0.245517</td>\n",
       "      <td>0.167493</td>\n",
       "      <td>0.100540</td>\n",
       "      <td>0.111737</td>\n",
       "      <td>0.139508</td>\n",
       "      <td>0.071148</td>\n",
       "      <td>0.202421</td>\n",
       "      <td>26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>0.087176</td>\n",
       "      <td>0.148152</td>\n",
       "      <td>0.252261</td>\n",
       "      <td>0.107210</td>\n",
       "      <td>-0.002205</td>\n",
       "      <td>0.058429</td>\n",
       "      <td>0.114613</td>\n",
       "      <td>0.154443</td>\n",
       "      <td>0.064202</td>\n",
       "      <td>0.077505</td>\n",
       "      <td>...</td>\n",
       "      <td>0.082416</td>\n",
       "      <td>0.250200</td>\n",
       "      <td>0.198064</td>\n",
       "      <td>0.156323</td>\n",
       "      <td>0.028019</td>\n",
       "      <td>0.087621</td>\n",
       "      <td>0.160530</td>\n",
       "      <td>0.101771</td>\n",
       "      <td>0.192524</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>0.124348</td>\n",
       "      <td>0.317686</td>\n",
       "      <td>0.115676</td>\n",
       "      <td>-0.039929</td>\n",
       "      <td>-0.074344</td>\n",
       "      <td>0.143456</td>\n",
       "      <td>0.133786</td>\n",
       "      <td>0.226559</td>\n",
       "      <td>0.084337</td>\n",
       "      <td>0.236249</td>\n",
       "      <td>...</td>\n",
       "      <td>0.246913</td>\n",
       "      <td>0.200249</td>\n",
       "      <td>0.242660</td>\n",
       "      <td>0.151708</td>\n",
       "      <td>0.241589</td>\n",
       "      <td>0.122659</td>\n",
       "      <td>0.162770</td>\n",
       "      <td>0.196408</td>\n",
       "      <td>0.164206</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>0.163235</td>\n",
       "      <td>0.249315</td>\n",
       "      <td>0.146782</td>\n",
       "      <td>0.239550</td>\n",
       "      <td>-0.008325</td>\n",
       "      <td>0.102159</td>\n",
       "      <td>0.214904</td>\n",
       "      <td>0.240244</td>\n",
       "      <td>0.103068</td>\n",
       "      <td>0.210963</td>\n",
       "      <td>...</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.243000</td>\n",
       "      <td>0.220480</td>\n",
       "      <td>0.265362</td>\n",
       "      <td>0.013241</td>\n",
       "      <td>0.214885</td>\n",
       "      <td>0.183110</td>\n",
       "      <td>0.159444</td>\n",
       "      <td>0.227234</td>\n",
       "      <td>22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>0.158082</td>\n",
       "      <td>0.244756</td>\n",
       "      <td>-0.029606</td>\n",
       "      <td>0.215339</td>\n",
       "      <td>0.069442</td>\n",
       "      <td>0.192513</td>\n",
       "      <td>0.158772</td>\n",
       "      <td>0.207780</td>\n",
       "      <td>0.117690</td>\n",
       "      <td>0.136911</td>\n",
       "      <td>...</td>\n",
       "      <td>0.243000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.187517</td>\n",
       "      <td>0.161334</td>\n",
       "      <td>0.080408</td>\n",
       "      <td>0.080120</td>\n",
       "      <td>0.285077</td>\n",
       "      <td>0.057834</td>\n",
       "      <td>0.147561</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>0.181133</td>\n",
       "      <td>0.328094</td>\n",
       "      <td>0.163706</td>\n",
       "      <td>0.134585</td>\n",
       "      <td>-0.056780</td>\n",
       "      <td>0.093202</td>\n",
       "      <td>0.125200</td>\n",
       "      <td>0.288166</td>\n",
       "      <td>0.141619</td>\n",
       "      <td>0.261479</td>\n",
       "      <td>...</td>\n",
       "      <td>0.220480</td>\n",
       "      <td>0.187517</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.169237</td>\n",
       "      <td>0.087062</td>\n",
       "      <td>0.207930</td>\n",
       "      <td>0.099492</td>\n",
       "      <td>0.029027</td>\n",
       "      <td>0.118481</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>0.288083</td>\n",
       "      <td>0.400561</td>\n",
       "      <td>0.072575</td>\n",
       "      <td>0.205383</td>\n",
       "      <td>-0.029405</td>\n",
       "      <td>0.119560</td>\n",
       "      <td>0.233753</td>\n",
       "      <td>0.283431</td>\n",
       "      <td>0.077829</td>\n",
       "      <td>0.242289</td>\n",
       "      <td>...</td>\n",
       "      <td>0.265362</td>\n",
       "      <td>0.161334</td>\n",
       "      <td>0.169237</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.039089</td>\n",
       "      <td>0.315618</td>\n",
       "      <td>0.122392</td>\n",
       "      <td>0.158943</td>\n",
       "      <td>0.251346</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.092794</td>\n",
       "      <td>0.103856</td>\n",
       "      <td>0.043145</td>\n",
       "      <td>0.094626</td>\n",
       "      <td>-0.172705</td>\n",
       "      <td>0.151886</td>\n",
       "      <td>-0.007819</td>\n",
       "      <td>-0.005587</td>\n",
       "      <td>-0.093685</td>\n",
       "      <td>-0.041338</td>\n",
       "      <td>...</td>\n",
       "      <td>0.013241</td>\n",
       "      <td>0.080408</td>\n",
       "      <td>0.087062</td>\n",
       "      <td>0.039089</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.152726</td>\n",
       "      <td>-0.039400</td>\n",
       "      <td>0.069477</td>\n",
       "      <td>0.012725</td>\n",
       "      <td>25</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>0.185628</td>\n",
       "      <td>0.365101</td>\n",
       "      <td>0.234544</td>\n",
       "      <td>0.159678</td>\n",
       "      <td>-0.066141</td>\n",
       "      <td>0.035962</td>\n",
       "      <td>0.168046</td>\n",
       "      <td>0.266753</td>\n",
       "      <td>0.193870</td>\n",
       "      <td>0.201240</td>\n",
       "      <td>...</td>\n",
       "      <td>0.214885</td>\n",
       "      <td>0.080120</td>\n",
       "      <td>0.207930</td>\n",
       "      <td>0.315618</td>\n",
       "      <td>-0.152726</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.028414</td>\n",
       "      <td>0.134884</td>\n",
       "      <td>0.144587</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>0.144161</td>\n",
       "      <td>0.219111</td>\n",
       "      <td>-0.039937</td>\n",
       "      <td>0.144439</td>\n",
       "      <td>-0.066380</td>\n",
       "      <td>0.100289</td>\n",
       "      <td>0.221606</td>\n",
       "      <td>0.154125</td>\n",
       "      <td>-0.063637</td>\n",
       "      <td>-0.001629</td>\n",
       "      <td>...</td>\n",
       "      <td>0.183110</td>\n",
       "      <td>0.285077</td>\n",
       "      <td>0.099492</td>\n",
       "      <td>0.122392</td>\n",
       "      <td>-0.039400</td>\n",
       "      <td>0.028414</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.026660</td>\n",
       "      <td>0.134684</td>\n",
       "      <td>27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>0.005380</td>\n",
       "      <td>0.140468</td>\n",
       "      <td>0.059261</td>\n",
       "      <td>0.054221</td>\n",
       "      <td>0.102173</td>\n",
       "      <td>-0.010641</td>\n",
       "      <td>0.005159</td>\n",
       "      <td>0.047907</td>\n",
       "      <td>0.053103</td>\n",
       "      <td>0.157727</td>\n",
       "      <td>...</td>\n",
       "      <td>0.159444</td>\n",
       "      <td>0.057834</td>\n",
       "      <td>0.029027</td>\n",
       "      <td>0.158943</td>\n",
       "      <td>0.069477</td>\n",
       "      <td>0.134884</td>\n",
       "      <td>-0.026660</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>-0.003157</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>0.145754</td>\n",
       "      <td>0.268175</td>\n",
       "      <td>0.265866</td>\n",
       "      <td>0.203177</td>\n",
       "      <td>-0.045759</td>\n",
       "      <td>0.313789</td>\n",
       "      <td>0.046504</td>\n",
       "      <td>0.196631</td>\n",
       "      <td>0.211752</td>\n",
       "      <td>0.074777</td>\n",
       "      <td>...</td>\n",
       "      <td>0.227234</td>\n",
       "      <td>0.147561</td>\n",
       "      <td>0.118481</td>\n",
       "      <td>0.251346</td>\n",
       "      <td>0.012725</td>\n",
       "      <td>0.144587</td>\n",
       "      <td>0.134684</td>\n",
       "      <td>-0.003157</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>34 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "           1         2         3         4         5         6         7  \\\n",
       "1   1.000000  0.231297  0.065869  0.058290 -0.019313  0.055071  0.298865   \n",
       "2   0.231297  1.000000  0.164515  0.273920 -0.163867  0.168359  0.302533   \n",
       "3   0.065869  0.164515  1.000000  0.030626 -0.127232  0.076830 -0.064591   \n",
       "4   0.058290  0.273920  0.030626  1.000000  0.028030  0.161103  0.084728   \n",
       "5  -0.019313 -0.163867 -0.127232  0.028030  1.000000 -0.016522  0.046765   \n",
       "6   0.055071  0.168359  0.076830  0.161103 -0.016522  1.000000  0.075521   \n",
       "7   0.298865  0.302533 -0.064591  0.084728  0.046765  0.075521  1.000000   \n",
       "8   0.081741  0.283711  0.254749  0.259842 -0.015356  0.142143  0.176210   \n",
       "9   0.050880  0.167143  0.190225  0.014458  0.004066  0.193062  0.048967   \n",
       "10  0.121065  0.113720  0.172798  0.086001  0.048524  0.072850  0.128083   \n",
       "11 -0.017714  0.143385  0.154351  0.299998  0.052768  0.045258 -0.034573   \n",
       "12  0.090746  0.272458  0.258385  0.242838  0.032546  0.048919  0.051618   \n",
       "13  0.137045  0.158494 -0.001768  0.024502 -0.082011  0.151125  0.058614   \n",
       "14  0.132741  0.234365  0.275718  0.100823 -0.025042  0.024520  0.266535   \n",
       "15  0.270691  0.317535  0.181697  0.206648 -0.098275  0.194779  0.236407   \n",
       "16 -0.045149 -0.007777 -0.047224  0.020141  0.010517  0.132037  0.113191   \n",
       "17  0.100358  0.300339  0.094073  0.164856  0.013194  0.041638  0.121134   \n",
       "18  0.107239  0.238500  0.076736  0.186204 -0.045489  0.193957  0.059147   \n",
       "19  0.158246  0.192932  0.151736  0.195696  0.017797  0.129658  0.079941   \n",
       "20 -0.088408  0.153199  0.126975  0.129019  0.058423  0.094837  0.027974   \n",
       "21  0.123733  0.239491  0.112038  0.107437 -0.157204  0.197821  0.051098   \n",
       "22  0.239593  0.315955  0.134811  0.052380 -0.109882  0.136943  0.317797   \n",
       "23  0.216014  0.314191  0.192691  0.222751 -0.097145  0.040756  0.068366   \n",
       "24  0.087176  0.148152  0.252261  0.107210 -0.002205  0.058429  0.114613   \n",
       "25  0.124348  0.317686  0.115676 -0.039929 -0.074344  0.143456  0.133786   \n",
       "26  0.163235  0.249315  0.146782  0.239550 -0.008325  0.102159  0.214904   \n",
       "27  0.158082  0.244756 -0.029606  0.215339  0.069442  0.192513  0.158772   \n",
       "28  0.181133  0.328094  0.163706  0.134585 -0.056780  0.093202  0.125200   \n",
       "29  0.288083  0.400561  0.072575  0.205383 -0.029405  0.119560  0.233753   \n",
       "30  0.092794  0.103856  0.043145  0.094626 -0.172705  0.151886 -0.007819   \n",
       "31  0.185628  0.365101  0.234544  0.159678 -0.066141  0.035962  0.168046   \n",
       "32  0.144161  0.219111 -0.039937  0.144439 -0.066380  0.100289  0.221606   \n",
       "33  0.005380  0.140468  0.059261  0.054221  0.102173 -0.010641  0.005159   \n",
       "34  0.145754  0.268175  0.265866  0.203177 -0.045759  0.313789  0.046504   \n",
       "\n",
       "           8         9        10      ...             26        27        28  \\\n",
       "1   0.081741  0.050880  0.121065      ...       0.163235  0.158082  0.181133   \n",
       "2   0.283711  0.167143  0.113720      ...       0.249315  0.244756  0.328094   \n",
       "3   0.254749  0.190225  0.172798      ...       0.146782 -0.029606  0.163706   \n",
       "4   0.259842  0.014458  0.086001      ...       0.239550  0.215339  0.134585   \n",
       "5  -0.015356  0.004066  0.048524      ...      -0.008325  0.069442 -0.056780   \n",
       "6   0.142143  0.193062  0.072850      ...       0.102159  0.192513  0.093202   \n",
       "7   0.176210  0.048967  0.128083      ...       0.214904  0.158772  0.125200   \n",
       "8   1.000000  0.088855  0.339105      ...       0.240244  0.207780  0.288166   \n",
       "9   0.088855  1.000000 -0.086335      ...       0.103068  0.117690  0.141619   \n",
       "10  0.339105 -0.086335  1.000000      ...       0.210963  0.136911  0.261479   \n",
       "11  0.200004  0.187460  0.139939      ...       0.205511  0.128390  0.219803   \n",
       "12  0.257476  0.152552  0.192923      ...       0.208951  0.215667  0.172584   \n",
       "13  0.028347  0.091298  0.104138      ...       0.050050  0.027336  0.111930   \n",
       "14  0.309100  0.133893  0.257692      ...       0.264244  0.219171  0.183122   \n",
       "15  0.303881  0.167131  0.268551      ...       0.289369  0.400601  0.292267   \n",
       "16  0.136252  0.040168 -0.018488      ...       0.051846 -0.025101  0.055884   \n",
       "17  0.311772  0.042635  0.223358      ...       0.242571  0.193467  0.195947   \n",
       "18  0.227068 -0.017300  0.099241      ...       0.055842  0.120995  0.168918   \n",
       "19  0.244671  0.013216  0.126369      ...       0.220274  0.148490  0.231832   \n",
       "20  0.143561  0.052735  0.196288      ...       0.145799  0.033281  0.072919   \n",
       "21  0.164966 -0.000306  0.110194      ...       0.163645  0.140799  0.258101   \n",
       "22  0.334644  0.071909  0.224188      ...       0.346415  0.165297  0.316277   \n",
       "23  0.228696 -0.030098  0.155276      ...       0.343526  0.194341  0.245517   \n",
       "24  0.154443  0.064202  0.077505      ...       0.082416  0.250200  0.198064   \n",
       "25  0.226559  0.084337  0.236249      ...       0.246913  0.200249  0.242660   \n",
       "26  0.240244  0.103068  0.210963      ...       1.000000  0.243000  0.220480   \n",
       "27  0.207780  0.117690  0.136911      ...       0.243000  1.000000  0.187517   \n",
       "28  0.288166  0.141619  0.261479      ...       0.220480  0.187517  1.000000   \n",
       "29  0.283431  0.077829  0.242289      ...       0.265362  0.161334  0.169237   \n",
       "30 -0.005587 -0.093685 -0.041338      ...       0.013241  0.080408  0.087062   \n",
       "31  0.266753  0.193870  0.201240      ...       0.214885  0.080120  0.207930   \n",
       "32  0.154125 -0.063637 -0.001629      ...       0.183110  0.285077  0.099492   \n",
       "33  0.047907  0.053103  0.157727      ...       0.159444  0.057834  0.029027   \n",
       "34  0.196631  0.211752  0.074777      ...       0.227234  0.147561  0.118481   \n",
       "\n",
       "          29        30        31        32        33        34  most_similar  \n",
       "1   0.288083  0.092794  0.185628  0.144161  0.005380  0.145754             7  \n",
       "2   0.400561  0.103856  0.365101  0.219111  0.140468  0.268175            29  \n",
       "3   0.072575  0.043145  0.234544 -0.039937  0.059261  0.265866            14  \n",
       "4   0.205383  0.094626  0.159678  0.144439  0.054221  0.203177            11  \n",
       "5  -0.029405 -0.172705 -0.066141 -0.066380  0.102173 -0.045759            33  \n",
       "6   0.119560  0.151886  0.035962  0.100289 -0.010641  0.313789            34  \n",
       "7   0.233753 -0.007819  0.168046  0.221606  0.005159  0.046504            22  \n",
       "8   0.283431 -0.005587  0.266753  0.154125  0.047907  0.196631            10  \n",
       "9   0.077829 -0.093685  0.193870 -0.063637  0.053103  0.211752            34  \n",
       "10  0.242289 -0.041338  0.201240 -0.001629  0.157727  0.074777             8  \n",
       "11  0.166906 -0.009510  0.072732  0.053302  0.060894  0.224745             4  \n",
       "12  0.158460 -0.022365  0.192056  0.017305  0.169414  0.117850            15  \n",
       "13  0.055918  0.100567  0.001916  0.123836 -0.060468  0.252181            21  \n",
       "14  0.204197 -0.079143  0.198989  0.185249  0.059410  0.155889            17  \n",
       "15  0.395746  0.100289  0.225039  0.260701  0.125557  0.269022            27  \n",
       "16  0.000392 -0.035567  0.048703  0.103241 -0.038202  0.100845             8  \n",
       "17  0.283689 -0.018320  0.108554 -0.015052  0.292868  0.203139            22  \n",
       "18  0.227482  0.020453  0.113469  0.027196  0.010731  0.156155            22  \n",
       "19  0.181748 -0.010906  0.254832  0.044762  0.083175  0.097739            22  \n",
       "20  0.034996 -0.009259  0.084532  0.001876  0.217904  0.197544            17  \n",
       "21  0.154051  0.093902  0.100144  0.076863  0.153935  0.238476            28  \n",
       "22  0.243542  0.132188  0.244902  0.008299  0.161652  0.220335            17  \n",
       "23  0.167493  0.100540  0.111737  0.139508  0.071148  0.202421            26  \n",
       "24  0.156323  0.028019  0.087621  0.160530  0.101771  0.192524            14  \n",
       "25  0.151708  0.241589  0.122659  0.162770  0.196408  0.164206             2  \n",
       "26  0.265362  0.013241  0.214885  0.183110  0.159444  0.227234            22  \n",
       "27  0.161334  0.080408  0.080120  0.285077  0.057834  0.147561            15  \n",
       "28  0.169237  0.087062  0.207930  0.099492  0.029027  0.118481             2  \n",
       "29  1.000000  0.039089  0.315618  0.122392  0.158943  0.251346             2  \n",
       "30  0.039089  1.000000 -0.152726 -0.039400  0.069477  0.012725            25  \n",
       "31  0.315618 -0.152726  1.000000  0.028414  0.134884  0.144587             2  \n",
       "32  0.122392 -0.039400  0.028414  1.000000 -0.026660  0.134684            27  \n",
       "33  0.158943  0.069477  0.134884 -0.026660  1.000000 -0.003157            17  \n",
       "34  0.251346  0.012725  0.144587  0.134684 -0.003157  1.000000             6  \n",
       "\n",
       "[34 rows x 35 columns]"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cos_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x20a96244408>"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1080x1080 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(15,15))\n",
    "sns.heatmap(cos_df.iloc[:,:-1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x20a95b078c8>"
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAyYAAANSCAYAAACQhNrlAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4yLjIsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+WH4yJAAAgAElEQVR4nOzdd5hdZbk34N9KiEcQCBAglV4siLRQVHoICQlIpCjNBoKoIN/RgwVRLAiiiAcURVREiqAQECIRiPQiHYKC9JoOgRDqMZlZ3x/JiRmySTlk1jvB+76ufV2z937XmncxK5v5zfOsd1V1XQcAAKCkbqUnAAAAIJgAAADFCSYAAEBxggkAAFCcYAIAABQnmAAAAMUJJgAAwCKpquqMqqqmVFX19zd4v6qq6pSqqh6pqureqqo2XdA+BRMAAGBRnZlk6Hze3yXJerMfhyT5+YJ2KJgAAACLpK7r65M8N58huyc5q57lliQrVFXVd377XGpxTrCVGc8+5tbyzOOAzb5Yegp0QdPa/6f0FOhips58qfQU6IIeeGFc6SnQRb30yuNV6TksjK7++/HbVlnnM5lV5fhfp9d1ffoi7qZ/kqfnej5u9msT32iDTg8mAADAkmN2CFnUIPJ6rULifAOZVi4AAGBxG5dktbmeD0gyYX4bCCYAAMDidmmSj89enWurJC/Udf2GbVyJVi4AAGhWe1vpGbxpVVWdl2T7JCtXVTUuyTFJeiRJXdenJRmdZFiSR5K8kuRTC9qnYAIAACySuq73XcD7dZLPL8o+tXIBAADFqZgAAECT6vbSM+iSVEwAAIDiBBMAAKA4rVwAANCkdq1craiYAAAAxQkmAABAcYIJAABQnGtMAACgQbXlgltSMQEAAIoTTAAAgOK0cgEAQJMsF9ySigkAAFCcYAIAABSnlQsAAJpkVa6WVEwAAIDiBBMAAKA4rVwAANCk9rbSM+iSVEwAAIDiBBMAAKA4rVwAANAkq3K1pGICAAAUJ5gAAADFCSYAAEBxrjEBAIAmtbvGpBUVEwAAoDjBBAAAKE4rFwAANKi2XHBLKiYAAEBxggkAAFCcVi4AAGiSVblaUjEBAACKE0wAAIDitHIBAECTrMrVkooJAABQnGACAAAUp5ULAACa1N5WegZdkooJAABQnGACAAAUp5ULAACaZFWullRMAACA4gQTAACgOMEEAAAozjUmAADQpHbXmLSiYgIAABQnmAAAAMVp5QIAgCZZLrglFRMAAKA4wQQAAChOKxcAADTJqlwtqZgAAADFCSYAAEBxWrkAAKBBdd1WegpdkooJAABQnGACAAAUp5ULAACa5AaLLamYAAAAxQkmAABAcYIJAABQnGtMAACgSe783pKKCQAAUJxgAgAAFKeVCwAAmmS54JZUTAAAgOIEEwAAoDitXAAA0KT2ttIz6JJUTAAAgOIEEwAAoDitXAAA0CSrcrWkYgIAABQnmAAAAMVp5QIAgCa1a+VqRcWkAUcfd1K2Hb5PRhxwaOmp0LCNttskP7761Jx83c+z+2f3mOf9fuv0z3cv/n7OeeiC7HrI7h3e2+VTu+bEK0/OiWNOybADd2tqynSygdtvll9d+8v85oZf5yOf23ue91dbZ0B+/MeTMuqRS7PXZ/bs8N5vbz4zp435WX52+U/zk8tObmrKFPD+HbbIyBvOzcU3n5dPHLb/PO+vse7qOWPUz3PzE1flgEP3KTBDOtMPTzwmY/92TW659c/ZaOMNWo5ZY40Buea6i3PPvVfnt2f9JD169EiSrL/+2rnqmpGZ+vwD+cIRB3fY5mennZDHn7g9t91+eacfA/xfCCYNGDFscE476djS06BhVbduOfC7n8nxn/hOvrjT4fngh7ZJ//UGdBjz0rSXcuYxv8qoX/6xw+urrb96Bu07OEd96Mh8eej/y6aDBqbPmn2bnD6doFu3bvn8sZ/P0R//Rg7e8TPZYffts/p6q3cYM33ai/n5Madl5OkjW+7jyx/5aj439LAcPvyIJqZMAd26dctXjvtivrD/f2Xv7T6WISN2ylrrr9lhzPTnp+fEo0/OOaedX2aSdJqdh2yfddZdMxttuEMOP+xr+e+TW//+8N1jv5pTf/LrbPy+HTNt2gv5xCc/kiR5/vkXcuR/fTunnPyrebY59+yRGTHik505fXhT5htMqqrasqqq5Wd/vXRVVd+uqmpUVVUnVFXVs5kpLvkGbrxhei6/XOlp0LB1N14vk5+YmClPT07bjJm5edSN2Xzwlh3GTJ/6Qh6995G0zeh4o6X+6w7Iw3c/lH++9s+0t7Xn/lvvyxZDtmpy+nSCd268fiY8MSGTnpqUmTNm5tpLr8v7d+74c31h6gt5aOxDmTljZqFZUtoGm7w7Tz8xPuOfmpiZM2bmykuuynZDtu4w5vmp03L/2AecJ29Bu+46OOede1GS5Pbb70nPnsund59V5hm33Xbvz8UX/zlJcu45I7PrrjsnSZ55ZmruuvPezJgxY55tbrrptjz/3LROnD28OQuqmJyR5JXZX5+cpGeSE2a/9ptOnBcs8Vbqs1KmTnx2zvOpE6dmxT4rLdS2Tz/0VN61xXuy7ArL5W1vf1s22WHT9Oq3cmdNlYb06rNynpnwzJznz058Niv36bXwO6jrHHfu9/LTy07JLvvt0gkzpCtYtc8qmTx+ypznUyY+k1X7+Pf/76Jvv94ZN27inOcTxk9Mv359Oozp1WvFTHthetraZv1Ra/z4SenXr3ej8+RNqtu79qOQBV383q2u6//9c8zAuq43nf31jVVV3fNGG1VVdUiSQ5LkZz86Np/++L5vfqawhKlSzftivXDbjn9kXC497eIcfe638trLr+XJ+59I28y2BW9Il1a1OiUW8pxIkv/c40t5bvJz6dmrZ77/u+Py9KNP5++3/n3xTZCu4U2eJyzZqhYfFPXrToCFGQNLogUFk79XVfWpuq5/k2RsVVUD67q+o6qq9ZPMWyOcra7r05OcniQznn3MvxT+LU2dNDW9+v7rr5y9+vbK85OfW+jtr/n9X3LN7/+SJNnnyAPy3KSpi32ONOvZic9mlX7/aslYue/KmTp54X+uz80+f16Y+kJuuvzmvGvjdwomb0FTJj6T3v1XnfN81b6r5JnJz85nC5Z0h3zmY/nkp2YtYnDnnfdmwIB/XVPYr3/fTJw4ucP4Z599Liv0XD7du3dPW1tb+vfvk4kTpwSWdAtq5fp0ku2qqno0yXuS/LWqqseS/HL2e8AbeHTsw+mzVt+sstqq6d5jqXxgt61zx5jbFnr75XvNuoyrV7+Vs8XQrXLTJdd31lRpyINjH0r/Nful92q9s1SPpbL9h7bLLWNuWaht/2Pp/8jS71h6ztebbbtpnnjwiU6cLaXcf88DWW2tAem3Wt8s1WOp7Lz7oFx/xY2lp0UnOv0XZ+cDWw3PB7Yanj+NujL77j9rFcfNN98406e/mMmTnplnm+uvvyUf/vCsls79D9gzl102ptE58ya1t3ftRyHVwpT+qqpaLsnamVVhGVfX9eQFbDKHikly5DHfz+1335tp06an10or5HMHfSx77jak9LSKOmCzL5aeQiM23mGzfOKbB6Zb9+659g9/ycU/vTA77T/rZ/+Xc69Iz1VWyPGjTszSyy6Tur3Oa6+8mi/tdHhefenVfOuC47LcisulbcbMnHXsb/L3m+4tfDSdb1r7/5SeQqfbfIfNc+i3Dkm37t1z5e+vzHk/OT/DDxiWJLnsnNFZcZUV85PLTskyyy6Tur09r77yWg7Z8TNZfqXlc8wvv5Ek6d69e6655Nqc95O3/opMU2e+VHoKRXxwx63yxe98Id27d8ul51+WM04+O3t+fNaS4iPPuiS9VlkpZ13+y7xjuXekbm/PKy+/mo9s97G8/NIrC9jzW8MDL4wrPYVOddKPv5OdBm+bV195NYce+uXcfdffkiQjLz4jn//cVzNp4pSsueZqOfOsn2TFFXvm3rH356AD/zP//Oc/s2rvlXPDjZdmueWWTXt7nZdffjkDN905L774Un5z5snZZtut0qvXipky5dl879j/zlm//UPho128Xnrl8RbNkF3Pazed26V/P377B/cv8t9xoYLJmyGY0Mq/SzBh0fw7BBMWzb9rMGH+3urBhP87wWTxKBVM3PkdAACa5M7vLbnBIgAAUJxgAgAAFKeVCwAAGlTX7k3WiooJAABQnGACAAAUp5ULAACaZFWullRMAACA4gQTAACgOK1cAADQpForVysqJgAAQHGCCQAAUJxgAgAAFOcaEwAAaJLlgltSMQEAAIoTTAAAgOK0cgEAQJMsF9ySigkAAFCcYAIAABSnlQsAAJpkVa6WVEwAAIDiBBMAAKA4rVwAANAkq3K1pGICAAAUJ5gAAADFaeUCAIAmWZWrJRUTAACgOMEEAAAoTjABAACKc40JAAA0yTUmLamYAAAAxQkmAABAcVq5AACgSe783pKKCQAAUJxgAgAAFKeVCwAAmmRVrpZUTAAAgOIEEwAAoDitXAAA0CSrcrWkYgIAABQnmAAAAMVp5QIAgCZZlaslFRMAAKA4wQQAAChOKxcAADTJqlwtqZgAAADFCSYAAEBxggkAAFCca0wAAKBJlgtuScUEAAAoTjABAACK08oFAABN0srVkooJAABQnGACAAAUp5ULAACaVNelZ9AlqZgAAADFCSYAAEBxWrkAAKBJVuVqScUEAAAoTjABAACK08oFAABN0srVkooJAABQnGACAAAUJ5gAAADFucYEAACaVLvGpBUVEwAAoDjBBAAAKE4wAQCAJrW3d+3HQqiqamhVVQ9WVfVIVVVfbfF+z6qqRlVVNbaqqvuqqvrUgvYpmAAAAAutqqruSU5NskuS9yTZt6qq97xu2OeT3F/X9UZJtk/yo6qq3ja//QomAADAotgiySN1XT9W1/U/k5yfZPfXjamTLFdVVZVk2STPJZk5v51alQsAAJpU16VnMF9VVR2S5JC5Xjq9ruvT53reP8nTcz0fl2TL1+3mp0kuTTIhyXJJPlrX81+OTDABAADmmB1CTp/PkKrVZq97PiTJPUl2TLJOkjFVVd1Q1/X0N9qpVi4AAGBRjEuy2lzPB2RWZWRun0pyUT3LI0keT/Ku+e1UxQQAAJq0kCtfdWG3J1mvqqq1koxPsk+S/V435qkkg5LcUFVV7yTvTPLY/HYqmAAAAAutruuZVVUdluSKJN2TnFHX9X1VVR06+/3Tknw3yZlVVf0ts1q/vlLX9bPz269gAgAALJK6rkcnGf26106b6+sJSXZelH12ejA5YLMvdva3YAl0zp0nlZ4CXdCAdYaVngJdTLfKpZDM6+1L9Sg9BXhzlvxWrk7hEx8AAChOMAEAAIoTTAAAgOJc/A4AAE2a/w3Q/22pmAAAAMUJJgAAQHFauQAAoEF1e116Cl2SigkAAFCcYAIAABSnlQsAAJrkzu8tqZgAAADFCSYAAEBxWrkAAKBJbrDYkooJAABQnGACAAAUp5ULAACa5AaLLamYAAAAxQkmAABAcVq5AACgSW6w2JKKCQAAUJxgAgAAFCeYAAAAxbnGBAAAmuQak5ZUTAAAgOIEEwAAoDitXAAA0KTand9bUTEBAACKE0wAAIDitHIBAECTrMrVkooJAABQnGACAAAUp5ULAACa1G5VrlZUTAAAgOIEEwAAoDitXAAA0KTaqlytqJgAAADFCSYAAEBxggkAAFCca0wAAKBJlgtuScUEAAAoTjABAACK08oFAAANqtstF9yKigkAAFCcYAIAABSnlQsAAJpkVa6WVEwAAIDiBBMAAKA4rVwAANCk2qpcraiYAAAAxQkmAABAcVq5AACgSVblaknFBAAAKE4wAQAAitPKBQAATWq3KlcrKiYAAEBxggkAAFCcYAIAABTnGhMAAGiS5YJbUjEBAACKE0wAAIDitHIBAECTassFt6JiAgAAFCeYAAAAxWnlAgCAJlmVqyUVEwAAoDjBBAAAKE4rFwAANKhutypXKyomAABAcYIJAABQnFYuAABoklW5WlIxAQAAihNMAACA4gQTAACgONeYAABAk1xj0pKKCQAAUJxgAgAAFKeVCwAAmlS783srKiaLyUbbbZIfX31qTr7u59n9s3vM836/dfrnuxd/P+c8dEF2PWT3Du/t8qldc+KVJ+fEMadk2IG7NTVlCjv6uJOy7fB9MuKAQ0tPhQbtMGjr3HTHn3PL3Vfk8P88uOWY753w9dxy9xW55qZLsuFG70mS9OvfJxeN+m1uuO2yXHfLqBx86MeanDadYIdBW+eG2y/LzXddnsP+36dbjvnuCUfl5rsuz1U3XZwNN3p3klnnwoWjfpPrbx2Va/96aT596AFzxp92xo8y5oaLMuaGi3LbvWMy5oaLGjkWFp8dd9omt9x5eW67Z0y+8J+HtBxz3A+Ozm33jMl1N1+a983+jEiSk089Lv949K+54ZY/dRj/oRFDc+Otl2XKtAey8Sbv7dT5w5shmCwGVbduOfC7n8nxn/hOvrjT4fngh7ZJ//UGdBjz0rSXcuYxv8qoX/6xw+urrb96Bu07OEd96Mh8eej/y6aDBqbPmn2bnD6FjBg2OKeddGzpadCgbt265fs/+mb22+vgbLPFrvnwnsOz/jvX6TBm0OBts9Y6a2SrTYbkv474Zn5w0jFJkpkz23LM0Sdkmy2GZ9hO++RTB+8/z7YsObp165bjTjw6++/1mWy35W4ZsdeweX6eOw7eNmuvvUY+sOnQHHnEMfn+j/73XJiZbx/9g2y75W4ZPniffPLT+83Z9tADv5TB2+yRwdvskcsuHZPRo8Y0fmz833Xr1i0n/OiYfHTPg/PBzYdlj712nee82Gnn7bL2Omtmi40H54tHfCM//PG357x3/rkX5aN7HDTPfv9x/8P55P6H5a833d7pxwBvhmCyGKy78XqZ/MTETHl6ctpmzMzNo27M5oO37DBm+tQX8ui9j6RtRluH1/uvOyAP3/1Q/vnaP9Pe1p77b70vWwzZqsnpU8jAjTdMz+WXKz0NGrTpZu/L4489lSefGJcZM2bkjxeNztDhgzqMGTp8UC4475IkyZ13jM3yPZfPqr1XyZTJz+RvY+9Pkrz80st5+MFH06df78aPgcVjk802zBOPPZWnnpx1Llwy8s8ZMmzHDmOGDtsxF5w/61y46457s3zP5bJq75UzZfKz+dvYfyRJXn7plTz80GPp03fVeb7HbiOG5I8Xju78g2Gx2XTg+/L4Y0/mySeezowZM3LxyMuyy/CdOozZZdig/OG8i5Mkd94+Nj17LpfevVdJkvz15jvy/PMvzLPfhx96NI888njnHwALr73u2o9CBJPFYKU+K2XqxGfnPJ86cWpW7LPSQm379ENP5V1bvCfLrrBc3vb2t2WTHTZNr34rd9ZUgYL69OudCeMnznk+Yfyk9OnbMVz07ds74+caM3HCpPR9XQBZbfX+ee/73p277hjbuROm0/Tp2zvjx0+a83zihEnzhIs+fVfNhA5jJqfv686XAav3y4Ybvjt33Xlvh9e3+sBmefaZqXn8sSc7YfZ0lr59e2fCuH/9zCe0+Pfft1/vjJ97zPjJ84yBJVWnXPxeVdUhSQ5Jks1W2ijrLLtmZ3ybLqNKNe+LCxk2xz8yLpeednGOPvdbee3l1/Lk/U+kbWbbgjcEljhVi4+K1K/7sGj1cTLXmGXesUx+ffYp+cbXjs9LL768eCdIY6oWJ8Pr/7fRcszrz4WzTs43j5r3XBix5/BcPFK1ZEmzoJ/5wo6BJdV8g0lVVQOT/DDJ+CRfS3JGki2SPJTkkLqu7261XV3Xpyc5PUk+usaIt/y/lqmTpqZX339VOXr17ZXnJz+30Ntf8/u/5Jrf/yVJss+RB+S5SVMX+xyB8iaOn5x+/f91DVm//n0yadKUjmMmTE7/ucb07dcnkybOGrPUUkvljLNPycg/jHLtwBJu4oRJ6d+/z5znffv1yeSJ854L/TqM6T3nfFlqqaXy67P+Oxdd8KeMHvWXDtt17949w3bbKUO237sTj4DOMGHCpPQb8K+feb+5/v3PGTN+UvrPPaZ/73nG0PXVbrDY0oJauX6W5AdJLktyc5Jf1HXdM8lXZ79HkkfHPpw+a/XNKqutmu49lsoHdts6d4y5baG3X75XzyRJr34rZ4uhW+WmS67vrKkCBd1919+y9jprZPU1+qdHjx4ZscewXDH66g5jrhh9dfbed9bKfZsN3CgvTn8xUyY/kyT58U+PzcMPPppfnHpm01NnMbvnrr9nrXXWyGqzz4Xd99wlV/z5mg5jrvjz1dl7n1nnwqYD3zf7XJjVNnzST7+bhx96LL849bfz7Hvb7d+fRx5+PBMnTO78A2GxuvvOv2XttdfM6msMSI8ePfLhPYfn8tFXdRhz+Z+vzkf2/XCSZLPNN8r06S9l8uzPCFjSLaiVq0dd139OkqqqTqjr+sIkqev6qqqqTuz02S0h2tvac8Y3f5mjzjom3bp3z7V/+EvGPfx0dtp/SJLkL+dekZ6rrJDjR52YpZddJnV7nWEH7pYv7XR4Xn3p1XzxtK9kuRWXS9uMmTnjm6fn5enaM/4dHHnM93P73fdm2rTpGTTigHzuoI9lz92GlJ4WnaitrS1f+6/v5vyLfp3u3bvlvHNG5sEHHsnHD/xokuSsM36fv1x5XQbtvG1uvefKvPrKazni80clSbbYatN8ZN8Ruf/vD+aqG2Zd+Hrcd36cq8b4Q8aSqK2tLUcd+b2cN/KX6d69W84/5+I89MAj+finZp8Lv/l9rrry+gwavG3+evflefWV1/Kfn/96klnnwt777J7773twznLAx3/nv3P17HNh9z13cdH7EqqtrS1fPfI7ueDiX6db9+753dkX5sEHHsknD9wnSXLmGednzBXXZqedt8vtY/+SV195NV/43NfmbH/6GSflg1tvkZV6rZh7/3F9TjjulJx79oUZtuvgfP+H30ivlVfK7y44PX//2z/ykQ/Pu3oXlFbNry+xqqq/JjkmSc8kJyY5oq7rP1ZVtV2SH9V1PXBB3+DfoZWLRXfOnSeVngJd0IB1hpWeAl1Mt8oaLcxrRvvM0lOgi3p2+kOtrubrcl78wq5d+vfj5U75U5H/jguqmByaWa1c7UmGJPlsVVVnZtY1J63vDAYAALCI5vunqLqux9Z1PaSu613qun6grusj6rpeoa7rDZK8s6E5AgAAb3Fvpkb+7QUPAQAAWLAFLRd87xu9lcTdfAAAYFG1t5eeQZe0oGtMemfWtSXPv+71KrOWDwYAAHjTFhRM/pRk2bqu73n9G1VVXdspMwIAAP7tzDeY1HX9hotc13W93+KfDgAAvMW583tLFogHAACKE0wAAIDiFnSNCQAAsDhp5WpJxQQAAChOMAEAAIrTygUAAA2qa61craiYAAAAxQkmAABAcVq5AACgSVblaknFBAAAKE4wAQAAitPKBQAATdLK1ZKKCQAAUJxgAgAAFCeYAAAAxbnGBAAAGlS7xqQlFRMAAKA4wQQAAChOKxcAADRJK1dLKiYAAEBxggkAAFCcVi4AAGhSe+kJdE0qJgAAQHGCCQAAUJxWLgAAaJAbLLamYgIAABQnmAAAAMVp5QIAgCZp5WpJxQQAAChOMAEAAIoTTAAAgOJcYwIAAE1y5/eWVEwAAIDiBBMAAKA4rVwAANAgd35vTcUEAAAoTjABAACK08oFAABNsipXSyomAABAcYIJAABQnFYuAABokFW5WlMxAQAAihNMAACA4rRyAQBAk6zK1ZKKCQAAUJxgAgAAFKeVCwAAGlRr5WpJxQQAAChOMAEAAIoTTAAAgOJcYwIAAE1yjUlLKiYAAEBxggkAAFCcVi4AAGiQ5YJbUzEBAAAWSVVVQ6uqerCqqkeqqvrqG4zZvqqqe6qquq+qqusWtE8VEwAAYKFVVdU9yalJBicZl+T2qqourev6/rnGrJDkZ0mG1nX9VFVVqy5ov4IJAAA0aclv5doiySN1XT+WJFVVnZ9k9yT3zzVmvyQX1XX9VJLUdT1lQTvVygUAAMxRVdUhVVXdMdfjkNcN6Z/k6bmej5v92tzWT7JiVVXXVlV1Z1VVH1/Q91UxAQAA5qjr+vQkp89nSNVqs9c9XyrJZkkGJVk6yV+rqrqlruuH3minggkAADToLbAq17gkq831fECSCS3GPFvX9ctJXq6q6vokGyV5w2CilQsAAFgUtydZr6qqtaqqeluSfZJc+roxlyTZpqqqpaqqWibJlkn+Mb+dqpgAAAALra7rmVVVHZbkiiTdk5xR1/V9VVUdOvv90+q6/kdVVZcnuTezLvf/VV3Xf5/ffgUTAABo0FuglSt1XY9OMvp1r532uuc/TPLDhd2nVi4AAKA4wQQAAChOMAEAAIpzjQkAADTorXCNSWdQMQEAAIoTTAAAgOI6vZVrWvv/dPa3YAk0YJ1hpadAFzTu0dELHsS/laX7bVN6CnRB667Qr/QU4M2pq9Iz6JJUTAAAgOIEEwAAoDircgEAQIOsytWaigkAAFCcYAIAABSnlQsAABpUt1uVqxUVEwAAoDjBBAAAKE4rFwAANMiqXK2pmAAAAMUJJgAAQHGCCQAAUJxrTAAAoEF1bbngVlRMAACA4gQTAACgOK1cAADQIMsFt6ZiAgAAFCeYAAAAxWnlAgCABtXtVuVqRcUEAAAoTjABAACK08oFAAANquvSM+iaVEwAAIDiBBMAAKA4rVwAANAgq3K1pmICAAAUJ5gAAADFaeUCAIAGaeVqTcUEAAAoTjABAACKE0wAAIDiXGMCAAANcuf31lRMAACA4gQTAACgOK1cAADQIMsFt6ZiAgAAFCeYAAAAxWnlAgCABtW1Vq5WVEwAAIDiBBMAAKA4rVwAANCgur30DLomFRMAAKA4wQQAAChOKxcAADSo3apcLamYAAAAxQkmAABAcYIJAABQnGtMAACgQe783pqKCQAAUJxgAgAAFKeVCwAAGlS3a+VqRcUEAAAoTjABAACK08oFAAANquvSM+iaVEwAAIDiBBMAAKA4rVwAANAgq3K1pmICAAAUJ5gAAADFaeUCAIAGtddauVpRMQEAAIoTTAAAgOK0cgEAQINqrYaKvZsAACAASURBVFwtqZgAAADFCSYAAEBxggkAAFCca0wAAKBBdV16Bl2TigkAAFCcYAIAABSnlQsAABrkzu+tqZgAAADFCSYAAEBxWrkAAKBB7vzemooJAABQnGACAAAUp5ULAAAa5AaLramYAAAAxQkmi8nA7TfLr679ZX5zw6/zkc/tPc/7q60zID/+40kZ9cil2esze3Z477c3n5nTxvwsP7v8p/nJZSc3NWUasMOgrXPTHX/OLXdfkcP/8+CWY753wtdzy91X5JqbLsmGG70nSdKvf59cNOq3ueG2y3LdLaNy8KEfa3LaFHT0cSdl2+H7ZMQBh5aeCg348UnfyQP335i77hyTTTZ+b8sxa665Wm6+cVT+cd+N+d25P0+PHj2SJLvttnPuunNM7rj9ytzy19H54Ac2n7PN4YcdlHvuvipj77k6Xzj8040cC4vH1ju8P3+++cJccetFOfjwT7Qc8/XvfSlX3HpRLrn2d3nPhu+c8/pyyy+bk3/9/Yy+6YJcduMfsvHADZMk79xgvZw/+te59Nrz8vOzT8o7ln1HI8cCi0owWQy6deuWzx/7+Rz98W/k4B0/kx123z6rr7d6hzHTp72Ynx9zWkaePrLlPr78ka/mc0MPy+HDj2hiyjSgW7du+f6Pvpn99jo422yxaz685/Cs/851OowZNHjbrLXOGtlqkyH5ryO+mR+cdEySZObMthxz9AnZZovhGbbTPvnUwfvPsy1vTSOGDc5pJx1beho0YJehO2a9ddfKu96zdT772a/k1J8e33Lc8cd9Pf99yi/z7g22zvPPv5ADP7VvkuTqq2/MppsNzsDNd87Bh3wpv/jFiUmSDTZ4Zw46aL+8/wPDs+lmgzN82E5Zd921Gjsu/u+6deuWb57w5Ry87xHZdeuPZPgeO2ed9Tv+7LYd9IGssfbqGbLlHvnml47LMT/46pz3vv69L+WGq/+aYR/cOyN22C+PPvR4kuTYk47Oj757aj60/b4ZM/qaHPR5f+wqrb2uuvSjFMFkMXjnxutnwhMTMumpSZk5Y2auvfS6vH/nrTqMeWHqC3lo7EOZOWNmoVnStE03e18ef+ypPPnEuMyYMSN/vGh0hg4f1GHM0OGDcsF5lyRJ7rxjbJbvuXxW7b1Kpkx+Jn8be3+S5OWXXs7DDz6aPv16N34MNG/gxhum5/LLlZ4GDdhttyE5+9wLkyS33nZXeq7QM336rDrPuB22/2BGjrwsSXL22Rdk9w8NSZK8/PIrc8a8Y5llUs9uWn/Xu9bLrbfelVdffS1tbW25/oZbMmL3oZ19OCwG79t0gzz1+NMZ9+T4zJgxM6MvHpNBQ7frMGbQLtvlkj/MOh/G3vn3LN9zuayyaq+8Y9l3ZOBWm+TCc2f9P2XGjJl5cfpLSZK11l09t//1riTJzdfdlp133aHBo4KFJ5gsBr36rJxnJjwz5/mzE5/Nyn16LfwO6jrHnfu9/PSyU7LLfrt0wgwpoU+/3pkwfuKc5xPGT0qfvh3DRd++vTN+rjETJ0xK39cFkNVW75/3vu/dueuOsZ07YaBR/fv1ybinJ8x5Pn7cxPTv16fDmF69Vsy0aS+kra0tSTJu/MT06/+vMbvvPjR//9t1ufSS3+bgg7+UJLnvvgeyzTZbZaWVVszSS789uwzdMQMG9GvgiHizevdZJRPHT57zfNLEyendd5V5x0yYa8yEKendd9Wstmb/PDd1Wo4/5ZhcdNU5+e5JX8/Sy7w9SfLwA49lx6HbJkmGfmhQ+vb3hy66pvkGk6qqelZV9f2qqh6oqmrq7Mc/Zr+2wny2O6Sqqjuqqrpj3EtPL/5ZdzFVi4rXoqy28J97fCmHDTs8X//4N/KhT+ya927Zus+YJUur82KeE6PlufOvMcu8Y5n8+uxT8o2vHZ+XXnx58U4QKKpq8SFRv+4zYkFjLrnk8rx3w+2y514H5dvfOjJJ8sADj+SHPzw1l//5vIz+07kZe+/9aZvZtphnT6dYiHPijcYs1b173vO+d+a8My/MHoMOyKuvvJaDD/9kkuSoI76T/Q/cOyPHnJV3LLtMZvxzRmfMHt60BVVM/pDk+STb13Xdq67rXkl2mP3aBW+0UV3Xp9d1PbCu64EDll1t8c22i3p24rNZpd+//qKxct+VM3Xy1IXe/rnJzyWZ1e510+U3510bv3MBW7AkmDh+cvr17zvneb/+fTJp0pSOYyZMTv+5xvTt1yeTJs4as9RSS+WMs0/JyD+MyuhRY5qZNNCpPnvoJ3LH7VfmjtuvzISJkzJgtX9VMvoP6JsJEyd3GP/ss89lhRV6pnv37kmSAf37dvhr+f+64cZbs/baa6RXrxWTJL858/xsseXQ7DBozzz//LQ8/MjjnXhULC6TJ07pUM3o07d3pkx6dt4xc1XW+/RbNVMmPZNJE6dk8oQpufeu+5IkV4y6Ku9536zfJx5/5Mkc9JHDs+fgj+eyi67MU0+Mb+BomJ+6rrr0o5QFBZM167o+oa7rSf/7Ql3Xk+q6PiHJ6vPZ7t/Kg2MfSv81+6X3ar2zVI+lsv2HtsstY25ZqG3/Y+n/yNLvWHrO15ttu2meePCJTpwtTbn7rr9l7XXWyOpr9E+PHj0yYo9huWL01R3GXDH66uy97+5Jks0GbpQXp7+YKZNntQX++KfH5uEHH80vTj2z6akDneTnp/02AzffOQM33zmXXnpFPrb/XkmSLbfYNNNfmD7PHy+S5Nrrbs6eew5PknzsY3vn0lFXJknWWWfNOWM22fi9edvbemTq1OeTJKusMqudeLXV+mXEiF1y/u//2JmHxWLyt7vvzxprr57+q/dLjx5LZdiHB+fqK67vMObqy6/P7h+ZdT5stNl78+L0l/LMlKl5dsrUTJwwOWuts0aS5P3bbj7n4veVVp4VWKuqyqFfPDDn/7b1QjxQ2oJusPhkVVVfTvLbuq4nJ0lVVb2TfDLJW79HayG1t7Xn1G/8PMedc2y6de+eK39/ZZ586KkMP2BYkuSyc0ZnxVVWzE8uOyXLLLtM6vb2jDhoRA7Z8TNZfqXlc8wvv5Ek6d69e6655Nrcce2dJQ+HxaStrS1f+6/v5vyLfp3u3bvlvHNG5sEHHsnHD/xokuSsM36fv1x5XQbtvG1uvefKvPrKazni80clSbbYatN8ZN8Ruf/vD+aqGy5Okhz3nR/nqjHXv+H3463hyGO+n9vvvjfTpk3PoBEH5HMHfSx77jak9LToBKP/fFWGDt0xD/7jprzy6qv59Ke/OOe9UZeclUMOPTITJ07O1476Xn53zs/ynW99OfeMvS9n/Oa8JMkeHx6WAw7YKzNmzMxrr76W/fb/7JztL/j9L7NSrxUzY8bMfOELX8+0aS80fnwsura2tnz3qz/Ir39/Srp1756Rv7s0jzz4WD76iT2SJL//7UW57i83ZdudPpgrb7s4r73yWo464jtztj/2qBPzw59/Jz3e1iNPPzk+R31h1nvDPzwk+x84KwRfedm1uei8Uc0fHCyEap7exbnfrKoVk3w1ye5Jeiepk0xOcmmSE+q6fm5B32DIaru4tyXzuGe6tgLmNe7R0aWnQBezdL9tSk+BLmjdFVzMT2sPTLm9XB/SIri13x5d+vfjLSdcVOS/43wrJnVdP19V1cgkF9Z1fXtVVRskGZrkHwsTSgAAABbGfINJVVXHJNklyVJVVY1JskWS65J8taqqTeq6/l4DcwQAAN7iFnSNyV5JNk7yH0kmJRlQ1/X0qqp+mOTWJIIJAAAsgi7dx1XQglblmlnXdVtd168kebSu6+lJUtf1q0naO312AADAv4UFBZN/VlW1zOyvN/vfF6uq6hnBBAAAWEwW1Mq1bV3X/5MkdV3PHUR6JPlEp80KAADeotoL3sSwK1vQqlz/8wavP5vk2VbvAQAALKoFtXIBAAB0ugW1cgEAAItRrZWrJRUTAACgOMEEAAAoTjABAACKc40JAAA0yM0AW1MxAQAAihNMAACA4rRyAQBAg+pYLrgVFRMAAKA4wQQAAChOKxcAADSovS49g65JxQQAAChOMAEAAIrTygUAAA1qtypXSyomAABAcYIJAABQnFYuAABokBsstqZiAgAAFCeYAAAAxWnlAgCABrWXnkAXpWICAAAUJ5gAAADFCSYAAEBxrjEBAIAGWS64NRUTAACgOMEEAAAoTisXAAA0yHLBramYAAAAxQkmAABAcVq5AACgQVq5WlMxAQAAihNMAACA4rRyAQBAg9xgsTUVEwAAoDjBBAAAKE4rFwAANKhdJ1dLKiYAAEBxggkAAFCcYAIAABTnGhMAAGhQu+WCW1IxAQAAihNMAACA4rRyAQBAg+rSE+iiVEwAAIDiBBMAAKA4rVwAANCg9tIT6KJUTAAAgOIEEwAAYJFUVTW0qqoHq6p6pKqqr85n3OZVVbVVVbXXgvaplQsAABrUXi3ZN1isqqp7klOTDE4yLsntVVVdWtf1/S3GnZDkioXZr4oJAACwKLZI8khd14/Vdf3PJOcn2b3FuMOTjEwyZWF2KpgAAABzVFV1SFVVd8z1OOR1Q/oneXqu5+Nmvzb3Pvon+XCS0xb2+2rlAgCABnX1GyzWdX16ktPnM6RVL9rrD+u/k3ylruu2aiFb1wQTAABgUYxLstpczwckmfC6MQOTnD87lKycZFhVVTPruv7jG+1UMAEAABbF7UnWq6pqrSTjk+yTZL+5B9R1vdb/fl1V1ZlJ/jS/UJIIJgAA0Kgl/QaLdV3PrKrqsMxabat7kjPqur6vqqpDZ7+/0NeVzE0wAQAAFkld16OTjH7day0DSV3Xn1yYfVqVCwAAKE4wAQAAitPKBQAADWpfsm/83mlUTAAAgOIEEwAAoDitXAAA0KD2ljdOR8UEAAAoTjABAACK08oFAAANqktPoItSMQEAAIoTTAAAgOK0cgEAQIPcYLG1Tg8mU2e+1NnfgiVQt0qxjnkt3W+b0lOgi3l1wg2lp0AXtOyA7UpPAegEfjsEAACK08oFAAANai89gS5KxQQAAChOMAEAAIoTTAAAgOJcYwIAAA1y5/fWVEwAAIDiBBMAAKA4rVwAANAgd35vTcUEAAAoTjABAACK08oFAAANcuf31lRMAACA4gQTAACgOK1cAADQIK1cramYAAAAxQkmAABAcVq5AACgQbUbLLakYgIAABQnmAAAAMUJJgAAQHGuMQEAgAZZLrg1FRMAAKA4wQQAAChOKxcAADRIK1drKiYAAEBxggkAAFCcVi4AAGhQXXoCXZSKCQAAUJxgAgAAFKeVCwAAGtRelZ5B16RiAgAAFCeYAAAAxWnlAgCABrnBYmsqJgAAQHGCCQAAUJxWLgAAaJBWrtZUTAAAgOIEEwAAoDjBBAAAKM41JgAA0KC69AS6KBUTAACgOMEEAAAoTisXAAA0qL0qPYOuScUEAAAoTjABAACK08oFAAANcuf31lRMAACA4gQTAACgOK1cAADQIDdYbE3FBAAAKE4wAQAAitPKBQAADWrXzNWSigkAAFCcYAIAABQnmAAAAMW5xgQAABrkzu+tqZgAAADFCSYAAEBxWrkAAKBBFgtuTcUEAAAoTjABAACK08oFAAANsipXayomAABAcYIJAABQnFYuAABoUHtVegZdk4oJAABQnGACAAAUp5ULAAAa1O4Wiy2pmAAAAMUJJgAAQHFauQAAoEEauVpTMQEAAIoTTAAAgOIEEwAAoDjXmAAAQIPaS0+gi1IxAQAAihNMOsH7d9giI284NxfffF4+cdj+87y/xrqr54xRP8/NT1yVAw7dp8AM6Sw7DNo6N9x+WW6+6/Ic9v8+3XLMd084KjffdXmuuunibLjRu5Mk/fr3yYWjfpPrbx2Va/96aT596AFzxp92xo8y5oaLMuaGi3LbvWMy5oaLGjkWFq8fn/SdPHD/jbnrzjHZZOP3thyz5pqr5eYbR+Uf992Y35378/To0SNJsttuO+euO8fkjtuvzC1/HZ0PfmDzOdscfthBuefuqzL2nqvzhcNbn3Ms+Y4+7qRsO3yfjDjg0NJToQEn/ejbuf++G3LH7Vdm4/l8Xtxw/aW57+/X55yzfzbn82KffUbkjtuvzB23X5lrr7k4G2446/8z66+3dm679fI5j2em3J/DDzuosWOChSGYLGbdunXLV477Yr6w/39l7+0+liEjdspa66/ZYcz056fnxKNPzjmnnV9mknSKbt265bgTj87+e30m2225W0bsNSzrv3OdDmN2HLxt1l57jXxg06E58ohj8v0fHZMkmTlzZr599A+y7Za7ZfjgffLJT+83Z9tDD/xSBm+zRwZvs0cuu3RMRo8a0/ix8ebsMnTHrLfuWnnXe7bOZz/7lZz60+Nbjjv+uK/nv0/5Zd69wdZ5/vkXcuCn9k2SXH31jdl0s8EZuPnOOfiQL+UXvzgxSbLBBu/MQQftl/d/YHg23Wxwhg/bKeuuu1Zjx0VzRgwbnNNOOrb0NGjA0CE7ZN1118p7Ntgmn/v8V/KTU45rOe57x34tp/zkV9ngvdtm2rRp+dQnZ/2h84knns5Og/fOwM13zvHHn5yfnXpCkuShhx/LFlsOzRZbDs1W7x+WV155NZdcenljx0VH7am79KMUwWQx22CTd+fpJ8Zn/FMTM3PGzFx5yVXZbsjWHcY8P3Va7h/7QGbOmFlolnSGTTbbME889lSeenJcZsyYkUtG/jlDhu3YYczQYTvmgvMvSZLcdce9Wb7nclm198qZMvnZ/G3sP5IkL7/0Sh5+6LH06bvqPN9jtxFD8scLR3f+wbBY7bbbkJx97oVJkltvuys9V+iZPn3m/fnusP0HM3LkZUmSs8++ILt/aEiS5OWXX5kz5h3LLJO6nvU/jXe9a73ceutdefXV19LW1pbrb7glI3Yf2tmHQwEDN94wPZdfrvQ0aMBuu+2cc84dmSS57ba7s8IKy7f8vNh++w/mootmf16cc2E+NPvz4pZb7sy0aS8kSW697e707993nm133HHrPPb4k3nqqfGddRjwfyKYLGar9lklk8dPmfN8ysRnsmqflQvOiKb06ds748dPmvN84oRJ84SLPn1XzYQOYyanb9/eHcYMWL1fNtzw3bnrzns7vL7VBzbLs89MzeOPPdkJs6cz9e/XJ+OenjDn+fhxE9O/X58OY3r1WjHTpr2Qtra2JMm48RPTr/+/xuy++9D8/W/X5dJLfpuDD/5SkuS++x7INttslZVWWjFLL/327DJ0xwwY0K+BIwI6S79+fTJu3FyfF+Mnpl+Lz4sXXpg+5/Oi1Zgk+dQn98kVV14zz+t77/2h/OH3lyzmmcObN99gUlXV8lVVHV9V1dlVVe33uvd+Np/tDqmq6o6qqu545pVJbzTsrama96Xa7T3/LVTVvD/81//oW46Z6wRZ5h3L5NdnnZxvHnV8Xnrx5Q7jRuw5PBePVC1ZEi3o574wYy655PK8d8PtsudeB+Xb3zoySfLAA4/khz88NZf/+byM/tO5GXvv/Wmb2baYZw80aXF8XiTJdtu9P5/85Efz9a93bAXr0aNHdh0+OCNnV1soo+7ij1IWVDH5TWb9qj0yyT5VVY2squo/Zr+31RttVNf16XVdD6zreuAqy8yb4N/K/n979x0nd1XuD/xzSGIDCRAxpEkT9SLShCAWeglFWgDhAtKEi5Wr/uQieOWKoCCKIhdBLDSRIkWC9CtVEQhCQEAUBJWQTUJLAiZIQs7vj6xrNhmygNn5bsL7zWtfu/OdM7PPZA8z88zznPOd3PFEBg/756fkbx2yfJ6Y9GSDEdEuHRMmZthcn3APGbpCJnVMnmfMpG6fgg8ZOjgTJ84Z079///zo7O/kkp/9Ilde/n/dbtevX79s++EtMuaSq3rxEbAwffyQfbsWoE7omJjhI/5ZyRg2fEgmdEzqNv7JJ5/OMssMTL9+/ZIkw4cNSceE7mOS5JZf3Z5VVlkxgwYtmyQ548zzM3KDUdl089F55pkpeejhR3vxUQG94ZD/2LdrUfqEjkndKp/Dhg1JR4vni4EDl+56vph3zBprvCunnXpCdt31wDz99JRutx219aYZN+6+TJ7svQl9T0+Jyaq11sNrrT+vte6Q5K4k15dSBrUhtkXSA+MezIiVh2foiCHpP6B/ttpx89x8za+aDos2GHfXfVl51RUzYsVhGTBgQHYcvU2uuap7Cf2aq67PbnvsmCRZd7018+y0ZzO5M3E98X+/mof++Ei+f8pZ8933RptsmIcferTlG1X6plNPOyvrrb9V1lt/q4wZc0322WvXJMkGI9fNtKnTuhLSud14060ZPXq7JMk+++yWMZdfmyRZddWVusass/Yaed3rBuSpp55Jkiy//Jyn4xEjhmannbbJ+Rf8vDcfFtALTvv+WV0L0y8fc0323mt0kmTkyHUydeqzLZ8vbrrp1uyyS+fzxd675vLO54sRI4bmwgt+kP0POLTlBxW7775jLrhQGxd9U08nWHx9KWWJWuvsJKm1HltKGZ/k5iRL9Xp0i6AXX3wxJxzx7Zx83rfSr98SGXP+FXnkj3/O6I/OeTN68dmXZdDyy+Xsq3+QJd+8ZOrs2dnzoN2y+8b75G/PTe/h3unLXnzxxRzxhWNz3sU/SL9+S+T8n1yaPz74cD66/0eSJGefcUF+ee3N2XzLjfKbu6/OjOnP57OfPDJJMvJ962a3PXbMA/f/oWs74K8f/Z1cf93NSZIdR29j0fsi7MqrfplRozbLH37/60yfMSMf+9jnuq67/LKzc/AhX0hHx6R88Yhj89OffC9H/89hGXfP/fnxGeclSXbZedvsvfeumTlzVp6f8Xz+fa+Pd93+Zxf8IMsNWjYzZ87KZz5zZNeiVxYvXzjquIy9+95MmTItm++0dz5x4D4Z/eGtmw6LXnDV1ddn1KjN8vsHfpXp02fkoIM/33XdZT8/K4d8/LB0dEzKkV/6es45+5R85X++kHHj7ssZZ87Z6fOII/4zyy23TL570rFJklmzXsz7PzAngXnjG9+QzTf/UD75qcPb/8DoxgkWWyvz9iR2u7KUbyS5ttb6f/McH5Xk5Frraj39gvWGfMgKC+bz+Iynmg6BPuiJ6d5U092MCbc0HQJ90FLDN246BPqovz//WIvVvn3P/1tpzz79/vibfz6vkX/HBbZy1VoPSzKtlLJ+kpRSVi+lfC7JEi8nKQEAAHg5FtjKVUo5Ksk2SfqXUq5LskGSG5McXkpZp9Z6bO+HCAAAi48mT2LYl/W0xmTXJGsneX2SiUmG11qnlVJOSHJ7EokJAADwL+tpV65ZtdYXa63Tk/yp1jotSWqtM2LdDgAAsJD0lJi8UEp5U+fP7/3HwVLKwEhMAACAhaSnVq6Naq1/T5J/bBncaUCSfXstKgAAWExZYdLaAhOTfyQlLY4/mcQpQwEAgIWip1YuAACAXtdTKxcAALAQWajdmooJAADQOIkJAADQOK1cAADQRtW+XC2pmAAAAI2TmAAAAI3TygUAAG1kV67WVEwAAIDGSUwAAIDGaeUCAIA2mm1XrpZUTAAAgMZJTAAAgMZJTAAAgMZZYwIAAG1khUlrKiYAAEDjJCYAAEDjtHIBAEAb2S64NRUTAACgcRITAACgcVq5AACgjWY3HUAfpWICAAA0TmICAAA0TisXAAC0UbUrV0sqJgAAQOMkJgAAQOO0cgEAQBvZlas1FRMAAKBxEhMAAKBxWrkAAKCN7MrVmooJAADQOIkJAADQOIkJAADQOGtMAACgjWwX3JqKCQAA0DiJCQAA0DitXAAA0Eazq+2CW1ExAQAAGicxAQAAGqeVCwAA2kgjV2sqJgAAQOMkJgAAQOMkJgAA0EazU/v018tRShlVSvlDKeXhUsrhLa7fq5Ryb+fXraWUtXq6T4kJAADwspVS+iU5Jck2SVZPsmcpZfV5hj2aZONa65pJvprk9J7uV2ICAAC8EiOTPFxrfaTW+kKS85PsOPeAWuuttdZnOi/elmR4T3dqVy4AAGij2sf35SqlHJzk4LkOnV5rnbviMSzJY3NdHp9kgwXc5YFJrurp90pMAACALp1JyIJar0qrm7UcWMqmmZOYfLCn3ysxAQAAXonxSUbMdXl4kgnzDiqlrJnkh0m2qbU+1dOdWmMCAAC8EmOTrFZKWbmU8rokeyQZM/eAUsrbklySZJ9a6x9fzp2qmAAAQBvNbjqAf1GtdVYp5VNJrknSL8mPa633l1IO6bz+tCRfTjIoyfdKKUkyq9a63oLuV2ICAAC8IrXWK5NcOc+x0+b6+WNJPvZK7lMrFwAA0DgVEwAAaKOXe3b11xoVEwAAoHESEwAAoHFauQAAoI36+pnfm6JiAgAANE5iAgAANE4rFwAAtNGifoLF3qJiAgAANE5iAgAANE4rFwAAtFGtduVqRcUEAABonMQEAABonFYuAABoo9lOsNiSigkAANA4iQkAANA4iQkAANA4a0wAAKCNnPm9tV5PTB6cOr63fwWLoDf0H9B0CPRBb19maNMh0McsNXzjpkOgD3pu/E1NhwD0Aq1cAABA47RyAQBAG1XbBbekYgIAADROYgIAADROKxcAALSRM7+3pmICAAA0TmICAAA0TisXAAC0Ua1auVpRMQEAABonMQEAABqnlQsAANpodtMB9FEqJgAAQOMkJgAAQOMkJgAAQOOsMQEAgDaqzvzekooJAADQOIkJAADQOK1cAADQRrO1crWkYgIAADROYgIAADROKxcAALRRrVq5WlExAQAAGicxAQAAGqeVCwAA2siuXK2pmAAAAI2TmAAAAI3TygUAAG1UtXK1pGICAAA0TmICAAA0TmICAAA0zhoTAABoo9nO/N6SigkAANA4iQkAANA4rVwAANBGGrlaUzEBAAAaJzEBAAAap5ULAADaaLZmrpZUTAAAgMZJTAAAgMZp5QIAgDbSytWaigkAANA4iQkAANA4rVwAANBGtWrlakXFOxIyIQAAEpxJREFUBAAAaJzEBAAAaJxWLgAAaCO7crWmYgIAADROYgIAADROYgIAADTOGhMAAGijao1JSyomAABA4yQmAABA47RyAQBAGznze2sqJgAAQOMkJgAAQOO0cgEAQBs583trKiYAAEDjJCYAAEDjtHIBAEAb2ZWrNRUTAACgcRITAACgcVq5AACgjezK1ZqKCQAA0DiJCQAA0DiJCQAA0DhrTAAAoI2qNSYtqZgAAACNk5gAAACN08oFAABtNNuZ31tSMQEAABonMQEAABqnlQsAANrIrlytqZgAAACNk5gAAACN08oFAABtZFeu1lRMAACAxklMAACAxklM/gUnfPOo3PO7G3Lb7VdlrbXf3XLMiisOzw03XZpx916fs84+OQMGDEiSvOMdq+SXN1ycp555MJ859KBut/neacfn0T+PzR1jr+71x8DCtdkWH8ptv706d4y7Lp/57MEtx3ztG1/KHeOuy023jsmaa63edfykU76W3//pN7nltl90G7/DTqPyq9uvyOQpD2btddbo1fjpHR/cdMNcdetFueb2S3LQp/dtOebIYz+fa26/JJfd+NOs/p53dh1/89JL5aQfHZcrf/2zXPGrC7P2eu9Jkrzz3avl/Ct/lDE3npdTzzkxSy61ZFseCwvXid/6Sh64/5bcOfbarL126/+/V1ppRG65eUzuv+/m/OSc73W9juyxx065c+y1uXPstbnxhkvznvf8W5LkHautkjtuv7rr64nJD+TTnzqwbY+J9vnS107MRtvtkZ32PqTpUHiFah//rykSk1dpq603yapvXylrvWfTfPpTX8x3Tjqm5bivHnN4Tjn5R1l7zc0yZcrU7Lvf7kmSZ56Zmi/8v6/kuyf9cL7bnHvOxdlpp/16M3x6wRJLLJHjv3VUPjL6oHxg/W2zy67b5x3vXLXbmC222jirrLpSRq69ZT536H/nhG9/peu688+9JB/ZZf43D79/4KHst9en8ptfj+31x8DCt8QSS+TLxx+Wg/Y8NNt/cPdst8tWWfUdK3cbs9Hm78+Kq7wtW2+wS778+a/lqG8c3nXdkcd+Prdc/5ts+4HdstOm/54//fHRJMkxJ34p3/rqKdlhkz1z3ZU35MBP7tPWx8W/btTWm+btb185q7/7Q/nEJ/8rJ3/3ay3HHXvMF/Pdk3+Yd6+xUaZMmZL999sjSfLnPz+WLbbcLeutv1W+/vWT8r1Tjk+S/PGhRzJyg1EZucGovG/DbTN9+oxcNsYHXYujnbbdMqed2Pr9ByyKJCav0vbbb5nzzr0kSTJ27LgMHLh0Bq+w/HzjNt54w1x66VVJknN/cnG2336rJMkTTzyVu357b2bOnDnfbX796zvyzNNTejF6esO6662ZRx/5S/7y58cyc+bMXHrxFdlmuy26jdlm281z4XmXJkl+O/aeDBz45gwePGfe/ObWO/PMM1Pnu9+H/vinPPzwo73/AOgVa6777vz10ccy/i+PZ+bMWbny0uuy+aiNu43ZfJuNc9mFVyRJ7vntfVl64Juz/FsHZcmllsx671snF517WZJk5sxZeXbac0mSld/+toz9zV1JkltvuiNbbb9pGx8VC8OHP7xVfnLuxUmSO+64O8sss3RWWOGt843bZJMP5JJL5syPc35yUXbYYeskyW23/TZTpsx5zrj9jrszbNiQ+W672WYfzCOP/iV//evjvfUwaNB6a78nA5d+c9NhwEIjMXmVhgwdnPHjO7ouT3i8I0OHrtBtzKBBy2bK1Gl58cUXkySPPz4xQ4cObmuctM+QIYMzYfzErssTJkzMkHn+3kOGDs7jc495fNJ8Y1i8DF5h+XQ8Pqnr8sSOSRk8ZPn5x0yYa8yEyRk85K0ZsdKwPP3UlHz9u0flkl/+JF898ci88U1vSJI89OAj2WzURkmSUTtsniHDzKNFzdChK2T8+Aldlx9/ideRqd1eR+YfkyT777dHrrn2hvmO77bbDrnwgssWcuTAv2p2rX36qykLTExKKSuUUk4tpZxSShlUSvmfUsrvSikXllLm/2jmn7c7uJRyZynlzpmznl34UfcBpZT5jtV5/pAvZwyLD3OCll7O3/wlxvTv1y+rr/nOnHfmRdll870zY/rzOejT+yVJjjj06Ox1wG65+Lqzs+RSb8rMF+avvtK3LaznjI033jD77feRHHlk91awAQMGZPvttszFndUWgL6up4rJmUkeSPJYkhuSzEiyXZJbkpz2UjeqtZ5ea12v1rregP6LT4nx4P/YJ7fedkVuve2KdHRMzvDh/8zNhg4bko6OSd3GP/nk01lm4NLp169fkmTYsBXS0TG5rTHTPhMmTMzQ4f/8JHPo0BUycZ6/94THJ2bY3GOGDZ5vDIuXSR2Tu1UzVhgyOJMnPjn/mLkqZysMfWsmT3wiEzsmZ9KEybn3rvuTJNdc/susvuachfGPPvyXHLj7pzN6y4/mikuuzV//rFVnUXDIf+zbtSh9QsekDB8+tOu6YS/xOjKw2+tI9zFrrPGunHbqCdl11wPz9DwtwKO23jTjxt2XyZO7zzeAvqqnxGRwrfXkWutxSZaptR5fa/1rrfXkJCu2Ib4+5fTvn5P3v2+7vP992+UXl1+bPffaJUmy/vprZ9q0ZzNp4hPz3ebmm2/LzjtvkyTZa+/RueKK69oaM+1z929/l1VWWSlvW3F4BgwYkJ1Hb5err/xltzFXX3V9dt9z5yTJe9dfK9OmPZdJk+afNyw+fnf3A1lxlbdl2NuGZsCA/tl25y1z/TU3dxtz/dU3Z8fdt0uSrPXeNfLstOfyxOSn8uTkp9IxYVJWXnXO0+2GG63ftfh9ubcsm2TOJ+qHfO6AnH/WxW18VLxap33/rK6F6ZePuSZ77zU6STJy5DqZOvXZTJw4/wcVN910a3bZZc782GfvXXP55dcmSUaMGJoLL/hB9j/g0DzUYh3a7rvvmAsu1MYFLDrKgtpISin31FrX6vz5mFrrl+a67t5a65o9/YKl3rTyYtuncuK3j84WW26UGdNn5JBDDsvdd/0uSXLxpT/OJz9xeCZ2TM5KK43ImWefnGWXHZh773kgBx7w2bzwwgt56+C35JZfjcmb37xUZs+u+dvf/pb11t0qzz77XM4486R8aKP3ZdCgZTN58pM59pjv5OyzLmz40S5cb+g/oOkQesUWW22cY487Ikv065efnnNRvv3N07LfAXN20Dnzx+cnSY7/1lHZbIsPZcb0GfnMJ76YcXfflyQ5/ccn5gMfHJnlBi2bJyY/leO/9t2ce85F2Xb7LXPcCf+dQW9ZLlOnTst9v/t9dt958dz68y1vGNh0CL1io83fnyOO+VyW6NcvF/90TL7/nTPykX3nfLBxwVlzNtH47+MOy4c22zDPT38+Rxx6dO675/dJknet8Y4cc+KRGfC6AXnsL4/niM8cnWlTn80+B+2RvQ7YNUly7RU35sRj/reZB9fLHp02sedBi7CTvnNMttpqk0yfPiMHHfz53HXXvUmSy35+Vg75+GHp6JiUlVd+W845+5Qst9wyGTfuvuy3/6F54YUXcuqp38jOO23TtbB91qwX8/4PzElg3vjGN+RPD9+Rd/3bBzJt2uLXUv3c+JuaDqFP+MJRx2Xs3fdmypRpGbTcMvnEgftk9Ie3bjqsRg14yyrz9z/2Qast/94+/f74oSd+28i/Y0+JydFJvlFrfW6e429PclytddeefsHinJjw6i2uiQn/msU1MeHVW9wTE14diQkvRWKycDSVmPRf0JW11i+XUkaWUmqtdWwpZfUko5I8+HKSEgAAgJdjgYlJKeWoJNsk6V9KuS7JBkluTHJ4KWWdWuuxvR8iAAAsPprckrcvW2BikmTXJGsneX2SiUmG11qnlVJOSHJ7EokJAADwL+tpV65ZtdYXa63Tk/yp1jotSWqtM5LM7vXoAACA14SeKiYvlFLe1JmYvPcfB0spAyMxAQCAV6xGK1crPSUmG9Va/54ktda5E5EBSfbttagAAIDXlJ525fr7Sxx/MolTyQIAAAtFTxUTAABgIereiMQ/9LT4HQAAoNdJTAAAgMZp5QIAgDaabVeullRMAACAxklMAACAxklMAACAxlljAgAAbVSrNSatqJgAAACNk5gAAACN08oFAABtZLvg1lRMAACAxklMAACAxmnlAgCANrIrV2sqJgAAQOMkJgAAQOO0cgEAQBvN1srVkooJAADQOIkJAADQOK1cAADQRtUJFltSMQEAABonMQEAABonMQEAABpnjQkAALSRM7+3pmICAAA0TmICAAA0TisXAAC00WzbBbekYgIAADROYgIAADROKxcAALSRXblaUzEBAAAaJzEBAAAap5ULAADaaLZWrpZUTAAAgMZJTAAAgMZp5QIAgDayK1drKiYAAMArUkoZVUr5Qynl4VLK4S2uL6WU73Zef28pZd2e7lNiAgAAvGyllH5JTkmyTZLVk+xZSll9nmHbJFmt8+vgJKf2dL9auQAAoI1mZ5Fv5RqZ5OFa6yNJUko5P8mOSR6Ya8yOSc6uc/rWbiulLFNKGVJr7XipO1UxAQAAupRSDi6l3DnX18HzDBmW5LG5Lo/vPPZKx3SjYgIAAHSptZ6e5PQFDCmtbvYqxnSjYgIAALwS45OMmOvy8CQTXsWYbiQmAADQRrXWPv31MoxNslopZeVSyuuS7JFkzDxjxiT5aOfuXO9LMnVB60sSrVwAAMArUGudVUr5VJJrkvRL8uNa6/2llEM6rz8tyZVJtk3ycJLpSfbv6X4lJgAAwCtSa70yc5KPuY+dNtfPNcknX8l9SkwAAKCNZjvze0vWmAAAAI2TmAAAAI3TygUAAG1UF/0zv/cKFRMAAKBxEhMAAKBxWrkAAKCN7MrVmooJAADQOIkJAADQOK1cAADQRlUrV0sqJgAAQOMkJgAAQOMkJgAAQOOsMQEAgDZy5vfWVEwAAIDGSUwAAIDGaeUCAIA2sl1wayomAABA4yQmAABA47RyAQBAG2nlak3FBAAAaJzEBAAAaJxWLgAAaCONXK2pmAAAAI2TmAAAAI0rdgVon1LKwbXW05uOg77FvKAV84JWzAtaMS9YXKiYtNfBTQdAn2Re0Ip5QSvmBa2YFywWJCYAAEDjJCYAAEDjJCbtpf+TVswLWjEvaMW8oBXzgsWCxe8AAEDjVEwAAIDGSUwAAIDGSUzapJSyTCnlolLKg6WU35dSNmw6JtqvlPLjUsrkUsp9cx1bu5RyWyllXCnlzlLKyCZjpL1KKW8opdxRSrmnlHJ/KeUrnceXK6VcV0p5qPP7sk3HSvssYF6c0Pk6cm8p5dJSyjJNx0r7LGBefLVzTowrpVxbShnadKzwalhj0iallLOS3FJr/WEp5XVJ3lRrndJ0XLRXKWWjJM8lObvWukbnsWuTfLvWelUpZdskh9VaN2kwTNqolFKSLFlrfa6UMiDJr5IcmmSXJE/XWo8rpRyeZNla6381GSvts4B5sXSS62uts0opxyeJefHasYB58UCtdVrnmM8kWb3WekiDocKromLSBqWUpZNslORHSVJrfUFS8tpUa705ydPzHs6cNxtJMjDJhLYGRaPqHM91XhzQ+VWT7JjkrM7jZyXZqYHwaMhLzYta67W11lmdx29LMryRAGnEAubFtLmGLZk5zyGwyJGYtMcqSZ5IckYp5e5Syg9LKUs2HRR9xn8mOaGU8liSbyb5YsPx0GallH6llHFJJie5rtZ6e5LBtdaOJOn8/tYmY6T9XmJezO2AJFe1PzKa9FLzopRybOfryF5JvtxkjPBqSUzao3+SdZOcWmtdJ8nfkhzebEj0IR9P8tla64gkn01nZY3Xjlrri7XWtTPn0++RpZQ1mo6J5i1oXpRSjkwyK8m5TcVHM15qXtRaj+x8HTk3yaeajBFeLYlJe4xPMn6uT7suypxEBZJk3ySXdP78syQWv79GdbZ43phkVJJJpZQhSdL5fXKDodGgeeZFSin7Jtk+yV7VQtHXrHnnxVx+mmR02wOChUBi0ga11olJHiulvLPz0OZJHmgwJPqWCUk27vx5syQPNRgLbVZKWf4fOyuVUt6YZIskDyYZkzlJazq/X9ZMhDThpeZFKWVUkv9KskOtdXqTMdJ+C5gXq801bIfMeQ6BRU7/pgN4Dfl0knM7d+R6JMn+DcdDA0op5yXZJMlbSinjkxyV5KAkJ5VS+id5PsnBzUVIA4YkOauU0i9zPiy6sNb6i1LKb5JcWEo5MMlfk+zWZJC03UvNi4eTvD7JdXM2aMptdl96TXmpeXFx54efs5P8JYk5wSLJdsEAAEDjtHIBAACNk5gAAACNk5gAAACNk5gAAACNk5gAAACNk5gAAACNk5gAAACN+/92UpuBizyqmAAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<Figure size 1080x1080 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(15,15))\n",
    "sns.heatmap(cos_df.iloc[[5,17,29,31,32],[5,17,29,31,32]], annot=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
